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Carpal tunnel syndrome (CTS) is a compression neuropathy of the median nerve. Patients may 
experience discomfort in the hand and wrist, altered sensation and functional deficit. The management 
of mild to moderate CTS involves local corticosteroid injection (CSI) and night splinting (NS). The aims 
of the studies presented in this thesis were to describe the epidemiology of CTS and to develop 
prognostic models to predict future likely outcomes in patients presenting with CTS in a primary care 
setting. Evidence for predictors of treatment effect (CSI or NS) were also explored.  
The estimated crude prevalence of patients presenting with CTS in UK primary care (using data from 
the Clinical Practice Research Datalink - CPRD) increased from 26.03 per 10,000 person years in 1993 
(95% CI 25.10 to 27.00) to 36.08 per 10,000 person years (95% CI 35.45 to 36.72) in 2013. The 
proportion of patients having carpal tunnel release surgery (CTR) changed over the study period 
increasing from 19.35% in 1993 to a peak in 2009 at 29.32% and then decreasing to 27.3% in 2013.  
A systematic review of 16 cohort studies reporting on the course and prognosis of CTS showed that 
prolonged symptom duration, a positive Phalen’s test, and thenar wasting were associated with poor 
outcome over a follow-up period of between six months and 12 years. However, not all associations 
were statistically significant and many studies were deemed to be at increased risk of bias (particularly 
relating to study attrition, confounding, and/or statistical analysis or reporting), hence the overall 
judgement regarding their predictive value remained inconclusive. A CPRD cohort of 91,412 patients 
with CTS was developed. 20.24% of the cohort had a recorded episode of CTR within 3 years of 
diagnosis. A prognostic model predicting time to surgical intervention was developed using Cox 
regression and included age, obesity, alcohol use, smoking and having multi-site pain, an inflammatory 
condition or a neck symptoms (adjusting for region and deprivation). The predictive capability of the 
model was limited, C statistic 0.59 (95% CI 0.58 to 0.59). Multivariable linear regression modelling using 
data from a randomised controlled trial (INSTINCTS) was used to develop a prognostic model 
predicting patient reported outcome at six months. The final model included the baseline Boston 
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Carpal Tunnel Questionnaire score, the symptom severity score, and the absence of any other neck or 
upper limb symptom. The optimism-adjusted model calibrated poorly, overestimating the severity of 
outcome in patients with less severe observed CTS, and underestimating the severity of outcome in 
patients with more severe observed CTS.  
A second systematic review including four RCTs summarised evidence for predictors of treatment 
effect. The results from one trial indicated that the effect of CSI was larger in patients with more severe 
nerve conduction and baseline symptom scores. Exploratory analysis of a small set of a priori defined 
candidate predictors of treatment effect using INSTINCTS data suggested that at six months, CSI was 
less effective than NS in patients with unilateral symptoms compared to those with bilateral CTS. 
However, results need to be carefully interpreted given the lack of significant interaction, the 
possibility of a unit of analysis error and a very small sample size.  
In summary, patients with CTS presented in primary care with increasing frequency between 1993 and 
2013. However, since around 2008, the proportion of patients receiving surgical treatment was 
observed to decrease, despite being considered clinically effective for most patients. Lower rates of 
surgery may be associated with changes in access to the procedure. This highlights the need for optimal 
management to be provided in primary care. Assuming the CPRD population to be representative, at 
least 20% of patients presenting with CTS did not respond well to their initial management in primary 
care. There is likely to be clinical benefit in identifying this group early in the course of their symptoms, 
and explore any differential treatment response, in order to better target treatment to the individual 
and identify those who are likely to require surgery. However, the prognostic models developed in this 
thesis performed poorly. It seems that the prediction of CTS is complex and potentially includes 
prognostic factors not measurable in CPRD or trial data. Similarly, no confirmatory evidence was found 
that could be used to match treatment options to individuals. Therefore, patients with CTS can be 
initially managed in primary care using current guidance and should be routinely followed up and 
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1 Background and introduction 
 
Summary 
Carpal tunnel syndrome (CTS) is a common focal compressive neuropathy caused by entrapment 
of the median nerve at the level of the wrist. CTS can be classified into three clinical categories of 
mild, moderate and severe, according to symptom severity. Most research to date has been 
conducted in the moderate to severe categories and within a secondary care setting. However, 
most patients will initially present in primary care, a setting where little research into CTS has 
been conducted. The rationale of this thesis is therefore to investigate the epidemiology, 
prognosis and primary care management of carpal tunnel syndrome, with a view to exploring 
ways in which the treatment of patients presenting in primary care can be improved and 
streamlined.  
This chapter will discuss: the clinical presentation and pathophysiology of CTS; available evidence 
with regards to its epidemiology across all healthcare settings; an approach to the diagnosis of 
CTS; treatment options commonly utilised in primary care and the cost implications of CTS. The 
PROGRESS framework, which underpins the structure of this thesis will also be introduced and 
associated terminology defined.  
1.1 Carpal tunnel syndrome 
Carpal tunnel syndrome (CTS) can be defined as,  
“a symptomatic compression neuropathy of the median nerve at the level of the wrist.”1 pg 389 
Clinical symptoms include but are not limited to: pain and/or discomfort in the hand, wrist and 
forearm; paraesthesia and loss of sensation in the median nerve distribution of the hand, a weakened 
grip strength and associated functional loss.2 Whilst there may be no objective examination findings, 
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a positive response to provocation tests (such as Phalen’s or Tinnel’s test) may be elicited and in severe 
cases, thenar wasting may be observed. 
 The history of carpal tunnel syndrome 
CTS was first described by Paget in 1854, whereby two cases of compression of the median nerve, one 
post-traumatic and one idiopathic, and their successful treatment using splinting, were described. 3 
Putnam then published a case series describing 37 patients presenting with certain common features,  
“…these cases agree in presenting as a common symptom a disturbance of the subjective 
sensibility of the skin, giving rise to what is known popularly as numbness, recurring 
periodically, coming on especially at night or very early in the morning.”4 pg 147   
Putnam, influenced by the thinking of Raynaud, hypothesised that the condition was caused by 
acroparaesthesia; an alteration in blood supply to the nerves supplying the affected district. 
Recommended treatments included galvanic current, phosphorus, strychnine, potassium bromide and 
cannabis.4 
In the early 20th century Hunt, Marie and Fox provided an alternative hypothesis for the cause of 
atrophy of the thenar eminence, which at the time was understood to be due to an entirely different 
pathological process to that of the paraesthesia. They described the compression of the motor branch 
of the median nerve as the cause of muscle atrophy. Hunt, Marie and Fox concluded that transection 
of the annular ligament could stop the development of the condition. This conclusion was disregarded 
for the next 30 years, due to the existence of other possible explanations.5 Clinicians had observed that 
motor alternations were often accompanied by sensory changes and hypothesised that this must be 
caused by compression of the brachial plexus at the thoracic outlet. The use of X-rays had recently 
been developed (1895), prompting cervical ribs to be targeted as the cause of compression, as they 
represented a visible anatomical anomaly in some patients with CTS. As a result, removal of the cervical 
rib became the most common treatment of CTS in the first 40 years of the 20th century.5 
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Learmonth published the first description of carpal tunnel release (CTR) surgery in cases of post-
traumatic compression.6 The open surgical technique remains a successfully used approach, as does 
endoscopic surgery, first described by Chow in 1989.7 
Brain et al. and later Phalen et al. were the first to describe idiopathic CTS from clinical and anatomo-
pathological perspectives. Brain et al described the idiopathic compression of the median nerve being 
frequent in the general population and hypothesised it was due to age-related vascular degeneration 
causing ischaemia and reactive oedema. He further hypothesised that this cycle of ischaemia, oedema 
and compression required CTR to interrupt it.5 Phalen’s series of publications included: a clear 
description of the clinical presentation and diagnostic tests (to include the Phalen’s test); the 
epidemiology of CTS, based on his clinical observations, and a further recommendation of CTR as the 
correct approach to treatment.5 
Simpson published the first paper describing the use of electromyography (EMG) to support the 
diagnosis of CTS in 1956.8 Following the introduction of this investigative technique to quantify the 
level of disruption to neural function, little has changed in the approach to diagnosing, investigating 
and treating CTS: Phalen’s test is still commonly used in diagnosis; EMG in its investigation and surgical 




 Anatomy of the carpal tunnel  
 
The anatomy of the carpal tunnel is presented in the transverse and coronal planes in Figure 1-1 and 
Figure 1-2 respectively. The carpal tunnel is described as the space deep to the transverse carpal 
ligament (TCL) (also referred to as the flexor retinaculum or the anterior annual ligament), bordered 
posteriorly by the carpal bones. The TCL extends from the ulnar side of the wrist from both the hook 
of hamate in the distal row of the carpal bones and the triquetrum in the proximal row, to the scaphoid 
and trapezium on the radial side. Running through the carpal tunnel are the median nerve and nine 
flexor tendons including the flexor digitorum profundus (FDP) and flexor digitorum superficialis (FDS) 
tendons to the index, middle, ring and small fingers, as well as the flexor pollicis longus (FPL) tendon.9 




Figure 1-1 Anatomy of the carpal tunnel. Taken from Gray’s 






 Anatomy of the median nerve 
The median nerve originates from the brachial plexus. After entering the axilla it courses with the 
brachial artery into the cubital fossa. It gives off an articular branch as it passes the elbow joint. The 
nerve then arises from the cubital fossa and passes through the forearm giving off the anterior 
interosseous branch and palmer cutaneous branch. The palmar cutaneous branch of the median nerve 
supplies the cutaneous skin of the palm and usually arises approximately 6cm proximal to the 
transverse carpal ligament, so does not pass through the carpal tunnel. Sensation to the palm is 
therefore not usually affected in CTS, which, by definition, is caused by compression of the median 
nerve within the carpal tunnel. After passing through the carpal tunnel the median nerve gives rise to 
the: 
Figure 1-2 Anatomy of the carpal tunnel. Taken from Gray’s 
Anatomy, initially published 1918. Copyright lapsed. 
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• Digital cutaneous branches to the common palmer digital branch and the proper palmar digital 
branch, which classically provides sensory innervation to the three radial digits and the radial 
half of the 4th digit (see Figure 1-3) 
• Motor innervation to the thenar eminence, first and second lumbricals (abductor pollicis 
brevis, opponens pollicis and flexor pollicis brevis) and the radial two lumbricals.  
Motor deficit caused by compression of the median nerve at the carpal tunnel therefore includes 
weakness in abduction and opposition of the thumb and can effect grip strength.10, 11  
Figure 1-3 Sensory innervation of the hand ©Keele 2013 
 
 Pathophysiology 
The pathophysiology of CTS is likely to involve mechanical trauma within the carpal tunnel and a 
subsequent increase in pressure on and ischaemic injury to the median nerve.11 
1.1.4.1  Mechanical trauma and increased pressure 
Activities involving repetitive flexion and extension of the wrist are implicated in the pathological 
mechanism of CTS, with experimental work suggesting the greater the duration and level of pressure, 
the greater the dysfunction of the nerve.12 
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The normal pressure of the carpal tunnel lies between 2 and 10 mmHg.11 Pressure can be exerted on 
the median nerve within the carpal tunnel by interstitial fluid and direct contact from adjacent tissues. 
Thickening of the synovium results from the effect of an increase in interstitial pressure whilst 
repetitive flexion and extension of the wrist creates the effect of direct contact pressure. The pressure 
of the carpal tunnel increases by 10-fold on wrist flexion and 8-fold on wrist extension. Wrist extension 
causes the volar carpal ligament to compress the carpal contents against the carpal bones. Increased 
pressure during wrist flexion is due to pressure from the TCL compressing the flexor tendons and bursa 
against the radial head.13 
1.1.4.2 Nerve injury  
The mechanism of nerve injury can be described as being acute or chronic. Acute compression 
neuropathies occur when there is a sudden increase in pressure causing the capillaries in the vasa 
nervorum to collapse, leading to subsequent ischaemia and a physiologic conduction block. This is 
rapidly reversible with a quick return to normal conduction once the compression is removed. Likely 
symptoms include short lived paraesthesia and numbness.  
Chronic compression models are more relevant to entrapment neuropathies such as CTS and occur 
when there is a prolonged increase in pressure. Observations made during carpal tunnel release 
surgery (CTR), indicate the median nerve is often thinned in the area of entrapment with swelling of 
the nerve at the proximal edge of entrapment. Reasons for this observed swelling include: an 
accumulation of axoplasm, reactive neural oedema and fibrosis following chronic inflammatory 
changes.13 
A feedback loop consisting of prolonged compression of the endoneural capillary system, subsequent 
changes in the blood nerve barrier, ischaemia and local metabolic changes ensues. This process leads 
to axonal degeneration and further inflammatory response, which then exacerbates the cycle of 




1.2 The epidemiology of carpal tunnel syndrome 
 Prevalence and incidence 
CTS is the most frequently presenting of the entrapment neuropathies14 and many studies have sought 
to define its prevalence and incidence. Such epidemiological studies have been diverse in their 
approach to the populations studied and case definitions of CTS applied.15 
There is no ‘gold standard’ method of identifying CTS and no consensus on the most appropriate 
research case definition.16 A systematic review by Boocock et al identified seven different research 
definitions of CTS proposed in the literature.17 Descatha performed a comparison study to assess the 
agreement between the various definitions used to define CTS, by classifying 1107 newly hired workers 
by each case definition. The Kappa statistic was used to measure agreement between the definitions. 
The prevalence of CTS ranged from 2.5% to 11% with the percentage of misclassification between 1 to 
10%. Levels of agreement between the definitions was described by the author as acceptable (Kappa 
0.30 – 0.85). Despite acceptable agreement, the different definitions lead to a substantial range in 
reported prevalence.18  
Table 1-1 below summarises studies that have reported a prevalence or incidence estimate for CTS to 
allow comparison of the study method and case definitions used, up until the time period described 
by the study presented in this thesis (2013). Table 1-2 further summarises the reported prevalence and 
/ or incidence by gender, where available. Of the 15 studies identified, 11 used clinical codes recorded 
by a clinician at consultation or a clinical diagnostic approach to define an episode of CTS. The 
remainder required additional electrophysiological confirmation or were based on nerve conduction 
study (NCS) findings to elicit a CTS diagnosis. The reported prevalence ranged from 3720 to 5700 per 
100,000 person years (12 studies). The reported incidence was less stable and ranged from 72 to 8200 
per 100,000 (3 studies). 
Of note, the most recent study set in UK primary care, utilised data from between 1992 and 2000.19 
The commissioning of services requires current evidence. Updating the data to describe the current 
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prevalence and incidence of patients presenting in primary care with CTS would therefore be of use to 
policy makers to help plan and commission services appropriately.  
10 
 
Table 1-1 Comparison of population studies reporting the prevalence and / or incidence of carpal tunnel syndrome 
Study Identifier Study method Definition of CTS Comments 
De Krom et al. 1992 
 
Survey of a random age sex stratified 
sample of the general population taken 
from the population register of Maastricht 
between 1983 and 1985 
Questionnaire based on symptoms and signs  
Ferry et al. 1998 i) Cross sectional survey to estimate the 
point prevalence of hand symptoms (from 
a random sample of 1000 individuals from 
the UK general population, aged 18 to 75 
years) and  
ii) nerve conduction testing of a weighted 
sample 
- Circa. 1998 (not stated) 
- point prevalence determined 
Based on nerve conduction studies using 
defined cut offs 
Subjects over 54yrs had a higher prevalence 
than younger participants. No difference 
between genders was noted. 
Nordstrom et al. 1998 Prospective study conducted in the general 
population of the Marshfield Epidemiologic 
Study Area, Wisconsin, between 1991 and 
1993 
1. any diagnosis of possible, probable or 
definite CTS; 
2. any diagnosis of probable or definite CTS; 
and 
3. any diagnosis of possible , probable or 
definite CTS plus at least one of six clinical 
signs 
A 3.5 fold increase in CTS incidence was noted 
compared with data from 20 years previously in 
the same study population 
Atroshi et al. 2000 Survey of a random sample of the age sex 
stratified general population of Southern 
Sweden, in 1997 
Diagnosis based on clinical examination and 
positive electrophysiological findings 
The population prevalence of symptoms was 
14.4%; the prevalence of clinically and 
electrophysiologically confirmed CTS was 2.7% 
Papanicolaou, McCable & Firrell 2001 Cross-sectional study to evaluate 
prevalence of carpal tunnel syndrome in 
the General population of the United 
States  
Katz hand diagram After correcting for nonresponders the lowest 
possible estimate of CTS was 3.72% 
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Mondelli, Giannini & Giacchi 2002 Prospective study of patients referred to 
four electrodiagnostic laboratories in the 
Siena area, Italy. 
Mean annual incidence calculated from 
time period 1991 to 1998 
Diagnosis based on clinical history and 
electrodiagnostic evidence of a reduced 
distal conduction velocity of the median 
nerve (American Academy of Neurology 
standards) 
Of the patients presenting 79.7% were women. 
The mean age at diagnosis was 55.0 +/- 14.4 
years (range 16 to 97) 
Bland, Rudolfer 2003 Prospective collection of 
neurophysiological and clinical data of 
patients referred to two electromyography 
clinics in the UK between 1991 to 1993 and 
1992 to 2001  
Based on nerve conduction studies using 
defined cut offs 
An increase in diagnosed cases was observed 
between the two data collection periods; 
attributed to referral of milder cases. Median 
nerve impairment was more severe in the 
elderly and men at all ages. 
Latinovic, Gulliford & Hughes 2006 Population study based in a general 
practice database of consulting primary 
care patients from 253 practices between 
January 1992 and 31 December 2000. 
Read and OXMIS codes for carpal tunnel 
syndrome  
Most frequent in women aged 45-54. In 2000 
operative treatment was undertaken for 31% of 
incident CTS presentations 
Bonger et al. 2007 Analysis of the first and second Dutch 
National Survey of General Practice, 
conducted in 1987 and 2001 
International Classification of Primary Care 
coded diagnosis 
A crude increase in incidence over time was not 
statistically significant after subdividing by age 
and sex. Incidence rates were related to the job 
level in women, but not men 
Dieleman et al. 2008 Population study based in a general 
practice database (Integrated Primary Care 
Information database): data of consulting 
primary care patients in the Netherlands 
between 1996 and 2003 
ICPC coded diagnosis Neuropathic pain was noted to affect almost 1% 
of the population. Mononeuropathies and 
carpal tunnel syndrome were the most common 
causes 
 
Gelfman et al. 2009 Analysis of medical records linkage system 
1981-1985 to 2000-2005 of residents of 
Olmsted County, Minnesota (Rochester 
Epidemiology Project) 
Clinical coding with a sample verified by full 
record review 
An increase in incidence was observed over the 
study period. An increase in young individuals 
seeking care for less severe CTS in the mid-
1980’s was followed in the 1990’s by an 
increasing incidence in older people  
Atroshi et al. 2011 Analysis of the Skane Health Care Register 
(inhabitants presenting to public health 
Physician diagnosed  
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providers), incident cases identified 
between 2006 - 2008 
Jenkins et al. 2012b Prospective audit of  patients referred to a 
regional hand service based in secondary 
care in Scotland between November 2004 
and May 2010 
Symptoms of pain or paraesthesia in the 
median nerve distribution and one or more 
of: nerve conduction deficit, thenar muscle 
wasting or positive Tinel’s or Phalen’s sign 
Mean age of presentation 55.1years (range 22 
to 96, SD 13.5 years). 
Mean body mass index at presentation 29.5 
kg/m2 
CTS more common in: females (OR 1.9, 95% CI 
1.5 to 2.5) 
Incidence varied significantly between 
deprivation groups: most deprived 81/100,000 
and least deprived 62/100,000 (OR 1.3, 95% CI 
1.1 to 1.6) 
Jenkins et al. 2013 Prospective audit of patients referred to a 
regional hand service based in secondary 
care in Scotland between November 2004 
and May 2010, who were employed 
Clinical diagnosis based on history and 
examination, in most cases substantiated by 
nerve conduction studies 
The greatest incidence as in caring and leisure 
occupations (197 per 100,000) and the lowest 
incidence was in the associate professional 
group (37 per 100,000) 
Dale 2013 Pooled analysis of six prospective studies 
collecting data from >50 workplaces, over 
variable time frames 
A pooled case definition was derived to 
include clinical and elctrodiagnostic criteria 
7.8% of 4321 subjects studied had prevalent 
CTS, with an additional 204 subjects meeting the 
CTS criteria, leading to an incidence of 2.3 cases 





Table 1-2 Summary of reported incidence and prevalence by gender 




Prevalence or Incidence per 100,000, per annum Female / male ratio 
All Female Male 
De Krom et al. 1992 
 
The Netherlands  
1983 - July 1985  
(Prevalence) 
5700 5800 600 9.66 
Atroshi et al. 2000 Sweden 
1997 
(Prevalence) 
3800 4600 2800 1.64 





3720   4.8 
Ferry et al. 1998 United Kingdom 
Not stated 
(Incidence) 
8200 6400 8200 0.78 
Nordstrom et al. 1998 United States 
1991 - 1993 
(Incidence) 
346 373 318 1.17 
Mondelli, Giannini & 
Giacchi 2002 
Italy 
1991 – 1998 (mean) 
(Incidence) 
276 506 139 3.64 
Bland, Rudolfer 2003 
 
Kent, UK 
1991 - 2001 
(Incidence) 
105 120.5 60 2 
Huddersfield, UK  61.5 30 2 
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 192.8 87.8 2.23 















2001 180 280 90 3.11 
Dieleman et al. 2008 
 
The Netherlands 
1996 - 2003 
(Incidence) 
233.1    
Gelfman et al. 2009 United States 
(Incidence) 
1981-1985 
258 337 177 1.90 
2001-2005 424 542 303 1.79 
Atroshi et al. 2011 Sweden 
2006 - 2008 
(Incidence) 
 428 182 2.35 
Jenkins et al. 2012b 
 
Scotland 
2004 - 2010 
(Incidence) 
72 98 43 2.28 
Jenkins et al. 2013 Scotland 
2004 - 2010 
(Incidence)  
103    
Dale 2013 United States 
(Incidence) 






 Disease associations 
There are many cited aetiological factors associated with CTS including: obesity, occupational and 
recreational hand use20 hypothyroidism, diabetes, autoimmune disease, rheumatological disease, 
arthritis, renal disease, trauma, infectious disease and substance misuse, late pregnancy although this 
usually only presents (transient) symptoms.21 In some instances CTS may be a presenting feature of a 
condition such as diabetes or hypothyroidism but guidelines suggest routinely testing for such 
conditions only when other features lead to clinical suspicion.22, 23 
1.3 Assessing carpal tunnel syndrome 
Whilst there is no universally accepted ‘Gold Standard’ test for identifying a case CTS,16 attempts have 
been made to develop standardised criteria for use in clinical practice and research purpose, based on 
history and examination findings. 
 The clinical assessment of carpal tunnel syndrome 
Rempel et al used a consensus process to develop an approach to CTS diagnosis, for use in 
epidemiologic studies. Whilst the 12 medical researchers who contributed to the exercise felt that the 
ideal scenario for a CTS diagnosis to be made was to have both NCS study findings and symptom 
characteristics present, in the absence of NCS, combinations of symptoms and examination findings 
could be acceptable. Classic / probable CTS was defined as,  
“numbness, tingling, burning or pain in at least 2 of digits 1, 2 or 3. Palm pain, wrist pain, or 
radiation proximal to the wrist is allowed.”24 pg 1450 
The basis for describing the anatomical distribution of symptoms was based on the work by Katz et al, 






Wainner et al in 2005 developed a clinical prediction rule of the likelihood of a CTS diagnosis. They 
performed standardised clinical testing (history, neurological examination, wrist-ratio index and 
provocative testing) on 82 consecutive patients referred for NCS. They used a visual analog scale, the 
Brigham and Women’s Hopsital Hand Symptom Severity Scale and Function Status Scale (also referred 
to as the BCTQ, see below) and the Katz hand diagram25 as self-reported outcome measures. Logistic 
regression identified five test variables (shaking hand for symptom relief, wrist-ratio >0.67, symptom 
severity score >1.9, diminished sensation in the median sensory field and age >45 years) that could be 
entered into the clinical prediction rule to produce likelihood ratios and post-test probabilities of CTS. 
Electrodiagnosis was accepted as gold standard for diagnosis but at the time of publication, the rule 
was still to be validated and tested for usability in a clinical setting.26  
Graham et al developed standardised criteria for the diagnosis of carpal tunnel syndrome (also known 
as CTS-6), using a Delphi technique. The validation process was carried out using the decisions of two 
expert panels as a reference standard for CTS. One panel assessed case vignettes (used in preference 
to patients to maintain objectivity) and gave a binary outcome which was used to produce a logistic 
regression model of the highest-ranking criteria and another panel who estimated the probability of 
CTS in each of the same case histories. The correlation of the model and the panel was 0.71 27 The 
statistically significant (P < 0.05) criteria were: 
• Numbness in the median nerve distribution 
• Nocturnal numbness 
• Weakness / atrophy of the thenar musculature 
• Tinel’s sign positive  
• Phalen’s sign postive 
• Loss of 2-point discrimination.28 
Graham et al suggest that use of the standardised tool could aid epidemiological research by reducing 
the variability in criteria used to identify CTS cases. It was postulated that ‘non experts’ in primary care 





model, into groups that could be treated non surgically, referred for surgery or referred for 
investigation / considered for having an alternative diagnosis.27 
Graham et al went on to validate the diagnostic tool clinically and studied the value added by 
electrodiagnostic testing to the pre-test probability of CTS given by the CTS-6. They found that the 
average change in the pre and post-test probability was between -0.02 and -0.06 depending on the 
electrodiagnostic criteria used. They concluded that for the majority of patients (referred into tertiary 
care) considered to have CTS on the basis of history and examination alone, electrodiagnostic tests did 
not add any further clinically relevant diagnostic information.16 
Guidelines from the American Academy of Orthopaedic Surgeons (AAOS) discuss how the history of 
the presenting complaint and physical examination findings assist in the diagnosis of CTS and can help 
plan management interventions.21 Keith et al reported that after an extensive review of available 
literature, a high level of evidence was not available to assess the diagnostic utility and predictive value 
of such information.21 However, when The AAOS updated their Clinical Guidelines in 2016; this primary 
approach to diagnosis by clinical assessment remained the same.29 Despite a lack of high-level evidence 
for a standardised approach to diagnosis, expert opinion is generally used to suggest that symptoms, 
clinical examination and, in certain situations, electrodiagnosis can be combined to provide a 
satisfactory level of confidence in a CTS diagnosis.21 This review could not however define which 
combination of tests could be used most accurately to identify CTS, due to the small number of studies 
of studies using a variety of case definitions.  
Despite a number of recommendations in the literature, there remain no universally agreed and 
accepted criteria for the definitive diagnosis of CTS in routine clinical use.30 Of note, none of the tools 
described above have been derived from a primary care population. Work prior to this thesis involved 
developing agreed clinical criteria with which to diagnose patients presenting in primary care with CTS, 
for the purposes of entry into a pragmatic randomised control trial, which will be referred to in later 
chapters.31 The questions and associated flow diagram for use in the agreed clinical criteria are 





Figure 1-4 Questions to be asked to a patient presenting with hand or wrist symptoms 
1. Do you have numbness or tingling in your wrist, hand or fingers? 
2. Do your symptoms spare your little finger? 
3. Are the symptoms worse at night? 
4. Do the symptoms wake you up at night? 
5. Have you noticed your hand is weak; for example, have you found yourself dropping things? 
6. Do you find shaking your hand, holding your hand or running it under warm water improves your symptoms? 
7. Are the symptoms made worse by activities such as driving, holding a telephone, using vibrating tools or                     
typing? 
8. Have splints or injections helped with your pain if you have had it in the past? 
 
 
1.3.1.1 Differential diagnoses to consider 
Alternative diagnoses that may be considered in patients presenting with discomfort and / or altered 
sensation in the distal upper limb include: cervical radiculopathy, peripheral neuropathies, 
wrist/trapeziometacarpal arthrosis, wrist tendonitis/tenosynovitis, ulnar neuropathy, Raynaud’s 
phenomenon, arterial injury or thrombosis, nerve laceration, neuroma, brachial plexus injury, other 
© Keele University 2013 





nerve entrapment syndromes, pain syndromes, annular ligament injury, ‘double crush syndromes’ and 
motor neurone disease.21 
 Assessing the severity of carpal tunnel syndrome 
Attempts have been made to formulate standardised clinical criteria with which to assess the severity 
of CTS and likelihood of treatment outcome (i.e. based on the patient’s history and examination 
findings and without the input of further investigations).  
The landmark paper which has influenced much of the more recent literature on the diagnosis, impact 
and outcome of CTS and its treatment was the development of a self-administered questionnaire for 
the assessment of severity of symptoms and functional status in carpal tunnel syndrome (The Boston 
Carpal Tunnel Questionnaire - BCTQ) by Levine et al in 1993.32 The questionnaire was initially 
developed using a clinical consensus exercise. It was then piloted and tested in two cohorts of patients: 
a prospective cohort study for determination of reproducibility, internal consistency, validity and 
responsiveness to change and a separate cohort of surgical patients for responsiveness to change. 
Levine et al concluded that the questionnaire was able to evaluate the course of CTS and the 
effectiveness of operative and non-operative interventions.32  
In order to predict a satisfactory outcome from CTR, Kamath et al. (2003) developed a screening 
questionnaire based on the BCTQ32 and tested the sensitivity of this screening questionnaire (now the 
Stothard questionnaire) in a prospective study of 58 patients referred to an NCS clinic, for 
electrodiagnostic testing. Symptomatic improvement after CTR was used as evidence of the ‘true’ 
diagnosis of CTS. The questionnaire was shown to be 85% sensitive with a positive predictive value 
(PPV) of 90% whereas electrodiagnosis was found to be 92% sensitive with a PPV of 92% in predicting 
response to surgery. It was suggested that the scored questionnaire could replace NCS; where if a 
patient scored more than five, they could be referred directly for surgery, to decrease waiting times 
and save money. The study was carried out in secondary care but the authors felt that it could be used 
by primary care physicians to diagnose CTS, which would be alleviated by surgery. They argue that the 





Atroshi et al also developed a brief measure of symptom severity, derived from the BCTQ. They 
subjected the 11 symptom severity items and 8 functional status items to factor analysis and item 
response theory. By comparison with a validation sample of 213 patients assessed using the 
QuickDASH questionnaire, they proposed a 6-item CTS symptom scale to be used as a brief measure 
of symptom severity.34 
The trial referred to later in this thesis, used criteria presented by the British Society for Surgery to the 
Hand (BSSH) to classify the severity of CTS as being mild, moderate or severe. The following 
classification system was used to include patients with mild and moderate disease and exclude those 
with severe CTS: 
• Mild: intermittent paraesthesia (nocturnal, position of hand, pregnancy, hypothyroidism) 
• Moderate: constant paraesthesia (interference with activities of daily living, constant night 
waking) 
• Severe: constant numbness or pain, wasting of thumb muscles and / or activities of daily living, 
weakness of thumb muscles30 
 Nerve conduction studies  
Nerve conduction studies may be referred to under the umbrella terms of: electrophysiology; 
neurophysiology and electrodiagnosis. These terms can also be used to include electromyography 
(EMG), which involves the study of the motor innervation of muscles. For the purposes of consistency, 
the investigation of nerve conduction in the investigation and diagnosis of CTS will be referred to as 
nerve conduction studies (NCS).  
CTS is a syndrome of signs and symptoms caused by compression of the median nerve in the carpal 
tunnel. Compression leads to demyelination, which reduces the performance of the nerve. The 
electrophysiological performance of a nerve can be quantified by NCS. The velocity of conduction from 





measured. Demyelination causes a reduction in the velocity of nerve conduction. The location of this 
slower conduction indicates where the compression or damage is occurring.  
Electrophysiological measures were first used to define CTS in the 1950’s5 and modern methods of NCS 
have been reported to have a diagnostic sensitivity and specificity level of approximately 95% in clinical 
populations, when compared with direct ultrasound imaging, used as a confirmation of visualised 
nerve compression.35 Early cases of CTS may have higher false negative rates than more severe cases, 
and may therefore be missed by nerve conduction studies.36 
The clinical use of confirmatory testing in CTS remains controversial.2 As already established, CTS is 
essentially a clinical syndrome that may be diagnosed following a good history taking and examination. 
However, the AAOS recommend nerve conduction studies are performed: 
• To differentiate from other potential clinical diagnoses 
• When thenar atrophy / persistent numbness is present, in order to differentiate from other 
peripheral nerve problems and to inform whether more severe nerve injuries require further 
diagnostic evaluation and / or warrant aggressive management 
• If clinical diagnosis is suggestive of CTS and surgical management is being considered. 21  
If NCS are to be used, the AAOS recommend that the testing protocol should follow the American 
Academy of Neurology, American Academy of Physical Medicine and Rehabilitation and American 
Association of Neuromuscular & Electrodiagnostic Medicine (AAN/AANEM/AAPMR) guidelines for 
diagnosis of CTS: 
• Sensory nerve conduction velocity (NCV) studies to the median nerve with distal latency 
compared to the ulnar and radial nerve 
• Median motor nerve conduction in most patients 
• Needle EMG at the physicians discretion.37 
Keith et al’s review of electrodiagnostic tests could not determine that any method was clearly 





situation diagnostic accuracy estimates from case-control studies using well-defined patient groups 
with and without disease, may not be applicable to the clinically presenting population. A further 
systematic review did not recommend NCS if symptoms of CTS are well defined.38 
Most reports acknowledge a diagnostic role for NCS, however the debate remains as to whether they 
are necessary in all cases.39 The Joint Royal College of Surgery and British Orthopaedic Association 
Commissioning Pathway suggest NCS should be a secondary care investigation done when there is:  
• an equivocal clinical examination and history 
• persistent or recurrent carpal tunnel syndrome 
• an unclear diagnosis suggestive of a peripheral neuropathy.40 
 Other modalities of diagnostic investigation 
Diagnostic ultrasound, pressure specified sensorimotor devices, computer aided tomography and 
magnetic resonance imaging have been suggested as diagnostic investigations for CTS. Imaging is not 
routinely performed to establish a CTS diagnosis, however may be used to investigate for differential 
diagnoses. Ultrasound has been shown to be a useful investigative tool as it can detect changes in the 
surface area of the median nerve as it passes underneath the flexor retinaculum.41  
Keith et al concluded that there was no evidence in their review that such investigations currently offer 
superior diagnostic value to current practice and do not recommend them for use in the routine 
evaluation of patients with CTS.21 
1.4 The treatment of carpal tunnel syndrome 
Options for the treatment of CTS can be classified as being either surgical or conservative (non-
surgical). Surgical treatment is usually offered to those with severe CTS, whilst conservative treatments 
are recommended as an initial treatment for those: who have symptoms without evidence of 
denervation of the median nerve; in whom surgery is contraindicated or have intermittent symptoms 





options include local corticosteroid injections (CSI), night splinting (NS), oral steroids, therapeutic 
ultrasound, electromagnetic field therapy, workplace adaptation and traditional cupping.43 The 
majority of these treatment modalities are not routinely available in primary care. CSI and NS form the 
mainstay of interventions in the management of carpal tunnel syndrome, as indicated by national care 
pathways22, 23 and guidelines,40 thus will be the treatment options focused on in this thesis.  
 Wrist splints 
The principle of resting (night) wrist splints is to immobilise the wrist in a neutral position, thereby 
alleviating pressure on the median nerve as it passes through the carpal tunnel. The splint may be worn 
solely at night, when most patients find their symptoms are most severe due to prolonged wrist flexion 
and hence increased pressure in the carpal tunnel, or at night as well as during daytime activities which 
trigger symptoms. Splints are available to purchase over the counter or custom-fitted splints may be 
provided by occupational therapists.44 
Page et al conducted a Cochrane review of randomised and quasi-randomised trials comparing 
splinting with no treatment (or placebo) or with other non-surgical interventions. 19 studies were 
identified, randomising 1190 participants. Concerns with bias were noted regarding allocation 
concealment and blinding. The authors’ conclusions suggest there is limited evidence that night 
splinting is more effective than no treatment in the short term (less than 3 months follow-up). The 
authors also reported insufficient evidence regarding the effectiveness and safety of one splint design 
over another. They did however suggest that evidence is insufficient and that more research is needed 
on the long-term effects of this intervention.42 
Splinting may therefore be a treatment option for some patients but there is limited evidence 
regarding its effectiveness compared to no treatment, other conservative treatment options or 
surgery.  





Local (as opposed to systemic) corticosteroid injections are a common treatment option for mild to 
moderate CTS, or severe cases awaiting surgery and can be administered in primary care by trained 
clinicians.31  
A Cochrane Review evaluating the effectiveness of CSI for CTS versus placebo injection or other non-
surgical interventions concluded that CSI do provide improvement in symptoms after one month, 
although symptom relief beyond this period was not clearly demonstrated.45 Of the 12 studies included 
in the review, seven used methylprednisolone as the injectate at a dose of between 15mg and 40mg.46-
52 Other drugs used in the included studies were: dexamethasone; betamethasone; triamcinolone and 
hydrocortisone. The authors were not able to identify a particular drug or dose of drug as being clearly 
superior.45 A systematic review by Huisstede et al also concluded that evidence of short term benefit 
of CSI exists, but that mid and longer term follow up was required.43 
A more recent RCT not included in the systematic reviews, assessed the clinical effectiveness of 
different doses of methylprednisolone injection in CTS. Three groups (37 patients in each) received 
80mg of methylprednisolone, 40mg of methylprednisolone, or placebo. The mean change in symptom 
severity scores at 10 weeks was greater in the 80mg of methylprednisolone group and the 40mg of 
methylprednisolone group, when compared to placebo (-0.64 (95% CI -1.06 to -0.21; P=0.003) and -
0.88 (95% CI -1.30 to -0.46; P<0.001)) respectively. There was no significant difference between the 
two doses at 10 weeks (0.24 (95% CI 0.24 to 0.69; P=0.29). The only group to show a significant 
reduction in the rate of surgery at 1 year was the 80mg of methylprednisolone group compared to 
placebo (0.24 (95% CI 0.24 (0.06 to 0.95; P= 0.41)). There were no serious adverse events recorded.53 
This trial provides some longer-term data suggestive that steroid injection may be clinically effective 
in reducing symptoms and the number of patients having surgery, but perhaps only at a dose of 
corticosteroid higher than those in regular clinical use. Further research is required to investigate 
whether steroid injections have the potential to reduce the rate of CTR, in the longer term, and at what 
dose.  
Some guidance exists suggesting the inclusion of a local anaesthetic (LA) with the steroid when 





median nerves were randomly assigned to three treatment groups: 40mg of triamcinolone; 4ml of 1% 
procaine and 40mg of triamcinolone and 1% procaine. NCS and a visual analogue scale of symptoms 
were carried out at baseline, two months and six months after treatment. Improvement in some 
electrophysiological measures and the visual analogue scale were noted in all groups at two and six 
months (P<0.05). The only significant differences noted between groups were an improvement in 
some electrophysiological findings and visual analogue scale results in the combined group when 
compared with procaine alone at two and six months (p<0.05). There was no comment regarding 
patient acceptability or cost.54 There appears to be clinical consensus within the literature that 
additional local anaesthetic does not add any clinical benefit to the procedure, but likewise is unlikely 
to cause harm.   
 Comparison of splinting versus corticosteroid injection and rationale for further study 
in this area 
CSI and NS, the two mainstay treatment modalities used by clinicians and patients in a primary care 
setting, had been compared in three randomised control trials, other than the INSTINCTS trial, which 
will be discussed later in this thesis. 55-57 Sevim et al evaluated the effectiveness of CSI and NS in mild 
and moderate CTS. 120 patients with electrophysiologically confirmed CTS were randomised to either 
night splinting (60 patients), or beclomethasone injected proximally to the carpal tunnel (30 patients) 
or distally to the carpal tunnel (30 patients). After one year, clinical symptoms and NCS results were 
evaluated. The trial excluded patients who were non-compliant with splinting but suggested that the 
compliant cohort showed significant clinical and electrophysiological improvements whilst the 
injections groups did not.55 Ucan compared the use of splinting, splinting plus local steroid injection 
and open CTR in patients with mild to moderate CTS with symptoms (and an electrophysiological 
diagnosis) for at least six months. The 57 hands included in the study were randomised to one of the 
three treatments (23 received injection, 23 received injection plus splinting, and 11 received CTR). 
Follow up was at three and six months with NCS, BCTQ and a patient satisfaction questionnaire. At 3 





electrophysiological outcomes, however at six months both measures deteriorated in the steroid and 
steroid with splinting group, whilst the CTR group continued to improve (BCTQ functional score 
P=0.03).56 So et al also compared the efficacy of CSI with NS in 50 patients with CTS diagnosed using 
AAN criteria. They reported that at 4 weeks, both the CSI and NS groups showed an improvement in 
the symptom severity scale of the BCTQ (-0.670 +/- 0.614 and -0.38 +/- 0.475, P= 0.07 respectively), 
however only the CSI group showed improvement in their function and patient satisfaction score.57   
These trials were relatively small and set in a secondary care environment using case definitions which 
included NCS findings. Ucan et al did not aim to compare splinting with injection alone.56 It is therefore 
unlikely that these trials present robust evidence of the effectiveness of splinting versus injection 
generalisable to the primary care population, where patients can be assumed to present in the earlier 
stages of the condition and are more likely to have a milder symptom profile (if being treated as 
opposed to referred directly into specialised services). Clinicians are therefore unable to base their 
decisions as to which intervention is most appropriate on robust trial evidence. The INSTINCTS trial 
(Injection versus Splinting in Carpal Tunnel Syndrome) was designed to contribute to this evidence.58, 
59 
INSTINCTS was a pragmatic randomised clinical trial, recruiting from a primary care population, in 
order to further establish the comparative effectiveness of six weeks of night resting splint use  with a 
single steroid  injection.58 As explained further in Chapter 2, this thesis will utilise data from the 
INSTINCTS trial to describe the prognosis of the trial population, develop a prognostic model predicting 







 Carpal tunnel release surgery 
Carpal tunnel decompression or release surgery (CTR) is a well-established treatment for CTS. It is 
considered to be the most effective treatment to alter the relationship between the median nerve and 
the carpal tunnel.2 CTR is routinely carried out under local anaesthetic as day case surgery. Open and 
endoscopic approaches can be used to release the flexor retinaculum. Adjuncts to the release include 
a tenosynovectomy, neurolysis of the median nerve and lengthening or reconstruction of the flexor 
retinaculum.60 A Cochrane review of surgical approaches did not find that either technique was more 
successful than the other and concluded the decision to use an open or endoscopic approach should 
be guided by surgeon and patient preference rather than evidence.61 
Patient satisfaction with the outcome of surgery appears high.2 A review of the surgical treatment of 
CTS reported that 70% - 90% of patients undergoing a CTR report a good outcome.62 A retrospective 
cohort study observing patients after CTR for a mean of 13 years described that 88% of patients were 
either completely satisfied or very satisfied with their post-operative outcome. 74% reported their 
symptoms had completely resolved and 1.8% (113 patients) had undergone repeat surgery.63 Surgery 
does carry a risk of complications including damage to nerves, arteries, tendons and the development 
of complex regional pain syndrome. Complication rates have been reported to be between 1 and 25% 
of patients.2 Surgery should not therefore be considered a benign treatment option. 
A systematic review by Turner et al, summarised predictors of an adverse surgical outcome and found 
prognostic factors included: diabetes; poor health status; thoracic outlet syndrome; double crush 
syndrome; alcohol misuse; normal nerve conduction studies; neurolysis; thenar wasting and workers 
compensation cases.62 
CTR provides an effective mode of therapy for patients who have failed to respond to conservative 
treatment or who have severe CTS.23 There is little evidence however that CTR is an appropriate initial 
management option for patients presenting in primary care with mild to moderate symptoms, 
especially in the absence of high-quality trial evidence that conservative management is ineffective. 





effective management approach for all patients, if the much cheaper options are shown to be effective. 
In fact, commissioners are restricting access to referral and surgery in some healthcare localities due 
to this64 and more robust evidence of the effectiveness and correct use of primary care options is 
required to potentiate benefits, reduce potential harms and maintain a cost effective approach to the 
primary care management of CTS.  
1.5 The costs implications of carpal tunnel syndrome 
The economic burden of CTS is likely to be high. An estimated $2 Billion is spent on the 400,000 to 
500,000 cases of CTS treated with surgery in the United States each year.65 CTS is a recognised 
occupational health condition and as such impacts upon the financial situation of workers and the 
workplace. Data from the US suggests the median number of days per person away from work due to 
CTS, when compared to other occupational and major disabling illnesses and injuries, is relatively high 
at 27 days.66 
Hospital Episode Statistics, publicly available NHS healthcare data,67 provide an estimate of the number 
of CTR’s in an annual period. In England in 2012-13, 48,705 completed consultant episodes were 
recorded (mean age 59 years).67 This figure underestimates the total number of contacts patients had 
with specialists as the data do not include patients having CTR in the community, as is becoming more 
common place, whereby trained GP’s and allied health professionals are delivering surgical 
interventions in appropriate primary care settings.  This further highlights the need for more research 
to be based in these evolving settings. 
Miranda et al 2013, suggest an overall treatment cost for a patient having a CTR in their NHS Trust 
(including consultation) to be £877.60 (+/- £4.01).68 If this is taken to be representative of the rest of 
the English population in 2013, an estimated £42,743,500 would have been spent in one year, on 
patients having CTR surgery.  
Miranda et al further provide a helpful estimation of patient burden and cost when considering 





in their cohort experienced long term relief from conservative management whilst 62% progressed to 
surgery with an average symptom duration of 8 month (from initial clinic consultation). The authors 
did not identify any difference in treatment costs between groups (£824.82 +/- £49.79 injection group 
versus £877.60 +/- £4.01 surgery group, P=0.29) but did observe that patients who initially received 
conservative management required more clinic appointments and were treated for longer periods. 
Their entire surgical cohort reported long-term relief, leading them to conclude that although 
injections are an important first-line treatment; this is likely to be limited to particular patient groups.68 
It should also be recognised here that the figures quoted for patients receiving an injection include the 
mean number of outpatient appointments required and that the cost of a local corticosteroid injection 
to the department was £5.18.68 
Conservative management in the community is not considered in these costings and as such 
substantial cost saving may be possible if referral and indeed surgery can be avoided by effective 
primary care management.  
1.6 The prognosis of carpal tunnel syndrome 
The prognosis of CTS, particularly in the presenting primary care population, has not been clearly 
established. A frequently cited study by Padua et al (2001) described the course of untreated CTS over 
a 10 to 15-month follow-up period. 196 patients who had not received treatment (274 hands) were 
assessed at baseline using clinical and electrophysiological methods. 27% of patients improved 
according to their electrophysiological classification and 34% improved symptomatically. The authors 
found clinical and electrophysiological measures improved more in patients with more severe initial 
impairment compared with those with milder initial impairment. The main predictors of a satisfactory 
clinical outcome were: a shorter symptom duration and younger age. Bilateral symptoms and a 
positive Phalen’s test predicted poorer outcome.69 
The outcome of surgically managed CTS will not be discussed in this thesis, but few studies have 
observed the prognosis of conservatively managed CTS and none of these have been set in the primary 





1.7 An introduction to the PROGRESS Framework 
Prognosis has its etymological roots in the Greek pro – ‘before’ and gignōskein 'know'.70 Prognosis 
therefore means foreseeing, predicting or estimating the likelihood of future events. Prognosis 
research can be defined as:  
“…the investigation of future outcomes (endpoints) among people with a given baseline health 
state (startpoint), in order to improve health.”71pg 1  
Overall prognosis research thus focuses on the average course of health-related conditions in groups 
of people.71 Prognosis research is important for a number of reasons: it shapes the  development of 
public health policy; allows research into the comparative effectiveness of health services; informs the 
development of potential new interventions and the trials required to test these; moves from the 
limitations of a diagnostic medical model to a prognostic one and can identify new conditions or 
phenotypes.71 
The systematic reviews and empirical studies presented in this thesis will follow the PROGnosis 
RESearch Strategy (PROGRESS) Framework. This Framework includes four distinct but related research 
themes. The definition and underlying principles of these themes were developed by members of the 
Medical Research Council (MRC) funded PROGRESS Partnership, with the aim of, 
“…explaining how [each of these four prognosis research themes] provide important evidence 
that can be used at multiple (translational) pathways toward improving clinical outcomes—
from the discovery of new interventions, through to their evaluation and implementation in the 
clinical management of individual patients, and to examining the impact of interventions and 
healthcare policies on patient outcomes.” 71 pg 2 
These four research themes will be described in further detail throughout the thesis but in summary 
are: 






II. Prognostic factor research: where a prognostic factor is any measure that is associated with a 
subsequent outcome, prognostic factor research examines the impact of such prognostic factors on 
overall prognosis.72 
III. Prognostic model research: where a prognostic model includes multiple prognostic factors in 
combination to predict the risk of a future outcome, prognostic model research moves from predicting 
average risk to predicting the risk of an outcome at the level of the individual.73 
IV. Stratified care research: where stratified care refers to the targeting of treatments according to 
baseline characteristics shared by a subgroup of patients, stratified care research aims to identify 
priority areas for stratification, identify predictors of treatment response and examine the effect of 
stratified care approaches in healthcare.74 
These research themes will be followed in order to describe the overall prognosis of CTS, identify 
factors that predict its outcome and work to develop models that predict outcome for individuals. Data 
from a randomised trial will be used to explore whether a stratified approach may improve outcomes 
in patients with CTS treated conservatively in primary care.  
1.8 Summary 
CTS is a common condition causing distressing symptoms and functional deficit, as well as placing 
potential financial burdens on patients and the wider healthcare and socioeconomic environments. 
There is debate surrounding the methods used in its diagnosis. Prognosis is unclear, particularly for 
those patients treated conservatively. The initial management of CTS is likely to occur in primary care 
where the most common interventions are CSI and NS. More severe cases or those not responding to 
conservative approaches are likely to be treated surgically. There is some suggestion that referrals for 
and episodes of surgery are increasing. 
Most research to date investigating the epidemiology, prognosis and management of CTS, has taken 
place outside of the primary care setting in patients with more severe disease. Chapter 2 will present 





the epidemiology, prognosis and non-surgical management of carpal tunnel syndrome, in primary care 







2 Aims, objectives and study design 
 
Summary 
This chapter presents the aims, objectives and methodological overview of the thesis. A 
summary of the overall structure, together with a brief outline of individual studies and 
chapters, is provided. 
2.1 Thesis statement 
CTS is a common condition affecting the distal upper limb, which can cause distressing symptoms and 
functional deficit. Current understanding regarding the epidemiology and prognosis of CTS, with 
specific focus on patients presenting in primary care, is lacking. Treatment options that can be 
delivered to patients in the primary care environment exist; yet guidance as to who is likely to fail to 
respond and / or require surgery is not available. As such, new evidence is required to explore ways in 
which treatments may be best targeted to individuals in order to improve clinical outcomes but also 
to identify patients who are more likely to require referral for consideration of surgery. 
2.2 Aims and objectives 
The initial aim of this PhD was to update the evidence describing patterns in the prevalence, incidence 
and management of CTS presenting in UK primary care and to estimate the proportions of patients 
receiving treatment in its various forms over time. Secondly, the studies in this thesis aimed to improve 
the primary care management of patients with CTS by identifying patients who are likely to respond 
to the different treatment options available in primary care and predict which patients are less likely 
to respond and eventually need surgery.  





1a.  Estimate trends in the annual prevalence and incidence of CTS diagnosed in primary care between 
1993 and 2013 
1b.  Estimate trends in healthcare use of patients with CTS between 1993 and 2013 
2a. Summarise available evidence regarding the course of conservatively managed CTS and the 
predictors of its outcome  
2b.  Develop a prognostic model to predict poor outcome in conservatively managed CTS, as defined 
by (the first occurrence of) carpal tunnel release surgery, in a cohort of patients identified in the 
Clinical Practice Research Datalink 
2c.  Develop a prognostic model using individual patient data from a randomised controlled trial to 
predict future change in patient-reported CTS-symptoms following primary care management  
3a.  Summarise available evidence regarding predictors of response to common primary care 
treatments of CTS; in particular corticosteroid injection and night splinting  
3b.  Investigate if a priori defined candidate predictors of treatment effect (effect modifiers), predict 
a better outcome from either corticosteroid injections or night splinting in primary care patients 
with CTS 
2.3 Methodological overview 
To address the overall study objectives, the following designs and their corresponding PROGRESS study 
type were: 
1a:  Epidemiological analyses over time (using the Clinical Practice Research Datalink) to estimate 
prevalence and incidence of CTS 
1b: Cross-sectional analyses over time (using the Clinical Practice Research Datalink) to describe 





2a: Systematic literature search and narrative synthesis of cohort studies to summarise available 
evidence regarding the overall prognosis and predictors of future outcomes in patients with CTS 
treated conservatively (PROGRESS I & II) 
2b:  Retrospective cohort study using population data from the Clinical Practice Research Datalink to 
develop a model predicting treatment of CTS with carpal tunnel release surgery (PROGRESS III) 
2c: Prospective analysis (prognostic model study) of individual participant data from a randomised 
controlled trial (secondary analysis of the INSTINCTS trial) (PROGRESS III) 
3a:  Systematic literature search and narrative synthesis of trials to summarise available evidence 
regarding predictors of response to treatment (local corticosteroid injection and night splinting) 
in patients with CTS (PROGRESS IV) 
3b: Subgroup analysis of data from a randomised controlled trial to explore a priori defined predictors 
of treatment effect (local corticosteroid injection and night splinting) (PROGRESS IV) 
2.4 Thesis structure  
This thesis is divided into the following 9 chapters:  
1. Introduction 
This chapter provides an overview of CTS as a clinical condition. A background of its pathophysiology, 
clinical diagnosis and management is presented. The chapter contextualises CTS as a common 
bothersome condition with a paucity of evidence regarding its management in a primary care setting. 
The concept of the PROGRESS Framework is introduced. 
2. Aims, objective and study design 
3. The epidemiology of CTS: Trends in the prevalence, incidence and surgical management of carpal 






The prevalence and incidence of CTS in the UK primary care population over a 20 year period are 
described, using data from the Clinical Practice Research Datalink (CPRD). The proportion of prevalent 
patients receiving interventions, including CSI and CTR, for each annual period between 1993 and 2013 
are presented. Joinpoint regression is used to indicate significant changes in trends over time. 
4. The prognosis of carpal tunnel syndrome: The clinical course and prognostic factors in 
conservatively managed carpal tunnel syndrome - a systematic review and narrative synthesis of 
cohort studies 
Following a systematic search of the literature, this chapter provides a summary of the evidence 
regarding the clinical course of patients with CTS managed conservatively and identifies predictors of 
poor outcome. 
 
5. The prognosis of carpal tunnel syndrome: Predicting surgical intervention in patients presenting 
with carpal tunnel syndrome in primary care – a cohort study set in the Clinical Practice Research 
Datalink 
A cohort derived from patients identified in chapter 3 is observed over a three-year period. 
Candidate predictors identified in the literature and through clinical consensus are used to develop a 
Cox regression model predicting surgical intervention.  
 
6. The prognosis of carpal tunnel syndrome: Describing the course of symptoms and predicting outcome 
in patients with carpal tunnel syndrome receiving conservative management as part of a randomised 
controlled trial (Injection versus Night Splints in Carpal Tunnel Syndrome) 
Candidate predictors tested in chapter 5 are limited by the need for them to be identifiable in 
consultation data. Further candidate predictors identifiable in clinical trial data are tested and used to 






7. The management of carpal tunnel syndrome: Matching patients to treatments in carpal tunnel 
syndrome - A systematic review and narrative synthesis of trial evidence 
In order to identify candidate moderators to be tested in chapter 8, a systematic search of clinical trials 
is conducted and evidence of potential moderators, as targets for inclusion in a sub-group analysis, 
described. 
8. The management of carpal tunnel syndrome: Testing predictors of the effect of treatments for carpal 
tunnel syndrome in primary care – An exploratory analysis of data from the INSTINCTS (Injection versus 
Night Splints in Carpal Tunnel Syndrome) trial 
An exploratory analysis of data from the INSTINCTS trial was conducted to explore the potential 
moderating effect of a small number of candidate predictors. 
9. Summary, discussion, implications and conclusions 
An overall summary and synthesis from each element of the thesis are presented. The clinical 
implications are described and recommendations for future research discussed. 
2.5 Illustration of the thesis plan 
Figure 2-1 below provides an illustrated overview of the chapters, study type, setting and their 
correspondence to the PROGRESS research framework.75
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•Chapter 3: Cross-sectional analyses 
over time (incidence, prevalence, 
treatment)
Epidemiology
•Chapter 4: Systematic literature search 
and narrative synthesis (Type I & II)
•Chapter 5: Predicting surgical 
intervention using EHR data (Type III)
•Chapter 6: Predicting course of CTS 
symptoms in trial participants (Type III)
Prognosis
Type I: overall prognosis
Type II: prognostic factor research
Type III: prognostic model research
•Chapter 7: Systematic literature 
search and narrative synthesis 
(Type IV)
•Chapter 8: Exploratory 
subgroup analysis of trial data 
(Type IV)
Management
Type IV: predictors of treatment 
effect
 
Plan of thesis according to: 
• Research type (PROGRESS framework)* 
• Study method 





Study Setting: Clinical Practice Research Datalink Scientific literature INSTINCTS trial data 










This chapter has presented the aims and objectives of this thesis and outlined the study designs and 
methodological approaches utilised. The overall thesis structure has been summarised. Chapter 3 will 
present epidemiological studies, using consultation data from primary care, to describe the trends in 
the prevalence, incidence and management of CTS over time. This in turn will contextualise the 







3 The epidemiology of carpal tunnel syndrome: trends in the 
prevalence, incidence and management of carpal tunnel syndrome 
between 1993 and 2013 - an observational analysis using the Clinical 
Practice Research Datalink 
 
 Summary 
The aim of this chapter is to describe the epidemiology of CTS in the setting of UK primary care. 
Firstly, the trends in the annual prevalence and incidence of CTS diagnosed in primary care 
between 1993 and 2013 are estimated. Secondly, trends in the health care use of these 
patients are described. Joinpoint regression is used to identify and quantify significant changes 
in any trends identified.  
The work in this chapter has now been published in a peer-reviewed journal under a Creative 
Commons License. Images have been reproduced with permission:  
Burton CL, Chen Y, Chesterton LS, van der Windt DA. Trends in the prevalence, incidence and 
surgical management of carpal tunnel syndrome between 1993 and 2013: an observational 
analysis of UK primary care records.BMJ Open 2018;8:e020166 
 
3.1  Introduction 
Prevalence is an absolute measure of the frequency of an existing disease in a given population at a 
point in or over a period of time. Prevalence estimates can help to inform healthcare planners about 
the needs of their community and calculate the levels of service required. The incidence of a disease 
indicates the proportion of newly developed or diagnosed cases of a disease and is a useful measure 
in analytical research when studying trends.76, 77 Quantifying the burden of CTS in patients presenting 
in a primary care setting and describing their management will help to contextualise the subsequent 





 Using electronic health records in research 
General practice consultation databases, which hold electronic patient records, are of growing 
importance in research as they provide data on healthcare use from large samples, generally accepted 
to be representative of the UK population.78, 79 A number of national anonymised sets of routinely 
collected consultation data now exist including: the Clinical Practice Research Datalink (CPRD); the 
Health Improvement Network (THIN); the SAIL Databank and QResearch.79, 80 There are also regional 
databases such as the Consultations in Primary Care Archive (CiPCA), which are based on a smaller 
number of general practices.(Jordan et al. 2006)  
Over 98% of the UK population are registered with a General Practitioner (GP).81 GP’s and other 
primary care practitioners are the first point of contact for most patients presenting with non-
emergency health-related issues. Patients can be referred from primary to secondary or other 
specialist care, if felt appropriate. The levels of care in the NHS can be described as service tiers: Tier 
1 refers to primary care; Tier 2 is a combination of some specialist services and some community-based 
services (e.g. a community based physiotherapist managing patients in a primary care setting); Tier 3 
is a multi-disciplinary outpatient team (e.g. an extended scope practitioner managing patients in a 
community based musculoskeletal clinic), based in the community and Tier 4 refers to specialised 
services based in secondary care (e.g. an orthopaedic surgeon managing patients in a hospital 
outpatient clinic). GP’s can be considered to be the ‘gatekeepers’ of the UK National Health Service 
NHS).82 
The electronic information held in consultation databases relate to patients and their interactions that 
have taken place in general practice, for example: demographic information; prescription details; 
symptoms; diagnoses; tests and immunisations as well as referral data and data collected from 
secondary care correspondence (usually key diagnoses and treatments). Databases can therefore be 
considered to represent current and previous healthcare activity and have therefore been used as the 





trends; health economic analyses; prognosis research; comparative effectiveness research and 
randomised controlled trials.82 
 The use of codes in general practice consultation data 
Coded clinical terms are used to define episodes of care and should be used to record patients’ 
interactions on the computer systems used in primary care, such as EMIS (Egton Medical Information 
Systems Ltd). Codes allow patient information to be captured, stored and retrieved in clinical language.  
The ever-expanding library of clinical terms used in practice can be assigned Read codes and include: 
categories of signs and symptoms, treatments and therapies, investigations, occupations, diagnoses 
and appliances. Read Codes therefore make up a hierarchical ‘thesaurus’ of terms, stored by the 
computer. In practice, clinical staff are expected to enter at least one morbidity code for each patient 
contact. 
Other coding systems do exist. Oxford Medical Information Systems (OXMIS) codes were developed 
concurrently with Read codes in the 1980’s, however these have since been mapped to their Read 
code equivalents, which have been used almost exclusively by UK based GP’s since the mid 1990’s. 
Read Codes (CTV3) have since been merged with the College of American Pathologist’s SNOMED RT 
(Reference Terminology) to form SNOMED CT (Clinical Terms).83 SNOMED CT is currently being phased 
in across primary care and should be applied across the NHS before April 2020.84 
 The quality of general practice consultation data 
For research set in consultation databases to be valid, the clinical information they contain needs to 
be of consistently high quality. CPRD, stipulates data quality criteria for patients (acceptable ‘research 
useable’ patients) and for practices (‘up to standard’ data) to be fulfilled. A hierarchy of data quality 
exists. Objectively recorded information such as prescriptions being the most accurate. Quality then 
decreases as coding becomes more subjectively applied, as found in the coding of diagnoses and the 
recording of lifestyle / socio-economic data.79 Whilst entry standards are imposed on practices, 





A systematic review of 49 studies based in consultation data by Khan et al, which commented on the 
validity, accuracy, concordance and recording of terms, showed that most diagnoses coded in CPRD 
were well recorded with a positive predictive value of 80% or above. However, acute diagnoses (e.g. 
acute liver failure) were found not to be as well recorded.85 The review further identified differences 
in date between actual and coded diagnoses, which whilst small led the review authors to recommend 
that such discrepancies be considered when observing time dependent outcomes.85 
Jordan et al reported that whilst trends across age and sex groups were similar, GPRD (now CPRD) gave 
a lower prevalence for any musculoskeletal condition, rheumatoid arthritis and osteoarthritis than  
other databases.86 Jordan et al suggest that this may have been due to there being no requirement in 
GPRD for each chronic condition in each consultation to be coded. They therefore suggest caution in 
interpreting trends in prevalence.86 
As well as the quality of the data available, the problem of missing data should be considered when 
using consultation databases in research. Understanding missing data can be complex. For example, 
body mass index may be recorded more frequently in patients with diabetes, and blood pressure in 
those with cardiovascular disease. Such data is therefore likely to be ‘missing not at random’. Likewise, 
absence of a Read code does not necessarily indicate absence of disease and there is a risk that 
information stored in free text may be missed.82  
Despite these potential limitations, the benefits of using consultation databases in research include: 
the very large amount of coded patient information held including morbidity and lifestyle variables; 
the long-term follow-up available, and in the case of CPRD, the potential to link with other healthcare 
data sources such as Hospital Episode Statistics (HES) and postcode linked deprivation measures.87 The 
strengths of having a large sample size over a prolonged period should be weighed against the risk of 
the data quality being less satisfactory, when compared to the alternatives which would include 
manually intensive clinical record searches at a patient level or potentially expensive and limited 





Following an initial pilot study in the locally held CiPCA, CPRD was used to estimate the trends in the 
epidemiology and healthcare use of patients with CTS diagnosed in primary care, over time. The next 
section will briefly describe the pilot study and how it was used to inform the methods of the larger 
CPRD study. 
3.2 Pilot study using the Consultations in Primary Care Archive 
 A summary of the aims, methods and findings of the pilot study 
The aim of the pilot study was to develop and test the methods and procedures necessary to perform 
analysis in the larger CPRD database. The pilot study would also produce epidemiological data from 
the local North Staffordshire population, which could potentially be compared with the results of the 
national database (this comparison has not taken place as part of this thesis).  
Adults aged 18 years and over were included, and a series of descriptive analyses conducted to 
estimate the prevalence and incidence of CTS in each annual period between 2000 and 2010. Read 
code and prescription linkage to treatments of corticosteroid injection (CSI) and splinting (NS) for CTS 
were developed and used to estimate the healthcare use of patients with CTS over time. Evidence of 
CTR was identified from the patient record using a pre-defined list of Read codes.  
Read codes to be used to identify CTS diagnoses were agreed through clinical consensus with other 
practicing clinicians, as described more fully in 3.3.3.1. Individuals with a diagnosis of CTS or a code for 
treatment of CTS were identified in each calendar period. Individuals with no previous consultation for 
CTS in the two-year period preceding the index diagnostic consultation were identified as incident 
cases. The denominator for prevalence and incidence was the mid-year registered adult population for 
each annual period. Crude estimates (with 95% confidence intervals) were directly standardised to the 
general age-sex population structure of the UK. 
The standardised prevalence increased marginally over the observe period from 20 per 10,000 (95% 





The total incidence remained largely stable at around 16 per 10,000 person years.  The female: male 
ratio of incident cases decreased from 2.1 in 2000 to 1.7 in 2010. The median age of the incident 
population was 54 years for males and 53 years for females, across the years. 
Between 2000 and 2010, the proportion of prevalent individuals having surgery appeared to have 
increased from 10% to 26%. The median age of male and female cohorts receiving surgery, increased 
over time. The female: male ratio of those having surgery fluctuated over time but averaged at 1.2.  
 Implications of the pilot study 
The pilot study demonstrated that estimating epidemiological trends using general practice 
consultation data was both feasible and produced results comparable with the literature summarised 
in 1.2.1. The observed population (registered population in CiPCA practices) was however relatively 
small when compared with CPRD (124,000 versus 11.3 million patients, over the total period of the 
data collection). CiPCA also represents a single healthcare locality. Experience from working with 
recruitment centres from across the country for the INSTINCTS trial highlighted the variability in clinical 
practice in the management of CTS. There was therefore a substantial risk that CiPCA would not be 
representative of the national population. In order to observe a larger population, representative of 
the UK population, over a longer time period, the study was further developed and conducted in the 
CPRD. 
3.3 Trends in the prevalence, incidence and management of carpal tunnel 
syndrome between 1993 and 2013 - an observational analysis using CPRD: 
Methods 
 Population and setting: the Clinical Practice Research Datalink 
The Clinical Practice Research Datalink (CPRD) is a live database of anonymised medical records from 





practices in the UK. 4.4 million active (alive and registered) patients currently contribute information 
to the datalink, which equates to 6.9% of the UK population.82 CPRD is broadly representative of the 
UK general population in terms of age, gender and ethnicity.82 The datalink includes coded health data, 
including data on: demographics; symptoms; tests; diagnoses; therapies; health-related behaviours 
and referrals to secondary care. 75% of contributing practices contribute to the CPRD linkage scheme. 
Patient level data can therefore be linked with Hospital episode Statistics (HES); Mortality data (via 
Office for National Statistics); Index of Multiple Deprivation and Townsend scores and disease 
registers. Whilst general practice consultation databases have their limitations when used for research 
as described above, their potential for epidemiological research is substantial and to date over 2,300 
research studies based in CPRD have been published.82, 87  
 Ethics and data governance 
The CPRD has National Research Ethics Service Committee approval for observational research using 
primary care data and data linkages. CPRD is a joint project run by the Medicines and Healthcare 
Regulatory Agency (MHRA) and the National Institute for Health Research (NIHR). CPRD is owned by 
the Department of Health and operates within the MHRA. CPRD operates within UK and European laws 
of information governance and strives to protect patient confidentiality.   
In order to access data, researchers must have a protocol approved by the Independent Scientific 
Approvals Committee (ISAC). The protocol for this study (14_167) was approved on 16th September 
2014 and can be found in Appendix A. 
 Selection of Cases 
3.3.3.1 Identification of codes  
In order to identify the Read codes used to record a clinical diagnosis of CTS, a list of possible codes 






Table 3-1 Candidate Read codes for carpal tunnel syndrome 
Read code Term Details 
F340. Carpal tunnel syndrome / CTS                                                                                                                                                                                
7N081 [SO]Median nerve                                                                                                                                                                                       
F346. Median nerve entrapment                                                                                                                                                                                
7N08H [SO]Median nerve - hand                                                                                                                                                                                
7N08D [SO]Median nerve - forearm                                                                                                                                                                             
F341. Other median nerve lesions                                                                                                                                                                             
F3410 Median nerve neuritis                                                                                                                                                                                  
F3411 Median nerve compression in forearm                                                                                                                                                                    
F3412 Anterior interosseous nerve lesion                                                                                                                                                                     
F341z Median nerve lesions NOS                                                                                                                                                                               
7N08K [SO]Median nerve, thenar motor branch                                                                                                                                                                  
 
General Practitioners from the Primary Care Centre Versus Arthritis were approached by email and 
asked which code or codes they would use in clinical practice to code a patient with a diagnosis of CTS, 
which they were clinically confident about. They were also asked to add any other terms they would 
use. 8 GP’s responded and reported that F340 was the only code that they would use in the clinical 
scenario posed. 1 GP commented that he would use 85BE to code that he had delivered an injection 
to the carpal tunnel. 1 GP commented that he would use hand pain / wrist pain / hand symptom / wrist 
symptom NOS if the patient ‘did not obviously have CTS.’ 
3.3.3.2 Inclusion criteria 
The study population consisted of men and women over 18 years of age. It was decided not to include 
patients under the age of 18 years as firstly, CTS in a paediatric population is rare88 and a code for CTS 
unlikely to be accurate and secondly, would have limited the data available as not all practices 
contribute data from minors to CPRD. Patients were required to have ‘up to standard’ and ‘acceptable 
patient’ data, for two years prior to an incident episode and at the point of diagnosis for a prevalent 
episode. These terms are defined by CPRD. The ‘up to standard’ metric is based on the continuity of 





meets the quality criteria. The ‘acceptable patient’ metric is based on the presence of a registration 
status; the patient record itself and there being a valid age and gender.82  
When carrying out pilot work within CiPCA, a review of free text comments (available in CiPCA but not 
CPRD) highlighted the fact that Read codes relating to surgery were frequently used to code 
consultations pertaining to CTS. For example, to code consultations where wounds were reviewed or 
fit notes issued. It was also noted that surgical codes could be the only code used to identify a patient 
with CTS. For example, a patient may initially be coded using a more general hand pain code (hence 
not identified by the inclusion criteria) and then have a CTS specific surgery code attributed to them 
following referral and eventual surgery. The same was true of carpal tunnel injection, although the 
numbers were much smaller. In line with the methodology used by Latinovic et al19 in their GPRD based 
study, individuals with a code for CTS, carpal tunnel release or a carpal tunnel injection were included 
as CTS cases. Table 3-2 shows the final set of Read codes selected to identify patients with CTS. All 
Read codes required conversion to the ‘medcodes’ utilised by CPRD. All recorded episodes of care (e.g. 
GP consultations, telephone consultations, administration entries) were considered in the inclusion 
criteria.  
Table 3-2 Read codes selected to identify prevalent cases of CTS 
Read code Term Details 
F340 Carpal tunnel syndrome                                                                                                                                                                                 
85BE.00 Injection of carpal tunnel 
70560 Carpal tunnel release                                                                                                                                                                                  
70564 Endoscopic carpal tunnel release                                                                                                                                                                       
7056011 Carpal tunnel decompression 
 
3.3.3.3 Distinguishing prevalent and incident cases 
The prevalence of individuals consulting with CTS was calculated per annum. The numerator for 
prevalence was the number of patients with a record of a CTS diagnosis or evidence of an episode of 
CTR or a CSI, in each calendar year. In order to determine annual incidence, the numerator was the 





during a run-in-period of two years. This two-year run-in period was based on expert consensus that 
aimed to estimate the period of time within which it was felt unlikely that a patient with ongoing 
bothersome symptoms would not have consulted. CTS may have presented as a new episode in the 
contralateral wrist sometime after the index presentation, hence it was not felt possible to use the 
criteria as ‘no previous recorded episode’ to define incidence.  
The denominator population for calculating the prevalence was the total up-to-standard person-years 
contributed to CPRD by patients over the age of 18 years of age, for each annual period between 1st 
January 1993 and 31 December 2013. As all incident patients were required to have at least 2 calendar 
years registration prior to the event date, the denominator population were also required to have 
registration at the mid-point of the year, two calendar years before the index year, in order to be able 
to apply the same criteria to both the numerator and denominator populations.  
3.3.3.4 Identifying episodes of healthcare use 
3.3.3.4.1 Carpal tunnel release surgery 
Episodes of CTR were identified using Read codes as shown in Table 3-3. In addition to the codes used 
to define prevalence and incidence, ‘re-release of carpal tunnel’ and ‘revision of carpal tunnel release’ 
were included as a surgical episode (if the first code used to record surgery). These terms were not 
included in prevalence or incidence definitions as they may not have indicated an episode of 
‘idiopathic’ CTS but rather iatrogenic symptoms following previous (unsuccessful) surgery. Of note 






Table 3-3 Read codes used to identify an episode of carpal tunnel injection and carpal tunnel release 
surgery 
Read Code Term details 
85BE.00 Injection of carpal tunnel 
7056000 Carpal tunnel release 
7056200 Re-release of carpal tunnel 
7056400 Endoscopic carpal tunnel release 
705A100 Revision of carpal tunnel release 
7056011 Carpal tunnel decompression 
 
The pilot study demonstrated that that substantial variation in the number of surgical episodes per 
patient existed. This variation was felt likely to be due to the issue of surgical intervention codes being 
used as consultation codes, following the initial episode. For example, a patient attending for sickness 
certification following surgery may be attributed a further surgical code. Repeat use of codes may 
however have indicated a true repeat surgical episode if the patient had a ‘redo’ procedure due to 
complications, or had the contralateral hand operated on. It was not however possible to distinguish 
between these. It was therefore decided to only count the first episode of CTR in a patient’s records. 
This approach was acknowledged to risk the rate of surgery being underestimated. 
3.3.3.4.2 Corticosteroid injection 
Corticosteroid injections used as a treatment for CTS were identified in two ways. Firstly, the Read 
code (85BE: Injection of carpal tunnel) was used to identify coded episodes of treatment delivery. 
However, there was concern that the exact procedural code may not have been applied (‘Injection of 
steroid’ or ‘Injection of steroid into wrist joint’ are also available to use but are less specific). Therefore, 
a further method of identifying CTI was developed. 
When a drug is used in primary care, it is usual practice to code the intervention and generate a 
prescription in the patient’s notes to demonstrate that a drug has been prescribed and / or 
administered. Even if a drug has been used from practice stock, a prescription is required to allow the 





a locally injected corticosteroid. These drugs are listed in Chapter 10.1.2.2 of the British National 
Formulary.89 CPRD data includes all such prescriptions and the date they were prescribed. This should 
therefore allow the patient’s unique identification number to be linked with the details of a 
prescription including the BNF Chapter and the date of issue of the prescription.  
All prescriptions from Chapter 10.1.2.2 were identified. These prescription data were then merged 
with a database listing all patients identified by Read code as having a diagnosis of CTS (using the F340 
diagnostic code). In order to link a prescription of a locally injected corticosteroid with a consultation 
tagged as a being related to CTS, a further database was produced to show patients who had been 
prescribed a corticosteroid within four weeks of a consultation for CTS. The four-week period was 
decided on through consensus between three GP’s who routinely perform CSI’s based on the 
assumption that the consultation should either be coded as a CTS or CSI or that the injection would be 
prescribed within 4 weeks of a consultation, where a decision had been made to inject. 
The database containing entries coded with an episode of CSI and the database containing linked 
prescriptions were then merged. An episode of CSI was therefore defined as an episode with either a 
coded consultation for a CSI or evidence of a prescription for a locally injected corticosteroid issued 
within a 4-week period of a coded consultation for CTS. As it is clinically possible and even likely that 
some patients benefit from more than one injection, clinical consensus set the total number of 
injections that a patient may have over the timespan of their registration, at four. 
3.3.3.4.3 Wrist splinting 
Several Read codes for the provision of splints are available as listed in Table 3-4. It was known from 
the pilot study that these codes were used infrequently. It was decided to reaffirm this finding in CPRD. 
It is unlikely that a separate code for the recommendation of splinting would be used in a consultation. 
Splints are neither prescribed nor distributed in general practice. If they were recommended, it is likely 
that the suggestion to a patient to source them form a pharmacy or online provider would be recorded 





Table 3-4 Read codes used to identify an episode of wrist splinting 
Read code Term details 
8O1C Provision of splint 
8O1C0 Provision of working splint wrist brace 
8D562 Passive wrist extension splint 
8D563 Active wrist extension splint 
8O1C0 Provision of working splint wrist brace 
8O1C Provision of splint 
 
3.3.3.4.4 Nerve conduction studies 
The data for NCS was based on Read coded entries, as per Table 3-5 and additional investigation entries 
in the patient record. Up to two episodes were allowed over the full follow-up period (one episode per 
hand). It is acknowledged that access to NCS varies by region or healthcare locality. Locally, one would 
have to refer to the local musculoskeletal interface service (tier 3) to access such investigations. Only 
highly diligent coders might include a code for this from an outpatient letter so, along with CSI, NCS 
are unlikely to be completely identified in CPRD.   
Table 3-5 Read codes used to identify an episode of nerve conduction studies 
Read code Term details 
8HRE Referral for nerve conduction studies 
70652 Nerve conduction studies 
 
3.3.3.4.5 Referrals 
Using the Read codes shown in Table 3-6, coded episodes of referrals were sought using data from 
CPRD. In addition, the referrals database was also searched and merged with the coded CTS tagged 
consultation data. A referral to the destinations in Table 3-6 were assumed to be linked to CTS if it 






Table 3-6 Read codes used to identify an episode of referral 
Read code Term details 
8H54 Orthopaedic referral 
8H4B Referred to rheumatologist 
8HTd Referral to rheumatology clinic 
8HRE Referral for nerve conduction studies 
70652 Nerve conduction studies 
8H Further care 
8H77 Refer to physiotherapist 
8H7J Refer to occupational therap. 
8H55 Neurosurgical referral 
8H46 Neurological referral 
8H59 Referral to plastic surgeon 
 
The number of referrals to each speciality or intervention was recorded and the demographics of the 
referred cohort, described. In addition, it was be assumed that patients with a surgical episode must 
have had a referral from primary care, therefore patients with a surgical episode without a referral 
code, were included in the referral data.   
3.3.3.4.6 Sickness certification  
Unlike CiPCA which stores sickness certification (or fit note) data, CPRD does not have such a feature. 
Read codes as shown in Table 3-7 were therefore matched to CTS consultations and recorded if the 
dates of the events corresponded.  
Table 3-7 Read codes used to identify an episode of sickness certification 
Read Code Term details 
9D1 MED3 doctor’s statement 
9D11 MED3 issued to patient 
9D17 MED3 NOS 
9D19 MED 3 issued by hand not fit 







 Statistical methods 
Crude age and sex specific annual prevalence and incidence were determined for each calendar year 
between 1993 and 2013. Due to lower numbers of patients in the initial years of CPRD (1987 to 1992), 
results are reported from 1993 onwards. For confidence interval calculation, a Poisson distribution was 
used.  
In order to consider the effect of a changing population structure over the study time-frame, crude 
values for prevalence and incidence were directly standardised to the age-sex population structure 
(aged 18 years and above) of the UK in 2013, using population estimates provided by the website of 
the Office of National Statistics.90 There was no substantial difference between crude and standardised 
rates, hence the standardised values were presented as a sensitivity analysis and the crude figures 
reported in the main analysis. This was done in order to maintain consistency between the different 
parts of the study; episodes of healthcare use were described as the percentage of the crude prevalent 
population undergoing the intervention in question.  
Emerging trends were described and Joinpoint regression used to identify when significant changes 
occurred in the underlying trend (a joinpoint). This process assisted the exploration of the influence of 
changes in practice over the observed period. 
3.3.4.1 Joinpoint regression 
Joinpoint regression is a statistical modelling approach to the analysis of trends. JOINPOINT 
REGRESSION PROGRAM (version 4.3.1.0) was used to conduct the analysis. This software utilises trend 
data and fits the simplest joinpoint model that the data will allow. A model with zero jointpoints would 
indicate there being no significant change in the trend being observed. The software then tests 
whether further joinpoints can be added to the model. The user is able to test whether an apparent 
change is statistically significant. The tests of significance use a Monte Carlo Permutation method and 





number of joinpoints was set at five (the maximum allowed). The best fitting model according to the 
software package was selected.  
3.4 The prevalence of carpal tunnel syndrome in CPRD: Results 
Table 3-8 presents the total number of individuals presenting in primary care with a CTS coded episode 
per annum, between 1993 and 2013 along with the total person years contributing to CPRD and the 
associated crude prevalence. The final column demonstrates the female: male ratio. Table 3-9 further 
presents the median age and age range of patients with CTS.          Figure 3-1 demonstrates the change 
in population prevalence, by age and gender groups over time and          Figure 3-2 demonstrates the 
prevalence of CTS stratified by age and gender at the end of the observed period in 2013. The 
associated numerical data represented in these graphs can be found in Appendix B1. Table 3-10 and 




Table 3-8 Crude prevalence of carpal tunnel syndrome (n/10,000 person years) per calendar year, as presented in UK primary care (CPRD) 
 
  
Year Number of 
person years 
Number of prevalent 
individuals 
Total crude prevalence per 10,000 person 
years, (95% confidence interval) 
Female prevalence per 10,000 person 
years, (95% confidence interval) 
Male prevalence per 10,000 person 
years, (95% confidence interval) 
Female: 
male 
1993 1117443 2909 26.03 (25.10 to 27.00) 37.52 (35.96 to 39.13) 13.69 (12.72 to 14.71) 2.74 
1994 1198256 3188 26.61 (25.69 to 27.55) 37.23 (35.73 to 38.79) 15.21 (14.23 to 16.25) 2.45 
1995 1286800 3343 25.98 (25.11 to 26.88) 36.64 (35.20 to 38.12) 14.58 (13.65 to 15.56) 2.51 
1996 1437567 3706 25.78 (24.96 to 26.62) 36.75 (35.38 to 38.16) 14.09 (13.23 to 15.00) 2.61 
1997 1681756 4190 24.91 (24.17 to 25.68) 34.87 (33.64 to 36.14) 14.34 (13.53 to 15.18) 2.43 
1998 1899393 4884 25.71 (25.00 to 26.45) 36.57 (35.38 -37.79) 14.22 (13.46 to 15.01) 2.57 
1999 2289158 5696 24.88 (24.24 to 25.54) 35.21 (34.14 to 36.30) 14.01 (13.32 to 14.72) 2.52 
2000 2787457 6998 25.11 (24.52 to 25.70) 34.82 (33.86 to 35.81) 14.90 (14.26 to 15.57) 2.34 
2001 3057458 8137 26.61 (26.04 to 27.20) 36.46 (35.52 to 37.42) 16.31 (15.67 to 16.98) 2.23 
2002 3385511 9722 28.72 (28.15 to 29.29) 39.33 (38.40 to 40.28) 17.64 (17.00 to 18.29) 2.23 
2003 3552908 11124 31.31 (30.73 to 31.90) 43.61 (42.66 to 44.59) 18.53 (17.90 to 19.18) 2.35 
2004 3712172 12622 34.00 (33.41 to 34.60) 47.20 (46.23 to 48.19) 20.33 (19.68 to 20.99) 2.32 
2005 3808183 12741 33.46 (32.88 to 34.04) 46.37 (45.42 to 47.34) 20.09 (19.45 to 20.74) 2.31 
2006 3857487 12718 32.97 (32.40 to 33.55) 45.82 (44.88 to 46.78) 19.69 (19.07 to 20.33) 2.33 
2007 3904068 13222 33.87 (33.29 to 34.45) 46.35 (45.41 to 47.31) 20.99 (20.35 to 21.65) 2.21 
2008 3897624 14030 36.00 (35.40 to 36.60) 49.12 (48.15 to 50.11) 22.46 (21.79 to 23.14) 2.19 
2009 3894989 14500 37.23 (36.60 to 37.81) 50.68 (49.69 to 51.68) 23.35 (22.68 to 24.05) 2.17 
2010 3842773 14166 36.86 (36.26 to 37.48) 49.75 (48.76 to 50.75) 23.57 (22.88 to 24.27) 2.11 
2011 3769676 13529 35.89 (35.29 to 36.50) 47.98 (47.00 to 48.97) 23.36 (22.67 to 24.07) 2.05 
2012 3714877 13388 36.04 (35.43 to 36.66) 47.57 (46.59 to 48.56) 24.05 (23.35 to 24.78) 1.98 
2013 3473094 12532 36.08 (35.45 to 36.72) 47.19 (46.18 to 48.21) 24.49 (23.75 to 25.25) 1.93 
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Table 3-9 Age and gender of patients with prevalent carpal tunnel syndrome between 1993 and 2013 
Year Female age range Female median age (25th and 75th percentile) Male age range Male median age (25th and 75th percentile) 
1993 18.20 to 98.70 49.33 (38.29, 61.50) 18.47 to 92.90 52.61 (41.50, 66.37) 
1994 18.10 to 95.09 49.45 (39.44, 62.25) 19.32 to 94.72 52.8 (42.31, 66.15) 
1995 18.13 to 94.70 50.18 (38.55, 62.17) 20.32 to 95.99 52.19 (41.45, 64.24) 
1996 18.11 to 93.64 50.23 (39.69, 62.06) 18.81 to 95.96 52.63 (41.09, 65.70) 
1997 18.56 to 95.81 50.65 (39.86, 62.05) 19.46 to 95.34 53.37 (42.39, 66.94) 
1998 18.23 to 99.72 50.71 (39.76, 62.06) 18.22 to 99.72 53.84 (43.00, 67.22) 
1999 18.13 to 100.09 51.49 (40.20, 62.07) 18.56 to 95.13 54.20 (44.17, 66.38) 
2000 18.30 to 101.55 51.90 (40.94, 63.57) 19.12 to 97.22 55.13 (43.79, 67.33) 
2001 18.00 to 99.84 52.76 (41.50, 64.57) 18.6 to 98.18 55.16 (44.18, 68.17) 
2002 18.02 to 102.20 52.85 (41.02, 64.07) 18.18 to 99.23 54.70 (44.28, 66.83) 
2003 18.20 to 97.18 53.61 (41.81, 64.58) 18.64 to 96.66 55.35 (44.41, 67.67) 
2004 18.02 to 97.17 54.53 (42.78, 64.67) 18.48 to 95.98 56.06 (44.57, 67.97) 
2005 18.36 to 103.25 54.42 (42.50, 64.94) 18.28 to 96.07 57.51 (45.24, 69.57) 
2006 18.03 to 101.93 54.49 (42.64, 66.17) 18.29 to 95.83 57.90 (45.49, 69.93) 
2007 18.21 to 99.78 53.68 (42.35, 65.77) 19.18 to 98.72 53.68 (42.35, 65.77) 
2008 18.42 to 102.67 53.84 (42.79, 65.81) 18.48 to 96.81 57.55 (46.44, 70.30) 
2009 18.06 to 100.15 54.00 (42.68, 66.63) 18.22 to 96.63 58.42 (46.90, 70.45) 
2010 18.17 to 99.16 54.08 (42.61, 66.95) 18.45 to 97.81 57.43 (46.37, 70.50) 
2011 18.06 to 98.46 53.96 (42.76, 67.48) 18.16 to 95.85 58.08 (47.07, 71.06) 
2012 18.11 to 98.97 53.66 (42.62, 66.98) 18.94 to 97.90 58.62 (47.51, 70.88) 
















































































































1 1993 2000 -0.8 -2.6 1.0 -1.0 0.3 
2 2000 2004 7.8 3.1 12.7 3.7 < 0.0 
3 2004 2013 1.1 0.4 1.8 3.4 < 0.0 
 
Table 3-8 and Table 3-9 present the prevalence (crude estimates) of patients presenting in primary 
care with carpal tunnel syndrome between 1993 and 2013 and the demographics of that population. 
The denominator population for prevalence increased from 1,117,433 person years in 1993 to 
3,473,094 person years in 2013. The total prevalence in 1993 was 26.03 per 10,000 person years (95% 
CI 25.10 to 27.00), and in 2013, 36.08 per 10,000 person years (95% CI 35.45 to 36.72). As shown in 
Figure 3-3 and corresponding Table 3-10, the prevalence of CTS appeared to decrease between 1993 
and 2000 (annual percentage change APC = -0.8, 95% confidence interval -2.6 to 1.0). It then increased 
between 2000 and 2004 (APC = 7.8, 95% CI 3.1 to 12.7) and then increased at a slower rate between 
2004 and 2013 (APC = 1.1, 95% CI 0.4 to 1.8). The female to male ratio reduced over time from 2.74 in 
1993 to 1.93 in 2013. The median age of female and male patients with CTS increased from 49 and 53 
years respectively in 1993 to 54 and 59 years respectively in 2013.          Figure 3-1 and          Figure 3-2 
further illustrate the crude prevalence of CTS over time stratified by age and gender. The prevalence 
of CTS appears to increase with age in the male population, whereas the prevalence in female 







3.5 The incidence of carpal tunnel syndrome in CPRD: Results 
Table 3-11 presents the total number of individuals presenting in primary care with a new episode of 
CTS, per annum, between 1993 and 2013 along with the total person years contributing to CPRD and 
the associated crude incidence. The final column demonstrates the female: male ratio. Table 3-12 
further presents the median age and age range of patients with incident episodes of CTS.          Figure 
3-4 demonstrates the change in population incidence, by age and gender groups over time and          
Figure 3-5 shows the incidence of CTS by age and gender in 2013. The associated numerical data 
represented in these graphs can be found in Appendix B2. Table 3-13 and Figure 3-6 show the Joinpoint 




Table 3-11 Crude incidence of carpal tunnel syndrome (n/10,000 person years) per calendar year, as presented in UK primary care (CPRD) 
Year Number of 
person years 
Number of incident 
individuals 
Total crude incidence per 10,000 
person years, (95% confidence interval) 
Female incidence per 10,000 person 
years, (95% confidence interval) 
Male incidence per 10,000 person 
years, (95% confidence interval) 
Female: 
male 
1993 783330 1584 20.22 (19.24 to 21.24) 28.72 (27.09 to 30.42) 11.17 (10.14 to 12.29) 2.57 
1994 868616 1797 20.69 (19.74 to 21.67) 28.52 (26.97 to 30.13) 12.38 (11.34 to 13.69) 2.30 
1995 1003593 1963 19.56 (18.70 to 20.45) 27.53 (26.12 to 29.00) 11.12 (10.20 to 12.10) 2.48 
1996 1065068 2142 20.11 (19.27 to 20.98) 28.39 (27.00 to 29.84) 11.37 (10.47 to 12.33) 2.50 
1997 1150299 2306 20.05 (19.24 to 20.88) 28.39 (27.05 to 29.79) 11.25 (10.39 to 12.16) 2.52 
1998 1300074 2696 20.74 (19.95 to 21.52) 29.65 (28.57 to 31.22) 11.37 (10.56 to 12.23) 2.61 
1999 1497673 3030 20.23 (19.52 to 20.10) 28.53 (27.35 to 29.75) 11.54 (10.77 to 12.34) 2.47 
2000 1682027 3462 20.58 (19.90 to 21.28) 28.66 (27.54 to 29.81) 12.15 (11.41 to 12.93) 2.36 
2001 2019596 4391 21.74 (21.10 to 22.40) 29.72 (28.68 to 30.79) 13.46 (12.74 to 14.20) 2.21 
2002 2456761 5718 23.27 (22.68 to 31.78) 31.78 (30.78 to 32.79) 14.47 (13.80 to 15.17) 2.20 
2003 2669111 6772 25.37 (24.77 to 25.98) 35.13 (34.14 to 36.14) 15.33 (14.67 to 16.02) 2.29 
2004 2779821 7868 28.30 (27.68 to 28.94) 39.22 (38.19 to 40.27)  17.10 (16.42 to 17.81) 2.29 
2005 3164506 8113 25.64 (25.08 to 26.20) 35.55 (34.63 to 36.48) 15.49 (14.88 to 16.12) 2.30 
2006 3307051 8337 25.21 (24.67 to 25.76) 34.91 (34.02 to 35.82) 15.27 (14.68 to 15.89) 2.29 
2007 3343009 8865 26.52 (25.97 to 27.08) 35.76 (34.86 to 36.67) 17.07 (16.45 to 17.71) 2.09 
2008 3341299 9437 28.24 (27.68 to 28.82) 38.23 (37.30 to 39.17) 18.06 (17.42 to 18.72) 2.12 
2009 3383196 9918 29.32 (28.74 to 29.90) 39.73 (38.79 to 50.68) 18.69 (18.04 to 19.36) 2.13 
2010 3357338 9634 28.70 (28.13 to 29.27) 38.70 (37.77 to 39.64) 18.46 (17.82 to 19.13) 2.10 
2011 3269296 9083 27.78 (27.21 to 28.36) 37.11 (36.19 to 38.05) 18.20 (17.54 to 18.87) 2.04 
2012 3222880 9011 27.96 (27.39 to 28.54) 36.44 (35.52 to 37.88) 19.23 (18.56 to 19.93) 1.89 




Table 3-12 Age and gender of patients with incident carpal tunnel syndrome between 1993 and 2013 
Year Female age range Female median age (25th and 75th percentile) Male age range Male median age (25th and 75th percentile) 
1993 19.40 to 96.11 49.51 (38.96 to 62.70) 18.72 to 89.90 51.49 (41.70 to 64.64) 
1994 18.10 to 95.09 50.18 (39.86 to 63.18) 19.32 to 94.72 52.93 (43.39 to 65.78) 
1995 18.13 to 94.70 50.81 (39.72 to 62.54) 20.32 to 95.57 52.79 (42.31 to 63.83) 
1996 18.22 to 93.64 50.81 (40.10 to 63.76) 18.81 to 95.96 52.45 (40.79 to 65.83) 
1997 19.10 to 95.81 51.27 (40.32 to 63.93) 21.30 to 95.30 55.05 (44.67 to 67.46) 
1998 18.23 to 99.72 51.02 (40.22 to 63.26) 19.60 to 97.22 54.35 (43.79 to 67.61) 
1999 18.13 to 100.09 52.15 (40.72 to 63.63) 20.51 to 91.48 55.04 (45.16 to 66.92) 
2000 18.30 to 98.61 52.58 (41.83 to 65.00) 20.64 to 91.03 55.44 (44.45 to 68.14) 
2001 18.00 to 99.60 53.23 (42.02 to 65.58) 18.60 to 94.66 55.37 (44.84 to 67.96) 
2002 18.02 to 102.2 53.79 (42.16 to 65.70) 18.18 to 96.04 54.69 (44.47 to 67.36) 
2003 18.35 to 96.35 54.51 (42.93 to 65.57) 18.64 to 96.08 55.62 (44.69 to 68.11) 
2004 18.02 to 97.17 55.42 (43.82 to 65.88) 18.48 to 95.98 56.79 (44.96 to 68.17) 
2005 18.36 to 99.51  54.91 (43.22 to 66.07) 18.28 to 96.07 57.94 (46.21 to 69.97) 
2006 18.22 to 101.87 54.97 (43.55 to 67.25) 18.29 to 95.46 58.18 (46.15 to 69.89) 
2007 18.21 to 99.76 53.93 (43.12 to 66.39) 19.18 to 96.49 58.14 (46.52 to 69.75) 
2008 18.48 to 96.46 54.58 (43.89 to 66.75) 18.48 to 96.46 57.91 (47.14 to 70.10) 
2009 18.11 to 99.27 54.88 (43.53 to 67.40) 18.22 to 96.63 59.19 (47.21 to 70.73) 
2010 18.17 to 97.80 54.88 (43.71 to 67.55) 18.45 to 93.60 57.35 (46.63 to 70.29) 
2011 18.21 to 98.46 54.72 (43.78 to 68.42) 18.21 to 95.12 58.93 (47.80 to 70.91) 
2012 18.11 to 98.83 54.30 (43.52 to 67.39) 18.94 to 97.90 59.14 (48.05 to 70.76) 
2013 18.27 to 100.73 55.02 (44.70 to 68.50) 19.21 to 102.85 58.84 (48.07 to 70.79) 
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1 1993 2000 0.3 -2.3 2.9 0.2 0.8 
2 2000 2004 6.9^ 0.5 13.7 2.3 <0.0 
3 2004 2013 0.7 -0.2 1.6 1.7 0.1 
 
Table 3-11 presents the annual incidence (crude estimates) for patients presenting in UK primary care 
with carpal tunnel syndrome between 1993 and 2013 and the demographics of the population. The 
denominator population for incidence, which is dependent on patients having 2 years up to standard 
data prior to the midpoint of the year in question, increased from 783,330 person years in 1993 to 
3,015,670 person years in 2013. The crude incidence in 1993 was 20.22 per 10,000 person years (95% 
CI 19.24 to 21.24)) and 27.68 per 10,000 person years in 2013 (95% CI 27.09 to 28.28). As shown in          
Figure 3-4 and Table 3-13, the results of the best fitting Joinpoint regression model suggest the 
incidence increased between 1993 and 2000 (APC = 0.3, 95% CI -2.3 to 2.9). It then increased more 
quickly between 2000 and 2004 (APC = 6.9, 95% CI 0.5 to 13.7), before slowing between 2004 and 2013 
(APC = 0.7. 95% CI -0.2 to 1.6). The female to male ratio reduced over time from 2.57 in 1993 to 1.88 
in 2013. The median age of female and male patients were noted to increase from 50 and 51 years 
respectively in 1993 to 55 and 59 years respectively in 2013. Table 3-12,          Figure 3-4 and          Figure 
3-5 further illustrate the incidence of CTS over time by age and gender. As with prevalence, the 
incidence of CTS appears to increase with age in the male population, whilst the incidence in women 






 Age and sex standardised estimates of the annual prevalence and incidence of CTS 
To test the effect of any change in the population structure over time on the observed crude estimates, 
a sensitivity analysis was performed. The crude estimates were directly standardised against the 
population structure in 2013, as provided by the Office of National Statistics.              Table 3-14 below 
presents these standardised estimates for prevalence and incidence in each calendar year. As the 
results were so similar (the 95% confidence intervals overlap in most instances), further analyses are 
not presented to prevent repetition, however the Joinpoint plots for standardised estimates can be 




             Table 3-14 Age and sex standardised and crude prevalence and incidence estimates for each calendar year between 1993 and 2013 
Year Age sex standardised prevalence 
(per 10,000 person years, 95% CI) 
Crude prevalence (per 10,000 
person years, 95% CI) 
Age sex standardised incidence (per 
10,000 person years, 95% CI) 
Crude incidence(per 10,000 person 
years, 95% CI) 
1993 26.27 (26.13 to 26.42) 26.03 (25.10 to 27.00) 19.95 (19.83 to 20.07) 20.22 (19.24 to 21.24) 
1994 26.83 (26.69 to 26.98) 26.61 (25.69 to 27.55) 20.46 (20.34 to 20.59) 20.69 (19.74 to 21.67) 
1995 25.90 (25.77 to 26.05) 25.98 (25.11 to 26.88) 19.20 (19.08 to 19.33) 19.56 (18.70 to 20.45) 
1996 25.64 (25.50 to 25.78) 25.78 (24.96 to 26.62) 19.61 (19.49 to 19.74) 20.11 (19.27 to 20.98) 
1997 24.64 (24.20 to 25.07) 24.91 (24.17 to 25.68) 19.42 (19.30 to 19.55) 20.05 (19.24 to 20.88) 
1998 25.42 (25.88 to 25.56) 25.71 (25.00 to 26.45) 20.05 (19.93 to 20.18) 20.74 (19.95 to 21.52) 
1999 24.57 (24.44 to 24.71) 24.88 (24.24 to 25.54) 19.51 (19.39 to 19.64) 20.23 (19.52 to 20.10) 
2000 24.77 (24.63 to 24.91) 25.11 (24.52 to 25.70) 19.73 (19.61 to 19.86) 20.58 (19.90 to 21.28) 
2001 26.22 (26.08 to 26.36) 26.61 (26.04 to 27.20) 20.75 (20.63 to 20.88) 21.74 (21.10 to 22.40) 
2002 28.22 (28.07 to 28.37) 28.72 (28.15 to 29.29) 22.22 (22.10 to 22.36) 23.27 (22.68 to 31.78) 
2003 30.81 (30.65 to 30.96) 31.31 (30.73 to 31.90) 24.28 (24.15 to 24.42) 25.37 (24.77 to 25.98) 
2004 33.51 (33.35 to 33.67) 34.00 (33.41 to 34.60) 27.00 (26.86 to 27.14) 28.30 (27.68 to 28.94) 
2005 32.98 (32.82 to 33.14) 33.46 (32.88 to 34.04) 24.56 (24.42 to 24.70) 25.64 (25.08 to 26.20) 
2006 32.55 (32.39 to 32.70) 32.97 (32.40 to 33.55) 24.14 (24.00 to 24.27) 25.21 (24.67 to 25.76) 
2007 33.48 (33.32 to 33.64) 33.87 (33.29 to 34.45) 25.52 (25.38 to 25.66) 26.52 (25.97 to 27.08) 
2008 35.59 (35.43 to 35.76) 36.00 (35.40 to 36.60) 27.07 (26.92 to 27.21) 28.24 (27.68 to 28.82) 
2009 36.81 (36.64 to 36.98) 37.23 (36.60 to 37.81) 28.19 (28.05 to 28.34) 29.32 (28.74 to 29.90) 
2010 36.40 (36.24 to 36.66) 36.86 (36.26 to 37.48) 27.53 (27.39 to 27.68) 28.70 (28.13 to 29.27) 
2011 35.28 (35.12 to 35.44) 35.89 (35.29 to 36.50) 26.59 (26.45 to 26.74) 27.78 (27.21 to 28.36) 
2012 35.50 (35.34 to 35.67) 36.04 (35.43 to 36.66) 26.75 (26.61 to 26.89) 27.96 (27.39 to 28.54) 





3.6 The management of carpal tunnel syndrome in CPRD: Results 
The CiPCA pilot study suggested that consultation coding for injections and splinting were inadequate 
and unlikely to represent the true number of interventions that occurred in primary care. This was 
retested in CPRD using the methods described in 3.3.3.4.2 with results again showing the frequency of 
recorded use being less than what would be expected. Although the results for CSI and NS will be 
presented, the focus of this section is therefore on the use of carpal tunnel release surgery. CTR is of 
particular interest as it firstly indicates that patients either have had severe CTS or have not responded 
to the treatments available to them in primary care and secondly as access to this procedure is 
restricted in some areas.64 
 Use of carpal tunnel release surgery over time 
Table 3-15 presents the rate and percentage of prevalent patients with CTS who had recorded episode 
of CTR in each calendar year between 1993 and 2013 and the associated demographics of this 
population. 71% of patients with any CTR code had a single (as opposed to multiple) CTR code in their 
record. As it was not possible to verify whether further codes were true ‘redo’ or contralateral 
episodes, as opposed to the code being reused in the consultation data, it is possible that the number 
of surgical episodes is underestimated.          Figure 3-7 represents the rate of surgery by gender over 
time and Figure 3-8  demonstrates the Joinpoint regression of this data with the associated statistics 






Table 3-15 Rate and percentage of patients with carpal tunnel syndrome with a recorded episode of 

























(25% and 75% 
percentile) 
1993 5.04 19.35 18.78 21.03 53 (43 to64) 55 (44 to 69) 
1994 5.70 21.42 20.62 23.52 53 (43 to 68) 58 (45 to 70) 
1995 6.19 23.81 23.40 24.92 53 (42 to 67) 55 (44 to 70) 
1996 5.41 20.99 20.48 22.43 53 (44 to 65) 52 (40 to 65) 
1997 5.70 22.89 22.14 24.81 53 (45 to 67) 56 (42 to 69) 
1998 5.73 22.28 21.28 25.00 53 (44 to 65) 53 (44 to 65) 
1999 6.24 25.09 24.60 26.38 54 (44 to 67) 56 (46 to 70) 
2000 6.41 25.54 24.84 27.23 54 (44 to 68) 56 (45 to 69) 
2001 6.88 25.87 25.95 25.68 55 (45 to 68) 58 (46 to 71) 
2002 7.02 24.46 24.19 25.09 57 (46 to 71) 55 (45 to 68) 
2003 8.26 26.39 25.88 27.66 56 (45 to 67) 57 (46 to 71) 
2004 9.34 27.48 27.38 27.74 56 (46 to 67) 57 (47 to 68) 
2005 9.70 29.00 28.31 30.65 57 (47 to 68) 58 (46 to 71) 
2006 9.36 28.40 28.31 28.61 57 (47 to 68) 60 (48 to 72) 
2007 9.71 28.66 28.26 29.59 56 (46 to 69) 59 (48 to 71) 
2008 10.53 29.25 29.00 29.82 56 (46 to 68) 60 (49 to 72) 
2009 10.92 29.32 28.73 30.66 56 (46 to 70) 61 (49 to 72) 
2010 10.40 28.22 27.57 29.62 57 (47 to 71) 61 (48 to 73) 
2011 9.47 26.37 26.11 26.93 57 (47 to 70) 61 (49 to 73) 
2012 9.48 26.31 25.89 27.19 57 (47 to 71) 60 (49 to 73) 











































Figure 3-8 Joinpoint analysis plot of the percentage of prevalent patients with a recorded episode of carpal tunnel release,  





Table 3-16 Joinpoint analysis of trends in the proportion of prevalent patients with a recorded episode 




















1 1993 2007 2.6 1.9 3.2 8.2 0.0 
2 2007 2013 -1.7 -3.1 -0.3 -2.6 <0.0 
 
Table 3-15,          Figure 3-7 and Figure 3-8 show that the proportion of prevalent patients receiving 
carpal tunnel release surgery, increased over the observed time period from 19.35% in 1993 to 27.3 % 
in 2013. This increase was observed in both female and male populations and in every year apart from 
2001, the percentage of males having surgery was greater than the percentage of females. Although 
the ratio of female and male populations receiving surgery fluctuated on a year on year basis, the 
general trend was a reduction in the female: male ratio (2.57 in 1993 and 1.7 in 2013), suggesting 
proportionally more men were having surgery compared to women. The median age of both male and 
female populations also appeared to increase, as shown in Table 3-15, from 55 and 53 years old in 
1993 (male and female respectively) to 62 years old in the male population and 57 years old in the 
female population, in 2010, after which the increase in age appeared to plateau. The increase in age 
was more apparent in the male population. 
As shown in Figure 3-8 and corresponding Table 3-15, the trend in the percentage of patients with a 
coded episode of CTR increased between 1993 and 2007 (annual percentage change APC = 2.6, 95% CI 
1.9 to 3.2). It then decreased between 2007 and 2013 (APC = -1.7, 95% CI -3.3 to -0.3).  
 Use of carpal tunnel injections over time 
Using both Read coded and linked prescription data Table 3-17 and Figure 3-9, show the proportion of 
prevalent patients who were given a carpal tunnel injection in each calendar year. Figure 3-10 shows 
the results of the Joinpoint regression of trends in the use of injections for CTS, with the associated 
statistics in Table 3-18.
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1993 1.77 6.33 6.54 5.70 52 (40 to 69) 57 (44 to 72) 2.63 
1994 1.54 5.43 5.07 6.36 51 (44 to 68) 55 (45 to 70) 2.30 
1995 1.43 5.23 4.84 6.28 50 (38 to 65) 50 (38 to 65) 2.52 
1996 1.38 5.10 4.62 6.42 51 (39 to 67) 55 (40 to 75) 2.54 
1997 1.62 5.89 5.23 7.61 55 (44 to 74) 54 (44 to 74) 2.31 
1998 1.44 4.89 4.54 5.87 53 (41 to 70) 55 (44 to 66) 2.32 
1999 1.67 6.06 5.64 7.17 53 (41 to 69) 59 (46 to 72) 2.47 
2000 1.49 5.32 5.05 5.97 56 (43 to 72) 56 (46 to 76) 2.24 
2001 1.38 4.68 4.21 5.78 57 (44 to 73) 58 (48 to 73) 2.36 
2002 1.63 5.19 5.09 5.44 56 (43 to 72) 59 (44 to 72) 2.24 
2003 1.82 5.31 5.22 5.54 57 (44 to 70) 58 (43 to 73) 2.29 
2004 1.82 4.83 4.77 4.99 58 (47 to 72) 57 (46 to 73) 2.37 
2005 1.76 4.87 4.89 4.84 58 (45 to 73) 62 (46 to 77) 2.21 
2006 2.06 5.67 5.50 6.18 59 (48 to 75) 61 (48 to 75) 2.38 
2007 2.20 5.79 5.91 5.50 60 (46 to 76) 61 (47 to 73) 2.17 
2008 2.33 5.79 5.70 5.99 57 (46 to 74) 61 (44 to 75) 2.19 
2009 2.33 5.43 5.38 5.54 59 (48 to 75) 61 (46 to 73) 2.10 
2010 2.82 6.70 6.87 6.33 57 (46 to 74) 57 (46 to 73) 2.03 
2011 3.27 8.06 7.91 8.37 58 (47 to 73) 63 (48 to 77) 2.07 
2012 3.20 7.75 7.49 8.29 56 (46 to 75) 63 (49 to 75) 1.96 
2013 3.23 7.97 7.80 8.32 58 (48 to 74) 64 (48 to 76) 1.82 
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Figure 3-10 Joinpoint analysis plot of the percentage of patients with a prevalent episode of carpal tunnel syndrome receiving a corticosteroid injection, over time 
 





Table 3-18 Joinpoint analysis of trends in the proportion of prevalent patients with a recorded episode 





APC Lower CI Upper CI Test 
Statistic (t) 
Prob > |t| 
1 1993 2005 -1.3 -3.2 0.7 -1.4 0.2 
2 2005 2013 6.6 4.3 8.8 6.3 <0.0 
 
The percentage of prevalent patients receiving an injection varied between 5% and 8% and was similar 
between males and females. Figure 3-10 suggests that there was a change in the use of CSI over time, 
in that its use appeared to reduce between 1993 and 2005 (APC = -1.29, 95% CI -3.2 to 0.7) and then 
increase between 2005 and 2013 (APC = 6.56, 95% CI 4.3 to 8.8).  
 Use of nerve conduction studies over time 
The crude data for the total, male and female population with a recorded episode of NCS is presented 
in Table 3-19 and                       Figure 3-11. Figure 3-12 further shows the Joinpoint regression of trends 






Table 3-19 Rate and percentage of patients with carpal tunnel syndrome with a recorded episode of 
nerve conduction studies per calendar year 
Year Episodes of NCS per 
10,000 person years 
% prevalent 
individuals with 
evidence of NCS 
% prevalent females 
with evidence of NCS 
% prevalent males 
with evidence of NCS 
1993 0.72 2.75 2.67 2.99 
1994 0.98 3.70 3.68 3.75 
1995 1.11 4.28 4.35 4.08 
1996 1.38 5.37 5.03 6.32 
1997 1.52 6.09 6.22 5.73 
1998 1.05 4.07 4.06 4.12 
1999 1.00 4.02 3.65 4.99 
2000 1.10 4.39 4.37 4.44 
2001 1.44 5.41 4.95 6.48 
2002 1.21 4.23 4.15 4.41 
2003 1.53 4.90 4.89 4.92 
2004 1.71 5.03 4.49 6.34 
2005 1.94 5.80 5.71 6.01 
2006 2.04 6.19 6.28 5.97 
2007 2.69 7.96 7.50 9.00 
2008 2.94 8.15 7.75 9.07 
2009 3.43 9.21 8.39 11.03 
2010 3.63 9.84 9.40 10.79 
2011 3.70 10.31 9.70 11.61 
2012 3.64 10.09 9.27 11.78 
2013 3.98 11.04 9.92 13.31 
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Figure 3-12 Joinpoint analysis plot of the percentage of prevalent individuals with a coded episode of nerve conduction studies, per year 
 











APC Lower CI Upper CI Test 
Statistic (t) 
Prob > |t| 
1 1993 2004 1.7 -1.8 5.3 1.1 0.3 
2 2004 2009 13.3^ 4.6 22.8 3.4 <0.0 
3 2009 2013 3.6 -2.8 10.5 1.2 0.2 
 
                      Figure 3-11 and Figure 3-12suggest an increase in the use of NCS, over the observed period 
(1.72 APC between 1993 and 2004; 13.32 APC between 2004 and 2009 and 3.64 between 2009 and 
2013).  
 Referrals for carpal tunnel syndrome over time 
The crude data for the total, male and female population with a coded referral or linked referral 
episode are shown in Table 3-21 and Figure 3-14. Figure 3-15 further demonstrates the Joinpoint 






Table 3-21 Rate and percentage of patients with carpal tunnel syndrome with a recorded episode of 
referral per calendar year 
Year Episodes of referral 
per 10,000 person 
years 
% prevalent 
individuals with a 
referral 
% prevalent females 
with a referral 
% prevalent males 
with a referral 
1993 5.15 19.80 19.38 21.03 
1994 5.84 21.96 21.01 24.43 
1995 6.41 24.68 24.18 26.02 
1996 5.59 21.69 21.47 22.32 
1997 5.90 23.68 22.94 25.58 
1998 6.11 23.77 22.90 26.14 
1999 6.86 27.58 26.83 29.58 
2000 7.07 28.15 27.62 29.45 
2001 7.63 28.67 28.58 28.88 
2002 8.20 28.54 28.26 29.19 
2003 9.32 29.76 29.27 30.97 
2004 10.59 31.16 31.30 30.81 
2005 10.91 32.60 32.13 33.71 
2006 10.46 31.73 31.61 32.04 
2007 10.78 31.82 31.40 32.76 
2008 11.73 32.59 32.42 32.98 
2009 12.27 32.95 32.25 34.52 
2010 11.64 31.58 31.09 32.65 
2011 11.23 31.30 31.08 31.76 
2012 11.46 31.80 31.31 32.80 
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Figure 3-15 Joinpoint analysis of the percentage of prevalent individuals with a referral 
 










APC Lower CI Upper CI Test 
Statistic (t) 
Prob > |t| 
1 1993 2005 3.6 2.8 4.4 9.7 <0.0 
2 2005 2013 -0.0 -0.8 0.7 -0.1 0.9 
 
Figure 3-14 and Figure 3-15 show an increase in referrals over the observed study period, which 
appeared to plateau over the latter part of the study.               Figure 3-13 shows that that orthopaedic 
surgeons and physiotherapists received the most referrals, and that the type of referral changed over 
time. Referrals to musculoskeletal clinics began in 2005 and continued to increase until the end of the 
observed period. In 2009, referrals specifically to GP’s with a specialist interest began to be recorded. 
Coded referral destinations may not be entirely accurate in that all local musculoskeletal clinic referrals 
are coded through ‘Choose and Book’ as orthopaedic referrals. Figure 3-15 illustrates the increase in 
referral rate of patients with CTS between 1993 and 2005 (APC 3.6%, 95% CI 2.8 to 4.4), followed by a 
plateau between 2005 and 2013 (APC -0.0, 95% CI -0.8 to 0.7). Only 8.6% of the patients with a surgical 
code, also had a referral code. It is therefore not feasible to calculate the proportion of patients 
referred, who received surgery.  
 Sickness certification for carpal tunnel syndrome over time 
With the provisos stated in the methods around identifying sickness certification in CPRD, all Read 
coded episodes of sickness certification were included. The proportion of patients with a diagnosis of 
CTS who received a sick note is presented in Table 3-22 and                         Figure 3-17 and Figure 3-18 







Table 3-22 Rate and percentage of patients with carpal tunnel syndrome with a recorded episode of 
sickness certification, per calendar year 
Year Episodes of sickness 
certification per 




% prevalent females 
with sickness 
certification 
% prevalent males 
with sickness 
certification 
1993 1.76 6.77 6.54 7.46 
1994 1.75 6.59 6.20 7.61 
1995 1.56 6.01 5.95 6.17 
1996 1.72 6.66 6.09 8.26 
1997 1.63 6.54 6.69 6.16 
1998 1.77 6.90 6.86 7.01 
1999 1.90 7.65 7.45 8.19 
2000 2.18 8.69 8.61 8.88 
2001 2.52 9.46 9.41 9.60 
2002 2.93 10.19 10.40 9.72 
2003 3.44 10.99 11.39 10.00 
2004 4.02 11.84 11.75 12.03 
2005 3.84 11.47 11.70 10.91 
2006 3.58 10.86 10.67 11.32 
2007 3.59 10.59 10.25 11.35 
2008 3.86 10.71 10.39 11.44 
2009 3.70 9.95 9.56 10.83 
2010 3.74 10.16 10.04 10.41 
2011 3.36 9.37 9.34 9.44 
2012 3.30 9.16 9.04 9.40 



















































Figure 3-18 Joinpoint analysis of episodes of sickness certification as a percentage of the prevalent population, per year 
  











APC Lower CI Upper CI Test 
Statistic (t) 
Prob > |t| 
1 1993 1997 -0.4 -3.3 2.7 -0.3 0.8 
2 1997 2004 9.1 7.4 10.9 11.8 < 0.0 
3 2004 2013 -3.2 -4.0 -2.3 -8.0 < 0.0 
 
                        Figure 3-17 and Figure 3-18 suggest that the use of sickness certification in patients with 
a diagnosis of CTS increased between 1997 and 2004 (APC 9.1, 95% CI 7.4 to 10.9) before decreasing 
over the remainder of the observed period (APC -3.20, 95% CI -4.0 to -2.3). 
 Use of wrist splints for carpal tunnel syndrome over time 
CPRD may substantially underestimate the number of patients to whom splinting is recommended for 
reasons previously mentioned (not a prescribed item and clinicians would not ordinarily add a specific 
Read code if they were recommending an approach to self-care). The frequencies and proportion of 






Table 3-24 Rate and percentage of patients with carpal tunnel syndrome with a recorded episode of 





































with a code 
for wrist 
splinting 
1993 0.00 0.00 0.00 0.00 0.00 0.00 
1994 0.00 0.00 0.00 0.00 0.00 0.00 
1995 1.00 1.00 0.00 0.03 0.04 0.00 
1996 2.00 2.00 0.00 0.05 0.07 0.00 
1997 3.00 0.00 3.00 0.07 0.00 0.26 
1998 0.00 0.00 0.00 0.00 0.00 0.00 
1999 4.00 1.00 3.00 0.07 0.02 0.19 
2000 2.00 0.00 2.00 0.03 0.00 0.10 
2001 7.00 7.00 0.00 0.09 0.12 0.00 
2002 10.00 5.00 5.00 0.10 0.07 0.17 
2003 6.00 6.00 0.00 0.05 0.08 0.00 
2004 25.00 18.00 7.00 0.20 0.20 0.19 
2005 19.00 10.00 9.00 0.15 0.11 0.24 
2006 16.00 14.00 2.00 0.13 0.11 0.05 
2007 33.00 30.00 3.00 0.25 0.33 0.07 
2008 19.00 11.00 8.00 0.14 0.11 0.19 
2009 28.00 21.00 7.00 0.19 0.21 0.16 
2010 8.00 7.00 1.00 0.06 0.07 0.02 
2011 69.00 54.00 15.00 0.51 0.59 0.35 
2012 59.00 49.00 10.00 0.44 0.54 0.23 
2013 28.00 21.00 7.00 0.22 0.25 0.17 
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3.7 The prevalence and incidence of carpal tunnel syndrome in CPRD: Discussion 
 Summary of main findings 
The prevalence of carpal tunnel syndrome in patients presenting in UK primary care, increased over 
the observed study period between 1993 (26.03 per 10,000 person years, 95% CI 25.10 to 27.00) and 
2013 (36.08, 95% CI 35.45 to 36.72), with a peak in 2009 (37.23, 95% CI 36.60 to 38.81). The ratio of 
female to male patients decreased over time, from 2.74 in 1993 to 1.93 in 2013. A similar increasing 
pattern in the incidence of CTS was also observed between 1993 (20.22, 95% CI 19.24 to 21.24) and 
2013 (27.68, 95% CI 27.09 to 28.28), with a peak in 2009 (29.32, 95% CI 28.74 to 28.82). A decrease in 
the female: male ratio was observed over time (2.57 in 1993 and 1.88 in 2013). The median age of 
female and male patients recorded with a diagnosis of CTS increased over the study period.  
 Interpretation of results 
Figure 3-3 and Figure 3-6 demonstrate a significant increase in the prevalence and incidence of CTS 
over the study period. The initial 6 years of CPRD data (1987 to 1993), in keeping with the population 
of CPRD, included small numbers of patients leading to wide confidence intervals in prevalence and 
issues calculating incidence (e.g. when no male patients were present in the prevalence group in 1987). 
From 1990 the population size of CPRD increased and the results become more stable between years. 
Data was therefore presented from 1993 onwards. At the time of data acquisition, 2013 was the most 
recent data available. 
Incidence was calculated based on prevalence, meaning the trends over time are understandably 
similar. The difference between the two measures is because prevalent patients who were still 
experiencing symptoms would present in consecutive annual periods, whereas incident patients would 
only present in the index year (unless being represented more than two calendar years following, as a 
new presentation). Incidence figures may also be slightly lower due to the criterion applied requiring 
patients to have two years full registration from the midpoint of the incident year. The denominator 
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population used for calculating incidence had the same criterion applied, which should have minimised 
this effect. 
Table 3-8 and Table 3-11 present the crude estimates of prevalence and incidence. These estimates 
were then directly standardised to the age sex structure of the 2013 UK population. This process 
controls for any change in the age and sex structure of the population over the observed period. The 
crude and standardised rates are very similar, as shown in              Table 3-14, suggesting that the 
population structure did not change over the observed period in a way that would impact the trends 
observed in the prevalence and incidence of CTS.  
Joinpoint analysis identifies and estimates the magnitude and significance of changes in trends. 
Prevalence decreased non-significantly (at a level of P< 0.05) between 1993 and 2000 before increasing 
significantly between 2000 and 2004 and at a slower rate between 2004 and 2013. Incidence was 
steady between 1993 and 2000 but increased significantly between 2000 and 2004 before plateauing 
out between 2004 and 2013. 
Joinpoint analysis points to events occurring at the ‘Joinpoints’ i.e. in 2000 and 2004, which may be 
related to the trends being observed. CPRD, as discussed in 3.1.3, relies on data being of sufficient 
quality in order to produce valid research. Information for Health was the UK Government’s 
information technology strategy for the NHS.92 It envisioned that by 2005 the person-based electronic 
health record, would have been fully implemented.93 Although associations with such events cannot 
be established using Jointpoint regression, it may be speculated that with the increasing use of IT 
systems in primary care and attention to coding, episodes of CTS were more frequently and accurately 
recorded. This would not however explain the continuing increase in the trend post 2005.   
Between 2000 and 2004, the Labour Government was implementing the second phase of its War on 
Waiting, i.e. the reduction of waiting times. For example, the target for the maximum wait for a day-
case procedure (i.e. a CTR) was reduced from 18 months to six months.94 Anecdotally, the managers 
of the local orthopaedic team recall a time in 2004 when the carpal tunnel release list was ‘blitzed’ and 
a large number of patients were operated on to ‘clear the waiting list.’ The peak in prevalence seen in 
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2004 may therefore be explained by the fact that patients requiring surgery were ‘accumulating’ 
between 2000 and 2004. They then received an effective treatment, which reduced the rate of further 
presentations in primary care for ongoing symptoms and hence the corresponding prevalence. This 
effect would not however be expected to impact upon the incidence, which disregards repeat patient 
presentations in subsequent annual periods, unless patients with a less specific initial code received 
treatment and appeared as an incident episode following a condition specific intervention.  
The change in trends in 2004 may also represent a change in service. The introduction of the Quality 
and Outcomes Framework (QOF) occurred with the introduction of the General Medical Services 
(GMS) contract in 2004. QOF can be considered to be a form of ‘performance related pay’ for practices. 
Although there has never been a domain for musculoskeletal health, the importance of coding to 
develop and maintain registers and evidence patient outcomes, may have influenced coding behaviour 
and in turn led to an increase in the more frequent and more specific use of the CTS Read code.  
At the same time as the introduction of QOF, Primary Care Trusts (PCT’s) were given a role in 
commissioning services, with the aim of better meeting the needs of the local population. The ability 
of PCT’s to commission new services heralded locally the development of the Musculoskeletal 
Interface Clinic (MIC), which acts as a ‘one stop shop’ for patients with musculoskeletal problems. A 
referral to this clinic from primary care may also be a reason why prevalent patients with persisting 
symptoms stopped presenting in primary care as they had open follow up in the MIC.  
These three factors (changes in coding behaviour, a reduction in waiting times, and service 
redevelopment) may all contribute to the change in trends of CTS presentations between 2000 and 
2004 but given the increase in incidence as well as prevalence during this period, there are likely to be 
additional reasons.  
CTS is associated with certain occupations. Blue-collar workers involved in manufacturing, 
construction, meat and fish-processing and work involving chain saws and white-collar workers in 
personal service industries, have been observed to be more likely to develop CTS.95 A change in the 
occupational structure of the population may therefore influence the prevalence of CTS. CTS as an 
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occupational condition may also influence consultation rates, if patients were pursuing a legal claim 
against their employer.  
The median age and gender ratios are similar to those presented in previous studies, as summarised 
in Table 1-2. The apparent trend of the female: male reducing over time, has not been previously 
commented on in the literature. The trend may pertain to the aetiology of the condition and its 
association with occupation. A social shift in occupations, either attracting more males than females, 
or attracting males into a previous more female orientated environment, may lead to a change in the 
gender ratio affected by CTS, if the occupation was associated with exacerbating CTS. This however 
remains conjecture and would require more precise observational studies to provide evidence for this 
hypothesis, since occupation is not recorded in CPRD, and trends in occupation cannot be derived from 
the presented data.  
As described in previous studies, CTS shows a peak in prevalence and incidence in women of middle 
age (50–59 years age group), potentially due to hormonal changes around the time of the 
menopause), while in the male population, the prevalence and incidence of CTS increased with age. 
Gelfman et al also described an increasing number of older people presenting with CTS.96 The increase 
in the prevalence and incidence of CTS in the older-aged male groups, may partially account for the 
observed decrease in the female-to-male ratio, over time. 
The aetiology of CTS was discussed in 1.2.2. A change in the prevalence of these factors, for example 
increasing rates of obesity97 and diabetes,98 may subsequently contribute to an increase in the 
incidence of CTS.  
 Findings in relation to other studies 
Table 1-1 and Table 1-2 summarise the prevalence, incidence and gender ratios of CTS observed and 
demonstrate the substantial differences that exist between studies; including the case definition of 
CTS used, methodology applied and population and setting observed. Comparing this study to others 
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is therefore difficult in that it is not clear how similarities and differences in design explain variability 
in results.  
As discussed in 1.2.1, the prevalence of CTS in any given population is likely therefore to depend on 
the definition of CTS applied.18 The case definition in the study presented in this chapter was derived 
from clinician recorded diagnosis and treatment codes applied, which are very likely to have been 
based on clinical findings alone but may also have included those who had further investigations (NCS) 
and those who received definitive condition-specific treatment (CSI and / or CTR). Hence, this study 
used a pragmatic approach, across a large population that included all patients presenting to their GP 
with symptoms. These study methods assume that patients with symptoms present in primary care 
and receive a definitive code. CPRD will not capture patients with chronic symptoms who do not 
present in primary care or who are not attributed a code. 
The studies which are most similar to the one presented in this thesis are those of Latinovic et al and 
Bongers et al, both of which utilised primary care data in their methodology. A comparison is made in 
Table 3-25. Bongers et al noted an increase in incidence in the Dutch primary care population from 190 
(female) and 60 (male) per 100,000 population in 1987, to 280 (female) and 90 (male) per 100,000 
population in 2001.99 Latinovic et al’s results were similar stating an incidence in the UK primary care 
population in 2000 of 192.8 (female) and 87.8 (male) per 100,000 population.19 The female: male were 
2.2319 and 3.17 (1987) and 3.11 (2001).99  
As Latinovic et al was set in the General Practice Research Datalink, the forerunner to CPRD, one would 
expect similar results to be found. However, the results of the current study appear to show a higher 
incidence, more similar to the study by Bongers et al, set in The Netherlands. This is likely to be due to 
the different method of determining incidence. Latinovic et al selected only the first episode of CTS, 
whereas the current study required a two-year clear period prior to an incident episode being 
recorded. If the first ever criteria had been used, the incidence found by the current study would be 
slightly lower, but would still not match that of Latinovic et al. Further possible explanations of why 
the figures are not the same include the use of slightly different Medcode lists, the use of linked 
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prescription data, a different population (Latinovic only included practices with up to standard data 
for the entire 1992 to 2000 period) and a different criterion for determining the denominator 
population was applied. In this study, in order for the numerator and denominator populations to be 
treated equally, the denominator population for incidence had to have contributed up to standard 
data for the period 2 calendar years prior to the index year (measured at the midpoint). All these 
factors are likely to have contributed to the different rates observed between the studies.  
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Not all studies have identified increasing trends of CTS. One observational study by Roquelaure et al 
(2017) used multiple sources of data to observe the incidence of CTS in different situations. Hospital 
discharge data was used to estimate surgically treated CTS. The Pays de la Loire surveillance program 
of musculoskeletal disorders was used to estimate CTS compensated for as an occupational disease 
and the French National Health insurance system to estimate work-related diseases, over an 8-year 
period (2004 to 2011). A decrease in the annual incidence rates of surgically treated CTS (3.35 to 2.98 
per 1000 person years) and work related CTS (5.04 to 3.08 per 1000 employed person years) was 
observed but the incidence of CTS compensated for as an occupational disease increased over the 
study period (1.52 to 2.34 per 1000 person years).100 Whilst the authors acknowledge that certain 
population groups may not contribute to the data-sets (e.g. non-salaried workers and agricultural 
workers) and that compensation schemes would collect bilateral CTS as two episodes, they report that 
these factors are likely to have remained stable over the observed period and that the trends over 
time remain valid. They conclude that a series of occupational and non-occupational changes brought 
in over the course of the study reduced the likelihood of developing CTS, whereas campaigns 
increasing the awareness of ‘upper extremity musculoskeletal disorders’ in the workplace may have 
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prompted patients to seek compensation.100 The population described in this CPRD study is not likely 
to be very similar to the population observed in Roquelaure et al since it seems older / non-working 
patients were not identified, unless they had surgery.  
3.8 The management of carpal tunnel syndrome in CPRD: Discussion 
 Summary of main findings 
The proportion of patients with prevalent CTS having surgery in each calendar year increased over the 
study period from 19.35% in 1993 to 27.41% in 2013, with the median age of those having surgery also 
increasing by 4 years for women and 7 years for men. The ratio of female: male having surgery reduced 
from 2.63 in 1993 to 1.74 in 2013, suggesting that an increasingly greater proportion of prevalent male 
patients had surgery than their female counterparts. The coded use of CSI was relatively stable 
between 1993 and 2005 (APC = -1.29) with an increase in use between 2005 and 2013 (APC = 6.56). 
The use of splints, as expected, was poorly coded however results suggest that the use of NCS, referral 
to specialist care and sickness certification generally increased over the study period.  
 Interpretation of results 
Definitive treatment options for patients with carpal tunnel syndrome in primary care are limited to 
CSI and wrist splinting. The availability of CSI is dependent on a competent injector operating within 
the practice and splinting is normally recommended to patients as a ‘selfcare option’ i.e. whilst 
referrals may be made to an orthotist or occupational therapist, it is often the case that the patient is 
expected to acquire a splint from a pharmacist or online provider.  
Splinting was therefore poorly coded and as such further analysis was felt not to be sensible. The 
percentage of prevalent patients receiving a CSI was also relatively low and substantial uncertainty 
exists as to whether the results are truly representative of practice. However, two methods were 
employed to attempt to capture episodes of injection: the use of Read codes and linked prescription 
data. Injections delivered outside of primary care are unlikely to have been coded. 
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Figure 3-10  suggests an increase in the use or coding of CSI from 2005 until the end of the study period 
(APC 6.6). This may be associated with a move to full electronic patient records, meaning that a greater 
proportion of prescriptions issued for stock drugs were recorded in the patient record, as opposed to 
be written out manually. It may also represent a true increase in the use of CSI at a time where GP’s 
were adapting to the new GMS contract and directly enhanced services, that in effect pay GP’s to 
perform minor procedures (nb this is no longer the case).  
Along with splinting, CSI is a mainstay of primary care treatment and one would assume that all 
patients having surgery were very likely to have had an injection or tried splinting first, plus those who 
responded and did not require surgery. It is highly likely therefore that injections simply were not 
picked up by the methods applied or, patients who do receive CTI’s tend to receive them outside of 
primary care, e.g. the musculoskeletal interface clinic.  
If conservative treatment options were unsuccessful or not available, referral to specialist services 
would be necessitated in order to access further investigation and management. Figure 3-14 and 
Figure 3-15 demonstrate an overall increase in referrals over the study period, particularly between 
1993 and 2004. This preceded a period where referrals were almost the same each year (2005 and 
2013, APC -0.05), noting patients may have received more than 1 referral code in each annual period.  
This observation is interesting, particularly in the current climate of financial hardship within the NHS 
and the drive to scrutinise referrals and reduce costs. Referral of care and clinical responsibility 
between professionals is a complex area and involves a balance between several competing interests, 
particularly the GP acting as the clinical advocate of the patient as well as the gatekeeper of NHS 
resources. The referral process has a direct consequence on the patient’s experience of care as well as 
being a major cost-driver in the NHS. A ‘good’ referral should be: clinically necessary; to the most 
appropriate destination first time and use the correct process. Rates of referral can be influenced by 
population health needs, GP attitudes towards risk and patient pressure and expectation.101 
At a national level, GP referrals to outpatient services increased by 19 percent between 2005 and 
2009.102 Whilst the significant increase in referrals in this study preceded this, explanations for such an 
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increase could include: a true clinical need whereby patients have a better outcome if referred out of 
primary care; patient demand for referral being greater; fewer GP’s being able to offer CSI (although 
this would be contrary to the findings of this study) or a change in the phenotype of CTS meaning that 
symptoms were more severe and required consideration of surgery. It is also possible that the increase 
in Tier 3 type MIC’s meant that GP’s were more likely to refer patients into a service where a block 
contract exists (meaning that the cost is already covered by a block payment and covers the complete 
care of the patient). It may be that GP beliefs are such that patients receive better care in these clinics 
and that the need for them to provide injections (which takes time within an already time burdened 
day), is removed. It is likely that the reasons behind the observed trends are a combination of these 
factors.  
              Figure 3-13 demonstrates the destination of referrals in each year. The first time a referral to 
a musculoskeletal clinic was coded was in 2005 and to a GP with specialist interest, in 2009. This 
highlights the introduction of Tier 3 services; however the coding is unlikely to be truly representative 
of the referral destinations.  
Access to nerve conduction studies varies between locality and often requires the patient to have been 
referred into further care.                       Figure 3-11 and Figure 3-12 demonstrate an increase in the use 
of NCS over the observed study period. Interestingly, the proportion of patients having NCS increased 
at a time when referrals were not increasing. Perhaps GP’s had access to NCS and were using this as a 
means of investigation; avoiding referral or at least delaying it. It may also be that, whilst clinical 
guidelines did not change, new referral or treatment pathways demanded NCS in order to quantify 
severity and ration further treatment. It may also be a reflection on coding practice. 
It is also possible that as NCS have become more accessible with the advent of hand-held devices 
(which allow for a quick and relatively cheap test and computerised analysis to take place), its use in 
NHS clinics has increased. Whilst not supported by any change in any national guideline, an increase 
in use of investigations may represent a trend towards more risk-averse clinical practice, or indeed 
investigation results being used to ration access to CTR.  
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Joinpoint analysis of the use of surgery over time (Figure 3-8), suggests a significant increase between 
1993 and 2007 (APC = 2.6), followed by a reducing trend between 2007 and the end of the study in 
2013 (APC = -1.7). The initial increase in the apparent use of CTR may have been due to increased 
availability of the procedure, or have been an effect of the dissemination of the evidence generated 
by authors such as Gerritsen et al who, in 2002, published the results of a RCT showing CTR to be 
superior to splinting.103  
Substantial changes to the structure of the NHS were taking place at the time of the 2007 joinpoint. 
Around 2007 to 2008, practice-based commissioning (PBC) was being introduced. This gave GP’s 
notional budgets with which to purchase care for their patients. The aim behind this shift in funding 
streams was to align the clinical and financial responsibilities of primary care. The new commissioning 
consortia needed to find ways to reduce referrals and reduce costs of treatments. Referral 
management schemes were introduced and restrictions placed on procedures carried out in secondary 
care. Results showing a reduction in surgery rates would fit with restrictions being placed on the 
procedure (e.g. patients needing more serious symptoms for longer, having had tried injections and in 
some cases severe findings on nerve conduction studies). Such requirements may also explain the 
increase in the use of injections and nerve conduction studies being used as an alternative treatment 
and as a necessity prior to surgery, respectively.  
CPRD is not directly set up to monitor sickness certification, however, by using Read codes,                         
Figure 3-17 and Figure 3-18 are suggestive of an initial increase in sickness certification followed by a 
small but significant reduction in the proportion of patients having an episode of sickness certification 
between 2004 and 2013 (APC = -3.07). Reduction in sickness certification may represent either an 
improvement in care, meaning patients are able to return to work or stay at work or that patients were 
choosing to persevere at work rather than risk financial disincentives. It may also have been the case 
that the workplace had less of an effect on the incidence and severity of CTS. It seems more likely that 
with the development of electronic health records, sickness certification (or fit notes since 2010) are 
now embedded within the consultation and not necessarily coded as a separate entity.  
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 Findings in relation to other studies 
The increasing rate of CTR use has been recognised by other authors working in the NHS. Wildin et al’s 
audit data from one tertiary hand centre, suggested that the rate of CTR procedures had increased 
over the earlier 10 year period between 1989-9 and 2000-1.104 It would therefore be useful to observe 
the figures over these two periods and into more recent times to explore whether a trend truly exists 
and to hypothesise as to what the reasons behind this might be.  
Possible reasons include: increased access to specialist services, perhaps via tier 3 community clinics; 
increased litigation leading to more definitive treatments being sought and increased patient 
expectations and demand. It may also be possible that fewer GP’s were offering conservative 
management options, such as injections, and tended to refer patients into specialist care, where the 
operative rate was higher.  
Latinovic et al found that in 2000, 31% of CTS patients in the GPRD population had surgery.19 This is 
higher than the 25.54% described in this study. However, this study identified more individuals with a 
surgical code but used a different denominator, which partially explains the difference in reported 
rates of surgery. Latinovic et al used the incident population, whereas this study used the prevalent 
population as not all surgical episodes occurred in the same annual period as the incident episode (see 
below).  
A further study carried out over a similar time-period using the nationwide patient registry of Sweden, 
observed that between 2001 and 2009, both the incidence of CTS diagnosed in secondary or tertiary 
care and first time CTR increased. Incidence increased from 216 to 243 per 100,000 person years in 
women and from 95 to 119 in men. The mean annual increase in first time CTR over the study period 
was 5.1% in women and 6.2% in men. Substantial differences in the percentage of patients having 
surgery were observed depending on region (53 to 91% in women and 51 to 77% in men).105 
The effect of regional variation will be discussed further in Chapter 5, however it appears likely that 
the healthcare system in which the population is observed has a substantial impact on the reported 
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incidence of surgically treated CTS. The regional variation of CTR in the CPRD population over time is 
shown in Appendix B5. 
Predicting what may happen to the rates of CTS and CTR in the future, Bebbington and Furniss 
observed for shifts in the presentation of and procedures for hand conditions within HES data. Linear 
regression was used to predict future trends in hand surgery. The authors suggest that whilst absolute 
numbers of CTS diagnoses and CTR procedures increased between 1998 and 2011, the pre-2008 
increase in CTR was significantly steeper than the post-2008 slope (p<0.001).106 This is suggestive of a 
decrease in the surgical management of CTS in terms of the proportion of patients with CTS having an 
operation, but not necessarily in the numbers of surgical episodes in absolute terms, which Bebbington 
and Furniss predict will have increased by 99% (95% CI 65 to 132) in 2030 compared to 2011.106 The 
data from CPRD however, suggested a reduction in both real-term episodes of CTR as well as the 
proportion of the (increasing) prevalent population receiving surgical treatment. This difference may 
relate to the fact that linear regression modelling cannot account for the fact that services may be 
further rationalised or even decommissioned in the future. Whilst HES data will accurately identify CTR 
taking place in secondary care, it will not identify CTR taking place in the community.  
3.9 Methodological considerations 
Several limitations associated with the data used in this study exist. The quality of coding is a potential 
limitation of any research conducted using electronic healthcare data. This study relies on the 
clinician’s initial diagnosis and further coding of CTS, being correct. The coding of the subsequent 
management, referral and treatment is also required to be as sensitive and specific as possible. 
Measures were taken to reduce the effect of inaccuracies in coding (e.g. by including surgery and 
injection codes in prevalence measures, if diagnostic codes had not been used). However, as discussed 
in 3.3.3, misclassification may lead to the results not being entirely representative of the true clinical 
picture.  
Due to a lack of clarity in the accuracy of coding and the likelihood that associated clinical encounters 
following a CTR were coded using a surgical code, only the first surgical code could reliably be used to 
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indicate an episode of surgery. This is likely to have led to an underestimation of the frequency of true 
surgical episodes, as episodes on the contralateral hand will have been automatically excluded as they 
were indistinguishable from other clinical contacts using the same code. In fact, prevalence and 
incidence were also likely to have been underestimated as presentations in the contralateral hand are 
indistinguishable from repeat presentations for the ipsilateral hand. This is a possible reason as to why 
the proportion of patients having surgery is lower than that reported in some other studies 
(Tadjerbashi reported first ever CTR being as high as 81%).105 
A further consideration, which may have led to errors in the estimation of prevalence and incidence 
with regard to time period, was the fact that treatment codes were also used to evidence a diagnosis 
of CTS. As discussed in section 3.3.3, this was felt necessary in order to ensure that patients seeking 
and receiving care with symptoms of CTS were still included even if they had either received no code 
or a more generic code but still had a condition specific treatment. To not include such treatment 
codes may have led to a substantial underestimate of the population actively receiving care for their 
CTS symptoms.  
However, whilst the annual prevalence would be correct with regard to the period that the patient 
received care in, it is possible that incident patients were recorded in an annual period later than their 
initial yet un-identifiable incident presentation. It also means that, given the fact that they had surgery, 
patients with more severe symptoms may have been more likely to have been identified than those 
with less severe and potentially vaguer symptoms. This would potentially lead to an overestimate of 
the proportion of prevalent patients who had surgery, as those with milder and vaguer symptoms 
remained un-coded or otherwise un-identifiable by Read code.   
The coding frequencies for CSI were also apparently low, although these did increase over the study 
period. It is likely that, with the availability of MIC’s, patients were referred to this clinic where the 
injection took place. The intervention would then have been recorded in hospital records and not 
necessarily coded in primary care records on receipt of the clinic letter. 
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3.10 Clinical relevance of the findings  
This study has shown that as well as an increase in the number of patients consulting in primary care 
with CTS, a greater proportion of these patients are being referred out of primary care. Although this 
does not necessarily translate into an increased proportion of patients having surgery or indeed 
experiencing a better outcome, it does suggest an increase in the cost burden of the condition. If GP’s 
are not necessarily referring for assessment for surgery in each case, it is possible that more patients 
could be treated with NS and / or CSI within primary care and only referred when such treatment has 
failed or symptoms are severe. Learning how to most effectively manage CTS in primary care whilst 
understanding which patients are likely to require surgery, is likely to benefit both patients and the 
healthcare economy.  
3.11 Suggestions for further research 
Whilst CPRD provides a large sample size representative of the UK population, which has substantial 
benefits when estimating epidemiological trends, it cannot directly measure patient outcome. Surgery 
can be perceived as a ‘gold standard’ treatment, but it does not necessarily signify cure. Further 
research observing the characteristics of patients presenting in primary care with CTS in greater detail, 
in order to estimate their eventual outcome, may provide useful guidance to clinicians when deciding 
how best to counsel, treat or refer their patients with CTS. This thesis will present two prognostic 
studies with the aim of predicting firstly, an episode of surgery using a cohort derived from this study 
in CPRD and secondly, patient reported outcome in a trial population set in primary care.  
3.12 Conclusion 
This study has demonstrated that the prevalence and incidence of carpal tunnel syndrome increased 
over the study period between 1993 and 2013. Rates of referral for CTS have also increased over the 
study period, however in the later years of the study, the proportion of patients receiving surgery was 
observed to decline. Possible reasons for these observations have been proposed and are likely to be 
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associated with changes in healthcare delivery. In chapter 4, a systematic review and narrative 
synthesis of the literature will be presented with the aim of defining the clinical course of CTS and 
examining patient level predictors of outcome.
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4 The prognosis of carpal tunnel syndrome: The clinical course and 
prognosis of conservatively managed carpal tunnel syndrome - a 
systematic review and narrative synthesis of cohort studies  
 
 Summary 
The study reported in chapter 3 used data from electronic health records to describe the 
trends in the epidemiology and management of carpal tunnel syndrome presenting in UK 
primary care. It was concluded that whilst the prevalence and incidence of CTS was observed 
to increase over time, factors including changes in healthcare delivery were likely to have 
impacted on how CTS was managed. This chapter presents the identification and synthesis of 
scientific literature evaluating the clinical course and prognosis of carpal tunnel syndrome. The 
studies included in the review incorporate multiple settings and hence give a broader overview 
of prognosis and its possible determinants, not limited to a single healthcare setting. The aims 
of this chapter are therefore to summarise available evidence regarding the clinical course of 
conservatively managed carpal tunnel syndrome and to identify predictors of its outcome.  
The work in this chapter has now been published in a peer-reviewed journal under a Creative 
Commons License:  
Burton C, Chesterton LS, Chen Y, Van der Windt D. Describing the clinical course and prognostic 
factors in conservatively managed carpal tunnel syndrome: A systematic review. Archives of 
Physical Medicine and Rehabilitation. October 2015 97(5): 836-852.e1 
 
4.1 Introduction 
Summarising the evidence regarding the course of CTS and predictors of its outcome using studies 
from multiple healthcare settings will identify any gaps in the research evidence and / or provide a 
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summary against which observations from UK primary care patients can be compared. The principles 
of the type 1 and type 2 prognosis studies as outlined by the PROGRESS Framework introduced in 1.7 
will now be described in further detail. 
 Overall prognosis research 
Overall prognosis research generates estimates of the average or overall prognosis (likely future course 
or outcome) for a given population with a particular health problem. It is therefore of use to public 
health policy makers as it allows for the population burden of a condition to be ascertained and 
appropriate resources to be planned. Furthermore, understanding the likely future outcome of 
patients with a condition, in relation to current clinical practice (clinical course) or in the absence of 
care (natural history), allows the potential impact of new interventions to be more fully assessed.71 
Thus, the availability of information about overall prognosis makes for more robust informed shared 
decision making in clinical practice, by helping to answer questions such as ‘what is likely to happen if 
I do nothing?’ 
Potential limitations of prognosis research do exist. Henderson et al discuss the hazards of providing 
predictions of the course of a condition due to the implicit variability between individuals or individual 
clusters, (e.g. within clinicians, health care providers and geographical regions).107 It should therefore 
be emphasised that overall prognosis research is concerned with describing and understanding 
variations around the average course of a condition rather than that of the individual.71  
The systematic review and subsequent narrative synthesis presented in this chapter focus on 
summarising the results of existing prognosis research, which has investigated the course of untreated 
and conservatively managed CTS. The ‘startpoint’ for observing prognosis is ideally as early in the 
course of CTS as each individual primary study allows. The ‘endpoint’ varies across studies but is usually 
a specified patient reported outcome after a set time point, or referral for or episode of surgical 
management, marking the end of conservative management. The synthesis therefore seeks to describe 
the course of CTS managed with no treatment or conservative (non-surgical) management options.  
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 Prognostic factor research 
A prognostic factor (or predictor) is; 
“…any measure that, among people with a given health condition (startpoint), is associated 
with a subsequent clinical outcome (endpoint).72 pg 1. 
Prognostic factor research seeks to identify the predictive value of such factors and can begin to 
describe and explain the variability in overall prognosis, due to baseline differences between 
individuals.  
Research of individual prognostic factors may subsequently contribute to the development of 
prognostic models, whereby individual prognostic factors are combined in order to estimate the 
prognosis of an individual, based on their baseline characteristics. Prognostic factors may also 
represent potential predictors of treatment effect (treatment effect moderators), which may further 
contribute to a stratified care approach to a condition, i.e. whereby particular treatments are matched 
to patients based on their baseline characteristics. Prognostic factors may also represent modifiable 
targets for interventions and could lead to the development of new management strategies through 
an improved understanding of disease mechanisms.72  
Again, limitations to prognostic factor research exist. Riley et al discuss the fact that prognostic factor 
research studies are often poorly designed, analysed and reported. Recommendations for the 
improvement of prognostic factor research to help mitigate these issues were proposed. In order to 
reduce the risk of reporting bias, all factors and outcomes should be reported transparently, including 
null results. When summarising the findings of multiple studies, the ideal would be to prospectively 
plan and perform meta-analyses of individual patient data.72  
The second part of this systematic review and narrative synthesis seeks to identify predictors of 
outcome in patients with CTS being managed conservatively with treatments available in primary care. 
Whilst the rate and predictors of surgical outcome have been reported in the literature,108, 109 at the 
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time of preparing this review few studies and no systematic reviews had summarised the evidence for 
prognosis and prognostic factors in conservatively managed CTS. 
4.2 Methods 
The following work was based on a search conducted in 2013 and has since been published.110 The 
review and synthesis informed the design of the reported studies in subsequent chapters and as such 
has not been formally updated. However, section 9.2.2 describes any relevant updates in the literature 
and the potential impact they may have had on the findings of this review. The protocol for this review 
was registered on PROSPERO (CRD42013006608) and can be accessed at 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42013006608#.VYk_RflVhBc. 
Results of studies identifying or testing predictors of treatment effect (potential moderators) have 
been described in the review of intervention studies (trials) presented in Chapter 7. 
 Eligibility criteria 
To be eligible for inclusion in the review, studies were required to fulfil the following criteria as shown 
in Table 4-1 and Table 4-2. 
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Table 4-1 Summary of inclusion criteria 
 Inclusion criteria 
Population Adult population aged 18 years or over 
Diagnosed with carpal tunnel syndrome (method of diagnosis to be 
documented) 
Interventions or exposure The observation of patients with a diagnosis of CTS receiving no 
treatment or usual care (limited to conservative or nonsurgical 
management approaches) 
Outcomes Outcome measures able to indicate change in symptoms and/or 
function including: global improvement measures; Boston Carpal 
Tunnel Questionnaire score or similar disease or region specific 
outcome measure; return to work and / or requirement of further 
treatment (likely to be carpal tunnel release surgery). 
 
Associations of potential prognostic factors (baseline patient or disease 
characteristics) with these outcomes were required for inclusion in the 
second part of the review 
Setting Any healthcare setting  
Study design Retrospective or prospective cohort studies 
 
Table 4-2 Summary of exclusion criteria 
 Exclusion criteria 
Population Cohorts specifically of pregnant women with CTS 
Studies reporting conditions other than CTS 
Studies reporting outcomes in specific populations such as 
occupational groups  
Studies with a follow up of less than six weeks 
Studies investigating secondary CTS (e.g. post-traumatic) 
Interventions or exposure Studies reporting risk factors for onset of CTS (aetiology) as opposed to 
predictors of outcome (prognosis) 
Studies reporting prevalence and incidence alone 
Studies reporting only on outcomes following specific types of allocated 
/ randomised treatment (to be investigated in a later review)  
Study design Papers in languages other than English where no translation was 
available 
Designs other than those described in the inclusion criteria, e.g. case 
studies, cross-sectional studies, and clinical guidelines 
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 Search strategy 
The methods used to identify studies fulfilling the eligibility criteria will now be discussed.  
4.2.2.1 Medical Literature Databases 
Ten medical databases were searched for relevant articles, from their creation to December 2013. 
These databases are briefly described below using information relevant at the time of the search: 
4.2.2.1.1 MEDLINE 
MEDLINE (Medical Literature Analysis and Retrieval System Online) is the U.S. National Library of 
Medicine bibliographic database containing over 21 million references to journal articles with a focus 
on biomedicine. The records are indexed with National Library of Medicine (NLM) Subject Headings 
(MeSH). The database runs from 1946 to the present with some older material. Citations are sourced 
from over 5,600 worldwide journals and are created by the NLM, its partners and collaborating 
organisations.111    
4.2.2.1.2 EMBASE 
EMBASE (Excerpta Medical Database) is a biomedical and pharmacological database hosted by the 
publisher Elsevier. Embase contains over 22 million records from 1974 – present. The database utilises 
‘Emtree’ which is thesaurus of search terms.112  
4.2.2.1.3 AMED 
AMED (The Allied and Complementary Medicine Database) provides an alternative medicine database. 
It includes articles regarding complementary medicine, physiotherapy, occupational therapy and 
rehabilitation therapy. AMED contains records from 1995 onward and is produced by the Health Care 
Information Service of the British Library.113 
4.2.2.1.4 HMIC 
HMIC (Health Management Information Consortium (HMIC) is a compilation of data from the 
Department of Health’s Library and Information Services and King’s Fund Information and Library 
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Service. HMIC therefore covers official publications, journal articles and grey literature on: health 
service policy, management and administration. Information is focused on the UK and covers 1979 to 
present.114  
4.2.2.1.5 PsychINFO 
The PsycINFO database provide international coverage on psychology and allied fields, to include 
research within clinical fields. It runs from 1806 to date.114 
4.2.2.1.6 CINAHL 
CINAHL (Cumulative Index to Nursing and Allied Health Literature) provides information from the field 
of nursing and allied health professionals. Journals from biomedicine, alternative therapies, health 
sciences and health promotion are scanned for relevant articles. CINAHL covers the period from 1981 
to date and uses a thesaurus adapted from Medical Subject Headings (MeSH).114  
4.2.2.1.7 Cochrane  
The Cochrane Library contains seven databases that contain difference types of high quality, 
independent evidence to inform health-care decision making. The databases include: Cochrane 
Database of Systematic Reviews, Cochrane Central Register of Controlled Trials and the Cochrane 
Methodology Register.115 
4.2.2.1.8 TRIP  
Trip is a clinical search engine designed to provide access to high quality clinical research. The database 
has been online since 1997.116 
4.2.2.1.9 SCI-EXPANDED  
SCI-EXPANDED (Science Citation Index ExpandedTM), is accessed via Web of ScienceTM and provides a 
bibliographic and citation index from 8500 of scientific and technical journals from 150 disciplines.117 
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4.2.2.1.10 CPCI-S  
CPCI-S (Conference Proceedings Citation Index – Science) is accessed via Web of ScienceTM and holds 
research published from conferences, symposia, seminars, colloquia, workshops and conventions. By 
including conference proceedings, the resource aims to provide the user with research beyond that 
included in current journal literature. The resource has been on line since 1990.118 
4.2.2.2 Design of searches 
The electronic databases were searched using a combination of free-text, MeSH and database specific 
headings. The full search strategies can be found in Appendix C. These search strategies were 
developed with the input of experts in health informatics and used some pre-existing strategies 
available within the Primary Care Centre Versus Arthritis, already developed to identify particular types 
of study.  
“Carpal tunnel syndrome” was searched for using MeSH (or database-specific equivalent) terms and 
in free text. MeSH headings were ‘exploded’ to broaden their definition. Terms such as ‘entrapment 
neuropathies’ were included to ensure the search remained sensitive. The searches were combined 
using the Boolean operator “OR.”  
4.2.2.3 Additional search methods 
4.2.2.3.1 EthOS 
EthOS (Electronic Thesis Online Service) was searched from 1990 to December 2013 to identify 
previous theses relevant to carpal tunnel prognosis.  
4.2.2.3.2 Charity websites: Arthritis Research UK  
The Arthritis Research UK website (now: Versus Arthritis) was searched for further references.  
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4.2.2.3.3 Contacting experts   
Dr Graham Davenport, an Royal College of General Practitioners (RCGP) Musculoskeletal Champion 
and Prof Christina Jerosch-Herold, the Principal Investigator of a large cohort study investigating the 
prognosis of carpal tunnel syndrome, were approached and asked to search their personal literature 
collections for any further studies, not identified by the methods reported here.  
4.2.2.3.4 Conference Abstracts 
Conference abstracts from the Primary Care Rheumatology Society (now the Primary Care 
Rheumatology and Musculoskeletal Medicine Society – PCRMM) were searched from 2005 onwards. 
British Society of Surgery to the Hand / British Association of Hand Therapists combined scientific 
meeting abstracts were also searched.   
4.2.2.3.5 Reference checking 
References of all included full-text articles were hand-searched. 
4.2.2.3.6 Google Scholar 
The first 15 pages of Google scholar results for “carpal tunnel syndrome and prognosis” were searched 
to ensure all hits had been identified by the search.  
 Selection of eligible studies 
The citations identified using the methods described above were downloaded using Ovid SP and then 
transferred to and stored in REFWORKS (Legacy version). Duplicates were removed. All titles were 
screened against the eligibility criteria by the author. Full text review was undertaken for any abstract 
that could not be confidently excluded and could potentially fulfil the inclusion criteria. Abstracts and 
full texts were assessed independently by a second author (Dr Linda Chesterton – LC) to determine 
agreement. Any disagreements or queries were arbitrated through discussion.  
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 Assessing the risk of bias  
Whilst ‘assessment of study quality’ has been used to describe the critical appraisal of studies, this 
term also implies the extent to which the research was conducted to the highest standard. The quality 
of a study does not necessarily influence the likelihood of the conclusion being correctly estimated. 
‘Risk of bias’ is a preferred construct to consider when assessing the extent to which the results of a 
study can be believed. Bias is a systematic error in results or inferences, which lead to an over or under-
estimation of the truth. Differences in the risk of bias can help explain observed variation (or 
heterogeneity) between studies. A more rigorous study with a lower risk of bias is more likely to 
provide estimates closer to the truth. False positive conclusions may be drawn if the study effect is 
overestimated or the erroneous rejection of a true conclusion made if bias leads the effect to be 
underestimated. It is therefore important to consider the risk of bias of each study and consider this 
risk when pooling or combining effects.119 
In order to assess the risk of bias in prognosis studies, the Quality in Prognosis Studies (QUIPS) tool was 
used.120 It was decided to use this tool as opposed to other tools designed to assess the quality of non-
randomised studies, such as the Newcastle-Ottawa Scale,121 as this review was particularly focused on 
investigating predictors of outcome (i.e. prognosis and prognostic factors). QUIPS was developed 
specifically for this purpose, using a modified Delphi approach and nominal group technique, to define 
items which assess risk of bias in the six identified domains: 1. study participation; 2. study attrition; 3. 
prognostic factor measurement; 4. outcome measurement; 5. study confounding and 6. statistical 
analysis and reporting. Where studies investigated overall prognosis of untreated CTS and did not 
report on prognostic factors, bias domain 3 was not scored, as it was irrelevant. Bias domain 5 (study 
confounding) was scored in these studies, to judge if outcome could indeed be attributed to untreated 
CTS or whether or not confounding by treatment may have been present.   
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4.2.4.1 Using the QUIPS Tool 
For each of the six domains, the tool provides a number of cues as summarised in Table 4-3. In order 
to inform the judgement of the risk of bias within each study, supporting information and comments 
based on these cues were required from the publications. The author and LC made judgements and 
any disagreements were then brought to discussion, after which 100% agreement was achieved.  
Each cue and then each domain was graded as having a high, moderate or low risk of bias. To judge 
the overall risk of bias, studies were attributed a label of ‘a low risk of bias’ if all or most domains were 
described as low risk and at high risk of bias if all or most of the domains were judged as high risk. 
Studies were judged as being of moderate risk if all or most of the domains were of moderate risk.120 
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Table 4-3 Bias domains and cues provided by the QUIPS tool 
Bias domains and associated cues 
1. Study participation 
Source of target population, method used to identify population, recruitment period, place of recruitment, 
inclusion and exclusion criteria 
2. Study Attrition 
Proportion of baseline sample available for analysis, attempts to collect information on participants who 
dropped out, reasons and potential impact of subjects lost to follow-up, outcome and prognostic factor on 
those lost to follow up  
3. Prognostic Factor Measurement 
Definition of prognostic factor, valid and reliable measurement of prognostic factor, method and setting of 
prognostic factor measurement, proportion of data on prognostic factor available for analysis, method used 
for missing data  
4. Outcome Measurement 
Definition of outcome, valid and reliable measurement of outcome, method and setting of outcome 
measurement 
5. Study confounding 
Important confounders measured, definition of the confounding factor, valid and reliable measurement of 
confounders, method and setting of confounding measurement, method used for missing data, appropriate 
accounting for confounding 
6. Statistical Analysis and Reporting 
Presentation of analytical strategy, model development strategy, reporting of results 
Online resource from: Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing 
bias in studies of prognostic factors. Ann Intern Med. 2013 Feb 19;158(4):280-6. 
 Data Extraction 
Data were extracted by CB and checked by LC using a pre-defined data extraction form, which had 
been piloted and edited to ensure the required and correct information was captured.   
4.2.5.1 Data extraction from prognosis studies  
Data extraction included: details of the study setting; population demographics; diagnostic criteria of 
CTS used; management approaches used; prognostic factors (type of variable and how they were 
measured); outcome measures applied (definition and instrument used); sample size; rate of attrition 
and length of follow up. Concerning disease course, the proportion of patients with a poor outcome 
following conservative treatment or no treatment were recorded. All reported prognostic factors were 
listed and measures of association with their significance levels recorded. 
  




Pooling of results was deemed not possible due to heterogeneity with regard to study setting, the case 
definition of CTS applied, widely varying follow-up periods, the prognostic factors tested and measures 
of outcome used. Results regarding the course of symptoms in patients with untreated and 
conservatively managed CTS were therefore summarised narratively. Findings for the reported 
prognostic factors were synthesised by taking into account the number of studies evaluating each 
factor, the risk of bias of these studies and the consistency of available evidence (defined as significant 
association in the same direction of effect). A level of evidence was attributed to each prognostic 
factor, based on Sackett et al122 and Ariens et al123 and adapted for use with the QUIPS tool as shown 
in Table 4-4. 
Table 4-4 Levels of evidence for prognostic factors  
Level of evidence 
Strong Consistent findings (≥ 75%) in at least 2 cohorts with a low risk of bias 
Moderate Consistent findings (≥ 75%) in one cohort with a low risk of bias and at 
least one cohort with a moderate/high risk of bias 
Weak Findings of one cohort with a low risk of bias or consistent findings (≥ 75%) 
in at least 3 or more cohorts with a moderate / high risk of bias 
Inconclusive Inconsistent findings irrespective of study quality, or less than 3 cohorts 
with a moderate / high risk of bias 
No evidence No data presented 
Table based on Sackett et al122 and Ariens et al123 
  




 Summary of search results 
15,572 citations were identified by the search. The number of citations from each source are shown in 
Table 4-5. As summarised in Figure 4-1, there were 11,586 citations after duplicates were removed, 
146 following title screening and 42 following abstract screening. There were 16 studies included 
following full text screening. 
 
Table 4-5 Summary of search results 









SCI-EXPANDED + CPCI-S 370 
Total 15,572 
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 Study characteristics 
Table 4-6 summarises the characteristics of the studies including the QUIPS score, study design and 
setting, study population, interventions used in the study, the primary outcome measure including the 
definition of a poor outcome, and duration of follow-up. The table also presents the percentage of the 
cohort experiencing a poor outcome (e.g. proceeding to surgery) of conservative or no management.  
One study was a retrospective follow-up study of CTS cases identified in the Marshfield Epidemiologic 
Study Area, a population-based cohort in the USA.124 All other studies were based in secondary or 
tertiary care, of which six were surgical clinics and eight EMG laboratories. No studies were conducted 
in a primary care setting.  
The case definitions used to identify CTS differed between studies: six studies utilised clinical features 
only, whilst the remaining ten studies required an accompanying electrophysiological abnormality to 
be present. The combination of clinical characteristics used and the electrophysiological classification 
criteria also varied between studies. The interventions and combinations of interventions used in the 
conservative management of CTS in the studies included; wrist splinting (seven studies), non-steroidal 
anti-inflammatories (NSAIDS) (three studies), other analgesia (two studies), oral steroids (three 
studies), local steroid injections (six studies) and paraffin wax heat treatment (one study). Three 
studies provided conservative management without specifying which interventions were used. In four 
studies, the natural course of CTS was observed.69, 125-127 In some studies, parts of the cohort were 
treated surgically after initial conservative management. Surgical outcomes for these patients were 
not included in the review and surgery became the endpoint of observation. A range of outcome 
measures were applied: three studies used a surgical episode as a proxy for a poor outcome; one study 
used the Quickdash score;128 five used measures of global improvement; two used a change in 
symptom and function severity scores; one used the Historic and Objective Scale (Hi-OB)129; one used 
work absence; two observed electrophysiological changes and one used absence of clinical contact as 
an indicator of recovery. The follow-up periods ranged from 12 weeks to 10 years. 
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Table 4-6 Summary of study characteristics and results regarding the course of symptoms of prognostic cohort studies in carpal tunnel syndrome 
Author, year of 
publication and 
country 
Risk of bias 
(QUIPS score) 
Study population Interventions 
provided to entire 
cohort 
Primary outcome 
measure / duration 
follow - up 







experiencing a poor 
outcome 
Treated populations: prospective cohort studies 




High  Setting: tertiary 
hand and upper 
limb centre 
CTS diagnosis: 





Mean age: 49.3 
years 
 
N=25 patients (47 
wrists)  
Drop-out = 17% 
Splint: all wrists 
 
 




No surgery versus 
surgery by six 
months 
 
12 weeks, with an 






57% of wrists 




Moderate  Setting: hand clinic 
CTS diagnosis: 
clinical findings and 
electrophysiological 
abnormality   
 
67% female 
Mean age: males 57 
(s.d. 14) years; 




Splint: all patients 
 
Injection: 150 (55%) 
(of whom 38 had 
surgery) 
 











58% of patients 
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70+: 13 patients 
 
N=96 patients (155 
wrists)  
Drop-out = 0% 
Splint: 98 (63%) 
wrists 
 
Injection: 58 (37%) 
wrists 
 




Judgement made at 
follow-up: cured, 
temporary relief or 
no relief 
 










89% of patients 
 
Following surgery: 
5% of patients 





High  Setting: hand clinic 
CTS diagnosis: 




altered sensation or 
Phalen’s sign)  
 
75% female 
Mean age 55 years 
 
N = 229 patients 
(331 wrists)  








Oral steroid: 61 
(26.8%) patients 
 
Steroid injection: 38 
(16.4%) patients  
Success of therapy 
as defined by 
absence of 
symptoms for > six 
months 
 
Minimum of six 














66% of wrists 
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involving at least 2 
digits (thumb or 
index, middle or 
ring fingers) and 
symptom duration 




>55yr mean age 
68.0 years (sd 9.1); 
<55yr compensation 
non recipient 42.0 
years (sd 7.3); 
compensation 
recipient mean age 
39.0 years (sd 8.1). 
Non-surgical cohort 
>55yr mean age 
64.0 years (sd 7.0); 
compensation non-
recipient mean age 
41.0 (sd 8.9); 
compensation 
recipient mean age 
37.0 years (sd 8.8) 
 
N = 297 patients 
Drop-out = 31% 
Non-surgical cohort: 
34 patients received 
surgery at less than 
3 months and were 
not included in 
analyses 
 
By 30 months: 
Splint: 76 (94%) 
patients 
 





therapist: all  




health status were 





surgical to surgical 
cohorts after > 3 
months. 
 
Follow up took 
place at 6, 18 and 
30 months 
Would not be happy 
to live the rest of 
their lives with 
symptoms 
60% of patients 




Moderate  Setting: EMG 
laboratory  
CTS diagnosis:  
clinical findings, 
Treatment methods 











Rehabilitation   82% 
Surgery              77% 
Untreated          25% 
 










mean age 59.3 
years (sd 7.4); 
diabetic untreated 
group mean age 
54.6 (sd 11.1); 
idiopathic 
rehabilitation group 
mean age 47.8 
years (sd 9.9); 
idiopathic surgery 
group mean age 
49.2 (sd 9.8) 
 
N = 42 patients (80 
wrists)  




with splints, paraffin 







followed up in the 
early follow-up 
period (3-5 months) 










Rehabilitation   73% 
Surgery              85% 
Untreated         17% 










numbness and pain 
mainly at night. 
 
95.8% female 
Surgical cure group 
mean age 46 years 

















Between 5-10 years, 
Symptoms 
unchanged or worse 
 
23.7% of wrists 
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(range 24 – 70); 
unchanged / worse 
group 44 years 
(range 39 – 58); 
non-surgical cure 
group mean age 61 
years (range 48 – 
79); worse group 50 
years (range 30 – 
83) 
 
N = 165 patients 
(222 wrists) 
Drop-out = 69% 
(mean 5.9 years 
following surgery) 





High  Setting: EMG 
laboratory 
CTS diagnosis:  
clinical history and 
examination, 
confirmed using 
AAEM criteria and 
additional testing if 
this was normal 
 
81.3% female 
Mean age 53.6 
years 
 






Surgery: 27 (23%) 
patients 
Clinician review of 
medical records and 





Follow up took 




unchanged or worse 
68.5% of patients 





High  Setting: plastic 
surgery clinic 
CTS diagnosis: 
based on clinical 
symptoms  
 
Injection: 66 (49%) 
patients 
 
Surgery: 68 (51%) 
patients  
Symptom relief and 
/ or surgery 
 
22.5 +/- 0.5 months 
Progression to 
surgery 
62% of patients 





Mean age 56 years 
(sd 3) 
 
N = 134  
Drop-out 10% 





Moderate  Setting: EMG 
laboratory   
CTS diagnosis: distal 
motor latency was 
>4.7ms  
 
Gender and age not 
reported 
 



















that groups 1 and 2 
= cured and 3,4 and 
5 = not cured.  
 
Follow up was at 
least 2 years and 
defined as when the 
patient had reached 
a ‘steady state’ 
No evidence of cure 68% of patients 







Moderate  Setting: patients 





9-CM code 354.0 













Median follow- up 
1979 - 1983: 12.0 
years (5 and 95th 
Evidence of 
symptoms 
1 month: 75% of 
patients 
2 years:  40% 
8 years:  22% 
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clinical and / or 
electrophysiological 




Mean age 62 years 
 
N= 425  
Drop-out 0%  
 
Injection: 6 (1%) 
patients 
 
Splint: 295 (69%) 
patients 
 





184-1988: 7.3 years 
(5.0-9.8) 
 
Treated populations: Secondary analysis of Katz et al.1998 a 








involving at least 2 
digits (thumb or 
index, middle or 
ring fingers) and 
symptom duration 
of at least 1 month 
 
72% female 
Mean age 43 years 
(sd 11) 
 
N= 253 patients 
Drop-out =  20% 
 
Surgery: 179 (71%) 
patients  




were completed at 
6, 18 and 30m 
Work absence at 18 
months, due to CTS 
23% of patients 
Untreated populations: prospective cohort studies 




High  Setting: EMG 
laboratory  
CTS diagnosis:  as 
per Rempel et al  
The course of 
untreated CTS was 
observed 
The Historic and 
Objective Scale 
(HiOb) was used as 
the clinical 
Deterioration in the 
Historic and 
Objective Scale 
23.4% of patients 





Mean age 48.8 
years (sd 10.2) 
 
N = 132 patients 





according to Padua 
1997 (mild; 
moderate A; 
moderate B; Severe; 
Extreme) 
 
24.2 months (sd 
4.2) 




Moderate  Setting: EMG 
laboratory  






severe and extreme 
(Padua et al).  
 
78.8% female 
Mean age 48.8 
years (sd 10.2) 
 
N = 80  
Drop-out 84% 
The course of 





























Negative   50% 
Minimal     38% 
Mild          15% 
Moderate  27.5% 
Severe      0% 
Extreme    50% 
 
Negative   50% 
Minimal     31% 
Mild          58% 
Moderate 45% 
Severe     20% 
Extreme   0% 




Moderate  Setting: EMG 
laboratory  
CTS diagnosis:  
based on clinical 
diagnostic criteria 
proposed by the 
American Academy 
of Neurology and 
The course of 





and clinical changes 
were used to 










Stationary      57% 
Worsening     16% 
 
Stationary      45% 
Worsening     21% 
 
Stationary      61% 
Worsening     16% 









Mean age 52.0 
years (sd 13.4) 
 
N = 202 (267 wrists) 
with a further 62 
(87 wrists) re-













Stationary      46% 
Worsening     32% 
 
Stationary      62% 
Worsening     12% 
 
Untreated populations: retrospective cohort studies 




High  Setting: EMG 
laboratory  






Patients in an EMG 
lab with a diagnosis 






The course of 














improvement  25% 
(of which 100% had          
improvement in 
symptoms) 
Slight  improvement    
15% (of which 33% 
had worsening of 
clinical symptoms) 
No significant 
change  50% (of 
which 50% had 
worsening of clinical 
symptoms) 
Worsening                   
10% (of which 50% 
had worsening of 
clinical symptoms) 
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 Risk of bias 
The results of the assessment for the risk of bias are presented in Table 4-7. The percentage agreement 
with regard to judgement of the overall risk of bias was 75% and 100% following discussion. Further 
adjudication was therefore not required.  
The prognostic factor domain was not assessed in the four studies investigating course of CTS 
symptoms only. Eight studies were judged to have a moderate risk of bias and eight to have a high risk 
of bias. The domains that carried a particularly high risk of bias across all studies were: study attrition 
(12 studies); study confounding (10 studies) and statistical analysis and reporting (nine studies). Study 
attrition tended to be at high risk of bias as the follow-up response rates in several studies were low 
and the reporting of attempts to collect information on participants who dropped out was often 
lacking. Reasons for loss to follow-up were seldom provided and differences between those lost to 
follow-up and those actively followed up were not frequently compared. A high risk of bias due to 
confounding was also a frequent finding, largely because not all potential confounders were 
appropriately accounted for and hence the observed associations of the candidate prognostic factors 
with outcome were likely to be at least partly explained by other (unmeasured) variables. This was 
particularly true in studies using retrospectively collected data. Statistical analysis and reporting was 
commonly identified as being of a high risk of bias as presentation of the data was frequently 
insufficient and in some studies selective reporting of results was evident.  
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Table 4-7 Results of the methodological assessment of prognostic cohort studies on CTS (Hayden et al., 2013) 
Author (year) 1. Study 
Participation 









Overall Risk of bias 
Studies including an analysis of prognostic factors 




Low Moderate Moderate Moderate Moderate Moderate Moderate 
Duckworth et al. 
2013 
Moderate High Moderate Moderate High Low Moderate 
Goodwill. 1965 High High High High High High High 
Kaplan, Glickel & 
Eaton. 1990 
High High High High High High High 
Katz et al. 1998a Low Moderate Moderate Moderate Low High Moderate 
Katz et al 1998b Low High Moderate Low High Low Moderate 
Kiylioglu et al. 2009 Moderate High Moderate Moderate Moderate High Moderate 
Kouyoumdjian et al. 
2003 
Moderate High Moderate Moderate High High High 
Muhlau, Both & 
Kunath. 1984 
Moderate High Low Moderate Moderate Low Moderate 
Padua et al. 2001 Low Moderate Low Moderate Moderate Moderate Moderate 
Studies observing the course of CTS only (with no analysis of prognostic factors) 
Lian, Urkunde & 
Verma. 2006 
High High Not applicable High High High High 
Miranda, Asaad & 
Cerovac. 2013 
High High Not applicable High High High High 
OrtizCorredor et al. 
2008 
Moderate Moderate Not applicable Low High High High 
Padua et al. 1998 High High Not applicable Low High Low Moderate 
Resende et al. 2003 High High Not applicable High High Moderate High 
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 Course of carpal tunnel syndrome  
For each included study, Table 4-8 describes the course of CTS in conservatively managed or untreated 
patients, by describing the proportion of patients who experienced a poor or unsatisfactory outcome, 
the definition of which varied between studies (i.e. persisting or worsening symptoms, progression to 
surgery, or work absence due to CTS). Table 4-8 also summarises results regarding the course of CTS 
in terms of the percentage of patients reporting a poor outcome for different follow-up time points in 
order for between study comparisons to be made.  
Four studies examined the course of untreated CTS.69, 125-127 OrizCorredor et al observed that of 132 
patients with untreated CTS over a 2 year period, 23.5% showed a deterioration in the Historic and 
Objective Scale (HiOb) score but most patients did not show an electrophysiological deterioration (89 
remained the same, 33 recovered and 10 deteriorated). Only one patient experienced both 
electrophysiological and clinical deterioration.126 Padua 1998 et al reported whether the clinical 
outcome was unchanged or worse in groups of patients with different electrophysiological 
classifications. They found the clinical outcome was worse in 50% of patients with negative 
electrophysiology, 27.5% with moderate electrophysiological findings and 50% with extreme results.125 
Padua 2001 et al further observed the electrophysiological, symptomatic, functional, HiOb and pain 
changes in patients with CTS. They reported that between 12% and 32% of patients depending on their 
classification of electrophysiological severity worsened over time, whilst between 23% and 34 % of 
patients improved.69 Resende et al presented the change in electrophysiological measures and 
accompanying change in symptoms over four to nine year periods. They reported that 25% of patients 
had a marked improvement in electrophysiological outcome (100% of whom had improvement in 
terms of symptoms); 15% showed slight improvement (of whom 33% had worsening of symptoms); 
50% showed no significant change (of whom 50% had worsening in terms of symptoms) and 10% had 
a worsening of electrophysiological measurements (of whom 50% had a worsening of clinical 
symptoms).127  
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In summary, a range of 32 - 58% of participants receiving no treatment for CTS were reported to have 
a poor outcome at 12 months follow-up in two studies,69, 125 both of which were of moderate risk of 
bias. The studies reporting outcomes at 3 and 10 years reported a poor outcome in 23.4% 126 and 50% 
127 of participants respectively; both studies were at high risk of bias.  
In the nine cohorts of patients receiving conservative treatment: 68.5% to 75% of patients were 
reported to have a poor outcome within three months follow-up; 130, 131 82% within six months follow 
up 132; 23 – 89% within a 3 year follow up 124, 133-136  and 22 – 24% within 10 years  follow up.133, 137 A 
wide variation in findings was noted according to risk of bias, with studies of a moderate risk of bias 
appearing to show lower percentages of patients with a poor outcome (e.g. 23 – 68% at 3 years 124, 133-
135), compared to studies considered to be at a high risk of bias (82% at six months) 132 and 89% at 3 
years.136 Four studies used a surgical episode as a marker of a poor outcome of conservative 
management 68, 132, 138, 139. A range of 57% to 66% of patients were observed to receive surgery following 
conservative management over a period of between 1 and 3 years.68, 132, 138, 139 The reported course of 
conservatively managed CTS was highly variable but on average symptoms improved over time in most 
study populations.  
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Table 4-8 Course of carpal tunnel syndrome in conservatively treated or untreated patients (percentages not cumulative) 
Number of studies Sample size range % of cases reporting 
deterioration within 3 
months 
% of cases reporting 
deterioration within 
six months 
% of cases reporting 
deterioration within 12 
months 
% of cases reporting 
deterioration within 3 
years 
% of cases reporting 
deterioration within 15 
years 
Untreated cases 
4 69, 125-127 12 – 344  NA NA 32 - 58 23.4 50 
Studies observing cases receiving surgery as a consequence of conservative management failure (% of patients receiving surgery NOT outcome of surgery) 
4 68, 132, 138, 139 47 - 331 NA 57 58 62 - 66 NA 
Studies of conservatively managed patients reporting other definitions of negative outcome 
9 124, 130-137 80 - 425 68.5 - 75 82 % improvement of up to 
82% * 
 
23 - 89 22 - 23.7 
The percentages shown are not cumulative as it cannot be assumed that patients reporting a change in symptoms at six months would not have reported something different at an 
earlier or later date if the study had provided them with such opportunity 
Abbreviation: NA, not applicable                  *% change provided in a positive direction 131 
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Table 4-9 presents candidate prognostic factors tested in the studies and the reported associations 
with outcome. Not all studies presented estimates of association with confidence intervals. Some 
presented P values only; some simply reported a finding as non-significant. Therefore, the number of 
studies investigating each candidate prognostic factor, the number of studies at moderate or high risk 
of bias (none were of low risk) and the number showing an association (direction and significance) are 
summarised.  
In total 39 candidate prognostic factors were identified from the studies. All of these were found to 
have inconclusive levels of evidence of an association with poor outcome. This was due to 
inconsistencies between study findings, non-significant results, low numbers of studies investigating 
each factor and the moderate to high risk of bias of the studies included.  
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Table 4-9 Prognostic  factors and strength of association for an unfavourable outcome of carpal tunnel syndrome in patients who are conservatively treated or untreated 
Prognostic factor Direction of association and 
significance 
 
Risk of bias 
(number of studies) 
 
Number and % of studies 
demonstrating predictive 
association with a poor outcome 
(statistically significant) 
Level of evidence 
Demographic characteristics 
Female gender  +* 139 
+  124 







(1/6: 17 %) 
Inconclusive 
Increasing age (group not otherwise 
specified or >50 years) 
+* 69,134 
0 135 , 133 









3/10: 30 % 
(3/10: 30 %) 
Inconclusive 
Obesity + 124 
-* 131 
Moderate (2) 1/2: 50% 
(0/2: 0%) 
Inconclusive 
Litigation +* 134 
0 135, 133 
Moderate (3) 1/3: 33% 
(1/3: 33%) 
Inconclusive 
Deprivation quintile - 139 Moderate (1) 0/1: 0 % Inconclusive 
Vibration tool use - 139 Moderate (1) 0/1: 0 % Inconclusive 
Occupation status +*134 Moderate (1) (1/1: 100)% Inconclusive 




Diabetes +* 131 Moderate (1) (1/1: 100%) Inconclusive 
Diabetes or hypothyroid +124 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Pregnancy or injury associated CTS - 124 Moderate (1) 0/1: 0 % Inconclusive 
Arthritis +124 Moderate (1) 1/1: 100% Inconclusive 




Previous fracture or sprain 0132 High (1) 0/1: 0 % Inconclusive 
Stenosing flexor tenosynovitis +*132 High (1)  (1/1: 100%) Inconclusive 
Mental health status +*134 Moderate (1) (1/1: 100%) Inconclusive 
Disease characteristics 
Tinnel’s sign positive + 139 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Phalen’s sign positive +*69 Moderate (2) 
 
High (1) 
3/3: 100 % 
(2/3: 67%) 
Inconclusive 
+ 139  
+*132  
Thenar wasting +* 133 Moderate (2) 
 
High (1) 





Paraesthesia +*132 High (1) (1/1: 100%) Inconclusive 







Semmes Weinstein monofilament 
testing 
0135 Moderate 0/1: 0 % Inconclusive 































CTS category of severity124 +*124 Moderate (1) (1/1: 100%) Inconclusive 
Sensory SF-MPQ +139 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Affective SF-MPQ +139 Moderate 1 1/1: 100% Inconclusive 




SF-36 0138 High (1) 0/1: 0 % Inconclusive 
DASH 0138 High (1) 0/1: 0 %  
Hi-Ob -*69 Moderate (1) 0/1: 0 % Inconclusive 
Visual analog scale +139 Moderate (1) 1/1: 100% 
(0/1: 0%) 
Inconclusive 
Laterality: left only  -124 Moderate (1) 0/1: 0 % Inconclusive 
Laterality: right only -*124 Moderate (1) 0/1: 0 % Inconclusive 
Laterality: left > right -124 Moderate (1) 0/1: 0 % Inconclusive 
Laterality: right > left -124 Moderate (1) 0/1: 0 % Inconclusive 









Grip strength 0135 m 
- 139 m 
Moderate (2) 0/2: 0% Inconclusive 
Hand stress -*69 Moderate (1) 0/1: 0 % Inconclusive 










0 = not significant and direction not provided 
+ = predictive of a negative outcome 
- = not predictive of a negative outcome 
* = statistically significant 
 
CTS - carpal tunnel syndrome 
SF-MPQ – Short-Form McGill pain questionnaire 
SF-36 – Short-Form 36 
DASH – Disabilities of the arm, shoulder and hand questionnaire 
Hi-Ob – Historical objective scale 




 Summary of main findings 
Four studies observed the course of untreated CTS,69, 125-127 which is helpful when considering the need 
for, or potential impact of treatment. Two studies suggest that a proportion, ranging between 32% - 
58%, of yet to be identified patients will recover or remain stable in the absence of treatment in the 
initial 12-month period following diagnosis.  
Because of inconsistencies between study findings and the lack of studies with a low risk of bias, it was 
not possible to identify conclusive evidence for any of the factors reported by individual studies as 
predictors of a poor (or unsatisfactory) outcome of conservative management.  
There was however 100% agreement in at least three or more cohorts with a medium or high risk of 
bias that: symptom duration; a positive Phalen’s test; and thenar wasting were associated with a 
negative outcome of conservative management over variable time periods, however not all results 
were statistically significant and hence the overall judgement remained inconclusive.  
 Interpretation of results 
A certain period of ‘watchful waiting’ may be sensibly and safely considered when discussing treatment 
options with patients. The results also indicate however, that up to 70% of patients deteriorate and 
are likely therefore to require further intervention, whether that be a further injection, an alternative 
approach to conservative management or surgery. When considering potential mechanisms for 
recovery without further treatment Padua et al 1998 suggest that certain undefined CTS cases are self-
limiting due to a process of neural adaption, whereby the functional relationship between the nerve 
and the carpal tunnel adapts over time.125  
Because of outcomes being measured at discrete time points by each study, it was not possible to 
provide a cumulative proportion of patients recovering in each period, which may have provided more 
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clear information about what happens to patients with CTS over time. The data does however show 
that a proportion of patients can be observed to have deteriorated from baseline at any point between 
3 months and 10 years, suggesting that the course of CTS is likely to be widely variable. It is possible 
that the studies with longer follow up periods may also represent patients who improve and relapse 
over time, but as none of the studies were designed to observe the longitudinal course of CTS (i.e. at 
a week-to-week or month-to-month level), such a symptom course could not be illustrated by this 
review.  
With regard to symptom relapse, only one study136 specifically addressed this issue. Goodwill et al 
reported that 85% of patients initially responding to conservative treatment approaches relapsed 
within one to four years.136 The possibility of future relapse therefore questions the validity of 
observations of studies conducted over a shorter time frame and may to some extent explain the 
variability in findings in terms of response to specific treatments. 
The observed between-study variability may be explained by differences in study setting, study design, 
case definitions, interventions (the effectiveness of which cannot be compared between studies), and 
outcomes used but possibly also by differences in patient or disease factors (potential prognostic 
factors) between studies. 
Due to a lack of robust design and conduct of most of the included studies, the overall body of evidence 
identified was judged to be of moderate or high risk of bias. This limited whether the synthesised 
evidence could be considered to be conclusive and as such, evidence regarding the predictors of 
outcome of untreated and conservatively treated CTS was considered to be weak.  
None of the included studies were set in primary care. Apart from one study where data was collected 
from a general population sample, the further 15 studies were set in secondary care (including EMG 
laboratories). One could assume that by the time patients were reviewed in these settings and 
recruited to the study, time from symptom onset would have passed and recall bias affected the 
patients’ report of baseline factors, or baseline factors were collected at a much later point in the 
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disease course. In order to mitigate this issue and to capture the first point of clinical presentation of 
CTS and its earliest management, it would be beneficial to set a prognostic cohort study in primary 
care, where it is likely most patients present with their symptoms and commence initial treatment.  
 Predictors of outcome following specified modalities of conservative management: 
studies not included in the review  
This review included patients who had been treated using a ‘usual care approach.’ This means that 
studies in which all participants were treated according to a standardised treatment protocol (e.g. 
corticosteroid injection), were not included. Although such studies often aim to investigate response 
to a specific treatment, predictors of treatment effect (or treatment effect moderators or modifiers) 
are best identified through adequately powered randomised trials (see chapters 7 and 8). There were 
however a number of non-randomised studies or observational studies of a single arm of an RCT which 
aimed to identify predictors of response to a particular treatment modality that may be relevant to 
report here. These studies are identified below, and any potentially important information is 
highlighted.  
Gerritsen et al analysed the data of patients who were randomised to the splinting arm of a trial and 
reported that symptom duration ≤ 1 year and severity of paraesthesia at night ≤ 6 predicted success 
of splinting (predicted success 62 % versus actual success 67%).140 
Three further studies were identified which specifically observed the course of carpal tunnel syndrome 
following treatment with splinting and/or injection. 
Graham et al performed a prospective study assessing the outcome of corticosteroid injections 
combined with wrist splinting in 73 patients (99 wrists). They reported that at 1 year, 10 affected hands 
(10.2%) remained asymptomatic and had not required surgery. This group had a significantly shorter 
duration of symptoms pre-treatment (2.9 months versus 8.35 months; P = 0.039, Mann-Whitney test) 
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and had significantly less sensory change at baseline (40 % versus 72 %; P = 0.048, Fisher's exact test), 
when compared to the group that required surgical intervention.141  
In a five-year follow-up study of 824 patients who received a corticosteroid injection as treatment for 
CTS, Jenkins et al reported the overall 5-year rate of surgery was 15% at 1 year and 33% at 5 years. A 
multivariable Cox regression model showed that progression to surgery was independently associated 
with female gender (OR 2.06, 95% CI 1.50 - 2.83, P < 0.001), diabetes mellitus (OR 1.58, 95% CI 1.05 - 
2.39, P = 0.029) and the presence of positive nerve conduction results (OR 7.62, 95% CI 2.43 to 
23.9, P = 0.001).142.  
Meys et al also observed the course of CTS in patients treated with a local corticosteroid injection. Of 
the 113 patients treated with an injection, 67.4% required surgery by 12 months (much higher than 
observed by Jenkins et al). Multiple logistic regression showed that best performing model predicting 
a successful outcome of CSI included: a lower median nerve ultrasonographic cross-sectional area 
(CSA) at the pisiform bone (OR 0.76, 95% CI 0.61 – 0.95, P = 0.014); increasing age in years (OR 1.04, 
95% CI 1.00 – 1.08, P = 0.041) and a decreasing symptom severity score (OR 0.44, 95% CI 0.23 – 0.87, 
P = 0.018).143 Symptom duration was not significantly associated with the need for surgery, and there 
were no observations made for results of nerve condition studies or co-morbidities to compare with 
the results of Jenkins et al.  
 Methodological considerations 
A range of electronic databases considered to be important and relevant to the topic at the time, were 
searched following advice from experts in health informatics. Titles were screened by the author only 
due to the large number and the pressures of time. It remains possible that studies not included in 
databases and not identified through reference checking, Google Scholar and expert advice may have 
been overlooked, for example unpublished cohort studies. As the review did not find strong evidence 
for any of the prognostic factors tested, it is felt unlikely that further unpublished material would have 
strongly influenced the review’s conclusions.  
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Results of studies presenting only descriptive results and P-values were included in the prognosis 
review, without any risk estimates. All the potential evidence that was found was therefore included. 
It is possible that the lack of statistical significance in some studies was due to small sample sizes. This 
would contribute to a lack of stronger evidence for some of the included prognostic factors, rather 
than a genuine absence of association. Future prognosis research in the area of CTS should therefore 
ensure that estimates of associations with outcome are adequately reported and that the study 
population is of adequate sample size to investigate the hypothesised associations with outcome. 
The unit of analysis differed between studies, i.e. some studies analysed outcomes at patient level (not 
necessarily taking into account the laterality of the condition); whilst others analysed outcomes at 
wrist level (patients with bilateral symptoms would be included as 2 episodes, not taking dependence 
of outcomes within individuals into account). Issues relating to the statistical analysis of bilateral CTS 
have been discussed at length by Page et al.144 A unit-of-analysis error, which may give rise to overly 
narrow confidence intervals and small P values, may occur when data is analysed on the basis of the 
number of wrists without adjustment for non-independence.144 Such an error may occur in prognosis 
research, including the reviewed studies, and be a further source of bias. Future prognostic studies 
should, where possible, consider this risk of bias in their design and analysis plan. 
 Clinical relevance of the findings 
Patients presenting with CTS can be informed that there is evidence that some patients recover with 
no treatment or conservative treatment only. However, the proportion of patients who recover and 
the factors which may predict the likelihood of falling into this group have not been robustly 
determined. This is due to the fact that many of the studies have been based in secondary care, when 
one can assume patients’ symptoms are selectively more severe and more likely to require surgery. 
Likewise, high attrition rates may lead to surgical rates being overestimated, if it is assumed most 
patients lost to follow up recovered. 
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Longer symptom duration, a positive Phalen’s test and the presence of thenar atrophy are likely to 
predict poor outcome of conservatively managed CTS but need confirmation in further well-designed 
prognostic studies. Clinically, both a positive Phalen’s test and thenar atrophy are diagnostic indicators 
of CTS, so their role as predictors may also collide with the fact that a case is more likely to represent 
CTS rather than an alternative diagnosis. Thenar atrophy particularly indicates denervation of the 
muscle and its presence is an accepted feature of severity and indicates the need for (urgent) carpal 
tunnel decompression.  
The criteria and processes set by the review did not specifically identify electrophysiological severity 
as a significant predictor of a poor outcome of conservative management. This may have implications 
for services which ration surgery to patients with more severe results and suggest other factors should 
be taken into consideration alongside laboratory investigations. 
 Suggestions for further research 
In order to improve future research, key recommendations would include to identify patients with CTS 
at baseline using an agreed case definition. Patients should be followed up for a prolonged period, if 
relapse of symptoms is of interest (over 3 years); preferably at a number of time points using a clinically 
meaningful, valid and reliable outcome measure. This would allow a longitudinal picture of CTS to be 
mapped. Attempts could be made to reduce attrition or better describe the risk of attrition bias by 
collecting information from non-responders and to provide a description and reason for any loss to 
follow up. Ideally, all potential prognostic factors should be included and measured at baseline using 
valid and reliable measures.120 
4.5 Conclusion  
The systematic review of available literature has demonstrated that the course of untreated and 
conservatively treated CTS is likely to be variable and currently unpredictable. No consistent evidence 
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was found regarding prognostic factors that may help predict which patients respond less well to the 
conservative treatments that can be offered in primary care.  
The review highlights a number of gaps in the evidence with regard to the course, prognosis and 
conservative management of CTS in primary care and the need for further research in this area. The 
following chapter presents an analysis of data from primary care with the aim of developing a 
prognostic model that predicts an episode of surgery in patients presenting with CTS.  
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5 The prognosis of carpal tunnel syndrome: Predicting surgical 
intervention in patients presenting with carpal tunnel syndrome in 




Following the systematic review and narrative synthesis of studies detailing the course and 
prognosis of conservatively managed carpal tunnel syndrome presented in chapter 4, this 
chapter presents a prognostic cohort study of patients from a primary care population. The 
aim of this (type 3 prognostic) study was to develop a prognostic model based on candidate 
prognostic factors, derived from the literature and expert opinion and available in primary care 
consultation data, to predict the risk of poor outcome in CTS, as defined by (the first 
occurrence of) carpal tunnel release surgery. 
The work in this chapter has now been published in a peer-reviewed journal under a Creative 
Commons License:  
Burton C, Chen Y, Chesterton LS, Van der Windt D. Predicting surgical intervention in patients 




The development of two (type 3) prognostic models are presented in this chapter and the next. Each 
model predicts a different outcome or ‘end-point.’ The study presented in this chapter evaluates time 
to an episode of CTR, which is assumed to represent an inadequate outcome of the conservative 
management of CTS. The prognostic model developed in chapter 6 predicts patient reported outcome 
following the conservative management of CTS. The setting of each development dataset varies 
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between the prognostic models. The study in this chapter uses the electronic health data from a 
historical cohort of patients observed over time. The Clinical Practice Research Datalink and the use of 
consultation data in research has been introduced and discussed in chapter 3. Chapter 6 will use data 
from a prospectively designed randomised trial, where it was possible to add to the information 
requested from participants at baseline, and further analyse the results as a prospective cohort.  
Firstly, the concept of type 3 prognosis studies will be introduced. Then, the way in which candidate 
prognostic factors were identified will be presented. Next, the methods applied for the prognostic 
model study in CPRD will be described, guided by the criteria provided by TRIPOD (Transparent 
Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis),145 and the results 
presented and discussed. 
 Prognostic model research 
Other names for prognostic models include clinical prediction rules or tools and can be defined as: 
“…a formal combination of multiple predictors from which risks of a specific endpoint can be 
calculated for individual patients.” 73 pg 1 
A prognostic model translates the combination of multiple predictor (or prognostic factor) values of a 
particular individual with a given startpoint, into an absolute risk of that individual experiencing a 
particular endpoint (or outcome). Prognostic models are being used with increasing frequency in 
clinical practice, with the aim of enhancing informed decision making by providing estimates of likely 
outcomes for individual patients.73  
Key steps in building a prognostic model include: its development; its validation and its impact 
evaluation in a clinical practice setting. The development of a prognostic model involves the 
identification of a startpoint, endpoint (outcome) and prognostic factors to be included in the 
regression analysis. The predictive performance of a model is likely to be optimistic when tested in 
development data, especially when sample size is limited. It is possible to adjust for this optimism using 
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statistical techniques and subsequently provide adjusted measures of the model’s performance. It is 
preferable, before recommending a model for clinical use, to test its performance in different settings 
or datasets (external validation). Finally, the clinical and cost-effectiveness of a model should ideally 
be tested, in order to ensure that its application does indeed improve outcomes without causing harm 
and is economically viable to use in a particular clinical setting.73  
In order to reduce the risk of optimism or spurious findings the candidate prognostic factors to be 
included in a model should be clinically reasonable. The next section describes the processes applied 
to identify the prognostic factors used in the development of the prognostic models described in this 
chapter and in chapter 6. 
5.2 Identifying candidate prognostic factors   
A separate piece of work was conducted by the author before the start of this PhD, during the 
development of the INSTINCTS trial. The aim of this work was to identify from the literature and expert 
opinion, a limited number of candidate prognostic factors and predictors of treatment effect that could 
be collected in the participant questionnaires and clinical report forms. This information would also be 
used to identify candidate prognostic factors to collect from CPRD. Four approaches were used to 
identify candidate predictors of outcome and treatment effect. These approaches will now be 
summarised and will also apply to the candidate predictors tested in chapters 6 and 8.  
 Rapid review of the literature 
Firstly, a rapid review of the literature was carried out. This was not intended to be a full systematic 
review but rather a scoping exercise to identify potential predictors of outcome in carpal tunnel 
syndrome and its conservative management. This preceded the formal reviews presented in chapters 
4 and 7. Medline, Embase, PsychINFO and CINAHL were searched for prognostic studies of carpal 
tunnel syndrome. In total, 5549 citations were retrieved and 2039 duplicates extracted. A title search 
reduced the number to 235 citations of which 59 were utilised after the abstracts or full papers were 
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read as required. 63 candidate predictors were identified from the 59 studies and are included in the 
summary table shown in Appendix D2 . 
 Clinical think-tank 
General Practitioners, General Practitioners with a Specialist Interest in Musculoskeletal Medicine, 
Extended Scope Physiotherapists and Rheumatologists were invited from the Primary Care Centre 
Versus Arthritis at Keele University, to attend a think-tank at a time when the initial aims and objectives 
of this thesis were being identified. The specific aims of the think-tank were to: 
a. Identify routine practice and clinical challenges experienced by practicing primary care clinicians 
in the diagnosis, investigation and management of carpal tunnel syndrome 
b. Receive feedback on the proposed research questions in terms of clinical utility 
Specific to the area of generating candidate prognostic factors, the group were asked: 
• What patient features particularly worry you in terms of treatment outcome and prognosis and 
do you alter your management strategy based on these features? 
 
Seven GP’s and one Extended Scope Practitioner attended the think tank where semi-structured 
questions were asked to facilitate discussion. The results from these discussions are included in more 
detail in Appendix D2. 
 Survey of General Practitioners 
Further to the clinical think-tank and as part of the development of the INSTINCTS trial questionnaires, 
a brief survey was designed and sent out by email to 30 GP collaborators of the INSTINCTS trial, 
requesting them to identify predictors of CTS outcome and its different treatments. The aim was to 
identify factors that may not be extracted from the literature due to their inherently clinical nature or 
absence of evidence for their prognostic value. 
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The trial collaborators were asked to list the factors they identified from 1 to 4 (weakest to strongest 
association) to allow subsequent ranking to take place, as a means of reducing the list of potential 
prognostic factors down to a number that was appropriate to include in the statistical analysis in 
chapter 6. The scores have been displayed as the sum of all the responses. Seven GP’s (23%) responded 
after one reminder email. The table presenting the outcome of this survey can be found in appendix 
D1. 
 PRO-GRES study 
Finally, candidate prognostic factors were identified from a previously conducted study,146 which 
investigated the hypothesis that generic indicators can be used by GPs to assess the prognosis of older 
people with musculoskeletal pain. Methods including a GP survey and a systematic review of 
prognostic indicators for musculoskeletal pain in primary care had been used to develop a brief 
prognostic tool for use during the consultation.  
The brief prognostic tool includes the following domains: higher pain intensity, longer duration, 
multiple site / widespread pain, higher disability, higher levels of anxiety and depression, older age, 
poorer physical health, manual occupation, higher BMI, coping strategies, social support. Items 
included in this prognostic assessment tool were considered as candidate predictors for the design of 
the prognostic models developed in this thesis.  
 Combining the candidate predictors from different sources 
A total of 95 variables were identified as being candidate prognostic factors of the outcome of CTS and 
/ or predictors of treatment effect. At this stage variables representing the same concept but indicating 
different directions (e.g. unilateral versus bilateral CTS) had not yet been merged. The factors 
identified by the four different methods of data collection were combined and grouped into themes: 
comorbidities, clinical characteristics and demographics, for use at the different stages of the thesis as 
summarised in appendix D2. 




 Developing the risk prediction model: participants (setting)   
The study setting was the Clinical Practice Research Datalink, which has been described previously in 
section 3.3.1. The Independent Scientific Advisory Committee (ISAC) protocol for this study (14_167) 
was approved on 16th September 2014 and can be found in appendix A.  
5.3.1.1 Inclusion criteria 
The study population was derived from the incident cases identified in section 3.3.3, with a diagnostic 
Read code for CTS (Read code F340); as opposed to a treatment code (Carpal Tunnel Release or Carpal 
Tunnel Injection). This was in order to capture patients at their ‘start-point,’ i.e. as they first presented 
in primary care. A treatment code, whilst possibly being the first code used to denote a prevalent or 
incident episode, would suggest that this was not the patient’s initial presentation in primary care. All 
incident patients, identified between 1991 and 2013 were required to have at least two years up to 
standard research quality data, preceding the date of diagnosis. This cut off was previously decided 
upon in order to identify a new episode of CTS for the epidemiology studies described in chapter 3. In 
this study the two-year period was also required in order allow opportunity for the baseline candidate 
prognostic factors to be recorded and reduce the risk of bias due to variable observation periods 
between patients. Patients were aged 18 years and older at diagnosis.  
5.3.1.2 Exclusion criteria 
Patients with an incident episode associated with a surgical code were excluded, as it was not possible 
to identify when the patient was likely to have first presented in primary care.  
 Developing the risk prediction model: selecting candidate predictors 
The candidate predictors of CTS outcome identified in section 5.2 were subsequently assessed as to 
whether they could be identified in consultation data (i.e. by Read code or available linked data).  Table 
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5-1 presents the initial list of candidate prognostic factors and the time between the code and index 
CTS consultation. Codes for candidate predictors recorded beyond 2 years preceding the CTS code 
could not be included as there would be no consistency in record availability beyond this time point 
(see inclusion / exclusion criteria). 
Table 5-1  Initial candidate prognostic factors considered and their source in CPRD 
Demographic characteristics 
1. Age at diagnosis 
2. Gender 
3. GP Practice 
4. Obesity (Read code)* 
5. Excess alcohol consumption (Read 
code)* 
6. Current or ex-smoker (Read code)* 
7. Pregnancy status (Read code)** 
8. Perimenopausal women (define by age 
band) 
Comorbidities 
9. Affective disorders (anxiety or 
depression) (Read code)* 
10. Dyssomnia (Read code)* 
11. Hypothyroidism (Read code)* 
12. Diabetes (Read code)* 
13. Inflammatory conditions (Read code)* 
14. Other neck or upper limb disorders 
(Read code)* 
15. Multi-site pain including osteoarthritis 
(Read code)* 
16. Tendonitis / epicondylitis (Read code)* 
 
17. Previous wrist trauma (Read code)* 
Disease characteristics  
18. Laterality of symptoms (free text)*** 
19. Phalen’s sign (Read code / free text)*** 
20. Tinnel’s sign (Read code / free text)*** 
21. Weakness of thenar wasting (free text / 
Read code)*** 
22. Outcome of nerve conduction studies 
(Read code / free text)*** 
23. Symptom severity (free text)*** 
24. Time between first consultation and 
start of treatment  (Free text) 
25. Unemployed / receiving benefits / work 
role functioning to be measured by 
sickness certification and free text 
 
*Read code within 2 years prior to 
incident CTS consultation 
**Read code within 1 year prior to 
incident CTS consultation 
      ***Read code at time of consultation        
+/- 1 month 
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The candidate prognostic factors presented in Table 5-1 were tested in the CiPCA pilot study and 
further changes made following reflection on this exercise. ‘Perimenopause’ was dropped, as it is an 
indistinct term with no universally accepted classification and would be defined by age band and 
gender, which were already being included in the model development. Dysomnia was dropped as it 
was felt to be a consequence of CTS rather than a predictor. This change was also made knowing that 
poor sleep related to CTS symptoms could be included later in the prognostic model study based on 
INSTINCTS data (chapter 6). Neck and upper limb problems were limited to neck problems as the 
possible code list was extensive and overlapped with a number of other prognostic factors. There was 
also a substantial risk that codes relating to upper limb could represent poorly coded CTS rather than 
a distinct other problem. The pilot study demonstrated almost zero coding of Tinnel’s and Phalen’s 
test results. Sickness certification was also not included in the CPRD analysis as there was no accepted 
means of identifying sickness certification in CPRD (it was attempted in the epidemiology study based 
on Read code but results were considered to be unreliably low). Sickness certification is also not a 
baseline measure, rather a later consequence of the condition. Due to the national coverage of CPRD, 
region was included as a potential confounder due to known variabilities in the service provision of 
CTS services.64 Deprivation was included as it was available through linkage and felt to be potentially 
important as a both a predictor in its own right and as a proxy for occupation. The final list of candidate 
prognostic factors tested in CPRD and the source of the Read code lists are presented below in Table 
5-2. 
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Table 5-2 Final list of candidate prognostic factors 
Prognostic factor Method of measurement Time period to be applied Source of Read code list (where 
applicable) 
Age at diagnosis Routinely recorded data At time of index date  
Gender Routinely recorded data At time of index date  
GP Practice Routinely recorded data At time of index date  
Region Routinely recorded data At time of index date  
Deprivation score Routinely recorded data for practices which 
provide Index of Multiple Deprivation scores 
2010 quintile score  
Obesity Read code or from the Test table The closest recorded value preceding the 
index date 
 
Alcohol status Read code or from the Test table The closest recorded value preceding the 
index date 
 
Smoking status Read code or from the Test table The closest recorded value preceding the 
index date 
 
Pregnancy Read code Read code within a 1 year period prior to 
the index date 
Code list developed for purpose of 
this study using the Clinical 
Terminology Browser 
Affective disorders Read code Read code within a 2 year period prior to 
the index date 
Code list developed for previous 
studies. through clinical consensus  
Hypothyroidism Read code Read code within a 2 year period prior to 
the index date 
Code list developed for previous 
studies  
Diabetes Read code Read code within a 2 year period prior to 
the index date 
Code list developed for previous 
studies 147 
Inflammatory conditions Read code Read code within a 2 year period prior to 
the index date 
Code list developed for purpose of 
this study  
Neck conditions Read code Read code within a 2 year period prior to 
the index date 
Code list developed for use in the 
Versus Arthritis Primary Care Centre 
Multi-site pain (including osteoarthritis) Read code Read code within a 2 year period prior to 
the index date 
Code list developed for use in the 
Versus Arthritis Primary Care Centre 
Tendonitis / epicondylitis Read code Read code within a 2 year period prior to 
the index date 
Code list developed for use in the 
Versus Arthritis Primary Care Centre 
and developed for purpose of this 
study  
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Previous wrist trauma Read code Read code within a 2 year period prior to 
the index date 
Code list developed for use in the 
Versus Arthritis Primary Care Centre 
and developed for purpose of this 
study 
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The incidence of CTS and the use of surgery was shown by the CPRD analyses in chapter 3 to have 
changed over time in a non-linear fashion. The year of diagnosis was therefore included in the 
unadjusted univariable analysis, but it was not included in the development of the multivariable model. 
Including the year of diagnosis would limit the external validity of the model by applying the 
epidemiology and healthcare practice at one time point to the observations in another time period. 
Ideally, in order to keep them contemporaneous, prognostic models should be updated regularly. 
Whilst not ideal, in that the model is based in historical data, the model therefore presents average 
treatment observations over time. 
CTS associated with pregnancy is a well-recognised phenomenon and is likely to have a defined 
pathophysiological mechanism associated with hormonal changes. As such, its symptom course is 
likely to be different from non-pregnancy associated CTS. For this reason, univariable analysis was 
carried out but pregnancy associated CTS was not included in the multivariable model.  
Obesity was identified as a candidate prognostic factor. It is usually advised to use a continuous 
outcome in prognostic models where possible rather than apply cut-points, so as not to lose 
information. However, in this situation the closest BMI data preceding the index date was taken and 
dichotomised as being < or ≥ 30 rather than tested as a continuous variable. This is because Read codes 
for obesity were also being used and it can be argued that there is a clinical reason for using a BMI ≥ 
30 cutpoint, in that it is the definition of a discrete entity. Smoking and alcohol consumption were also 
more frequently observed as a categorical variable in CPRD (yes / no / unknown outcome to ‘smoker’ 
and ‘alcohol drinker’), than as ‘cigarettes per day’ or ‘alcohol units per week’ which were populated 
infrequently. These variables were therefore presented as categorical rather than continuous 
outcomes, as this resulted in fewer missing data and was considered to be more clinically meaningful.  
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 Developing the risk prediction model: outcome   
The ‘end-point’ of the observation was a coded episode of carpal tunnel release surgery (CTR). The 
maximum length of follow up was set to three years. Surgery occurring more than three years after a 
baseline diagnosis was felt, following discussion with a GP musculoskeletal expert (GD), unlikely to be 
related to the index episode. Three years was chosen to include the 2-year presumed time period 
during which an episode was considered to be ongoing, plus one further year for referrals, 
investigations and surgery to take place. The Read codes used to define an episode of CTR (not 
including re-do procedures) are shown in Table 5-3 
Table 5-3 Table of Read codes used to define a surgical outcome 
Read Code Term 
70560 Carpal tunnel release                                                                                                                                                                                  
70564 Endoscopic carpal tunnel release                                                                                                                                                                       
7056011 Carpal tunnel decompression 
 
 Statistical methods 
5.3.4.1 Sample size 
After the above iterative process, 17 candidate prognostic factors were identified that would be 
available in CPRD, to be included in the development of the prognostic model. It has been proposed 
that there should be at least 10 events per variable in a study using regression analysis to develop a 
prognostic model.148 The issue of sample size will be further discussed in Chapter 6 where it is a more 
pertinent issue, since the CPRD cohort was very large and the parameter per variable rate was not a 
concern.  
5.3.4.2 Statistical analysis 
Time-to-event or survival modelling is used when: the timing of the outcome of interest is important; 
patients drop out over time and not all patients are followed until a particular time point. Survival 
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modelling allows for all patients who are eligible at baseline to be included (therefore reducing bias) 
until their last point of follow up; a process called censoring.  
Cox proportional hazards modelling, a form of survival modelling, was used to determine the 
association between candidate prognostic factors and time to surgical intervention. It is acknowledged 
that patients may have required further surgery for revision or treatment of the contralateral hand, 
but for the purposes of this study the initial episode of CTS and subsequent primary CTS surgery was 
the sole focus.  
Cox regression modelling allows for the association of variables (in this case candidate prognostic 
factors) with time to ‘failure,’ to be estimated.149 Length of follow up is taken into account by the 
hazard rate derived by the model; the hazard rate being the probability of an event (surgery) occurring 
in the next instant of time, given it has not already occurred.150 This type of analysis was useful in the 
scenario of this study, as the time of surgery (end-point) could be determined and patients could 
potentially be lost to follow-up out over time (were recorded as deceased, left the practice or their 
practice no longer contributed to CPRD). The hazard of having an episode of surgery is therefore 
estimated by a cumulative hazard function (H(t)), providing an average risk over the observed period, 
taking into account censored patients and the fact that the hazard rate may change over time.  
Assumptions are made when applying a Cox proportional hazards model in that hazard functions 
should be proportional across different levels of a prognostic factor over time.150 The assumptions of 
the proportional hazards assumption were checked in this study using Schoenfield residual testing.151 
If the assumption is not met, it is then possible to add covariate-time interactions to the model to 
overcome the issue.152 Since for the reasons detailed above, year was not included in the model, time-
varying covariates were not introduced. The model therefore presents the hazard of surgery averaged 
over the observed period.  
Univariable (unadjusted) analysis was initially performed to identify the crude association of each 
prognostic factor with outcome. In order to be inclusive and reduce the risk of missing important 
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(combinations of) predictors, a backward selection procedure was applied to determine the prognostic 
factors in the final multivariable model. Prognostic factors with a P value > 0.1 were omitted at each 
step. 0.1 was chosen as the cut off rather than the more traditionally used 0.05, to reduce the risk of 
missing prognostic factors that had clinical importance.153 Prognostic factors eliminated were re-
entered in the final multivariable model with adjustment for the remaining prognostic factors to 
ensure that no omitted variable would be significant when other variables were not included in the 
model.  
The performance (discrimination) of the final multivariable model was assessed using concordance 
statistics (C-statistics), which is analogous to the receiver operating characteristics (ROC) curve for 
binary data.154 A C-statistic can be interpreted as the probability that the model correctly predicts an 
episode of surgery in a patient presenting in primary care with CTS, compared to those who do not 
have surgery. Flipping a coin (chance) would produce a C-statistic of 0.5. Given that the model 
performed poorly, further measures of model performance and validation were not carried out given 
it would not have clinical utility and further work, as presented in chapter 6 was planned.  
5.3.4.3 Missing data 
Missing data was judged to be ‘missing not at random’ (MNAR) (i.e. a patient with obesity was more 
likely to have a BMI recorded that someone who was not obese). Imputing data that is MNAR increases 
the risk of bias and Sterne et al suggest therefore that such missing data can only be addressed through 
sensitivity analyses examining the effect of different assumptions about the missing data.155 The 
management of missing data will be discussed further in chapter 6. 
Deprivation data was missing for patients whose practice did not contribute to ‘linked’ CPRD data. Data 
was also missing in a proportion of patients for some lifestyle variables including BMI, alcohol 
consumption and smoking. A sensitivity analysis using complete cases only was therefore carried out.  
  




 Describing the cohort 
91,412 patients were included in the cohort from 685 practices contributing to the CPRD. 18,500 
(20.2%) had surgery in the three-year period following the index presentation (absolute CPRD 
population rate: 1.52 episodes of surgery per 100 person years). The median time to surgery was 221 
days (interquartile range, IQR: 111, 409).  
2967 patients had a preceding incident episode denoted by a surgical code. 253 patients had a 
diagnostic code attributed on the same day as a carpal tunnel release code and eight patients were 
diagnosed on their ‘end date’ so had no follow up data to observe. These patients were excluded from 
the cohort, as it was not possible to observe the course between diagnosis and any treatment.  
Table 5-4 describes the demographic and clinical characteristics of the 91,412 patients included at 
baseline (the attribution of an incident CTS diagnosis code) and those without any missing data in 
collected prognostic factors (n = 44,522).  
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Table 5-4 Description of the entire cohort and cohort with complete data 
 All Patients Patients with complete 
data 
Participants 91,412 44,522 
Patients with a coded episode of 
surgery n (%) 
18,500 (20.24) 8,971 (20.15) 
GP practice 685 practices contributed 383 practices contributed 
Year of baseline diagnosis, median 
(IQR) 
2006 (2002 – 2010) 2007 (2003 – 2010) 
Year of surgery, median (IQR) 2007 (2004 – 2011) 2008 (2004 – 2011) 
Time to surgery in days, median (IQR) b 221 (111 – 409) 249 (118 – 559) 
Follow up time in days, median (IQR) b 1095.75 (385 – 1096) 1095.75 (370 – 1096) 
Demographics 
Age at diagnosis, median (IQR) 53 (42 – 66) 53.96 (43.20 – 66.31) 
Age group, n (%) 
18 – 29 
30 – 39 
40 – 49 
50 – 59 
















Female, (n)% 63,194 (69.13) 32,030 (71.94) 
Geographical region, n (%) 
North East 
North West 
Yorkshire & The Humber 
East Midlands 
West Midlands 






































































27.2 (23.9 – 31.2) 
 
54,209 (59.30) 
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Unknown 10,521 (11.51) - - 
Pregnancy (in female patients)**, n (%)  3,869 (4.23) 1,908 (5.96) 
Comorbidities 
Affective disorder***, n (%) 4,576 (5.01) 2,244 (5.04) 
Hypothyroidsim***, n (%) 1,904 (2.08) 951 (2.14) 
Diabetes***, n (%) 1,795 (1.96) 1,012 (2.27) 
Inflammatory condition***, n (%) 851 (0.93) 426 (0.96) 
Neck condition***, n (%) 2,371 (2.59) 1,113 (2.50) 
Multi-site pain (including 
osteoarthritis) ***, n (%) 
7,799 (8.53) 3,854 (8.66) 
Tendonitis / epicondylitis***, n (%) 850 (0.93) 421 (0.95) 
Wrist trauma***, n (%) 615 (0.67) 294 (0.66) 
IQR, interquartile range; na, not applicable 
* closest recorded value preceding the baseline diagnosis 
** identified between 1 year prior to baseline and baseline 
*** identified between 2 years prior to baseline and baseline 
a censored at episode of surgery 
b maximum follow-up 3 years 
c  applies at a practice level (not all practices contribute deprivation data) 
¶ Percentage of patients, excluding the ‘unknown’ category 
 
 Unadjusted univariable analysis 
Table 5-5 shows the unadjusted univariable association of each candidate prognostic factor with time 
to surgery.  
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Table 5-5 Unadjusted univariable analysis 
 Hazard ratio P value* 95% Confidence Interval 
Age at diagnosis 1.01 <0.001 1.01 to 1.02 
Age group 
18 – 29 
30 – 39 
40 – 49 
50 – 59 


















1.59 to 1.92 
2.05 to 2.52 
2.41 to 2.95 
2.43 to 3.00 
3.00 to 3.68 
Gender (female) 0.97 0.10 0.94 to 1.00 





Yorkshire & The Humber 
East Midlands 
West Midlands 
East of England 
South West 
South Central 


































1.05 to 1.36 
1.21 to 1.39 
1.13 to 1.35 
1.48 to 1.76 
1.34 to 1.53 
1.04 to 1.19 
1.12 to 1.29 
1.15 to 0.32 
1.00 to 1.24 
1.57 to 1.82 
1.19 to 1.37 
























0.912 to 1.01 
0.94 to 1.05 
0.87 to 0.98 
0.90 to 1.02 
0.96 to 1.04 














1.17 to 1.25 















1.01 to 1.11 















0.94 to 1.01 
0.94 to 1.03 
Pregnancy (if gender = female) 0.24 <0.001 0.21 to 0.28 
Affective disorder 0.96 0.30` 0.90 to 1.03 
Hypothyroidism 1.06 0.23 0.96 to 1.17 
Diabetes 1.26 <0.001 1.14 to 1.39 
Inflammatory condition 1.26 0.001 1.10 to 1.45 
Neck condition 1.15 0.001 1.06 to 1.25 
Multi-site pain (including osteoarthritis)  1.22 <0.001 1.58 to 1.27 
Tendonitis / epicondylitis 1.02 0.80 0.88 to 1.18 
Wrist trauma 1.04 0.65 0.87 – 1.24 
* P value obtained from each group compared to the referent group  
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 Final multivariable model 
Following the manual process of removing prognostic factors with a P value >0.1 and sequentially 
adding them back in; the final multivariable model was derived, as shown in Table 5-6. 
Table 5-6 Final multivariable model of all patient data 
 
Hazard ratio P value* 95% Confidence interval 






North West 1.30 <0.001 1.22 to 1.40 
Yorkshire & The Humber 1.26 <0.001 1.15 to 1.38 
East Midlands 1.65 <0.001 1.52 to 1.80 
West Midlands 1.43 <0.001 1.33 to 1.53 
East of England 1.09 0.013 1.02 to 1.18 
South West 1.16 <0.001 1.08 to 1.25 
South Central 1.31 <0.001 1.22 to 1.40 
South East Coast 1.20 <0.001 1.12 to 1.29 
Northern Ireland 1.18 0.004 1.06 to 1.33 
Scotland 1.78 <0.001 1.65 to 1.93 
Wales 1.32 <0.001 1.22 to 1.43 
North East 1.20 0.006 1.05 to 1.36 
Obesity 
   
Not obese 1   
Obese 1.23 <0.001 1.19 to 1.27 
Unknown 0.89 <0.001 0.84 to 0.94 
Deprivation 
   
1 (least deprived) 1   
2 0.96 0.137 0.91 to 1.01 
3 1.00 0.998 0.95 to 1.06 
4 0.94 0.053 0.89 to 1.00 
5 (most deprived) 0.98 0.486 0.92 to 1.04 
Unknown 0.92 0.001 0.87 to 0.96 
Alcohol use 
   
No 1   
Yes 1.05 0.034 1.00 to 1.10 
Not known 1.08 0.051 1.01 to 1.15 
Smoking status  
  
No 1   
Yes 1.06 <0.001 1.03 to 1.10 
Not known 1.01 0.563 0.97 to 1.07 
Inflammatory condition 1.13 0.085 0.98 to 1.29 
Neck condition 1.13 0.006 1.03 to 1.23 
Multi-site pain 1.10 <0.001 1.05 to 1.15 
* P value obtained from each group compared to the referent group 
All variables except age, region and deprivation met the Cox proportional hazards assumption. For 
these variables the model therefore considers the average effect on the hazard of surgery, over the 
three-year observed period.  The Harrell’s C concordance statistic for this model was 0.588 (95% CI 
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0.584 to 0.592), meaning the model discriminated 59% of the time between patients who had an 
episode of CTR and those who did not (slightly better than chance).  
 Sensitivity analysis using complete patient data only 
The process of building a multivariable model using a manual backward step approach, was then 
repeated in the data of patients who had complete data (i.e. entries for deprivation, BMI, smoking and 
alcohol status). The result of this process is shown in Table 5-7. The Harrell’s C concordance statistic 
for this model was 0.587 (95% CI 0.581 to 0.593). The HR’s for each prognostic factor in the 
multivariable models are compared in Table 5-8 showing in the complete case analysis; deprivation, 
smoking, alcohol and a history of neck problems do not remain in the final model. The hazard rates for 
age, obesity and a history of an inflammatory condition and multisite pain were similar in the two 
models.  
Table 5-7 Final multivariable model of complete case data 
 
Hazard Ratio P value 95% Confidence interval 
Age at diagnosis 1.02 <0.001 1.01 to 1.02 
Region 
   
London 1 (as referent)   
North East 1.39 <0.001 1.27 to 1.52 
North West 1.19 <0.001 1.06 to 1.34 
Yorkshire & The Humber 1.80 <0.001 1.60 to 2.03 
East Midlands 1.45 <0.001 1.32 to 1.58 
West Midlands 1.21 <0.001 1.11 to 1.32 
East of England 1.25 <0.001 1.14 to 1.36 
South West 1.35 <0.001 1.24 to 1.48 
South Central 1.30 <0.001 1.19 to 1.42 
South East Coast 1.28 <0.001 1.09 to 1.50 
Obese 1.21 <0.001 1.16 to 1.26 
Inflammatory condition 1.37 <0.001 1.14 to 1.64 
Multisite pain 1.08 0.04 1.00 to 1.15 
* P value obtained from each group compared to the referent group 
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Table 5-8 Comparison of multivariable models derived from all versus complete patient data 
 
All Patients (Hazard ratio) Complete Case (Hazard ratio) 
Age at event 1.02 1.02 
Region      
London 1 (as referent) 1 
North East 1.20 1.39 
North West 1.30 1.19 
Yorkshire & The Humber 1.26 1.80 
East Midlands 1.65 1.45 
West Midlands 1.43 1.21 
East of England 1.09 1.25 
South West 1.16 1.35 
South Central 1.31 1.30 
South East Coast 1.20 1.28 
Northern Ireland 1.18 na 
Scotland 1.78 na 
Wales 1.32 na 
Obesity   
 
Obese 1.23 1.21 
Unknown 0.90 na 
Deprivation   
 
1 (least deprived) 1 na 
2 0.96 na 
3 1 na 
4 0.94 na 
5 (most deprived) 0.98 na 
Unknown 0.92 na 
Alcohol use   
 
No 1 na 
Yes 1.05 
 
Not known 1.08 na 
Smoking status  
 
No                                                  1 na 
Yes 1.06 - 
Not known 1.01 na 
Inflammatory condition 1.13 1.37 
Neck condition 1.13 - 
Multi-site pain 1.1 1.08 
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5.5 Discussion  
 Summary of main findings 
17 candidate prognostic factors, derived from the literature and expert opinion, were identified and 
tested as prognostic factors of surgery in a cohort of 91,412 patients with physician diagnosed CTS, as 
recorded in the CPRD. 20.2% of the cohort had a recorded episode of CTR. The median time to surgery 
was 221 days (IQR 111 - 409). The final multivariable cox regression model performed poorly but 
confirmed the likely predictive value of prognostic factors including age, region, deprivation, obesity, 
being an alcohol drinker or smoker and having other pain, neck condition or inflammatory condition. 
Univariable analysis indicated that pregnancy in the preceding year was observed to reduce the risk of 
future surgery significantly. 
 Interpretation of results 
5.5.2.1 Prognosis of carpal tunnel syndrome 
20% of the cohort (patients with physician recorded diagnosis of CTS presenting in primary care) 
required surgery in the three-year period following their incident consultation, over the course of the 
study period. This figure underestimates the CPRD population who required surgery (27% over the 
study period), as there was a need, in order to conduct the ‘time to’ analysis, to exclude patients 
without a diagnostic code at baseline.  
An episode of surgery is likely to indicate that the patient’s symptoms or functional deficit due to the 
index episode of CTS had not been managed effectively using non-surgical approaches or had been 
severe enough at presentation to warrant expedited surgical consideration. These assumptions do not 
mean however, that the patients without a surgical episode were necessarily symptom free and 
functionally well at the end of follow up. Consultation data is unable to provide that level of patient 
orientated information. 
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The systematic review presented in chapter 4 concluded that the outcome of conservatively managed 
CTS was variable between studies and that this variability was likely to be due to the outcome measure 
applied and population observed. Four studies used a surgical episode as a marker of a poor or 
unsatisfactory outcome of conservative management. A range of 57% to 66% of patients were 
observed to receive surgery following conservative management over a period of between 1 and 3 
years68, 132, 138, 139. This range is substantially higher than the figure reported in this cohort study. As well 
as the fact that some patients who had surgery were excluded, this could also suggest either that the 
occurrence of surgery in this cohort was underestimated by the methods applied or that the 
population studied was very different to those reported in the review. All four of the studies included 
in the review were set in secondary or tertiary hand clinics, where one could assume the patients had 
already been ‘filtered’ by severity and non-response to ‘watchful waiting’ or treatment in primary care 
or equivalent. This CPRD derived cohort is likely to be more representative of the UK general practice 
population; although as discussed below the approach to the analysis is likely to have underestimated 
the true number of surgical episodes.  
5.5.2.2 Prognostic model determining risk of having a recorded episode of surgery 
The results of univariable analysis suggested that increasing age, year of diagnosis, geographical 
region, obesity, a record of alcohol consumption, diabetes, inflammatory conditions, neck conditions, 
and multisite pain all increase the risk of having surgery. However, on multivariable analysis, diabetes, 
for example, did not retain significance (at a level of P < 0.1). The final model itself did not perform 
well. Although some previous studies have suggested a prognostic value of these candidate predictors, 
evidence regarding these prognostic factors from the systematic review was not consistent, which is 
in keeping with the results of this study. 
Factors with the largest effect size in the final multivariable model included certain geographical 
regions (in particular Scotland and the East Midlands) and obesity. Region is likely to be a predictor of 
surgery due to the variability in local care pathways. It is important therefore that region, whilst it 
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cannot represent every different locally commissioned pathway, is included in the model to adjust for 
this potentially important confounder.  
Obesity has been identified by a recent meta-analysis of 58 studies, to be a predictor of CTR (adjusted 
OR = 2.02, 95% CI 1.92 to 2.13) as well as an aetiological factor of disease onset. This is likely to be due 
to the shape of the wrist exerting increased amounts of pressure on the median nerve.97 This study 
further suggests the role of obesity in predicting the need for surgery in patients presenting with CTS 
in primary care.  
Table 5-5 suggests that on univariable analysis, in the female population, the prognostic factor with 
the largest and significant effect size was pregnancy (HR 0.24 95% CI 0.21 to 0.28). Pregnancy was 
defined as any ante-natal code in the 12-month period preceding the date of diagnosis. This was to 
allow a minimum of 3 months and maximum of 12 months for acute resolution of pregnancy related 
symptoms. A systematic review of studies observing the incidence and natural history of PRCTS 
suggested that the estimated incidence of CTS in pregnancy ranges from 0.8% to 70%. Symptoms 
persisted in more than 50% of patients after 1 year and in 30% at 3 years. The review concludes by 
suggesting that with high rates of resolution, surgery should be reserved for cases in which 
conservative management fails, where functional impairment is debilitating or in severe cases.156 This 
cohort study, whilst unable to track resolution of symptoms post-delivery, suggests that recent 
pregnancy significantly reduces the risk of requiring surgery and that pregnant patients presenting 
with CTS may be reassured as such. Pregnancy was not included in the final model as, as well as having 
its own particular phenotype, it was felt that pregnancy would not be relevant to a large proportion of 
the population presenting with CTS in primary care with nearly 60% of the sample aged 50 or older, 
and 30% being male.  
 Methodological considerations 
The predictive performance of the model was poor, as indicated by the C-statistic of 0.59. As will be 
discussed and applied in chapter 6, a prognostic model can be adjusted for the optimism automatically 
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introduced through using the development data set. Following estimation and internal validation, a 
model can then be externally validated in a new data set, before being recommended for testing in a 
healthcare setting. Processes of internal and external validation were not applied to this model, as it 
was clear from the initial results that the model did not perform sufficiently well enough to consider a 
potential clinical application. Optimism was also unlikely to be an issue in such a large data set that is 
already purported as being representative of the population.  
The systematic review presented in chapter 4, although not conclusive, suggested that symptom 
duration, a positive Phalen’s test and thenar atrophy were likely predictors of the failure of 
conservative management. Whilst Read codes do exist for Phalen’s test and thenar atrophy, pilot work 
demonstrated they were seldom used and therefore unlikely to provide reliable data when extracted 
from CPRD. Likewise, CPRD data cannot provide a measure for patient preference nor practitioners’ 
referral and management behaviour that may also confound which patients are referred for surgery 
and when in the time course of their CTS. Missing important predictors are a key reason a prognostic 
model may not perform well and give rise to a low C-statistic.   
The existence of missing data is a substantial limitation when using consultation data. For example, in 
this dataset, 12% of the cohort had never had a BMI or smoking status recorded. As deprivation linkage 
was only available in practices in England and not the whole of the UK, this again limited the number 
of patients with complete data (to 46,890 patients, or 51 % of the original cohort). The complete case 
sensitivity analysis performed suggested deprivation, alcohol use and smoking history may not be 
significant predictors of surgery, as suggested by the full model.  
It is possible that results based on complete case analysis are biased, given the assumption that at least 
some of the data were not missing not at random. The baseline characteristics of the complete case 
sample are different compared to the analysis sample (proportionally more smokers and more patients 
with obesity), potentially indicating poorer health/lifestyle behaviour. If it is this that was associated 
with the probability of requiring surgery, different associations between predictors and outcome in 
the complete case versus main analysis would be found. 
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The use of consultation data in research relies on patient information being complete and accurate. It 
is possible that the coding of some prognostic factors and indeed diagnosis of CTS, was inaccurate or 
absent. For example, a history of neck pain in a patient presenting with CTS may not have received a 
Read code and hence not have been identified by the study. Patients with chronic conditions such as 
diabetes, due to the regular structured follow-up they receive in primary care, may have been more 
likely to receive a code than a patient presenting with a pain related problem. Likewise, although 
attempts were made to ensure that code lists were comprehensive; it is possible that relevant Read 
codes were not included in the generated lists. The consequence of this would be that bias was 
introduced to the model due to variability in the accuracy and completeness of coding, depending on 
the candidate predictor.  
The study was also reliant on a surgical episode being captured by clinical coding in the database. As 
procedures now take place outside of the secondary care environment, it was felt that Hospital Episode 
Statistics would in fact underestimate the episodes recorded in CPRD. Likewise, there remains a risk 
that administrative and coding processes did not identify every episode of CTR. If funding had allowed, 
it may have been possible to compare or combine the two approaches of i) relying on clinical 
administrative coding and ii) the use of data from Hospital Episode Statistics, but this was not feasible.  
As discussed in Chapter 3, the population studied in CPRD is likely to be different to the population 
observed in most other existing studies which are set in specialist clinics, where patients with mild to 
moderate disease are more likely to have already been treated or have improved and hence not 
referred. Patients with a surgical code only and no preceding diagnostic code, were not included in the 
observed cohort as a baseline analysis of candidate prognostic factors was not possible to conduct, 
neither was a time to analysis. It is possible that by excluding such patients (who had been included in 
the prevalence / incidence calculations) a less severe population was selected leading to a model that 
did not perform well in predicting a surgical event.  
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 Clinical relevance of the findings and suggestions for further research 
The aim of this study was to use consultation data to predict the risk of an episode of surgery in patients 
presenting in primary care with CTS, by developing a prognostic model. In order for a model to have 
clinical utility, it should have good predictive performance, that is maintained when the model is tested 
(externally validated) in populations that share a similar range of predictor variables, be unambiguous 
in its definitions of predictors and outcomes in order for them to be reproducible in other settings, and 
be tested in impact studies. Impact studies allow the effect of using the model in clinical practice, to 
include the effect of physician and patient behaviour, to be estimated and the clinical and cost 
effectiveness of care using the model to be considered.157 Whilst CPRD is accepted to be generalizable 
to the UK population,82 given the disappointing predictive performance of model presented in this 
chapter, it would need further development to improve its predictive performance before it could be 
further validated and investigated for its potential impact in clinical practice. Ideally, data from a high-
quality a-priori designed prospective cohort study or studies with sufficient information regarding 
prognostic factors would be required in order to do this. 
 Conclusion 
The final model performs inadequately but suggests the likely combined predictive value of several 
prognostic factors including obesity, being an alcohol drinker and presence of other musculoskeletal 
pain on future risk of CTR. Neither the systematic review, nor this CPRD cohort study have been 
successful in providing strong evidence for predictors of outcome in non-pregnancy related CTS. This 
is potentially because prognostic factors of greater importance have not yet been effectively identified 
and / or measured. Further work would be required to investigate the predictive performance of these 
candidate prognostic factors and develop a prognostic model that might have clinical utility.  
In the next chapter, a cohort will be constructed from participants of a randomised clinical trial and 
further analysed to develop an alternative prediction model for patients presenting with CTS in primary 
care. This study benefits from including prognostic factors purposively measured at baseline, including 
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symptom duration and severity, which could not be measured in CPRD. A well validated patient 
recorded outcome measure will also be available to more precisely measure change in symptoms and 
function over time. Using a patient reported outcome will also mitigate the confounding effect of local 
variation in access to CTR.  
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6 Describing the course of symptoms and predicting outcome in 
patients with carpal tunnel syndrome receiving conservative 
management as part of a randomised controlled trial (Injection 
versus Night Splints for Carpal Tunnel Syndrome) 
 
 Summary 
The aim of this chapter is to further explore if the patient reported outcome of carpal tunnel 
syndrome (CTS), presenting in a primary care setting, can be predicted. The study presented 
in this chapter uses data from the Injection versus Night Splints for Carpal Tunnel Syndrome 
(INSTINCTS) trial. The trial was conducted independently of the work this thesis and whilst CB 
was a member of the Trial Management Group, did not conduct the trial independently. The 
trial protocol and publication can be found at: 
Chesterton LS, Dziedzic KS, Van der Windt D, Davenport G, Myers HL, Rathod T, Blagojevic-
Bucknall M, Jowet S, Burton C, Roddy E, Hay EM. The clinical and cost effectiveness of steroid 
injection compared with night splints for carpal tunnel syndrome: The INSTinCTS radmonised 
clinical trial study protocol. BMC Musculoskeletal Disorders BMC. 2016. 17:415 
Chesterton LS, Blagojevic-Bucknall M, Burton C, Dziedzic KS, Davenport G, Jowett SM, Myers 
HL, R Oppong R, Rathod-Mistry T, Van der Windt DA, Hay EM, Roddy E. The clinical and cost-
effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome 
(INSTINCTS trial): an open-label, parallel group, randomised controlled trial. The Lancet, 
Volume 392 , Issue 10156 , 1423 – 1433 
 
6.1 Introduction 
In Chapter 5, the Clinical Practice Research Datalink (CPRD) was used to develop a prognostic model 
to predict the likelihood of patients with physician diagnosed CTS having future carpal tunnel release 
(CTR) surgery. This information could have been used by clinicians to help guide decision-making 
around the use of conservative management options and follow up in a primary care setting, or 
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whether it was more appropriate to refer patients for consideration of surgery. However, the model 
performed poorly and was considered not to have clinical utility. This may have been due to several 
reasons including: the importance of factors other than clinical prognostic indicators (i.e. variation 
between local commissioning pathways) or that it was not possible to measure or measure well, 
potentially important prognostic factors such as symptom severity and symptom duration in CPRD. It 
was hoped that using data from the INSTINCTS trial, whilst the sample size was much smaller than that 
available from CPRD, would afford the advantage of measuring at baseline potentially important 
candidate predictors that were not available from electronic patient data. The use of a patient reported 
outcome measure would more directly reflect the course of CTS symptoms over time than a decision 
to refer for CTR, which may be influenced by other non-clinical factors. 
The trial population, adjusting for intervention, was therefore prospectively observed as a prognostic 
cohort. The course of CTS was described using the Boston Carpal Tunnel Questionnaire (BCTQ) score. 
A-priori identified candidate prognostic factors were used to develop a prognostic model to predict 
patient-reported CTS at six months, following primary care management (corticosteroid injection or 
night splinting).  
The trial methods and results will first be summarised, followed by a description of the methods 
applied for the prognostic study, using the reporting guidelines provided by TRIPOD (Transparent 
Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis). 145 The 
development of the prognostic model will then be presented and discussed.  
6.2 Source of data: The INSTINCTS trial 
INSTINCTS is an open-label, parallel group, randomised control trial.59 The trial had a pragmatic design, 
meaning that it was intended to recruit a sample representative of the population in primary care 
presenting with CTS, amenable to conservative management. The exclusion criteria were limited and 
were designed to not restrict the participants eligible to participate too stringently, in order to 
maximise the generalisability of the results.  
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Participants were randomly assigned (1:1) to either treatment group using permutated blocks of sizes 
two and four, pre-stratified by research site. Treatment allocation was concealed during analysis. 
Participants randomly received either 20mg Methylprednisolone injected into the carpal tunnel using 
an approach between the proximal and distal wrist crease or a resting night splint to be worn at night 
for six weeks. Self-report at six weeks was used to assess adherence to splinting. 
Both trial interventions were treatment options commonly offered in primary care for CTS, and 
random allocation of the interventions avoided the risk of so-called treatment bias (or confounding by 
indication),158 which may affect the results of prognosis studies in observational cohorts. Finally, since 
the trial showed only small, non-significant differences at six months between the two arms, treatment 
was considered unlikely to influence results.  
 Participants  
Participants (≥ 18 years of age) with mild or moderate CTS were recruited from 25 primary and 
community musculoskeletal clinics and services. Eligible participants were required to have had a new 
episode of idiopathic CTS, as defined by criteria developed as part of a consensus survey of GPs from 
the PCRMM Society, for at least six weeks duration. Participants with bilateral disease were 
investigated based on the hand with the most severe symptoms. Exclusion criteria included: severe 
disease, previous surgery in the affected wrist, current or previous infection, pregnancy and lactation, 
treatment in the past six months and intercurrent illness. Written, informed consent was obtained 
from eligible patients. 
 Approvals and monitoring 
The INSTINCTS trial was approved by the National Research Ethics Service Committee North West – 
Liverpool (UK: reference 13/NW/0280) and the Medicines and Healthcare products Regulatory Agency 
(European Clinical Trials Database, number 2013-001435-8). An external trial steering and data 
monitoring committee oversaw the conduct and analysis of the trial. The trial was prospectively 
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registered with ClinicalTrials.gov on 16/01/2014 (NCT0.038542) and registered with Current Controlled 
Trials on 1/05/2014 (ISRCTN09392969).  
 Outcome measures 
Baseline data were collected using a self-completed questionnaire before randomisation. All outcome 
measures were collected at six weeks and all but adverse events were collected at six months. Further 
follow up took place at 12 and 24 months (data not available at the time of writing).  
The primary outcome measure for the trial was the overall score for symptom severity and limitations 
in hand function as measured by the Boston Carpal Tunnel Questionnaire (BCTQ)32 at six weeks. This 
is a condition-specific questionnaire referring to a typical 24-hour period in the previous 2 weeks. It 
has been shown to be highly reproducible, internally consistent, valid and responsive to clinical 
change.159 The BCTQ comprises of two sub-scales: the symptom severity scale (SSS: 11 items) and 
function severity scale (FSS: 8 items). Both sections are scored on 1-5 scales, with final scores for each 
dimension calculated as a mean score between 1 and 5. Higher scores indicate more severe symptoms 
and greater functional impairment.  
6.3 Describing the course of symptoms and predicting outcome in patients with 
carpal tunnel syndrome: Methods 
 Describing the course of CTS over a six-month period of time 
Whilst INSTINCTS reported the BCTQ scores at six weeks and six months for each intervention arm of 
the trial, this study summarises the course of both the combined (BCTQ sum score) and separate scores 
for symptom severity (SSS) and functional outcome (FSS) for the entire trial cohort at each of these 
time points.  
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 Developing the prognostic model: outcome   
The outcome measure (and ‘end-point’) for the model, was the sum score for symptom severity and 
functional limitation on hand function using the Boston Carpal Tunnel Questionnaire (as per the main 
trial), at six-month follow-up. Six-month data was chosen as the time point of interest as the six-week 
outcome was felt to represent too short a timeframe and lacked clinical importance. Whilst longer-
term outcome data may provide further clinical information, it was not feasible to wait for this data to 
become available and it was not expected that substantial differences in prognostic factor outcome 
associations at 12 or 24 months would be present, if they could not be detected at six months. Further 
(non-randomised) interventions such as repeat injections or episodes of surgery were more likely to 
have occurred at later time-points and as such may confound prognostic factor – outcome 
associations.  
 Developing the prognostic model: identifying and measuring candidate prognostic 
factors   
The approaches used to identify candidate prognostic factors and predictors of treatment effect have 
been described in section 5.2. The identified candidate predictors were amalgamated and grouped 
into a list of 69 single items by category (comorbidities, clinical characteristics and patient 
demographics). The list was further reduced to 41 items using the following reasons for exclusion: 
• Exclusion criteria for the trial (e.g. CTS during pregnancy, disease severity – including 
presence of thenar wasting) 
• Rare characteristics that would not carry significance within the study (e.g. acromegaly) 
• Information not available within the dataset (e.g. results of nerve conduction studies) 
• Items not measurable within the study (e.g. accuracy of placement of the steroid injection) 
• Items specific to surgical intervention (e.g. approach to surgery) 
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Of the 41 items, 21 were already included in pre-existing questions or items to be recorded in the case 
report forms (for example, symptom severity and demographic details respectively). When developing 
the additional questions, brevity was a major concern expressed by the Trial Management Group, in 
order to minimise patient burden. Validated single questions were used where possible, for example 
items from the Revised Illness Perception Questionnaire.160 Where validated questions were not 
available, questions from previous questionnaires developed in the Centre were utilised or if 
necessary, designed through agreement with members of the Trial Management Group and reviewed 
for content and presentation by the Research User Group.  
Two items (Phalen’s test and presence of thenar wasting) were collected in the case report form, 
however were not further considered as there was strong overlap with eligibility for the trial, (i.e. 
patients were highly likely by definition to have a positive Phalen’s sign and should not have had thenar 
wasting). As obesity was recognised as a candidate prognostic factor, this was added to the 
Confirmation of Eligibility and Randomisation case report form, to be recorded by the randomising 
clinician. Table 6-1 describes the candidate prognostic factors, type of question used and the source 
of the measure.   
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Table 6-1 Candidate prognostic factors measured at baseline 
Variable Outcome measure Source of outcome measure 
Gender   
Age   
Occupation   
Depression Two items (yes/no)  Progress brief assessment tool 146  
 
Sleep quality Revised 4 items (yes/no) Jenkins Sleep questionnaire161 
Functional disorders Single item question (yes/no) Progress brief assessment tool 
 
Obesity Body mass index Height and weight entered into CRF 
Absence / presence of any 
associated co-morbidity  
• Hypothyroidism 
• Diabetes 
• Neck and upper limb pain 
  
Laterality of symptoms Single item question (yes/no)  
If affecting dominant hand Single item question (yes/no)  
Recurrent symptoms Single item question (yes/no)  
Baseline symptom severity Boston Carpal Tunnel 
Questionnaire (whole scale) 
Levine et al32 
Baseline functional severity Boston Carpal Tunnel 
Questionnaire (whole scale) 
Levine et al 
Baseline Boston Carpal Tunnel 
sum score  
Boston Carpal Tunnel 
Questionnaire (whole scale) 
Levine et al 
Symptom duration / time to 
intervention 
Single item question Question developed for purpose of 
this study 
Postural symptoms only Single item question Question developed for purpose of 
this study 
Constancy of symptoms Boston Carpal Tunnel 
Questionnaire (single item) 
Levine et al 
Symptoms limited to night-time Boston Carpal Tunnel 
Questionnaire (single item) 
Levine et al 
Daytime symptoms Boston Carpal Tunnel 
Questionnaire (single item) 
Levine et al 
Nature of onset  Single item question Adapted from 162 
Multi-site pain Single item question Progress brief assessment tool 
Full symptom checklist likely to be 
over-burdensome 
Phalen’s sign Checked at eligibility screening   
Previous response of CTS to 
wrist injection / splint and 
surgery 
Multiple item question BeBack 163 
Previous response to any 
treatment 
Single item question BeBack 
Previous response to injection 
(any site) 
Multiple item question BeBack 
Acceptability / preference of 
treatment 
Single item question Question developed for purpose of 
this study 
Acceptability / expectation of 
treatment 
Single item question Question developed for purpose of 
this study 
Quality of patient education 
regarding the use of splints 
Single item question Question developed for purpose of 
this study 
Support of employer Multiple item question Adapted from Karasek questions  164 
Successful work role functioning Single item question Presenteeism scale 
If symptoms are work related Single item question Adapted from Karasek 
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If unemployed / receiving social 
support 
Single item question Question developed for purpose of 
this study 
Locus of control  Single item question Illness Perception Questionnaire 
(taken from the multi-item subscales 
(dimensions) 160 
Treatment control Single item question Illness Perception Questionnaire 
(taken from the multi-item subscales 
(dimensions) 
Adherence to treatment Single item question Question developed for purpose of 
this study 
Peri-menopause Female: age 45 – 55 years  
Perceived health scores Whole scale EQ 5D https://euroqol.org/eq-5d-
instruments/ 
Excess alcohol use Single item question North Staffordshire Osteoarthritis 
Project (NorStOP) 
Smoking Single item question NorStOP 
 
This pool of candidate predictors was further considered for overlap or redundancy in order to reduce 
them to a more acceptable number, with the initial aim of achieving 10 events (parameters) per 
variable, as per the recommendation of Peduzzi et al.148  
Continuous candidate predictors (age, BMI, BCTQ scores) were not categorised in order to preserve 
information and their potential non-linear trends were considered.165  
6.3.3.1 Further reduction in the number of candidate prognostic factors and description of missing 
data 
Following the process of defining variables, it was recognised that some of the candidate prognostic 
factors were not measured at baseline;  only applicable to a subgroup of participants (e.g. employment 
related factors); or they collided with other variables (e.g. taken from scales that were also measured 
in full or were composite measures like ‘peri-menopausal’, which was derived from age and gender).  
Table 6-2 shows the candidate prognostic factors that were removed and the reasons for their 
removal. 
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Table 6-2 Further reduction of candidate prognostic factors 
Removed candidate prognostic factor Reason for removal 
Employment related factors 132 (56%) of the participants were in paid 
employment, hence the predictors apply to only a 
subgroup of patients. It may be possible in the future 
to investigate the role of employment on the 
outcome of trial participants, in the future 
Individual items from the Boston Carpal Tunnel 
Questionnaire 
Individual items derived from the BCTQ will collide 
with the overall score. However, the symptom 
severity score (SSS) and functional status scale (FSS) 
will be considered 
“Particular position cause hand or wrist problems” This item is a diagnostic feature as opposed to a 
prognostic factor and as such the majority of patients 
are likely to have a positive response and as such the 
variable will not discriminate well 
Phalen’s test This item is a diagnostic feature screened for in the 
trial participants and used in the selection criteria 
and as such the majority of patients are likely to have 
a positive response 
Satisfaction with education received as part of the 
intervention  
This is not measured at baseline and hence cannot be 
included as a prognostic factor, which by definition 
are measured at baseline 
Treatment adherence This is not measured at baseline and hence cannot be 
included as a prognostic factor, which by definition 
are measured at baseline 
Menopause This collides with age and gender. However, it may 
need to be considered as a moderator as there may 
be a physiological reason why women with low levels 
of progesterone may respond to one treatment 
better than another 
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Functional disorders / multisite pain Functional disorders and multisite pain were 
described by the same outcome, hence they were 
combined 
 
6.3.3.2 Permissions for amending trial questionnaire 
In order to permit a more complete description of the baseline characteristics of the participants, 
additional questions were added to the original INSTINCTS baseline questionnaire, following discussion 
with the Trial Management Group (which included PPIE members). The addition of these questions to 
the baseline questionnaire was approved on 03/07/13 by the National Research Ethics Service 
Committee North West – Liverpool, following a request for a substantial amendment. The Patient 
Information Leaflet for INSTINCTS included a paragraph explaining that anonymised data may be used 
for further research, 
“The study information collected about you may be shared with other research teams to 
answer new research questions in the future. If this is the case, information will be anonymised. 
Your full name and contact details will not be disclosed.” 
The Internal Request for data to be released by the trial data custodian was signed on 24/2/17 by the 
Principal Investigator and a further amendment to acquire six week data signed on 31/01/19, in 
accordance with the Keele University Health and Social Care Standard Operating Procedure Number 
48. These requests can be found in appendix F. 
 Developing the prognostic model: statistical analysis   
Firstly, descriptive statistics were used to describe characteristics of the study population and 
illustrate the course of the SSS and FSS and sum BCTQ between recruitment (start-point) and six week 
and six-month (end-point) time points.  
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6.3.4.1 Missing data 
Missing data risks introducing bias into estimates and standard errors and should be examined and 
managed in order to reduce this risk.166 It is firstly important to consider why data might be missing. 
Missing data can be considered: missing completely at random (MCAR); missing at random (MAR) or 
missing nor at random (MNAR). The difference between MAR and MCAR being that a systematic 
difference between missing and observed values exists in MAR data, whereas in the case of MCAR 
data, there is no systematic difference leading to data being missing. Typically, data is assumed to be 
MAR, however there are no ways to test for this assumption. Options for handling missing data include 
complete case analysis and single imputation, however both these techniques are inefficient and waste 
data and in doing so can bias parameter estimates. They also do not account for the uncertainty in 
imputing values.  
If data is MAR (or MCAR), multiple imputation (MI) can be used to impute missing values ‘M’ times 
rather than once. This technique incorporates uncertainty into its estimates and thereby maintains an 
unbiased model. It is also efficient in that data is not lost. MI involves developing multiple datasets 
(whereby the number of datasets is equal to the % with any missing, so for example, 50 data-sets if 
50% of the original participants have some data missing) and performing the analysis in each of the 
datasets. The results of these analyses are then pooled to give an overall multiple imputed result. The 
outcome as well as the candidate predictors to be tested were included in the imputation model.167  
The number of participants with missing outcome and candidate predictor data and the baseline 
characteristics of these participants was considered. As data was collected at baseline in a trial setting 
and each patient followed up using standardised methods (using reminders via postcard, text 
messaging and telephone calls), any missing data was assumed to be at least missing at random (MAR), 
if not missing completely at random (MCAR).   
Multiple imputation using chain equations was therefore used to account for missing data and reduce 
the risk of bias. 37 imputations were used given the amount of missing data present (37%). As a 
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sensitivity analysis and in order to check whether the model developed using MI did result in a very 
different composition or performance of the prediction model, a complete case analysis was also 
presented. 
6.3.4.2 Methods 
As the outcome was a continuous variable, multivariable linear regression analysis was used to identify 
the combination of factors measured at baseline most strongly associated with symptoms and function 
limitation (BCTQ sum score) at six months.  
A backward stepwise sequential approach was applied to the data, meaning that all candidate 
predictors were included in the (full) model. Variables were then removed in turn, with the least 
significant first, using P < 0.1 as the acceptable level of significance. Each variable to have been 
removed was re-tested at each stage to ensure it should not re-enter the model. The model was 
considered to be complete when no variables in the model met the criteria for exclusion and none of 
the variables to have been excluded, met the criteria for inclusion. Residual plots were used to test if 
the use of linear regression was appropriate, without the need for transformation of the variables. As 
per the recommendation of Groenwold et al, treatment was included as an additional variable (co-
variate) during prognostic model development in order to adjust for any effect on the associations 
between prognostic factors and outcome.168  
A small sample size increases the risk of optimism in a prognostic model, which means that the strength 
of associations between candidate predictors and outcome is likely to be over-estimated. This can be 
particularly important if variables are included by chance and / or the effects of predictors are inflated. 
Optimism in a model means that the observed outcome for a new individual will be less extreme than 
the outcome predicted by the model (which has been fitted to the original dataset). This is the 
underpinning principle of ‘Stein’s paradox,’169 the result of which requires a model to be adjusted or 
penalised for optimism.165  
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Whilst it may have been preferable to adjust the model for optimism (internal validation) using a boot-
strapping procedure, after consultation with a statistician with particular expertise in this field, it was 
decided to use heuristic shrinkage as a means of uniform linear shrinkage of the model. Data had 
already been subject to multiple imputation and the possible detrimental effects of imputation 
combined with bootstrapping in the same dataset is an area of ongoing research.  
Boot-strapping is a process whereby participants are randomly selected from the original dataset (and 
replaced back into the original dataset), until a new dataset with an equal sample size is obtained. For 
internal validation of a prediction model, this process is often repeated 100 or 200 times, allowing for 
the developed model to be tested in a large number of samples, taking into account sampling 
variation.165 Heuristic shrinkage, proposed by Van Houwelingen and le Cessie170 is an example of 
uniform shrinkage. First the shrinkage factor is calculated based on the total degrees of freedom for 
the predictors in the model and the likelihood ratio statistic for testing the joint influence of all the 
predictors at the same time. This shrinkage factor is then applied to the Beta coefficients for all the 
variables in the model. The intercept of the equation is then calculated and the shrinkage factor 
applied, to give the final shrunken model equation. 
The performance of the shrunken model was then described by providing a calibration plot. Calibration 
is a graphical representation of how values predicted by the model compare with the values observed 
in the dataset. Discrimination is not possible to determine given the use of a continuous outcome, as 
by definition, discrimination it is the ability of the model to differentiate between individuals who do 
and do not experience the outcome. 
6.3.4.3 Sample size 
INSTINCTS was designed to detect a 15% greater improvement in the combined BCTQ score from an 
expected baseline value of 2.9 points in the corticosteroid injection group compared with night 
splinting, with a pooled standard deviation of 1.0 and standardised mean difference of 0.45. Given 90% 
power, 5% two-tailed significance and assuming 15% loss to follow up, 240 patients (120 in each arm) 
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were required. The final number of participants recruited to INSTINCTS was 234. For development of 
the prognostic model, this sample size was a given. The final list of candidate prognostic factors 
equates to 25 variables and, consequently, a case per variable rate (EPV) of 9.3 but 27 parameters and 
an event per parameter rate (EPP) of 8.6. 
A more precise post hoc sample size estimate was provided by using the Stata programme 
‘PMPSAMPSIZE.’171 This package was developed using the sample size calculation criteria 
recommended by Riley et al.172 The aim of a sample size calculation for developing a prediction model 
is to minimise the risk of overfitting and ensure the important parameters in the model are estimated 
precisely. This approach goes beyond the previous ‘rule of thumb’ (10 cases per variable) approach 
applied above. This more specific approach takes into account the anticipated R-squared of the model 
and the average value and standard deviation of outcomes in the model (in this case, the BCTQ at six 
months as presented in INSTINCTS).172 This sample size calculation using the Stata package was 
presented post hoc as the package became available following the development of the study protocol 
and the results therefore offer additional information regarding how robust (precise) estimates 
regarding the model’s performance might be.  
6.4 Describing the course of symptoms and predicting outcome in patients with 
carpal tunnel syndrome: Results 
 The participants 
INSTINCTS randomised 234 participants. 16 (6.8%) of participants did not have a complete BCTQ 
baseline score, and 48 (20.5%) of participants did not have a complete BCTQ score at six months. 57 
(24.3%) participants did not have complete data for the baseline or six-month time-point. In total, 
148 (63%) patients had complete data for all variables, BCTQ outcome as well as for candidate 
predictors. The distribution of features between all participants compared with complete cases are 
described in Table 6-3. Patients with complete data appear similar to the full cohort.  
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Table 6-3 Baseline description of participants 
 All participants (n=234) 
n (%) 

















52 (40 – 65) 
 
54.5 (15.2) 
55 (44 – 66) 













Dominant hand affected 









































Baseline Boston Carpal Tunnel 
































Onset of symptoms 
Suddenly: symptoms developed 
quickly within a few days 
Gradually: symptoms developed 


















Anxiety and / or depression (both 




































































Diagnosed with hypothyroidism 
Yes 
No 









Diagnosed with diabetes 
Yes 
No 









Any other conditions affecting 
neck, shoulder or elbows 
Yes 
No  











Perceived health scores  








Excess alcohol use 
Yes 
No  






















Received preferred treatment 
Yes 










Expectation that treatment given 
will improve symptoms 
Yes 













Locus of control  
There is a lot I can do to control 
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What I do determines whether 



































6.4.1.1 Clinical course of carpal tunnel syndrome 
Table 6-4 summarises the sum and component score of the BCTQ at baseline, six weeks and six months 
for the whole trial population, observed as a cohort. These values are represented graphically in Figure 
6-1. The number of participants at each time point are also shown as this descriptive analysis was 
based only on cases with information on the outcome at either six weeks or six months. 
Table 6-4 Scores of the Boston Carpal Tunnel Questionnaire over time 
Outcome 
measure 
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Figure 6-1 Graphical representation of the BCTQ and its component score over the course of the six 
month follow-up period 
 
Figure 6-1 shows a rapid improvement in symptoms and function between the start-point of the study 
and six weeks follow-up. These trajectories then slow, with a more gradual improvement over the 
following 4.5 months. 
 Model development  
6.4.2.1 Univariable and multivariable linear regression analysis of candidate predictors and BCTQ at 
six months, using multiple imputed data 
Table 6-5 shows the results of the univariable analysis of associations between candidate predictors 
and BCTQ at six months in the 37 multiple imputed dataset. Univariable (unadjusted) analysis 
demonstrated that at a significance level of 0.1, a more severe BCTQ sum score at six months was 
associated with bilateral symptoms, the dominant hand being affected, a more severe BCTQ SSS and 
FSS score at baseline, depression, poor sleep and a lower perceived health score. Table 6-6 then shows 
the final multivariable model developed in imputed data and in the complete case dataset. Following 
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imputed data included a more severe baseline BCTQ sum score, a less severe baseline symptom 
severity score and the absence of other neck and upper limb symptoms as being associated with a 
more severe BCTQ sum score at six months (adjusted R2 = 0.31). The model based on complete cases 
included a less severe baseline score being associated with a more severe sum BCTQ sum score at six 
months (adjusted R2 = 0.36). 
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Table 6-5 Univariable associations with outcome using multiple imputed data 
 Univariable analysis of association with BCTQ at six months 
using multiple imputed data 




Female 0.12 (-0.10 to 0.35) 0.28 
Age -0.00 (-0.01 to – 0.00) 0.39 
CURRENT CTS 
Bilateral symptoms 0.28 (0.05 to 0.50) 0.02 
Dominant hand affected  0.25 (-0.05 to 0.55) 0.10 
Recurrent symptoms 0.22 (-0.11 to 0.55) 0.20 
Baseline BCTQ score 0.64 (0.49 to 0.78) <0.01 
Baseline symptom severity 0.54 (0.38 to 0.70) <0.01 
Baseline functional severity 0.47 (0.36 to 0.59) <0.01 
Duration of hand or wrist problems 
<3 months 
3-six months 
6 – 12 months 
>12 months 
 
1 (as referent) 
-0.02 (-0.38 to 0.33) 
0.00 (-0.40 to 0.40) 






Onset of symptoms 
Suddenly: symptoms developed quickly 
within a few days 
Gradually: symptoms developed more 










Depression (both screening questions 
answered ‘yes’) 
0.33 (0.08 to 0.58) 0.08 
Poor sleep quality 0.23 (-0.00 to 0.45) 0.05 
Functional disorders / multisite pain 0.11 (-0.12 to 0.34) 0.36 
BMI  -0.00 (-0.02 to 0.01) 0.75 
Diagnosed with hypothyroidism 0.08 (-0.36 to 0.53) 0.72 
Diagnosed with diabetes 0.07 (-0.31 to 0.45) 0.72 
Any other conditions affecting neck, 
shoulder or elbows 
0.07 (-0.18 to 0.31) 0.59 
Perceived health scores  -1.33 (-1.90 to -0.76) <0.01 
Excess alcohol use -0.17 (-0.55 to 0.22) 0.40 
Current smoker 0.06 (-0.27 to 0.38) 0.74 
Received preferred treatment -0.06 (-0.30 to 0.19) 0.66 
Expectation that treatment given will 
improve symptoms 
-0.09 (-0.33 to 0.14) 0.44 
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There is a lot I can do to control my 
hand/wrist problems: 
Agree 
What I do determines whether hand/wrist 
problems get better or not: 
Agree 
 
-0.05 (-0.30 to 0.19) 
 
 





0.78   
Treatment control 











Injection (treatment) 0.09  (-0.14 to 0.31) 0.45 
 
Table 6-6 Multivariable model using backward stepwise variable selection in imputed data and 
complete cases 
 Multivariable analysis of association 
with BCTQ at six months  
 
IMPUTED DATA 
Multivariable analysis of association 
with BCTQ at six months 
 
COMPLETE CASES 
 Regression coefficient 
(95% confidence 
interval) 




Baseline BCTQ 0.95 (0.60 to 1.30) <0.01 -0.41 (-0.76 to -0.08) 0.02 
Baseline symptom 
severity 
-0.32 (-0.68 to 0.29) 0.07   
Any other condition 
affecting neck, 
shoulder or elbows 
-0.21 (-0.43 to 0.02) 0.07   
 Adjusted R2 = 0.31  Adjusted R2 = 0.36  
 
6.4.2.2 Checking linear regression assumption 
The residuals plotted on the y axis of Figure 6-2 represent the differences between the observed and 
predicted values ofsix- month BCTQ scores. The fact that the points are randomly dispersed around 
the horizontal axis, not clustered around lower digits of the y axis and that there are no clear patterns, 
suggest that linear regression is appropriate for this data and no further transformation of the variables 
is necessary.  
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Figure 6-2 residual plot of fitted values (of the BCTQ score)  
 
 
 Adjusting the final model for optimism and assessing performance  
The multivariable model was then adjusted for optimism using heuristic shrinkage. The statistical 











1 1.5 2 2.5 3 3.5
Fitted values




Figure 6-4 shows a histogram comparing the shrunken and original linear predictor, demonstrating 
how adjusting the model for optimism has reduced both the extremes of the distribution of the linear 
predictor and the mean of its distribution. This means that the predicted outcome for a new patient 
using the shrunken linear predictor would be less extreme than it would have been using the original. 
1. Calculating heuristic shrinkage for the continuous outcome: 
 S = 1 - ((p-2)/LR)   
Stata code LR = display -2*(e(ll_0)-e(ll)) 
S = shrinkage factor  p = parameter  LR = likelihood ratio 
=0.73943638 (m==1) 
=0.74086464 (m==2) 
2. Imputed model with shrinkage factor applied to beta coefficients: 
Original model 
E(Y) = 0.61 + (0.9541716*cts_BL) - ( 0.3246921*sev_cts_BL ) - (0.2108877*nul)  
E(Y) = predicted mean  
 Shrunken model 
E(Y) = ? + (0.70554919 *cts_BL) - ( 0.24008915*sev_cts_BL ) - (0.15593804*nul) 
3. Calculating the shrunken intercept: multiply each beta by the shrinkage factor, calculate the linear 
predictor minus the intercept using the shrunken betas. 
gen LP_shrunk = (0.70554919 *cts_BL) - ( 0.24008915*sev_cts_BL )- (0.15593804*nul) 
constraint define 1 LP_shrunk = 1 
mi estimate: cnsreg cts_6M LP_shrunk, constraint(1) = 1.010474 
E(Y) = 1.010474 + (0.70554919 *cts_BL) - ( 0.24008915*sev_cts_BL ) - (0.15593804*nul) 
Summary of original and shrunken linear predictor (LP): 







234 2.125345     0.4367796    1.277017    3.351376 
Heuristic LP 
m=1 
234 2.130975     0.3229707 1.50369    3.037547 
Original LP all 
data 
8875 2.126608     0.4437389    0.6846382    3.500507 
Heuristic LP all 
data 
8875 2.131909     0.3281167 1.065664     3.14782 
 
Figure 6-3 Process of applying heuristic shrinkage to the model 






 Calibration of the shrunken model 
Figure 6-5 then plots the expected and observed outcomes against each other to demonstrate how 
well the model is calibrated. Of note there is no R2 presented as the Betas in the model have already 













0 1 2 3 4
6 month BCTQ score
 Shrunken linear predictor 
 Original linear predictor 
Histogram comparing original and shrunken linear predictors
Figure 6-4 Histogram comparing the original and shrunken linear predictors 




The calibration plot of the shrunken model suggests that it does not perform well. Ideally, the points 
should align along the reference (dashed) line but instead they are in an almost vertical alignment. This 
suggests the model overestimates the severity of outcome in patients with less severe observed CTS 
and underestimates the severity of outcome in patients with more severe observed CTS. This also 
means the model does not discriminate very well between participants with different levels of BCTQ 
scores at six months; predicted BCTQ values appear to cluster around a score of 2. It is not possible to 
produce a discrimination statistic for the model given the use of a continuous outcome. 
6.4.4.1 Post hoc sample size calculation 
As described in 6.3.4.3, an alternative and more precise approach to assessing the number of 


















1 2 3 4
Calibration plot and histograms of expected and observed outcome 
0.00
1.29
1 2 3 4
Expected
Figure 6-5 Calibration plot of the shrunken model 
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included, the intercept of the regression equation and the standard deviation of the linear predictor is 
to apply PMSAMPSIZE 171 to the dataset.  Figure 6-6 below presents the process of in a posthoc sample 
size calculation. 
 
Based on the R2, number of parameters, the intercept and standard deviation of the outcome, this 
sample size calculation suggests that a participant per variable rate of substantially more than 10 (24 
variables) would be required to ensure the model is optimised to reduce the risk of overfitting. This is 
likely because the average change observed in the outcome measure over time was small.  
  
Process using the pmsampsize programme (Ensor et al): 
 
pmsampsize, continuous rsquared(0.29) parameters(27) intercept(2.66) sd(0.67) 
NB: Assuming 0.05 acceptable difference in apparent & adjusted R-squared 
NB: Assuming MMOE<=1.1 in estimation of intercept & residual standard deviation 
SPP - Subjects per Predictor Parameter 
Minimum sample size required for new model development based on user inputs 
 = 650 participants 
 
Worked in reverse: the number of parameters suited to this dataset: 
 
 pmsampsize, continuous rsquared(0.29) parameters(10) intercept(2.66) sd(0.67) 
NB: Assuming 0.05 acceptable difference in apparent & adjusted R-squared 
NB: Assuming MMOE<=1.1 in estimation of intercept & residual standard deviation 
SPP - Subjects per Predictor Parameter 
Minimum sample size required for new model development based on user inputs = 244 
* 95% CI for intercept = (2.57, 2.75), for sample size n=244 
* 95% CI for intercept = (2.61, 2.71), for sample size n=676 
 
Figure 6-6 Process using pmsampsize to calculate post hoc sample size 




The methods and findings of this prognostic study will now be discussed. Reflections on the differences 
between the prediction model developed in the CPRD dataset and this model alongside related 
research will be discussed in chapter 9, in terms of the different populations, outcomes, candidate 
predictors and statistical approaches used. 
 Summary of main findings 
A prognostic model was developed, using data from a randomised controlled trial, to predict patient 
reported outcome at six months following conservative management of mild to moderate CTS. The 
model, based in imputed data, included a small number of prognostic factors (BCTQ, SSS and neck and 
upper limb symptoms). The model was found to have poor predictive performance, likely due to the 
relatively small sample size and homogeneity within the cohort.  
 Methodological considerations 
It was decided to model the outcome of CTS using this trial data-set as there were substantial 
limitations with the model developed in the CPRD data; particularly the inability to include potentially 
important prognostic factors reflecting patient and disease characteristics. Data from the INSTINCTS 
trial was available and there was an a-priori plan to measure certain features at baseline in order to 
investigate prognosis and explore potential predictors of treatment effect (chapter 8).  
The trial had been designed pragmatically to represent patients presenting in a primary care setting 
with purposively few exclusions. The trial however was targeted at patients with mild to moderate CTS 
who would be amendable to primary care / conservative treatment options. Patients with features in 
their history or examination findings suggestive of severe CTS were excluded from the trial. Such 
patients should have been referred for consideration of surgery, perhaps with conservative treatment 
options used as an interim measure. This may have led to the trial population being relatively 
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homogenous and not necessarily representative of the entire CTS population presenting in primary 
care. A homogenous population with similar baseline features and outcomes would make a predictive 
model difficult to develop and demand a large sample size, as is illustrated above by the application of 
the PMPSAMPSIZE calculation in Figure 6-6. The performance (calibration) of the model and histogram 
of the shrunken linear predictor does suggest that firstly the model does not predict well and secondly, 
predictions are focused narrowly around the mean with little spread.  
Whilst measured at baseline, many of the candidate predictors were based on self-report. Items such 
as symptom duration were at particular risk of misclassification due to incorrect recollection. The 
quality of the data and precision of the candidate variables can therefore not be substantiated other 
than by the fact that completion of the baseline questionnaire was checked by the investigator prior 
to randomisation. However, established and validated tools were applied where possible. 
The pragmatic design of the trial was such that diagnosis of CTS was based on clinical opinion using a 
criteria developed to represent current practice. Some may argue that more objective measures of 
diagnosis including use of NCS should have been applied to the patients at inclusion, however clinical 
guidelines do support the trial’s approach to diagnosis. Misclassification of patients as having CTS or 
additional diagnoses (e.g. ‘double crush syndrome’) cannot be ruled out. It is of interest that patients 
with symptoms in their neck or upper limb appeared to exhibit greater improvement (adjusting for 
BCTQ and SSS in the model) than those that did not. This seems counter-intuitive and at odds with the 
CPRD model but may be due to sample size (small number of participants with additional neck or upper 
limb symptoms), misclassification, or correlation between this candidate predictor and other variables 
in the model (e.g. baseline symptom severity).  
Whilst not a survival analysis, events may have occurred in the cohort which altered the observed 
outcome, other than the initial set of candidate predictors and conservative intervention, and in effect 
acted as a competing benefit. The main trial reports that at six months, 30 (12.8%) of participants had 
had surgery.59 If patients with a poorer response to treatment or who had more severe CTS at baseline 
received surgery and presumably therefore experienced a satisfactory outcome, this may have 
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influenced the association of baseline prognostic factors with outcome and partly explain the weak 
performance of the model.  
The issue of laterality and the associated risk of a unit of analysis error will be discussed in Chapter 9. 
However, whilst bilateral CTS was included as a candidate predictor, attempting to distinguish between 
symptoms of each hand or wrist for research purposes, can be an issue for patients and affect the 
reporting in studies.173 
 Clinical relevance of the findings 
A reflection on the similarities and differences between this model and the model developed in CPRD 
data will be fully discussed in Chapter 9 in the context of results from previous research. Due to the 
limitations as discussed, the model does not appear to have clinical utility and would not be proposed 
as a useful tool in the management of CTS. A well performing model would have been further internally 
and externally validated and proposed as a tool to help identify patients who were likely to do well 
with conservative management and those who should be more closely observed / referred for 
consideration of surgery.  
 Conclusion 
The model presented in this Chapter was developed using the data of trial participants, being observed 
as a single cohort. The aim was to describe the clinical course of CTS in this population and predict 
patient reported outcome. Whilst patients did show improvement over time, the improvement was 
relatively small, and it would have required a much larger sample size than was available to test the 
already much reduced list of candidate predictors that had been developed. The post hoc application 
of PMPSAMPSIZE, highlighted the relative redundancy of a participant per parameter = 10 ‘rule of 
thumb.’  
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In Chapter 7, the focus will move from the general prognosis of CTS to its management and whether 
treatment options can be better targeted to patients, dependent on observations made at baseline, in 
order to improve the outcome of conservative management.   
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7 The management of carpal tunnel syndrome: matching patients to 
treatments in carpal tunnel syndrome - a systematic review and 
narrative synthesis of trial evidence 
 
Summary 
The aim of this chapter is to investigate candidate predictors of treatment effect (effect 
moderators) to common primary care treatments of carpal tunnel syndrome (CTS), specifically 
corticosteroid injection (CSI) and night splinting (NS). The available evidence regarding 
predictors of the effect of CSI and NS from randomised controlled trials will be summarised and 
any gaps in current knowledge identified. This will be achieved by conducting a systematic 
literature search and narrative synthesis of clinical trials that have performed subgroup analyses 
of their data and suggested likely predictors of treatment effect. Any identified or suggested 
moderators will then be considered for testing within INSTINCTS (Injection versus Splinting in 
Carpal Tunnel Syndrome) trial data in Chapter 8. Whilst non-confirmatory (given limited 
statistical power), results may suggest ways in which CSI and NS can be better targeted to 
patients, based on their baseline characteristics, with the future aim of improving patient 
outcomes and efficiency in healthcare. 
7.1 The concept of stratified care and moderators of treatment effect 
Stratified care can be defined as “the targeting of treatments according to the biological or risk 
characteristics shared by subgroups of patients.”74 Stratified care thus utilises information about an 
individual’s likely response to treatment to inform management decisions. This approach moves from 
the more traditional notion of stepped care, whereby patients are managed incrementally according 
   
210 
 
to treatments tried previously, to stratified care, whereby patients are offered treatment informed by 
their individual baseline profile.  
A stratified approach to management may be of benefit when treatment effect is inconsistent across 
patients due to at least one individual measure being associated with a change in treatment effect i.e. 
there is interaction between a patient-level variable and the effect of the treatment on the outcome. 
Such an interaction may represent a mechanism for the observed difference in treatment effect.74 
Prognostic factors are measures associated with an outcome, even in the absence of a particular 
treatment. A prognostic factor may also be a predictor of differential treatment response (or effect 
moderator), when there is a causal or mechanistically relevant effect.74 A moderator is therefore a 
characteristic, measured at baseline, which influences the relationship between an intervention and 
an outcome and hence predicts response to treatment.174 Most prognostic factors however are not 
moderators when tested for their association with the effect of treatment, while only in some 
instances moderators are not associated with outcome in the absence of treatment (and hence are 
not also prognostic factors).  
In terms of CTS, a stratified approach would mean suggesting to patients presenting with symptoms 
of CTS that they may do better with an injection compared to night splinting given that they or their 
wrist problem has certain characteristics. The outcome of this chapter is to begin to identify what these 
features (candidate moderators) in the case of treatment with either injection or splints might look 
like. 
This chapter will present a systematic review of trials testing CSI and NS as treatments for CTS. 
Moderators tested by these trials will be identified and the evidence for them appraised. Randomised 
trials are required as a study method to demonstrate, through the use of tests for interaction, that one 
intervention is significantly more effective than another (control or active), in patients with certain 
baseline characteristics.174, 175 This differs from the identification of prognostic factors, whereby, a 
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single treatment arm (or an observational cohort study) identifying general predictors, not necessarily 
unique to an intervention, are investigated.174 
7.2 Conservative treatment options of CTS: corticosteroid injection and night 
splinting 
 Carpal tunnel syndrome 
The pathophysiology of CTS is not fully understood, however theories exist as to how complex 
mechanisms interact and lead to the observed clinical syndrome. An increase in pressure in the carpal 
tunnel leads to disordered intraneural microcirculation, lesions in the myelin sheath and the axon and 
changes in the supporting connective tissue. Reduction in the endoneurial blood flow increases the 
permeability of the endoneurial vasculature resulting in the formation oedema. As well as further 
pressure changes from oedema, hypoxia occurs leading to axonal degeneration and median nerve 
neuritis. The upregulation of angiogenic factors (HIF-1 and VEGF) cause synovial hypertrophy, thus 
leading to further pressure changes and a positive feedback mechanism of neural damage.176 These 
interacting pathophysiological processes gives rise to localising symptoms, which include pain, 
numbness, tingling, and in the more severe cases, weakness and associated impairment of function.  
 Corticosteroid injections and night splinting 
The mainstay of treatment options deliverable in primary care are CSI and NS. A trial of such treatments 
is usually carried out and if unsuccessful, surgery may be considered to manually decompress the 
carpal tunnel. The mechanisms of action and evidence base for their use has been presented in 1.4, 
but will now be summarised: 
The rationale for the use of CSI is based on the theory that the steroid reduces oedema in the carpal 
channel and hence reduces the pressure on the median nerve from the surrounding tissues2 However, 
since the pathophysiology of CTS is complex and not fully understood,176 it seems reasonable to 
conclude that neither is the pharmacological action of a corticosteroid injection.  
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A Cochrane review evaluating the effectiveness of CSI for CTS versus placebo injection or other non-
surgical interventions concluded that CSI’s do improve symptoms in the short term, compared to 
placebo, however symptom relief beyond this period has not been clearly demonstrated.45 The more 
recent RCT by Atroshi et al provided some longer-term data suggestive that steroid injection may be 
clinically effective in reducing the symptoms of CTS and reducing the number of patients having 
surgery, but only at a dose of the steroid higher than what would perhaps ordinarily be used in clinical 
practice.53 Further research is hence required to investigate whether steroid injections have the 
potential to improve symptoms and the need for surgery, in the longer term and at what dose. 
The evidence base for the use of wrist splinting as a treatment for CTS is not as robust. A Cochrane 
review by O’Connor et al observed the effectiveness of multiple approaches to nonsurgical treatments 
of CTS, with the exception of CSI, to include wrist splinting. This review concluded that no significant 
evidence existed for the benefit of a nonsurgical treatment.177 Page et al conducted a Cochrane review 
of randomised and quasi-randomised trials comparing splinting with no treatment (or placebo) or with 
other non-surgical interventions. The authors’ conclusions suggest there is limited evidence that night 
splinting is more effective than no treatment in the short term (less than 3 months follow-up).42 
Splinting may be a treatment option for some patients but there is limited evidence regarding its 
effectiveness compared to no treatment or other conservative option. 
Given that evidence for the use of CSI and NS in the average population of patients with CTS is limited, 
whether the treatments may benefit particular subgroups of patients will now be investigated. Firstly, 
the evidence for predictors of treatment effect investigated in existing trials will be summarised, and 
in Chapter 8, the most promising candidate predictors identified from the literature and expert opinion 
will be tested within trial data. 
7.3  Methods 
The aim of this systematic review and narrative synthesis was to summarise evidence regarding 
predictors of the effect of CSI and NS tested in previously published randomised controlled trials. The 
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following work was based on a search conducted in 2013 run at the same time as the search for the 
systematic review presented in chapter 4. The review and synthesis informed the design of the 
reported study in a subsequent chapter and as such has not been formally updated. However, section 
9.2.3 describes any relevant updates in the literature and the potential impact they may have on the 
findings of this review. The protocol for this review was registered on PROSPERO (CRD42013006608) 
and can be accessed at  
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42013006608#.VYk_RflVhBc.  
 Eligibility criteria 
To be eligible for inclusion in the review, studies were required to fulfil the following criteria as 
described in Table 7-1 and Table 7-2. 
Table 7-1 Summary of inclusion criteria 
 Inclusion criteria 
Population 
General adult population (non-pregnant) aged 18 years or over 
Diagnosed with carpal tunnel syndrome (method of diagnosis to be 
documented) 
Interventions or exposure Patients receiving a steroid injection to the wrist or splints as a 
treatment for CTS 
Comparisons Where trials are being used to investigate moderators of treatment 
effect: placebo, surgery (carpal tunnel release) or alternative non-
surgical treatments were used as a comparator. 
Outcomes Outcome measures able to indicate improvement in symptoms and/or 
function including: dichotomised global improvement measures; 
positive changes in the mean Boston Questionnaire score or similar 
disease or region specific self-reported outcome measure; return to 
work, and no need for further treatment (likely to be carpal tunnel 
decompression surgery). 
Setting Any healthcare setting  
Study design Randomised controlled trials with evidence of an investigation of 
moderators or subgroup analyses 
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Table 7-2 Summary of exclusion criteria 
 Exclusion criteria 
Population Studies of pregnant women with CTS 
Studies reporting diseases other than CTS 
Studies reporting outcomes of specific populations (not the general 
population) 
Interventions or exposure Studies with a follow up of less than six weeks 
Studies investigating secondary CTS (e.g. post-traumatic) 
Comparisons Studies where the intervention or comparator is not a steroid injection 
or wrist splint 
Studies comparing methods of delivering treatments alone (e.g. 
injection technique) 
Study design Papers in languages other than English where no translation  is available 
Papers other than those described in the inclusion criteria, e.g. case 
studies and clinical guidelines 
 
 Search strategy 
The same databases and additional search methods were used and applied as described in 4.2.2. The 
electronic databases were searched using a combination of free-text, MeSH and database specific 
headings. The full search strategies can be found in appendix C. These search strategies were 
developed with the input of experts in health informatics and used some pre-existing strategies 
available within the Primary Care Centre, already developed to identify particular types of study.  
“Carpal tunnel syndrome” was searched for using MeSH (or database-specific equivalent) terms and 
in free text. MeSH headings were ‘exploded’ to broaden their definition. Terms such as ‘entrapment 
neuropathies’ were included to ensure the search remained sensitive. The searches were combined 
using the Boolean operator “OR.”  
This systematic review required randomised controlled trials to be identified by the search. Strategies 
used to identify trials were adapted from: 
• The Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: 
sensitivity- and precision-maximizing version (2008 revision); Ovid format 
(http://handbook.cochrane.org/chapter_6/6_4_11_1_the_cochrane_highly_sensitive_search
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_strategies_for.htm) This strategy was adapted for use within the other E-Databases 
depending on their specific search terms 
• Sign methodology filters (http://www.sign.ac.uk/methodology/filters.html#random) were 
used to search for trials within EMBASE 
 Selection of eligible studies 
The citations identified using the methods described above were downloaded using OVID SP and then 
transferred to and stored in REFWORKS (Legacy version). Duplicates were removed. All titles were 
screened against the eligibility criteria by the author. Full text review was undertaken for any abstract 
that could not be confidently excluded and could potentially fulfil the inclusion criteria. Abstracts and 
full texts were assessed independently by LC to determine agreement. Disagreements and queries 
were managed through discussion.  
 Data Extraction 
Data were extracted by CB and checked by LC using a pre-defined data extraction form, which had 
been piloted and edited to ensure the correct information was captured.   
Data extraction included details of the aims and objectives of the study, inclusion and exclusion criteria, 
recruitment and blinding procedures, intervention and setting, outcome and analysis and sub-group 
analyses reported. The sub-groups were then specifically described, the type of analysis presented and 
outcomes presented narratively.  
 Assessing the risk of bias  
In order to appraise the risk of bias and methodological quality of the included trials, it was decided to 
use two approaches. Firstly, the Cochrane Collaboration’s ‘Risk of Bias Tool’119 was used to judge the 
overall risk of bias for each trial included in the review. Secondly, the ‘Methodological Criteria for the 
Assessment of Moderators in Systematic Reviews of Randomised Control Trials’ by Pincus et al, were 
used to more specifically score quality of the moderation analysis.178  
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7.3.5.1 Using the Cochrane Risk of Bias Tool 
Bias can be defined as a “systematic error, or deviation from the truth, in results or inferences.”119 Bias 
can therefore lead to an overestimation or underestimation of the true intervention effect. Errors in 
the design, conduct and analysis of trials may lead to bias, however this is not a certainty, therefore 
the term ‘risk of bias’ is used. Considering the risk of bias in each study to be included in a systematic 
review was important to explain any observed variation in the study results and to alert to the 
possibility of erroneously making a false positive or false negative conclusion.119  
The Cochrane Risk of Bias tool is a domain based evaluation of six possible sources of bias: selection 
bias, performance bias, detection bias, attrition bias, reporting bias and other sources of bias (for 
example, claims the study may be fraudulent). Each study was judged under each of the seven domain 
headings as being of ‘low risk of bias,’ ‘high risk of bias,’ or ‘unclear risk of bias.’ The tool provides 
criteria under each heading by which each study is reviewed. Supporting information and comments 
based on these criteria were required for each study, to inform the judgement of the risk of bias. 
Judgements were made by the author and LC and disagreements brought to discussion, after which 
100% agreement was achieved. 
7.3.5.2 Using the Criteria Developed by Pincus et al 
Criteria to assess the quality of moderation analysis were developed by Pincus et al, following an 
identified need to extend contemporary advice about assessing the analysis of subgroups and focus 
specifically on the analysis of baseline factors that moderate treatment effect.178 
In order to develop the agreed criteria, Pincus et al identified methodological manuscripts found using 
a snowballing technique and searches of electronic databases. The initial criteria comprised of 19 
questions derived from this search are shown in Table 7-3. An international Delphi panel of 21 experts 
were then involved in a consensus exercise to agree the final criteria. The final criteria recommend 
whether moderation analysis from a trial can be considered to be either confirmatory or exploratory. 
Confirmatory analyses test a priori defined hypotheses and exploratory analyses inform future 
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(confirmatory) research or may inform clinical practice. Pincus et al proposed that for inclusion in a 
meta-analysis of moderators, three criteria should be met: baseline factors should be measured prior 
to randomisation, their measurement should be of sufficient reliability and validity and a specific test 
for interaction should be presented. In order to be considered confirmatory the analysis should also 
be planned a-priori and the factor selection based on either theory and / or evidence. These final 
criteria are summarised in Table 7-4.178  
This systematic review did not identify RCT’s in sufficient quantity or homogeneity to include in a meta-
analysis. The Pincus criteria were therefore adapted slightly and used to describe whether the 
moderation analysis presented in each individual paper could be considered to be confirmatory, 
exploratory or indeed insufficient.  
The authors suggest that the proposed criteria are less conservative than the guidance provided by the 
Consolidated Standards of Reporting Trials (CONSORT) statement (The Centre for Reviews and 
Dissemination and the Cochrane Handbook), in that the criteria allow for post-hoc subgroup 
comparisons and do not limit the number of sub-group analyses carried out at the meta-analytic stage. 
It is suggested that this prevents a too rigid set of criteria impeding the progress of research in the area 
of analysis of moderators and preventing the exploratory analysis of studies, which may go on to 
inform further research.  
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Table 7-3 Summary of the methodological criteria proposed by Pincus et al for the assessment of 
methodological quality of moderation analysis 
 Methodological criteria 
Stage 1 
Rationale 
1a. Was the analysis a-priori (planned in protocol rather than post-hoc)? 
1b. Was selection of factors for analysis theory / evidence driven? 
Method 
2a. Was there an equal distribution of moderators between groups at baseline? 
2b. Were moderators measured prior to randomisation? 
Power 
3a. Do authors report a power analysis for moderator effect (a-priori or post hoc, but using an a-priori ES, not 
the observed one? 
3b. Was sample size adequate for the moderator analysis (at least 4 fold the required sample size for main 
treatment effect in the lowest sub-group for the moderator effect)? 
3c. If not, were there at least 20 people in the smallest sub-group of the moderator? 
3d. Have authors employed analysis to compensate for insufficient power(i.e. boot-strapping techniques) 
Correction for multiple comparisons 
4a. Was the regression significant at P<0.006, or (if more than three comparisons) corrected or significance 
adjusted to P<0.01? 
4b. Did the authors explore residual variances of interactions if carrying out multiple two-way interactions? 
Measurement validity and measurement error. Was measurement of baseline and process factors reliable 
and valid (from published information) in the target population? 
5a. Is there evidence that the measurement error of the instrument is likely to be sufficiently small to detect 
the differences between sub-groups that are likely to be important? 
5b. Did the authors comment on measurement validity in reference to construct validity, face validity etc 
Analysis 
6a. Contains an explicit test of the interaction between moderator and treatment (eg regression) 
6b. Was there adjustment for other baseline factors? 
6c. Is there an explicit presentation of the differences in outcome between baseline sub-groups (eg 
standardised mean difference between groups, Cohen's d) 
Stage 2 
1. Difference between sub-groups should be clinically plausible 
2. Reporting of sub-group analysis is only justified in cases where the magnitude of the difference is large 
enough to support different recommendations for different sub-groups 
3. Within study comparisons are more reliable than between study comparisons 
4. At least ten observations should be available for each characteristic explored in sub-group analysis (ie ten 
studies in a meta-analysis) 
Adapted from 178 
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Table 7-4 Criteria for considering moderation analysis to be confirmatory or exploratory 








Criteria for the 
judgement of yes 
Exceptions 
1. Was the 
analysis a-
priori? 
Yes No Mention of explicit 
hypothesis planned in 
protocol stating which 
sub-groups will be tested 
for which outcome 
Criterion is not fulfilled 
in cases where the 
protocol includes a 
considerably large set of 
stated hypotheses or 
vague hypotheses (eg 
psychological factors will 








either or both: 
Yes No A description of 
theoretical background, 
or reference to other 
published evidence 
leading to the hypothesis 
Is not fulfilled in cases 
where the meta-analyst 
considers the theory / 
evidence to be weak, 
but should not form 
reason for exclusion 
i. Theory 
based? 
    
ii. Evidence 
based? 






Yes Yes Specific statement that 
baseline measurement 
occurred prior to 
randomisation 
Not applicable for 
baseline factors that do 
not change over time, 







Yes Yes If there is published 
evidence to support 
good measurement 
properties of 
measurements for target 
population, according to 
meta-analysts protocol 
Is not fulfilled where 
there is inadequate 
variability in baseline 
measure 
5. Contains an 





Yes Yes Ideally, Report a pooled 





Not fulfilled when sub-
groups are tested 
separately, or in 
excessive multiple 
testing 
Adapted from 178 
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The analyses of moderators from each trial were assessed by the author and LC -  A ‘yes’ / ‘no’ / ‘unsure’ 
judgement and the reason for the decision were made by the author and LC and disagreements 
brought to discussion, after which 100% agreement was achieved. 
 Analysis 
Substantial heterogeneity between the trials was found, related to trial inclusion criteria; 
interventions; outcomes and sub-groups included in the analysis. Therefore, the main findings and the 
outcome of the sub-group analyses were not pooled but discussed narratively, taking quality of the 
evidence (risk of bias and quality of moderator analysis) and the consistency of findings into account.  
7.4 Results 
 Summary of Search Results 
4729 citations were identified by the search. The number of citations from each source are shown in 
Table 7-5. As summarised in Figure 7-1 , there were 3354 citations after duplicates were removed, 136 
following title screening and 41 following abstract screening. There were four studies included 
following full text screening, which were not suitable for including in a meta-analysis. 
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Table 7-5 Summary of search results 









SCI-EXPANDED + CPCI-S 71 
Total 4729 
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7.4.1.1 Trial characteristics 
A summary of the main characteristics of the four trials identified by the search, suitable for narrative 
synthesis can be found in appendix E. All four trials were set in secondary care, three trials required a 
clinical diagnosis and electrophysiological confirmation of CTS, one (Atroshi et al) only required a 
clinical diagnosis. The inclusion and exclusion criteria differed: two trials (Atroshi et al and Ly-Pen et 
al) required a previous treatment of splinting + / - non-steroidal anti-inflammatories (NSAID’s) whereas 
Celiker et al and Gerritsen et al excluded patients with any previous treatment. Celiker et al had a more 
pragmatic exclusion criteria, and hence was more likely to be representative of the population 
presenting with symptoms in primary care, whereas the other trials excluded patients with co-
morbidities such as diabetes and hypothyroidism.  
In order to identify predictors of treatment effect, the systematic review required patients within the 
identified trials to receive either injection or splinting as one of the trial interventions. Atroshi et al 
compared two different doses of Methylprednisolone with placebo. Celiker et al compared 
Methylprednisolone with wrist splinting and NSAID’s. Gerritsen et al compared surgery with splinting 
whilst Ly-Pen et al compared surgery with injection. Follow-up ranged from 8 weeks to 18 months and 
no trial used the same outcome measure.  
Atroshi et al demonstrated Methylprednisolone was more beneficial than placebo and Ly-Pen reported 
that at 3 months a greater improvement was observed in the Methylprednisolone group, compared 
with the surgery group. Gerritsen et al observed a higher success rate in the surgery group compared 
to splinting but Celiker et al did not note a significant difference between splinting and injection. Due 
to the variation in the trial settings, populations, interventions, follow-up periods and outcome 
measures, the extent to which the trial outcomes can be compared was limited, and hence, meta-
analysis was not suitable.  
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7.4.1.2 Risk of bias  
As illustrated by Table 7-6, of the four included trials, two (Atroshi et al and Gerritsen et al) were 
considered to be of low risk of bias in six out of seven and seven out of seven of the Cochrane Risk of 
Bias domains, respectively. Celiker et al was felt to be at high risk of bias in two criteria, of unclear risk 
of bias in four criteria and low risk of bias in one criterion. This was largely because the reporting of 
the methods was unclear with respect to the generation of the randomised sequences and any blinding 
that may or may not have taken place. Ly-Pen et al was considered to be at high risk of bias in three 
criteria, unclear risk of bias in three criteria and low risk of bias in one criterion. This was due to the 
incomplete reporting of the methods regarding the handling of envelopes and blinding of participants 
and staff. There was a risk of attrition bias with missing outcome data, likely to be related to the true 
outcome with associated imbalance across the intervention groups. The trials by Atroshi et al and 
Gerritsen et al could therefore be considered to be of overall low risk of bias whilst the trials by Celiker 
et al and Ly-Pen et al could be considered to be of unclear risk of bias. 
With respect to the judgement of the methodological criteria for the assessment of moderators, Table 
7-7 shows that, given there was an a priori defined analysis of candidate moderators that had been 
selected based on theory, only Ly-Pen et al provided a moderation analysis, which could be considered 
confirmatory. Atroshi et al, Celiker et al and Gerritsen et al presented apparently ad hoc exploratory 
sub-group analyses.  
In summary, two trials (Atrohsi et al and Gerritsen et al) were considered to be at low risk of bias for 
overall trial conduct, and one of the trials (Ly-pen et al, which had an unclear risk of bias) can be 
considered to have provided an adequate level of quality of moderation analysis to be considered 
confirmatory. Due to the limited number of trials investigating different candidate moderators with 
different outcomes, meta-analysis was not possible.   
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Atroshi et al, 2013 53        
Celiker et al, 2002 48        
Gerritsen et al, 2002103        
Lypen et al, 2012 179        
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Atroshi et al, 201353         Insufficient 
Celiker et al, 2002 48        Insufficient 
Gerritsen et al, 2002 103        Insufficient 
Ly-pen et al, 2012 179        Confirmatory 
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 Predictors of treatment effect 
The sub-group analyses presented in each included trial are summarised in Table 7-8. Attempting to 
compare the trial results was unlikely to be helpful due to the significant heterogeneity in methods, 
interventions and outcomes. With regard to the sub-group analyses, only Atroshi et al and Ly-Pen et 
al present a formalised model with interaction terms. The two remaining studies elude to the fact 
narratively that subgroup analyses were carried out. Gerritsen et al did write a further paper on the 
prognostic outcome of patients who received splinting but as this was not a moderation analysis and 
has been summarised separately in chapter 4.  
7.4.2.1 Symptom duration 
Both Atroshi et al and Celiker et al identified symptom duration as a possible predictor of treatment 
effect with cut offs at > 1 year vs. ≤ 1 year and > 9 months vs. ≤ 9 months, respectively. Atroshi et al 
reported that symptom duration did not moderate the response to Methylprednisolone injection 
compared to placebo. The difference in score change at 10 weeks was -0.81 (-1.20 to -0.43) in patients 
with a symptom duration of > 1 year, compared to -0.41 (-1.51 to 0.69) in those with a symptom 
duration ≤ 1 year. The test for interaction between symptom duration and treatment was reported as 
P = 0.47. Celiker et al reported narratively that “patients with symptom duration more than 9 months 
did not respond well to treatment in either group” (splinting or Methylprednisolone injection).  
7.4.2.2 Symptom and nerve conduction severity 
Atroshi et al also reported that the effect of Methylprednisolone injection on the 10 week post 
treatment symptom severity score, compared to placebo, was significantly larger in patients with 
higher baseline nerve conduction abnormalities (-0.87, -1.20 to -0.48 versus -0.26, -1.26 to 0.75; test 
for interaction P < 0.001) and more severe symptom scores at baseline (-1.02, -1.54 to -0.51 versus -
0.38, -0.82 to 0.05; test for interaction P < 0.001). 
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7.4.2.3 Patient preference 
Gerritsen et al investigated whether patient preference would affect response to treatment (methods 
and data were note reported) and reported that: 
“subgroup analysis showed that treatment effects did not depend on the patients’ preference 
prior to randomisation.”140 
No further detail was provided making further analysis difficult. 
7.4.2.4 Bilateral carpal tunnel syndrome 
Ly-Pen et al performed a sub-group analysis to test the robustness of their trial conclusion, concerned 
that patients with bilateral CTS (included at the wrist level) may respond to surgery or splinting 
differentially than those patients with unilateral disease. They did not find a significant subgroup 
effect, reporting a P value of 0.5 and hence discarded the hypothesis that “bilateral CTS responds 
differently” [to unilateral disease].180 Whilst the trial overall was not of low risk of bias, the moderation 
analysis was judged to be of such a quality as to provide confirmatory evidence. It can therefore be 
concluded that there is no evidence from this trial that bilateral or unilateral CTS responds differentially 
to either splinting or surgery.  
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Table 7-8 Summary of moderation analyses within included trials 
Author (Year) Candidate moderators Intervention Outcome Statistical test Results 
Atroshi et al 2013 
 
 
Duration of symptoms: 
>1y vs. ≤ 1y 
 
Nerve conduction study 
result: 
Moderately or severely 





≥ 3.0 vs. < 3.0 
Methylprednisolone 
(doses combined) (n=74) 
vs. placebo (n=37) 
Difference in symptom 
severity score change at 
10 weeks 
Mixed models with 
interaction terms 
(treatment by subgroup) 
Symptom duration >1y- 
(difference in change 
score between combined 
doses vs. placebo) 
0.81 (-1.2 to -0.43)
 vs. 
Symptom duration <1yr-
0.41 (-1.51 to 0.69) 
P value for interaction = 
0.47 
 
NCS moderate or severe-
0.87 (-1.25 to -0.48)
 vs.  
NCS normal or mildly 
abnormal  
-0.26 (-1.26 to 0.75) 
P value for interaction 
<0.001 
 
Baseline CTS SSS >3.0 
-1.02 (-1.54 to -0.51)
 vs. 
Baseline CTS SSS <3.0 
-0.38 (-0.82 to 0.05)              




“…the effect of 
Methylprednisolone on 
symptom severity score 
was larger in patients with 
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higher nerve conduction 
abnormality and baseline 
symptom severity scores.” 
Celiker et al 2002 
 
Duration of symptoms: 
>9m vs. ≤ 9m 
Wrist splints at night with 
acemetacine 120mg/day 
(NSAID) (16 wrists, 11 
patients) vs 40mg local 
Methylprednisolone (21 
wrists, 12 patients) 
Median nerve motor and 
sensory distal nerve 
latencies at 8 weeks 
  
Not reported “patients with symptom 
duration more than 9 
months did not respond 
well to treatment in 
either group” 
Gerritsen et al 2002 Patient preference Wrist splinting at night vs. 
open carpal tunnel 
release 
General improvement Not reported “subgroup analysis 
showed that treatment 
effects did not depend on 
the patients’ preference 
prior to randomisation” 
(data not shown) 
Ly-Pen et al 2005 
Spain 
Unilateral CTS vs. the most 
symptomatic wrist of 
bilateral CTS 
Local steroid injection vs. 
carpal tunnel release 
Percentage of wrists that 
reached ≥ 20% response 
for nocturnal 
paraesthesia at 3 months 
 
Hierarchical linear models 
with 3 levels 
Random effect of having 
bilateral CTS P > 0.5 
Discards…”the hypothesis 
that bilateral CTS 








 Summary of main findings 
In summary, few (four) randomised trials testing the effectiveness of corticosteroid injections or 
splinting and included a sub-group analysis, were identified. The trials were heterogeneous and 
moderation analysis was not always presented. Evidence from one trial suggests that participants with 
a higher symptom and electrophysiological severity scores exhibit a greater response to CSI compared 
to placebo, when compared to participants with lower severity scores.  
 Interpretation of results 
Subgroup analyses are performed in intervention studies in order to assess whether treatment effects 
vary across sub-populations. Outcomes between treatment groups are compared within subsets of 
patients, defined by their individual characteristics. The aim of a subgroup analysis is therefore to show 
if treatment effect varies depending on baseline patient characteristics. 181  
Whilst this can be a useful methodology to answer specific questions regarding the most effective 
application of a study intervention, such approaches have potential hazards.182-187 The criteria as 
described by Pincus et al represent a consensus of expert opinion about what should be included in a 
study testing moderators and recommend qualities that determine whether a study provides 
exploratory or confirmatory evidence for a candidate moderator.178  
None of the trials presented in this review were powered to perform moderation analysis. It is 
recommended that randomisation is stratified by potential moderators to ensure the subgroups of 
interest are sufficiently represented and that the trial is powered to detect any moderation effect.181 
Not having sufficient power can thus lead to false negative findings and hence a type II error.74 This is 
likely to apply to all trials included in this review as none were specifically powered for moderation 
analyses.  
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A statistical test of interaction is recommended in any model used to detect moderation 178, 181 but was 
only clearly presented in two trials.53, 180 The remaining trials appeared to present their sub-group 
findings on an ad-hoc basis with little information on the techniques employed to draw their 
conclusions given. No evidence of multiple statistical testing or data dredging was observed (which 
carries the risk of false positive results and hence type I errors).74 Symptom duration was the only 
candidate moderator to be explored by more than one trial and in each situation an apparently 
arbitrary cut-off (9 months and 12 months) was used. The categorisation of variables and outcome 
measures can also lead to false positive findings.74 Celiker et al report that patients with a longer 
symptom duration do worse than those with a shorter symptom duration overall (not quantified). 
Whilst Atroshi et al report no interaction between symptom duration and treatment effect, patients 
with a symptom duration > one year showed greater improvement over 10 weeks after 
methylprednisolone compared with placebo (difference in change score -0.81, 95% CI -1.20 to -0.43) 
compared to those with a symptom duration of less than 1 year (-0.41, -1.51 to 0.69). The lack of 
significant interaction may be due to sample size so the results of this trial are suggestive that patients 
with a longer symptom duration may respond better to CSI than no treatment.  
Symptom duration was identified as a candidate predictor of poor outcome in the review of 
observational prognostic studies. However, there was no high-quality consistent evidence of this 
across studies and this review of trial evidence does not confirm that patients with a longer duration 
symptoms may respond more or less well to steroid injection or splinting. It is unlikely that symptom 
duration necessarily equates to symptom severity and / or electrophysiological outcomes. Padua 1998 
et al describe how over time no clear trend in electrophysiological findings based on severity at 
presentation was observed.125 In their later study, Padua et al investigated the correlation between 
symptom severity and neurophysiological results and report that discordance between 
neurophysiologic evolution and symptom evolution occurred in 9% of patients.69 Thus, symptom 
duration is unlikely to be strongly associated with either clinical or electrophysiological severity but 
may still play a pathophysiological role which affects the likelihood of a spontaneous recovery or 
satisfactory response to treatment.  
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Atroshi et al’s results suggest that patients with higher baseline nerve conduction abnormalities and 
symptom severity scores show a greater response to injection than to placebo. If ‘no treatment’ or 
‘watchful waiting’ can be considered to be a valid treatment, one could argue that patients with CTS 
of higher severity should be considered for injection, over watchful waiting. It would be helpful to 
investigate for a differential treatment response between injection and a more active treatment such 
as splinting or surgery (which Atroshi does not present).  
Gerritsen et al and Ly-Pen et al appear to have been using sub-group analyses as a means of exploring 
the robustness of their main trial findings rather than investigating predictors that may be used to 
develop a stratified approach to care. This is likely to be the reason that methods and results of the 
analysis was not presented. Patient preference was identified as a potential moderator in Gerritsen’s 
trial comparing NS with CTR. Whilst not clearly expressed in the paper, one could assume that patients 
randomised to splinting may have felt less likely to receive benefit from their treatment, compared to 
those who had an operation. The evidence however did not substantiate this.  
Page et al have described how, by analysing outcome data based on the number of wrists, without 
adjusting for non-independence of bilateral observations, a unit-of-analysis error may occur. This could 
subsequently lead to overly narrow confidence intervals and small P values, hence increasing the risk 
of type I errors.144 By performing a sub-group analysis stratifying patients with bilateral and unilateral 
CTS and identifying no significant difference of treatment effect, Ly-Pen et al suggest that no such bias 
has been introduced into the study and that patients with unilateral versus bilateral disease do not 
respond to treatment any differently.  
No predictors of a differential treatment response were definitively identified, highlighting the need 
for further investigation in this area. Such investigation would ideally include a trial or number of trials 
which fulfil the requirements of Pincus et al in that the study method: is designed a-priori to test sub-
groups for pre-specified outcomes; that the selection of factors is clinically based on theory and / or 
evidence; moderators should be assessed prior to randomisation and measured adequately and that 
the statistical analysis includes a specific test of interaction.178  
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The number of trials available was limited due to the fact few had attempted or reported a sub-group 
analysis. The synthesis of available information was conducted at a study level and used published data 
only. Obtaining patient level data would have been a further possibility but as the trials were not 
designed to perform sub-group analyses and were so heterogeneous in their design, this approach was 
unlikely to obtain data that could be pooled and included in a meta-analysis.  
 Methodological considerations 
Electronic databases considered to be important and relevant to the topic were searched. Titles were 
screened by one person therefore human error may have led to some titles being erroneously 
excluded. Studies not included in databases and not identified through reference checking, Google 
Scholar and expert advice may have been overlooked, such as unpublished studies. As the review did 
not find strong evidence for there being predictors of treatment effect, it is unlikely that further 
unpublished material would have strongly influenced the conclusions made.  
 Conclusion 
This systematic review of trial data did not generate information that could be implemented clinically. 
In three of the four trials, the moderation analysis was of poor quality. None of the trials were powered 
to detect a moderation effect and apart from symptom duration, data for each of the candidate 
predictors came from one study only. Evidence exists suggesting that whether CTS is bilateral or 
unilateral does not differentially alter response to splinting or surgery. There is exploratory evidence 
that severity in terms of NCS results and patient reported symptoms do interact with the effect of CSI 
compared to placebo in that patients with more severe CTS show a greater improvement at 10 weeks 
following CSI than those with less severe CTS. This may mean that patients with more severe CTS 
should be offered treated at presentation rather than adopting a ‘watch and wait’ approach. Data from 
the INSTINCTS trial will now be used to further explore predictors of a differential treatment response 
to CSI versus NS in mild to moderate CTS.  
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8 Testing predictors of the effect of treatments for carpal tunnel 
syndrome in primary care – An exploratory analysis of data from the 




Following the systematic review and narrative synthesis of predictors of treatment effect 
presented in chapter 7, this chapter identifies selected candidate predictors of treatment effect 
highlighted by the systematic review and suggested by a clinical advisory group, and tests them 
in data from the INSTINCTS trial, which specifically compares CSI versus NS in a primary care 
population. Whilst exploratory, results may suggest ways in which CSI and NS can be better 
targeted at patients, based on their baseline characteristics, with the future aim of improving 
patient outcomes and efficiency in healthcare use. 
8.1 The INSTINCTS trial 
The INSTINCTS trial was an open-label, parallel group, randomised control trial.59 The methodology has 
been discussed in 6.2. The trial was designed to detect a 15% greater improvement in the combined 
BCTQ score,32 from an expected baseline value of 2.9 points, with a pooled SD of 1.0 and standardised 
mean difference of 0.45. Given 90% power, 5% two-tailed significance and assuming 15% loss to follow 
up, 240 patients (120 in each arm) were required to be randomised. The trial was not powered to 
detect a moderation effect and the analysis presented in this chapter is entirely exploratory. 
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 Overall trial results 
234 patients were randomised (118 to the night splint group and 116 to the corticosteroid group), 217 
returned their six-week questionnaire and 193 returned their six-month questionnaire. At six weeks, a 
significantly greater improvement in the overall BCTQ score was observed in the CSI group (mean score 
2.02 [SD 0.81]) than the NS group (2.29 [0.75]); adjusted mean difference -0.32 (95% CI -0.48 to -0.16; 
P=0.0001). At six months the NS group showed further improvement, whilst the corticosteroid 
injection group sustained their six-week level of improvement, however there was no statistically 
significant or relevant difference observed between the groups (0.06; 95% CI -0.11 to 0.23; p=0.499). 
No serious or unexpected events were reported.59  
Subgroup analyses based on participants with unilateral and bilateral symptoms and on those who 
received their preferred treatment allocation, were planned a-priori.58 There was no statistically 
significant difference in the comparative effect estimate of CSI versus NS between those with unilateral 
and bilateral CTS (-0.14, 95% CI -0.47 to 0.19). The adjusted mean difference for CSI versus NS was -
0.25 (95% CI -0.47 to -0.02) for patients with unilateral symptoms at six weeks and -0.15 (95% CI -0.48 
to 0.19) at six months. The adjusted mean difference for those with bilateral symptoms was -0.39 (95% 
CI -0.62 to -0.15) at six weeks and -0.01 (95% CI -0.25 to 0.23) at six months.  
Differences in BCTQ scores were observed in participants allocated their preferred treatment (n=42 
adjusted mean difference -0.52, 95% CI -0.93 to -0.12) compared with those who were not allocated 
the treatment of their preference (n=52, -0.12, 95% CI -0.50 to 0.26). Individuals who preferred and 
received CSI showed a greater effect than those who preferred and received a night splint (CSI: n=58, 
-0.60, -0.97 to -0.23 versus preferred NS: n=52, -0.22, -0.60 to 0.16). Those with no preference also 
showed less improvement (n=128, -0.24, -0.44 to -0.05). The trial concluded that for each subgroup 
analysed, any effect modification was not statistically significant.59 
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8.2 Exploratory subgroup analysis: Methods 
For the purpose of this thesis, further moderation analyses were carried out in order to explore 
whether predictors of treatment effect could be identified based on findings of the systematic review 
and clinical advisory group, also taking into consideration the prognostic factors included in the model 
developed in chapter 6. The intention was not to duplicate work conducted during the trial analysis 
but to develop methodological skills and test a small number of further plausible candidate 
moderators. 
In order to reduce the risk of ‘data dredging’ potentially leading to false-positive (type 1 errors), 
treatment-predictor interactions to be tested should fulfil proposed criteria as described in chapter 7; 
they should be based on plausible hypotheses based on theory or evidence.  
 Selection of candidate predictors of treatment effect 
8.2.1.1 Systematic review 
The systematic review presented in chapter 7 identified five potential predictors of treatment effect 
that had been tested in the subgroup analyses of previous trials, which had included CSI or NS as one 
of their interventions: symptom duration, NCS severity scores, baseline symptom severity scores, 
patient preference, and laterality. All but the NCS severity outcomes could be identified within 
INSTINCTS data. By the fact that they were tested in previous trials, rationale exists that these variables 
may be predictors of treatment effect and given the risk of a type 2 error in underpowered trials, it 
was considered worthwhile to replicate testing in INSTINCTS data. INSTINCTS would also allow 
symptom severity to be tested as a predictor of a differential response to CSI compared to NS (rather 
than placebo). 
8.2.1.2 Survey of General Practitioners 
In chapter 5, a survey of seven GP trial co-investigators was presented. These practicing clinicians were 
asked to identify potential predictors of outcome of CTS presenting in primary care. They were also 
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asked what factors they felt may predict a differential response to CSI and NS. The survey was 
conducted during the design of the trial in order to inform the development of the baseline 
questionnaire, with a view to performing future subgroup analyses. Table 8-1 presents the list of 
features reported by the clinicians, which may either increase or decrease the likelihood of a 
favourable response to each of the treatment modalities being tested. In order to allow subsequent 
ranking to take place, the clinicians were asked to rate the features they identified from 1 (least likely 
to predict a differential response to treatment) to 4 (most likely to predict a differential response to 
treatment). The scores have been displayed as a sum score. The variables have been highlighted 
according to whether they: 
i. could be extracted from INSTINCTS data and hence tested as candidate moderator (could 
be included in the analysis);  
ii. substantially overlapped with the exclusion criteria of the trial (exclusion);  
iii. did not represent a baseline characteristic (exclusion) or  
iv. would only apply to a small subgroup of the trial population (and as such could not be 
included as the sample size would be further reduced) (exclusion).  
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Table 8-1 Candidate predictors of treatment effect generated by GP survey 
NIGHT SPLINTING 
Likely to predict benefit Rank sum 
score 
Likely to predict failure Rank sum 
score 
Patients willing to try (for 2 weeks) 
/ Good compliance / Motivation 
9 Previous failure of splint to other 
wrist 
9 
Previous benefit from splint (to 
other wrist) 
8 Thenar muscle weakness or wasting 6 
Early morning pain and numbness 
predominate 
7 Splinting at night is not acceptable / 
not willing to try 
6 
Pregnant 6 Long symptom duration 6 
Nocturnal or wakening symptoms 
only 
5 History of anxiety / depression 4 
Short symptom duration 5 Continuous numbness 4 
No thenar muscle weakness or 
wasting 
4 Patients find splints uncomfortable 4 
Work ethic 3 Daytime symptoms 4 
Postural symptoms only 3 Poor compliance 4 
Patient asks for splint 3 Unemployed / On sickness benefit 3 
Good patient education 3 Poor education 3 
Symptoms not related to work 2 Symptoms related to work 2 
Symptoms not present at time of 
examination (may be evident on 
provocation) 
2 Previous surgery on the effected side 2 
Unilateral symptoms 2 Poor sleep because of CTS 2 
Intermittent night symptoms 2 Long time interval before 
commencing treatment 
1 
Mild symptoms 2 Patients who normally fail to 
improve no matter what you offer 
them 
1 
No previous anxiety / depression 1   
CORTIICOSTEROID INJECTION 
Likely to predict benefit Rank sum 
score 
 
Likely to predict failure 
Rank sum 
score 
Previous benefit from injection (to 
other wrist) 
11 Previous failure of injection (to other 
wrist) 
15 
Severe symptoms with defined 
distribution of symptoms 
6 Continuous numbness / symptoms 8 
No thenar muscle weakness or 
wasting 
5 Thenar muscle weakness or wasting 5 
Inflammatory arthritis causing CTS 5 Underlying OA 4 
Nocturnal or wakening symptoms 
only 
4 Diagnostic uncertainty 4 
Short duration of symptoms 4 Previous failure of injection to 
another joint 
3 
Good education 4 Muscle wasting 3 
Previous benefit from injection to 
another joint 
3 Recurrent symptoms 3 
Postural symptoms only 3 Needle phobia 3 
Accurate placement of injection 3 Co-existing WRULD or radiculopathy 3 
Intermittent symptoms / mild to 
moderate symptoms 
3 Unemployed / On sickness benefit 2 
Good post injection advice 3 Previous surgery on the effected side 2 
Patient requests 3 Slow progression of symptoms over 
long period of time 
2 
Self-limiting history like pregnancy 3 Severe symptoms  2 
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Good work ethic 2 Symptoms related to work 1 
Symptoms not present at time of 




 Able to extract from 
INSTinCTS data 
 INSTinCTS exclusion 
criterion or present in 
all patients 
 Not measured or not a 
baseline characteristic 
 Present in a small 
subpopulation of trial 
participants 
 
Patients flexible to ideas of 
management 
2 
Symptoms not related to work 1 
Positive provocation tests 1 
First attendance 1 
Abnormality in wrist like a previous 
fracture 
1 
No co-morbidity 1 
No thenar muscle weakness or 
wasting 
1 
Correct diagnosis 1 
 
8.2.1.1 Potential predictors of treatment effect and theories generated by a think tank 
Further to the GP survey, 7 GP’s and an extended scope practitioner took part in a think tank, set up 
to identify routine practice and clinical challenges experienced by practicing primary care clinicians in 
the diagnosis, investigation and management of carpal tunnel syndrome. The group were asked if they 
were able to identify factors at baseline that may change their pattern of treatment and for any 
reasoning behind their answer.  
It was commented that adherence to splinting would be an important factor determining whether it 
would be of benefit or not. Whilst the likelihood of future adherence could not be assessed at baseline, 
it was suggested that patients with an internal locus of control may be more likely to adhere to splinting 
and hence experience benefit, whereas patients with a more external locus of control may benefit 
more from a CSI. A further observation was that splints may not benefit patients who were ‘over a 
certain weight.’ 
 Final selection of candidate moderators to be tested 
As described in chapter 7, the pathophysiology of CTS is not fully understood. The therapeutic 
mechanisms of NS and CSI are therefore not entirely clear. Splinting maintains a neutral angle of the 
wrist, therefore preventing the increase of pressure within the carpal tunnel caused by flexion and 
extension. This may reduce the positive feedback mechanism of oedema, inflammation and 
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subsequent neural ischemia and damage. CSI’s likely suppress any inflammatory response to nerve 
damage. Without clear evidence of benefit from these treatments and a lack of clarity as to their 
mechanisms of action, it remains difficult to fulfil the requirement that factors to be tested as 
moderators should have a clear biological hypothesis behind their selection. Therefore candidate 
predictors were selected based on clinicians’ observations and experience, which can be used to aid 
selection and reduce the risk of ‘data dredging.’ Using the information available, a suggested 
mechanism of action has been provided for each potential moderator in Table 8-2. 
Table 8-2 also represents a consolidated list of candidate predictors of treatment effect, put forward 
by the clinicians in the survey, which can be identified within the main INSTINCTS trial data. The only 
variable generated by the systematic review, which does not appear in the list suggested by clinicians 
but is already reported in the main paper, was treatment preference. A high baseline symptom severity 
as a predictor of outcome of CSI was found only in the systematic review, whereas a low symptom 
severity score was listed by the clinicians as a potential predictor of benefit from night splinting. The 
think tank also purported locus of control and BMI as a candidate predictors of treatment effect with 
some background reasoning to their suggestion. 
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Table 8-2 Candidate predictors of treatment effect and potential hypothesis 


















9 Suggestive of mild 
symptoms. 
Symptoms exist 
during the time 
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opposed to other cause 
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A more active 
inflammatory process 
may be more amenable 
to treatment with a 
corticosteroid 














Patients would not be 
required to adhere to a 
course of treatment due 
to the ‘one off’ nature of 
the treatment 




Splints may not 
be tolerated or as 
effective in 
patients with a 
larger wrist 
   
 
 Unique to the modality of 
treatment 
 Appears as a candidate predictor 
of both modalities 
 
The number of candidate moderators was reduced further by excluding those with a summed rank 
score of less than four, unless they were also found in the systematic review or think tank. The final 
list of candidate predictors of treatment effect to be tested in INSTiINCTS data is shown in Table 8-3: 
Table 8-3 Final list of candidate predictors of treatment effect to be tested in INSTINCTS data 
Potential predictors of a differential 
treatment response 
Score for potential 
benefit from night 
splints 
Score for potential benefit from 
corticosteroid injection 
Nocturnal or symptoms on wakening only 9 4 
Short duration of symptoms 6 + review  4 + review 
No previous depression 5  
Intermittent symptoms 4 8 
Unilateral symptoms  2 + review - 
New episode - 4 
 
The final list of predictors of treatment effect to be tested was kept to a reasonable minimum (6 
candidate predictors). Since most randomised trials are not powered to detect interactions, false-
negative or type 2 errors may result. The sample size required to detect a treatment-predictor 
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interaction will often need to be at least four times greater than that required to detect the overall 
treatment effect.184 It is therefore acknowledged that any apparently statistically significant result 
would be considered exploratory and not confirmatory. Likewise, an absence of a statistically 
significant interaction may also be due to sample size and not a true null result.   
 Statistical analysis 
As per the main trial, analysis was performed on an intention to treat basis. Since the data was 
considered to be missing at random, as per the prognosis study, multiple imputation using chain 
equations was used to manage missing data. In order to avoid losing further power when testing for 
interactions, each analysis was set in an imputed data-set developed to include the interaction term 
in the chain equations.166 Injection (comparator) * moderator ‘yes’ (comparator) interactions with a P 
value of <0.1 would be suggestive of a significant interaction. 
Given the continuous outcome and categorical potential moderators variables, interaction terms were 
generated using the following categories (splint*moderator’no’; splint*moderator’yes’; 
injection*moderator’no’; injection*moderator’yes’). The number of participants in each category for 
each treatment were described.  
First, the crude treatment effect on the overall sum BCTQ outcome was presented. Secondly, an 
unadjusted test for interaction between the candidate predictor and treatment with the BCTQ 
outcome score was conducted. Thirdly, this model was adjusted for the variables included in the 
prognostic model developed in chapter 7 (baseline BCTQ score, baseline symptom severity and 
presence of associated neck and upper limb symptoms), which are considered to be potential 
confounders in this analysis. A stratified analysis was then carried out in each of the subgroups.  
Analysis was carried out using six-week and six-month outcome data. At the time of writing, 12 and 24 
months data were not available. Even if interactions did not appear to be statistically significant, 
exploratory sub-group analyses would be carried out with the acknowledgement that they would be 
under-powered but based on theoretical or clinical hypotheses.  
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Any positive findings would remain exploratory and would require external validation in a pre-stratified 
and adequately powered randomised controlled trial or in a future meta-analysis using Individual 
Patient Data -analysis (if appropriate trials were available to include in such an analysis).75 
8.3 Exploratory subgroup analysis: Results 
Table 8-4 shows the frequency distribution of candidate predictors with treatment at baseline, in an 
imputed dataset (n=234). 
Table 8-4 Distribution of candidate predictors between treatment groups at baseline 
 Nocturnal or 
symptoms on 
wakening 














































































Table 8-4 demonstrates that only laterality of symptoms (unilateral versus bilateral) was distributed 
equally between all groups (around half the trial participants had bilateral CTS) and randomisation 
appears to have split each sub-group equally between the interventions. Due to the initial sample size, 
the existence of some overlap between candidate predictors with trial inclusion criteria (e.g. patients 
had to have had symptoms for at least  six weeks, leading to a narrow window of opportunity to have 
had symptoms less than three months) and no pre-stratification by candidate predictors, there were 
very small numbers of participants in some sub-groups (e.g. seven patients with nocturnal or waking 
symptoms only who receive a splint).  
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 Interaction tests and subgroup analyses 
Table 8-5 and Table 8-6 present for six week and six month outcomes respectively: i. the crude 
treatment effect in the dataset imputed to include the treatment*predictor interaction, ii. the value 
for the interaction term between treatment and candidate predictor (to include the treatment and 
moderator as independent terms) and iii. the value of the interaction term between treatment and 
predictor, adjusted for covariates. The table also includes the stratified analysis for the trial population 
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Table 8-5 Six-week subgroup analysis 
 Nocturnal or symptoms 
on wakening only 
Short duration of 
symptoms (< 3 
months) 
No depression Constant symptoms Unilateral symptoms First episode 
Unadjusted linear regression analysis of six-week BCTQ outcome: Adjusted mean difference (95% confidence interval, P value) 
Treatment effect 
(injection versus night 
splinting)  
-0.29 
(-0.49 to -0.08, < 0.01) 
-0.31  
(-0.53 to -0.09, <0.01) 
-0.30  
(-0.51 to -0.09,<0.01) 
-0.31 
(-0.52 to -0.09,<0.01) 
-0.31  
(-0.52 to -0.09, <0.01) 
-0.29  
(-0.50 to -0.08,<0.01) 
Effect of candidate 
predictor 
-0.83  
(-1.30 to 0.36, <0.01) 
-0.22  
(-0.51 to 0.07, 0.13) 
-0.42  
(-0.66 to -0.17, <0.01) 
0.61 
(0.37 to 0.86, <0.01) 
-0.09  
(-0.31 to 0.14, 0.43) 
-0.12  
(-0.43 to 0.19, 0.44) 
Effect of treatment x 
predictor 
-0.04  
(-0.98 to 0.90, 0.93) 
-0.13  
(-0.71 to 0.46, 0.67) 
0.16  
(-0.30 to 0.61, 0.49) 
-0.21  
(-0.70 to 0.28, 0.40) 
0.47  
(-0.06 to 0.08, 0.03) 
-0.08  
(-0.89 to 0.54, 0.80) 
Adjusted linear regression analysis (baseline BCTQ, baseline symptom severity score, neck and upper limb symptoms) of six-week BCTQ outcome: Adjusted mean difference (95% 
confidence interval, P value) 
Treatment effect 
(injection versus night 
splinting)  
-0.30  
(-0.47 to -0.13, <0.01) 
-0.32  
(-0.50 to -0.14, <0.01) 
-0.32  
(-0.50 to -0.14, <0.01) 
-0.31  
(-0.49 to -0.14, <0.01) 
-0.32  
(-0.50 to -0.14, <0.01) 
-0.31  
(-0.48 to -0.13,<0.01) 
Effect of candidate 
predictor 
-0.28  
(-0.69 to 0.14, 0.19) 
-0.03  
(-0.27 to 0.22, 0.84) 
-0.08  
(-0.29 to 0.14, 0.48) 
0.29  
(0.05 to 0.52, 0.02) 
0.06  
(-0.13 to 0.24, 0.56) 
0.06  
(-0.20 to 0.32, 0.67) 
Effect of treatment x 
predictor 
-0.23 
(-1.01 to 0.55, 0.57) 
0.30  
(-0.19 to 0.79, 0.23) 
0.19  
(-0.19 to 0.57, 0.33) 
0.08  
(-0.40 to 0.55, 0.75) 
-0.15  
(-0.50 to 0.20, 0.40) 
-0.27  
(-0.78 to 0.23, 0.29) 
Subgroup analysis, to show mean difference in effect of injection compared to splinting, adjusted for the prognostic model (baseline BCTQ, baseline SSS and presence of neck or upper 
limb symptoms) in sub-group stratified by the candidate predictor. 




(-0.59 to 0.46, 0.77) 
n = 16 
-0.52  
(-1.03 to -0.01, 0.05) 
n = 36 
-0.38  
(-0.57 to -0.19, <0.01) 
n = 167 
-0.19  
(-0.62 to 0.24, 0.38) 
n = 54 
-0.23  
(-0.50 to 0.04, 0.09) 
n = 114 
-0.28 (-0.47 to -0.09, 
<0.01) 
n = 203 






(-0.50 to -0.14, <0.01)  




(-0.46 to -0.07, <0.01) 




(-0.58 to 0.21, 0.34) 




(-0.52 to -0.14, <0.01) 




(-0.63 to -0.16, <0.01) 




(-1.01 to 0.00, 0.05) 
n = 31 
 
0.23 
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8.3.1.1 Interactions between candidate predictor and intervention and subgroup analyses (six-week 
follow-up) 
In each imputed data-set, as per the main trial result, CSI favoured NS at six weeks. There were no 
significant interactions noted between candidate predictors and treatment intervention when 
adjusted for confounding. CSI favoured NS in each subgroup, however some subgroups appear to gain 
more benefit form CSI compared to NS. The minimal important difference (within group change) used 
in the main INSTINCTS trial was 15%, as measured by the BCTQ from an expected baseline of 2.9 (scale 
1-5, SD 1.0).58 According to these results, only patients with a short duration of symptoms and who 
have had recurrent CTS reach this threshold (-0.44). Descriptively, those with daytime symptoms as 
opposed to those with night or wakening symptoms only; those with no depression on screening 
compared with depression on screening; those with intermittent as opposed to constant symptoms; 
and those with bilateral symptoms as opposed to unilateral symptoms seemed to receive a greater 
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Table 8-6 Six-month subgroup analysis 
 Nocturnal or 
symptoms on 
wakening only 
Short duration of 
symptoms (< 3 
months) 
No depression Constant symptoms Unilateral symptoms First episode 
Unadjusted regression analysis of six-month BCTQ outcome: Adjusted mean difference (95% confidence interval, P value) 
Treatment effect (injection 
versus night splinting)  
0.13  
(-0.10 to 0.35, 0.26) 
0.12  
(-0.10 to 0.33, 0.29) 
 
0.11  
(-0.10 to 0.32, 0.30) 
0.10  
(-0.11 to 0.32, 0.34) 
0.13  
(-0.09 to 0.35, 0.24) 
0.12  
(-0.11 to 0.35, 0.32) 
Moderator effect -0.38  
(-0.86 to 0.10, 0.12) 
-0.01 
(-0.32 to 0.30, 0.97) 
-0.35  
(-0.60 to -0.11, <0.01) 
0.45  
(0.17 to 0.73. <0.01) 
-0.28  
(-0.51 to -0.05, 0.02) 
-0.20  
(-0.57 to 0.17, 0.30) 
Effect of interaction 
adjusted for treatment and 
moderator 
-0.39  
(-0.88 to 0.09, 0.11) 
0.40  
(-0.21 to 1.0, 0.20) 
0.21  
(-0.28 to 0.70, 0.40) 
-0.14  
(-0.69 to 0.41, 0.62) 
0.51  
(0.09 to 0.94, 0.02) 
0.34  
(-0.32 to 1.00, 0.31) 
Analysis adjusted for prognostic model (baseline BCTQ, baseline symptom severity score, neck and upper limb symptoms) 
Treatment effect (injection 
versus night splinting)  
0.14  
(-0.05 to 0.33, 0.15) 
0.12  
(-0.06 to 0.31, 0.19) 
0.11  
(-0.06 to 0.30, 0.21) 
0.11  
(-0.07 to 0.28, 0.22) 
0.13  
(-0.04 to 0.31, 0.14) 
0.11  
(-0.08 to 0.31, 0.24) 
Moderator effect 0.22  
(-0.20 to 0.64, 0.30) 
0.19  
(-0.69 to 0.46, 0.15) 
-0.01  
(-0.24 to 0.21, 0.90) 
0.11  
(-0.16 to 0.39, 0.41) 
-0.15  
(-0.35 to 0.04, 0.12) 
-0.03 
 (-0.36 to 0.30, 0.86) 
Effect of interaction 
adjusted for treatment and 
moderator 
0.20  
(-0.22 to 0.62, 0.35) 
0.25  
(-0.25 to 0.75, 0.33) 
0.25  
(-0.17 to 0.66, 0.24) 
0.05  
(-0.42 to 0.53, 0.84) 
0.22  
(-0.13 to 0.58, 0.22) 
0.11  
(-0.45 to 0.67, 0.70) 
Subgroup analysis, to show mean difference of injection compared to splinting, adjusted for the prognostic model (baseline BCTQ, baseline SSS and presence of neck or upper limb 
symptoms) in sub-group with and without the candidate predictor 




(-0.60 to 1.13, 0.49) 
 
0.30  
(-0.25 to 0.86, 0.27) 
 
0.05  
(-0.15 to 0.25, 0.64)  
 
0.05  
(-0.50 to 0.61, 0.83) 
 
0.28  
(0.00 to 0.55, 0.05) 
 
0.10  
(-0.09 to 0.31, 0.29) 
 
Group where predictor  
‘no’ 
 
Crude difference between 
groups 
0.09  




















(-0.46 to 0.91, 0.70) 
 
0.13 
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8.3.1.2 Interactions between candidate predictor and intervention and subgroup analyses (six-month 
follow-up) 
In each dataset, as per the main trial result, there was no significant difference in outcome between 
patients receiving CSI compared to NS at six months. In fact, whilst not significant, the direction of 
effect seemed to change. Likewise, no significant interactions between candidate predictor and 
intervention were identified when adjusted for the prognostic model. Patients with unilateral 
symptoms did appear to have a significantly less favourable outcome following CSI at six months when 
compared with NS. Whilst not statistically significant and based on very small subgroup differences, 
CSI may be less favourable than NS by six months in the following subgroups: those with nocturnal 
symptoms or symptoms on wakening only; those with a symptom duration of < 3 months; those with 
depression on screening and those with a recurrent episode.  
 
 




 Summary of main findings 
In summary, whilst no significant interaction between candidate predictor and intervention was found 
at either the six-week or six-month time-point, all sub-groups of participants showed a greater 
improvement at six-weeks if they received a CSI compared to those who were allocated to NS. By six-
months, as per the main trial, no significant difference between the treatment groups were observed 
apart from patients with unilateral symptoms seemingly having a poorer outcome if they received CSI 
compared to NS. What is not known is which further interventions (contralateral interventions or CTR) 
were received, hence unmeasured competing benefits may have influenced results. Alternatively, it 
may be possible that CSI leads to a higher risk of relapse following an initial short-term improvement.  
 Interpretation of results 
8.4.2.1 Nocturnal or symptoms on wakening only / constant symptoms 
Subgroups of patients with ‘nocturnal or symptoms on wakening only’ and with ‘constant’ (as opposed 
to intermittent) symptoms were defined based on questions within the BCTQ and can be considered 
as descriptors of severity. Patients with severe CTS (including constant paraesthesia) were excluded 
from the trial. This will have had the effect of reducing the heterogeneity of the severity of CTS seen 
within the sample, making it difficult to draw conclusions around whether patients with milder CTS can 
be treated in a different way to those with severe CTS (who should be referred for consideration of 
surgery). The six-week outcome data suggests that patients with symptoms not limited to night-time 
but without constant symptoms (i.e. more intermittent symptoms) show a greater improvement with 
CSI. However, by six months the adjusted mean difference between those that received CSI versus NS 
in each subgroup, was minimal. It appears possible that by six months, NS may favour patients with 
night only or intermittent symptoms, however the adjusted mean differences were very small and not 
significant.  
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8.4.2.2 Symptom duration 
A prolonged duration of symptoms (of which the definition varied), was suggested as a predictor of 
poor outcome (prognostic factor) in the systematic review presented in chapter 4. Symptom duration 
was included in the development of the prognostic model developed to predict 6-month outcome, 
based in the same INSTINCTS data, but was not included in the final model. It has also been tested as 
a predictor of treatment effect by Atroshi and Celiker as described in chapter 7. However, no 
convincing evidence of a prognostic or moderating effect was identified. There is some exploratory 
evidence that patients with a shorter duration of symptoms show a greater improvement at six weeks 
if they received CSI versus NS but no significant evidence of benefit in the longer term (six-month data).   
Whilst it seems clinically reasonable to suppose that prolonged symptoms would expose the nerve to 
greater pathophysiological damage over time and limit its recovery and rehabilitation potential, this 
cannot be substantiated by the work presented in this thesis. However, symptom duration could not 
be identified in CPRD and the INSTINCTS dataset is likely to be homogenous with regard to short versus 
long duration as patients with a very short duration (< six weeks) were excluded as were patients who 
had already received treatment. Only 15.4% of participants had a ‘short symptom duration.’ This is 
likely due to the fact patients delay presenting initially and then may have had to wait for a referral to 
an interface service, before recruitment to the trial. Further work could attempt to identify and 
randomise patients earlier in their course of symptoms and stratify on the basis of symptom duration. 
This work could also be criticised for categorising a continuous variable; however this was done at 
baseline as it was felt unlikely that patients would recall in days or indeed weeks how long they had 
had symptoms for. The decision was made pragmatically to include categories based on months.  
8.4.2.3 Depression 
The inclusion of depressive symptoms as a candidate predictor of treatment effect was largely based 
on the opinion of the think-tank and GP survey, rather than on carpal tunnel syndrome literature, 
although the review of prognosis studies did highlight one study which suggested a better mental 
health score was associated with being in work with CTS, in a non-operative cohort (P 0.04).134 It was 
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felt that patients with depression were less likely to do well overall but also less likely to respond to 
splinting. This hypothesis was based on the fact that patients with a poor mental health status may 
have a lower motivation to adhere to a treatment requiring regular application. In fact, the sub-group 
analysis suggests that whilst patients with no depression at baseline demonstrated a greater 
improvement with injection versus splinting at six weeks, those with depression showed no 
significantly greater benefit from either treatment.  
Whilst the prognostic study based in the same data did not include depression in the final model, this 
sub-group analysis suggests that these participants do not do as well with either treatment. However, 
29% of patients had responded to the baseline screening questions such that they were considered to 
have depressive symptoms. This higher than expected figure may be indicative of the effect CTS was 
having on their experience of symptoms and ability to function or that the screening questions were 
overly sensitive or non-specific. To test this more fully, a more complete questionnaire such as the 
Hospital Anxiety and Depression scale could be included, however on this occasion the trial 
management group and PPIE group felt further lengthy questionnaires at baseline were not 
appropriate. 
8.4.2.4 Laterality of symptoms 
The results of this secondary data analysis differ from those reported in the main INSTINCTS trial 
publication59 due to the set of variables adjusted for in the linear regression model. In the analysis 
presented in this chapter, participants with unilateral symptoms appeared to have a less favourable 
outcome at six months following treatment with CSI compared to NS, than patients with bilateral 
symptoms (0.28, 95% CI 0.00 to 0.55, P = 0.05 compared to 0.04, -0.20 to 0.28, 0.75).  
Participants were asked if they had bilateral CTS at the time of recruitment, and if so which of their 
wrists was the most severe. The more severe wrist was randomised to an intervention and the 
participant asked to complete outcome questionnaires based on the symptoms from the more severe 
wrist. The effect of any additional treatment to the contralateral wrist was not considered in this 
dataset, neither has the possibility of ipsilateral additional treatments (e.g. CTR or repeat injections). 
   
254 
 
Furthermore, participants may have found distinguishing the symptoms of one wrist from the other or 
both combined, difficult. 
The contralateral wrist was treated as per ‘usual care.’ It is difficult to assume that splinting one wrist 
would have a positive impact on the other, but it is possible to surmise that an injection in one wrist 
may have an effect on the other via a systemic action of the drug. This is contrary to what was observed 
however, so perhaps unlikely. Perhaps those who had one CSI had a poorer outcome at six months 
compared to those who had NS due to the fact the splint users could continue wearing the splint (and 
perhaps purchased a contralateral splint) for an extended period, longer than the effect of the local 
corticosteroid. However, this is conjecture. 
Following their Cochrane reviews of conservative interventions for CTS,42, 188, 189 Page et al examined 
how authors manage the allocation of interventions and the statistical analysis of CTS trials where 
participants with bilateral CTS are included.173 Of the 25 trials which included participants with bilateral 
CTS, 17 (68%) reported the method used to allocate interventions to each wrist and only one (4%) 
included a statistical method to deal with bilateral involvement. They suggest that not adjusting for 
non-independence of bilateral observations can lead to a unit-of-analysis error. This type of error can 
lead to overly narrow confidence intervals and small P values and the increase of type 1 errors.190 
Whilst this trial did not attempt to allocate an intervention to each wrist in the case of participants 
with bilateral CTS, it is possible that the effect of non-independence of bilateral observations may have 
biased the results and potentially account for the subgroup effect observed. The observation may also 
represent a type I error in that it is a spurious finding between the other non-significant interactions, 
secondary to the small sample size.  
8.4.2.5 First or recurrent episode 
This candidate predictor was a priority for the participants of the think tank and GP survey and had not 
been identified in previous literature. Clinical experience led to the hypothesis that patients with 
recurrent symptoms may not benefit from splinting and should be offered a CSI. The exploratory 
analysis suggests that whilst both groups of patients had a better outcome at six weeks with CSI versus 
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NS, those with recurrent symptoms showed a greater benefit than those with a first episode. However, 
the distribution of those with and without recurrent symptoms was not equal between groups, with 
only small numbers (14%) reporting a recurrent episode. This is possibly due to the fact participants 
were excluded if they had had treatment in the past six months or carpal tunnel release surgery on 
that wrist ever in the past.  
 Methodological considerations 
It was accepted a-priori that this study would be an exploratory non-confirmatory exercise to attempt 
to identify potential predictors of treatment effect that may later be tested in larger trials or IPD meta-
analysis of multiple trials. The sample size required to detect a single treatment-predictor interaction 
may need to be at least four times greater than that required to detect the overall treatment effect.184  
INSTINCTS was not powered to detect treatment*moderator interactions nor designed to stratify by 
the predictors to be tested.   
Attempts were however made to limit the number of candidate predictors, with selection made on 
the basis of evidence and / or a proposed biological mechanism.74 Such candidate predictors were 
measured at baseline using pragmatic yet accepted methods (questionnaire based) and interactions 
were tested alongside presentation of a stratified analysis. On this basis the methodological criteria 
developed by Pincus et al. for inclusion in a future meta-analysis were fulfilled.178  
There is no information available in this study as to what further interventions a patient may have 
received over the six-month period. The main trial reports that 17 (14.3%) of patients receiving CSI and 
14 (11.9%) patients treated with NS had had surgery at six months.59 It is not possible from the available 
data to determine if patients with bilateral symptoms were more or less likely to have had surgery or 
indeed a contralateral intervention.   
  




Whilst this data is not currently helpful in suggesting how conservative management options may be 
best matched to the baseline characteristics of patients with mild to moderate CTS, it may be of future 
benefit when taken into account alongside other studies in meta-analysis or used to inform the design 
of a stratified care trial. Whilst a statistically significant subgroup effect may be observed in patients 
with unilateral as opposed to bilateral CTS at six months, a unit-of-analysis error may be one of the 
explanations for this finding.  
The next chapter will draw together the results of the preceding studies and discuss the significance of 
their findings within the context of the literature. The clinical implications of the work will be 
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9 Summary, discussion, implications and conclusions  
 
 Summary 
The aim of this chapter is to provide a summary of the main findings of the studies presented 
in this thesis. The findings of these studies are placed in the context of the existing literature 
and their particular strengths and weakness discussed. The clinical implications and potential 
opportunities for further research are considered.   
9.1 Summary of main findings by thesis objective 
 Objective 1a. Estimate trends in the prevalence and incidence of CTS diagnosed in 
primary care between 1993 and 2013 (chapter 3) 
The estimated crude prevalence of patients presenting with physician diagnosed carpal tunnel 
syndrome in a UK primary care setting in 1993 was 26.03 per 10,000 person years (95% CI 25.10 to 
27.00), and in 2013, 36.08 per 10,000 person years (95% CI 35.45 to 36.72). Prevalence appeared to 
decrease between 1993 and 2000 (annual percentage change APC = -0.8%, 95% confidence interval -
2.6 to 1.0). It then increased between 2000 and 2004 (APC = 7.8%, 95% CI 3.1 to 12.7) and then 
increased at a slower rate between 2004 and 2013 (APC = 1.1%, 95% CI 0.4 to 1.8). The female to male 
ratio reduced over time from 2.74 in 1993 to 1.93 in 2013.  
Incidence was derived from the prevalent population and defined as those with a new presentation of 
CTS during the calendar year in question (no previous CTS code in the prior 2 calendar years). The crude 
incidence in 1993 was 20.22 per 10,000 person years (95% CI 19.24 to 21.24)), and for 2013, 27.68 per 
10,000 person years (95% CI 27.09 to 28.28). The results of the best fitting Joinpoint regression plot 
suggested the incidence increased between 1993 and 2000 (APC = 0.3, 95% CI -2.3 to 2.9). It then 
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increased more quickly between 2000 and 2004 (APC = 6.9, 95% CI 0.5 to 13.7), before slowing 
between 2004 and 2013 (APC = 0.7. 95% CI -0.2 to 1.6).  
 Objective 1b.  Estimate trends in health care use (corticosteroid injection and carpal 
tunnel release surgery) of patients with CTS between 1993 and 2013 (chapter 3) 
The proportion of patients with prevalent CTS with a recorded episode of CTR increased over the total 
observed study period from 19.35% in 1993 to 27.3 % in 2013. However, whilst the percentage of 
patients with a coded episode of CTR increased between 1993 and 2007 (annual percentage change 
APC = 2.6, 95% CI 1.9 to 3.2) the rate of surgical intervention then appeared to decrease between 2007 
and 2013 (APC = -1.7, 95% CI -3.3 to -0.3).  
Despite multiple methods of identifying the use of corticosteroid injection in the management of CTS, 
the rates observed were considered to be inaccurately low, suggesting episodes of CSI are not well 
coded or recorded in CPRD. Using the data available, it was determined that between 5 and 8% of 
patients received at least 1 injection and that the use of CSI reduced between 1993 and 2005 (APC = -
1.29, 95% CI –3.2 to 0.7) and then increased between 2005 and 2013 (APC = 6.56, 95% CI 4.3 to 8.8).  
 Objective 2a. Summarise available evidence regarding the course of conservatively 
managed CTS (overall prognosis) and the predictors of long term outcome (prognostic 
factors) (chapter 4) 
A systematic review of the literature identified four studies, which observed patients with untreated 
CTS. A range of 32% to 58% of participants receiving no formal treatment were reported to have a poor 
outcome at 12-month follow-up. Studies with a longer term follow up reported poor outcome in 23.4% 
of patients at 3 years and 50% at 10 years.  
Nine further studies were identified which observed patients who received conservative management 
for CTS. Between-study variation in estimates of prognosis were substantial and particularly 
dependent on the case definition of CTS and outcome measure applied. Of the four studies reporting 
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surgery as a marker of inadequate response to conservative management, a range of 57% to 66% of 
patients required CTR over a period of between 1 and 3 years.  
Eleven studies presented data on the association between 39 candidate prognostic factors and a poor 
outcome from conservative management. Substantial heterogeneity existed between studies in terms 
of setting, case definition, follow-up period and outcome measures. The studies were judged to be of 
moderate or high risk of bias. There was agreement in at least three studies that an increasing 
symptom duration; a positive Phalen’s test and the presence of thenar wasting were associated with 
a poor outcome over variable time periods. However, not all associations were statistically significant 
and since the studies were not considered to be at low risk of bias, the overall judgement regarding 
their predictive value remained inconclusive.    
 Objective 2b. Develop a prognostic model to predict poor outcome in conservatively 
managed CTS in a cohort of patients identified in CPRD (chapter 5) 
17 candidate prognostic factors, derived from the literature and expert opinion, were identified and 
tested as candidate prognostic factors of future surgery in a cohort of 91,412 patients with physician 
diagnosed CTS, as recorded in the CPRD. 20.24% of the cohort had a recorded episode of CTR. The 
median time to surgery was 221 days (IQR 111, 409). Univariable analysis indicated that pregnancy in 
the preceding year was observed to reduce the risk of future surgery, however as this was not relevant 
to the majority of the presenting population, it was not included in the final model. The final 
multivariable Cox regression model performed poorly, C statistic 0.59 (95% CI 0.58 to 0.59) but 
suggested the likely predictive value of combined prognostic factors including obesity, being an alcohol 
drinker and having other musculoskeletal pain.  
 Objective 2c.  Develop a prognostic model using individual patient data from an RCT to 
predict a future change in patient-reported CTS-symptoms (chapter 6)    
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234 participants from the INSTINCTS trial were observed prospectively over a 6-month period. The 
BCTQ (a condition-specific patient recorded outcome measure) was completed at baseline, six weeks 
and six months. By six months, the main trial had reported no significant difference between treatment 
arms and as such, the participants were observed as a single cohort, while adjusting for treatment 
allocation. The greatest improvements in terms of symptom severity and function score were seen at 
six weeks, however further improvement was observed at six months. Multivariable linear regression 
modelling indicated more severe baseline total BCTQ, less severe symptom severity score, and the 
absence of any other neck or upper limb symptoms as predictors of improvement in BCTQ score at six 
months. The small sample size resulted in optimistic predictions, and the optimism-adjusted model 
calibrated poorly; overestimating the severity of outcome in patients with less severe observed CTS 
and underestimating the severity of outcome in patients with more severe observed CTS.  
 Objective 3a.  Summarise available evidence regarding predictors of response to 
specific common primary care treatments of CTS; in particular corticosteroid injection 
and night splinting (chapter 7) 
The systematic review identified four trials which explored predictors (or moderators) of treatment 
effect. Whilst the quality of the subgroup analyses was judged inadequate in three of the four trials, 
potential predictors of treatment effect were identified. There is suggestion that the effect of CSI was 
larger in patients with higher nerve conduction severity and baseline symptom severity scores, 
however severity was likely to be a prognostic factor of outcome rather than a predictor of a specific 
treatment effect.53 Prolonged symptom duration (more than nine months) was also observed by 
Celiker et al to be a general predictor of poor outcome rather than of treatment effect. Neither patients 
randomised to wrist splints with acemetacine or a CSI (methylprednisolone 40mg) with a prolonged 
symptom duration, responded well to treatment.48 Neither wrist laterality nor patient preference were 
observed to act as predictors of treatment effect in the other trials included in the review.140, 179 
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 Objective 3b.  Investigate if a priori defined candidate predictors of treatment effect 
(effect modifiers), predict a better outcome from either corticosteroid injections or 
night splinting (chapter 8) 
INSTINCTS, an open-label, parallel group, randomised controlled trial compared the effectiveness of 
CSI to NS. A single local CSI was found to be more effective at reducing symptoms and the functional 
impact of CTS at six weeks, but by six months there was no significant between-group difference. 
Further to the subgroup analyses presented in the original trial publication,59 it was decided to explore 
whether particular groups of patients did benefit more from one treatment over another. Six candidate 
moderators were identified from the literature and expert opinion. Moderator*treatment interactions 
were tested and subgroup analyses carried out. At six months, CSI was significantly less effective than 
NS in patients with unilateral symptoms compared to those with bilateral CTS, when adjusting for 
potential confounders (baseline BCTQ, symptom severity and presence of neck and upper limb 
symptoms). However, there was no significant interaction and a true sub-group effect is unlikely given 
the small sample size and potential of a unit of analysis error.  
9.2 Updates and comparison to findings in the literature  
Where relevant, the discussion section of each chapter has reflected on how the findings of the studies 
presented in this thesis compare to what has been reported in the literature. Below is an update of 
studies published since the chapters in this thesis were completed and how they might affect the 
interpretation of findings, with particular reference to the recently published PALMS study.191 
 The epidemiology of carpal tunnel syndrome 
The findings of the CPRD epidemiology study presented in chapter 3 have already been discussed in 
the context of existing literature. In summary, the prevalence and incidence of CTS were observed to 
have increased in multiple populations. Rates of surgical referrals and episodes of surgery have also 
increased over time, however the proportion of patients having CTR in the CPRD population was 
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observed to be in decline and was generally lower than those reported elsewhere in the literature. As 
in other studies, regional variation was observed in the proportion of patients receiving surgery.64 Local 
variation in clinical pathways and restrictions placed on referrals for surgery were likely to explain some 
of the observed variation. This variation may also partly explain the poor performance of the prediction 
model presented in chapter 5, which could only account for variation occurring at the level of the older 
strategic health authorities (‘region’ variable in CPRD) and not fully adjust for variability at a lower 
‘practice or Clinical Commissioning Group’ level.  
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 Predicting outcome in conservatively managed carpal tunnel syndrome 
9.2.2.1 The prognosis of carpal tunnel syndrome   
In addition to the studies considered in the systematic review presented in chapter 4, the most relevant 
study concerning the prognosis of conservatively managed CTS to have been published since its 
completion, is the PALMS study.191 PALMS was a large (801 eligible consented participants) 
prospective, multicentre cohort study designed to predict the outcome of patients recruited in 
secondary care diagnosed with CTS following clinical review and confirmatory NCS. Patients were 
treated as per usual care (no treatment, CSI and / or CTR) and observed over an 18-month period. Of 
the 626 responders, 318 (51%) underwent CTR, 56 (9%) had CSI only and 252 (40%) had had no 
treatment by six month follow-up. By 18 months, 403 (64%) had undergone surgical management and 
21 had had a second injection and three a third. 165 (26%) of participants had no treatment at all. 
Outcome was judged to be a success if participants reported on a Global Rating of Change scale that 
they were ‘slightly improved, much better or cured.’ Predictors of global improvement following 
injection alone included a positive response to a prior injection (OR 0.18, 95% CI 0.07 to 0.47) and a 
shorter symptom duration (OR 0.69, 95% CI 0.54 to 0.98). A prognostic model was developed using the 
CTS-634, 192 as an outcome (a shorter form of the BCTQ). The final multivariable linear model predicting 
symptomatic improvement of CTS treated with injection included a lower symptom severity score at 
baseline (B=0.55, 95% CI 0.33 to 0.77) with an R2 of 22.9%. 
Whilst the performance of the models were not fully described, similarities to the prognostic model 
presented in chapter 6 exist. A lower symptom severity score at baseline appears to be predictive of a 
better outcome. However, the INSTINCTS model is also suggestive of a more severe overall BCTQ score 
being predictive of a better outcome (adjusting for neck and upper limb symptoms and the 
independent symptom severity score). Whilst it is established good practice to adjust for baseline 
severity in prognostic models in order to account for ‘regression to the mean,’ it is possible that the 
psychometric properties of certain items included in the full BCTQ led to the variations observed. The 
utility of the BCTQ and potential implications will be discussed in the next section. 
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The PALMS study demonstrates how, despite using a similar cohort and similar candidate prognostic 
factors, the variables included in final prognostic models can vary, depending on the outcome measure 
applied, length of follow-up, and treatment offered.  
9.2.2.2 Comparing the two prognostic models presented in this thesis 
This thesis presents two prognostic models, which predict the outcome of conservatively managed 
CTS. One study used routinely collected primary care data with a very large sample size, but with 
potential limitations around accuracy and completeness. The other model was set in trial data, with a 
much smaller sample size but which was more likely to represent data of high quality (intentionally 
and more precisely measured prognostic factors at baseline). The individual components of the final 
models were also limited to what was measureable and available in each data set. The CPRD model 
used a time-dependent binary outcome whilst the INSTINCTS model used a continuous outcome.  
In order to systematically compare the risk of bias present in each model, the QUIPS tool used in the 
systematic review presented in chapter 4, was used to critique and compare each model as shown in 
Table 9-1. In summary, the application of the QUIPS tool demonstrates that the overall risk of bias of 
the model developed in CPRD was judged to be high, whilst the risk of bias for the model developed in 
INSTINCTS data was judged to be low. As previously alluded to, sample size is likely to be a substantial 
determinant of the poor performance of the INSTINCTS model, but this is not picked up by the QUIPS 
tool, as it is an issue of precision rather than bias.  
Neither model performed well enough to be considered for further clinical development. The CPRD 
model discriminated between those who experienced the outcome (CTR) and those who did not 59% 
of the time. The calibration plot for the INSTINCTS model suggested the model tends to underestimate 
the severity of the more severe cases and overestimate the severity of the milder cases. The PALMS 
model also exhibits poor performance despite robust methodology, which leads one to question why 
the outcome of CTS appears to be difficult to predict. The answer is likely to be complex and multi-
faceted. Potential reasons for this will now be considered.  
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Table 9-1 Assessment of the risk of bias in each model presented in the thesis using the QUIPS tool (Hayden et al., 2013) 




Study Confounding Statistical Analysis 
and Reporting 
Overall Risk of bias 
CPRD study The source of the 
population is known 













The rate of attrition 
cannot be measured 
not the reasons for 











High risk  
The candidate 
prognostic factors 
are identified by 
Read code, which 
has a risk of 
misclassification. 
Appropriate cut-offs 
are used. The 
proportion with 
complete data for 





The outcome was 
well defined 
however limitations 
exist as to whether 
the method was 
valid and reliable 









It is likely that some 
confounders 
(particularly 
treatments and local 
commissioning 
guidelines) were not 
identifiable in the 
data. Imputation4 







Data is presented 
sufficiently to assess 
the adequacy of the 
analysis. The model 














outcome are likely 




particularly due to 
the unmeasurable 





INSTINCTS study The source of the 
population is known 










Study attrition was 
low and attempts 
made to collect data 
from participants 
who dropped out. 



















A valid and reliable 
outcome measure 
was used in the 









The method and 
setting for 
measuring 
confounding was the 
same for all 
participants. Missing 






Data is presented 
sufficiently to assess 
the adequacy of the 
analysis. The model 











outcome is unlikely 












9.2.2.3 Considering carpal tunnel syndrome as a ‘generic’ musculoskeletal condition  
The prospective observational study of primary care patients by Henschke et al aimed to identify 
generic predictors of poor outcome in patients with musculoskeletal pain, regardless of the location 
of their pain presentation. They concluded that the region of pain was not a significant predictor of 
outcome, but that generic predictors of outcome do exist. In chronic non-spinal musculoskeletal pain 
observed at 12 months: medication use (OR 2.17, 95% CI 1.31 to 3.59) and having the complaint in the 
previous year (2.0, 95% CI 1.18 to 3.49) were found to be generic predictors of poor outcome.193 Mallen 
et al as discussed in chapter 4, also described generic prognostic factors in a cohort of older people 
presenting with musculoskeletal pain in primary care. In patients presenting for the first time with a 
musculoskeletal condition: symptom duration (OR 3.26, 95% CI 1.15 to 9.29); pain interference (1.64, 
0.62 to 4.33) and multiple-site pain (2.75, 0.91 to 8.33) were found to be important predictors of poor 
outcome as defined by an unfavourable global rating of change (same, worse or much worse).194  
A further systematic review of generic prognostic factors for musculoskeletal pain in primary care was 
conducted by Artus et al. They summarised evidence from 78 prospective cohort studies based in 
primary care, which reported associations between predictors of outcome of multiple different 
musculoskeletal conditions. Whilst none of the studies investigated the prognosis of hand or wrist pain 
specifically, the authors concluded there was high quality evidence that pain intensity, widespread 
pain, high functional disability, somatisation and movement restriction can be considered generic 
prognostic factors of poor outcome for musculoskeletal pain.195  
It has not been shown that CTS can be considered a ‘generic’ musculoskeletal condition, however it 
could be assumed that there is some overlap. Symptom duration does appear from these generic 
studies and the systematic review presented in chapter 4 to be a likely important predictor of outcome 
in people with musculoskeletal conditions, and hence possibly also in CTS. This evidence was not 
identifiable in the analysis of CPRD data and the collection of this information in INSTINCTS was likely 
to have been biased by the inclusion / exclusion criteria. The empirical studies in this thesis have been 
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unable to substantiate the suggestion from the literature that symptom duration is an important 
prognostic factor in CTS, which would clinically be important if it could be shown that delaying the 
surgical treatment of non-responders to primary care management might increase the risk of adverse 
outcomes.   
9.2.2.4 Predicting the outcome of carpal tunnel syndrome considering pathophysiological 
mechanisms 
Although the studies in this thesis could not confirm the predictive value of symptom duration, 
pathophysiological mechanisms may explain why prolonged exposure of the median nerve to pressure 
might reduce the chance of recovery.2, 196 Such mechanisms and the fact that CTS is essentially an 
entrapment neuropathy rather than a muscle / skeletal condition may lead one to question whether 
CTS can be considered a ‘generic’ regional pain syndrome, especially given that pain is not always the 
predominant symptom.139  
Schmid et al examined the morphology of small unmyelinated and myelinated axons in patients with 
and without electrophysiologically diagnosed CTS. They concluded that compression of the median 
nerve at the wrist affects the small unmyelinated fibres distal to the compression as well as the large 
myelinated fibres, which are measured by NCS. It is these more distal small unmyelinated fibres that 
give rise to the neuropathic pain component of CTS. Schmid et al suggest that distal effects of 
entrapment include a reduction in intraepidermal nerve fibre density. This in turn is independent of 
electrodiagnostic severity (explaining the mismatch between patient reported severity and 
electrodiagnostic grading). Elongation of nodes in these small unmyelinated fibres is suggestive of an 
adaptive change of prolonged nerve compression and may suggest why some patients have fewer 
positive subjective symptoms (e.g. pain) but more negative objective symptoms (e.g. muscle wasting 
and weakness leading to functional impairment).196, 197  
These pathophysiological processes and their relationship with time and exposure question the utility 
of both symptom severity scales and electrodiagnostics as measures of severity and determinants of 
qualification for surgical treatment. In addition, Schmid et al also highlight the role of central 
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sensitisation as being a cause of persistent pain. However, in the case of CTS, even after longer-
standing symptoms, treatment of the peripheral trigger has been observed to lead to local and central 
relief from focal and widespread symptoms. Schmid et al suggest that symptom duration is an 
important consideration when making definitive treatment decisions (surgery or corticosteroid 
injection) for patients with CTS.198 
These observations from basic science studies suggest symptom duration to be an important factor to 
consider when deciding clinically whether a patient can be reasonably managed using a ‘watch and 
wait approach’ or whether a definitive (surgical) intervention is required. Likewise, the use of 
electrodiagnostics and symptom severity scales to diagnose and stratify patients is questioned as 
elements of nerve damage will not be measured by nerve conduction studies and the process of neural 
adaptation may mean that patients with poorer function may have relatively lower symptom severity. 
Such issues may also partly explain the poor performance of the models and difficulties in predicting 
outcome.  
9.2.2.5 Use of the Boston Carpal Tunnel Questionnaire 
The Boston Carpal Tunnel Questionnaire (BCTQ) is the only condition-specific patient recorded 
outcome measure for carpal tunnel syndrome.32 The BCTQ has previously been found to have good 
validity, reliability, responsiveness and interpretability.159 For this reason, it was used in its entirety as 
the primary outcome measure for the INSTINTCS trial58 and therefore the two nested studies 
presented in this thesis. 
Since the development and widespread use of the BCTQ, it has received criticism for its length and 
redundancy of certain components. Atroshi et al used item response theory to examine the latent trait 
and differential item functioning of the scale.34 Their aim was to produce a shorter form of the BCTQ 
by removing items that were significantly associated with other items and therefore found to be 
redundant on IRT analysis.  
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The effect of item redundancy should not have impacted on the optimisation of prediction in the model 
presented in chapter 6 and the full score remains a valid outcome measure for this purpose. The use 
of the full score also enabled symptom and function severity to be considered as predictors. 
Alternative outcome measures could have been used, such as the hand-wrist symptom intensity scale 
but there would have been no reasoning to do this other than seeking to develop a better performing 
model – to do this retrospectively could be considered as data-dredging, as it was not included in the 
a priori investigation plan and approved request for data use.   
 Update to systematic review of treatment moderators  
Other than the INSTINCTS trial itself, a rapid review of the literature for trials investigating the 
effectiveness of CSI or NS compared to other modes of conservative treatment since the review 
presented in chapter 7, found one small (25 participants in each arm) randomised clinical trial 
comparing CSI with NS.57 The BCTQ at 4 weeks was the primary outcome measure used. There was no 
significant difference between treatment arms observed (P=0.22) at this time point. There was no 
attempt to investigate for a subgroup effect.  
Identifying predictors of treatment effect has been difficult and is likely to require either a purposively 
designed large stratified care trial or an individual patient data meta-analysis of multiple trials (if 
suitable trials were to exist), in order to have sufficient power to test treatment*predictor interactions.  
9.3 Strengths and limitations 
 Strengths of the studies included in the thesis 
The studies presented in this thesis apply a range of methodologies and have used different study 
settings in order to describe the epidemiology and prognosis of carpal tunnel syndrome and explore 
how such evidence may be used to improve the primary care management of patients with CTS. 
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The thesis follows the PROGRESS framework,75 as outlined in chapter 1 and attempts to present 
findings from each of the four types of study in a structured manner. A very large electronic healthcare 
data set, representative of the general population was used to describe the clinical setting for the 
further studies, i.e. patients with physician diagnosed carpal tunnel syndrome, presenting in primary 
care. The same data-set was then used to develop a prognostic model that aimed to identify patients 
who were likely to require surgical intervention. Multiple sources of candidate prognostic factors were 
identified and tested in the model development. It was acknowledged that the predictive performance 
of the model meant it lacked clinical utility. A further model was therefore developed in data with the 
availability of a patient reported outcome measure and more precisely defined and measured 
prognostic factors, some of which were felt to be important and not measurable in CPRD data. This 
model also performed poorly and it was concluded that the prediction of CTS is complex and that the 
reasons for poor performance are likely to be multifactorial.  
Exploratory analysis in the same trial data attempted to identify predictors of treatment effect that 
might lead clinicians to be better able to discuss the likely benefits of management options particular 
to a patients’ individual profile. It appears that, based on current evidence, patient choice is likely to 
be the most helpful guide to therapy, given that no such predictors were reliably identified in the trial 
data. 
The use of the literature preceding and contemporaneous to these studies and available data from the 
empirical studies has been used to attempt to answer the initial research questions posed. Whilst no 
clinically useful conclusions could be drawn, this in is itself is helpful information. Data presented 
regarding overall prognosis does offer a helpful estimate for the likely course of symptoms, but 
clinicians may wish to take into account the potential influence of symptom duration, additional 
comorbidities / pain elsewhere, and baseline levels of symptoms when considering treatment options 
and referral.   
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The overall results of INSTINCTS probably offer the best estimate of likely response to CSI vs NS, 
regardless of patient characteristics, until such a time when evidence regarding moderators from 
larger trials or IPD meta-analysis emerge. 
 Limitations of the studies included in the thesis and alternative approaches 
The limitations as well as benefits of using the CPRD as a data source have been discussed in 3.1.3. In 
summary, whilst the sample sizes it provides can be very large, the quality of the data, in the case of 
CTS may be more limited. The definition of CTS was restricted to a specific code. It is possible that true 
cases of CTS were not included in the cohort due to a more generic code or symptom codes being used 
instead. This would have implications on both the findings of the epidemiology studies as well as the 
cohort study. Rates of prevalence and incidence would be underestimated, although trends would 
likely be the same. If the restriction to a single Read code meant that patients with milder or less well 
defined symptoms were excluded, it is possible that selection bias could have been introduced to the 
cohort and potentially affected associations within the sample.  
In this project, there was no funding to access linked Hospital Episode Statistics data. However, it was 
anticipated that administration coding of outpatient episodes would be adequate and the primary care 
data would identify episodes of CTR occurring outside of secondary care that HES would not be able 
to identify. Such episodes are likely to be increasing, as alternative providers deliver the service in 
primary care settings. In order to verify this assumption HES linkage would have been required.  
The overall prognosis and association between prognostic factors and outcome may have been 
influenced by various treatments offered to patients in the CPRD cohort. Apart from episodes of CTR, 
it is likely that un-recorded episodes of CSI, NS and other treatment modalities were used to treat 
patients. Variation in treatment may have affected both the overall prognosis and the performance of 
the model. The INSTINCTS cohort however offered the advantage of random treatment allocation, 
reducing the potential influence of treatment on associations between prognostic factors and 
outcome, and hence the performance and the model. However, confounding by indication may have 
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still affected the results after the initial six-week period, when patients were then able to seek other 
forms of treatment. 
INSTINCTS was a high quality randomised control trial providing a priori precise measures of candidate 
predictors at baseline and patient recorded outcomes at various time points. Whilst pragmatic and 
relatively non-exclusive, the trial was not designed to investigate prognosis, nor powered to predict 
treatment effect. CTR was not used as an outcome at six months as there was awareness that 
availability and criteria varied between centre. Patients who were to have surgery were unlikely all to 
have had it by six months given the mean time to surgery in CPRD was 9 months from initial 
presentation. Further work could explore the associations of baseline factors with an episode of 
surgery at 12 or 24 months. This would then allow the model developed in CPRD to be tested and 
updated in the higher quality INSTINCTS data, the major limitation still being the restricted sample size.  
Stepwise backward elimination procedures using a significance level of 0.1, were used to select 
variables in both prognostic models presented in the thesis. Multiple strategies for variable selection 
exist. However, each have their advantages and disadvantages.199 Despite avoiding univariable 
selection by starting with the full model, backward elimination can still lead to overfitting and 
optimism, particularly in smaller datasets. Alternative methods of variable selection include LASSO 
(least absolute shrinkage and selection operator) and elastic net. These methods also start with a full 
model but simultaneously penalise each predictor-outcome association, hence addressing the risk of 
overfitting.165  
Missing data in the INSTINCTS cohort was assumed to be MAR. In an attempt to reduce the potential 
bias introduced by missing it data, it was managed using multiple imputation. Lifestyle (smoking, 
alcohol, BMI and deprivation) data from CPRD was assumed to be MNAR and as such managed using 
a missing indicator method and complete case analysis. These approaches are subject to criticism. A 
missing indicator method is limited in a number of ways: bias may be introduced by residual 
confounding; the magnitude and direction of bias can become difficult to predict and as the results are 
not theoretically driven, they are potentially meaningless. Complete case analysis is also limited 
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because the data used in the model is not necessarily representative of the population. Discarding data 
also means that the sample size and therefore statistical power are reduced and the standard error 
increased.200  
Work by Peterson et al has shown that missing data for demographic characteristics (particularly 
weight) and disease status can be subject to multiple imputation in studies based in primary care data. 
However, this requires careful consideration of clinical associations and individual longitudinal 
trajectories.201 A method of imputation using a two-fold fully conditional algorithm has been proposed 
and tested.202  
A further source of bias in the studies described in the thesis is that caused by a unit of analysis error. 
Page et al suggest that unless considered in the statistical analysis, the non-independency of bilateral 
observations can increase the chance of type 1 errors (the rejection of a true null hypothesis).173 
Schmid et al suggest that neuro-immunological changes may be a cause of bilateral CTS and that when 
one wrist is objectively treated, it is possible to see resolution in the other wrist, as the systemic neuro-
inflammatory process is reduced.198 Laterality (i.e. whether the CTS affected one or both hands) could 
not be identified in CPRD and may have led to the episodes of CTR being underestimated over time. It 
may also have been an important prognostic factor to consider in the model but was not available. 
Approximately 50% of patients had bilateral CTS in the INSTINCTS cohort. However, only the worst 
affected wrist was allocated a treatment and the patient was asked to record their outcomes 
considering that wrist only. Laterality of symptoms was considered for inclusion in the prognostic 
model and tested for as a predictor of treatment effect. Whilst considering the very small sample size 
and lack of significant interaction, it is potentially suggested that patients with unilateral CTS 
experienced a less favourable outcome at six months if they were initially treated with a single injection 
rather than splinting. The subgroup difference was very small however and so were subgroup sizes. 
This result therefore is likely to be spurious.  
Poor performance of the models may have been due to missing or inadequately measured prognostic 
factors at baseline. A further study using data from the PALMS cohort by Jerosch-Herald et al examined 
   
274 
 
the association of psychological distress at baseline with health-related quality of life and costs of CTS 
in the subgroup of patients referred to secondary care.197 They concluded that patient reported 
symptom severity at baseline was positively associated with anxiety, depression, health-related quality 
of life (P<.0001 in each case) and societal costs, when adjusting for other important confounders. 
Anxiety but not depression was also associated with electrophysiological severity (p=0.027).197 Despite 
the inclusion of measures of anxiety and depression at baseline in both the CPRD and INSTINCTS model, 
as with any of the candidate predictors, if they were not measured in an effective manner (for example, 
due to limitations in the number of further questions added to the trial questionnaire or inadequate 
identification and coding), this may have further led to the poor performance of the prognostic models. 
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9.4 Clinical relevance of findings 
The studies presented in this thesis suggest that up to 75% of patients presenting in primary care can 
be reassured that their symptoms are likely to resolve or improve substantially, to the extent that they 
will not need an operation. This figure is higher than in other studies, which are generally set in 
secondary care and may therefore already have been pre-stratified by severity. INSTINCTS data does 
suggest that patients continue to experience improvements in symptom and function beyond six 
weeks post initial treatment. Whilst the number of patients with CTS presenting in primary care 
appeared to be increasing, fewer proportionally were observed to receive CTR. This may have been 
due to changes in access to surgery. The group of patients who were more likely to have surgery 
included those who were older, obese, drink alcohol, smoke and had other musculoskeletal pain and 
inflammatory conditions (adjusted for region and deprivation). A more severe overall BCTQ (with a 
lower SSS) and the absence of neck and upper limb symptoms may also predict a less favourable 
patient reported outcome score at six months. CTR is accepted to be an effective treatment and 
patients with severe or non-responsive symptom or functional disturbance should be provided with 
access to this treatment without undue delay or inappropriate dependence on electrodiagnostic 
findings. For patients with mild to moderate CTS, CSI and NS can be considered but it has not been 
possible to identify which patients are more likely to benefit from each treatment. 
The assertion that there exists a group of patients for whom conservative management will not 
sufficiently help and who are likely to require surgical intervention, does not consider the health 
economics of treating CTS. Such a health economic analysis is beyond the scope of this thesis but has 
been considered in the INSTINCTS. The studies presented may however contribute to the further 
debate around the rationalisation of healthcare and the restrictions imposed on clinicians as to which 
patients with what characteristics can be referred for surgery. 
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9.5 Contribution to future work 
Given that CSI and NS remain the mainstay of interventions available for CTS managed in primary care, 
the evidence base for any medium to longer-term benefit remains unclear. This evidence may be 
generated by the 12 and 24 month follow up of the INSTINCTS trial, although this is still unlikely to 
provide any clinically meaningful recommendations regarding targeting treatment to patients based 
on their baseline presentation.   
Considerations for further work may therefore include the design and testing of a stratified care 
intervention for CTS. This work has provided exploratory evidence of potential moderators to include 
in such an intervention, however additional research would be needed to further test the predictive 
value of baseline characteristics to confidently inform the design of such a stratified intervention.   
9.6 Thesis conclusion 
Carpal tunnel syndrome is a bothersome condition, which affects patients’ ability to function. The 
number of patients presenting in primary care with CTS was increasing whilst the proportion of 
patients accessing surgical treatment decreased. A substantial proportion of patients can be observed 
to improve over the short to medium term following conservative management, however some will 
not respond to treatment and have persisting symptoms. These patients are likely to include those 
with a higher combined symptom and function severity score at baseline and no other neck and upper 
limb symptoms. A combination of increasing age, obesity, being an alcohol drinker, smoker and having 
other neck, inflammatory or multisite pain can help predict the need for future surgery. All patients 
receiving primary care management for CTS should be observed and referred for consideration of 
surgical treatment if they fail to respond to corticosteroid injection or night splinting.  
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* Please state in your protocol the name of the reviewing Committee(s) and provide an outline of the 
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This protocol has been reviewed by the Keele CPRD steering group housed at the Arthritis Research UK 
Primary Care Centre. 
10. Type of Study (please tick all the relevant boxes which apply) 
 
Adverse Drug Reaction/Drug Safety  Drug Use   Disease Epidemiology
  
Drug Effectiveness   Pharmacoeconomic          Other  
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          Yes                             
 No 
Is statistical expertise available within the research team?     
  
                           If yes, please outline level of experience    
Ying Chen is a Research Associate in Biostatistics, with a PhD in Genetic Epidemiology and is currently 
working on a different study within CPRD. 
Kelvin Jordan is a Reader in Biostatistics, with a PhD in Medical Statistics and 20 years of experience. 
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PROTOCOL CONTENT CHECKLIST 
In order to help ensure that protocols submitted for review contain adequate information for protocol evaluation, 
ISAC have produced instructions on the content of protocols for research using CPRD data. These instructions are 
available on the CPRD website (www.cprd.com/ISAC). All protocols using CPRD data which are submitted for review 
by ISAC must contain information on the areas detailed in the instructions.  IF you do not feel that a specific area 
required by ISAC is relevant for your protocol, you will need to justify this decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted includes all the areas 
required by ISAC, or to provide justification where a required area is not considered to be relevant for a specific 
protocol.  Protocols will not be circulated to ISAC for review until the checklist has been completed by the applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, or if you 
answer ‘no’ and fail to include justification for the omission of any required area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for omission 
Lay Summary (max.200 words)         
Background         














      
Prognostic analysis 
Study Design         
Sample size/power calculation  
(Please provide justification of  
sample size in the protocol) 
        
Study population  
(including estimate of expected number of  






      
Selection of comparison group(s) or controls   Not applicable to this 
study 
Exposures, outcomes and covariates 
Exposures are clearly described  







      
      
Use of linked data  
(if applicable) 
        
Data/ Statistical Analysis Plan 
There is plan for addressing confounding  







      
      
Patient/ user group involvement †         
Limitations of the study design, data sources  
and analytic methods 
        
Plans for disseminating and communicating study 
results 
        
 
† It is expected that many studies will benefit from the involvement of patient or user groups in 
their planning and refinement, and/or in the interpretation of the results and plans for further 
work. This is particularly, but not exclusively true of studies with interests in the impact on quality 
of life.   Please indicate whether or not you intend to engage patients in any of the ways mentioned 
above. 
 
Voluntary registration of ISAC approved studies:  
Epidemiological studies are increasingly being included in registries of research around the world, including those 
primarily set up for clinical trials. To increase awareness amongst researchers of ongoing research, ISAC 
encourages voluntary registration of epidemiological research conducted using MHRA databases. This will not 
replace information on ISAC approved protocols that may be published in its summary minutes or annual report. 
It is for the applicant to determine the most appropriate registry for their study. Please inform the ISAC 
secretariat that you have registered a protocol and provide the location. 
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Lay Summary  
 
Carpal Tunnel Syndrome (CTS) is a common condition in which a nerve (known as the median nerve) 
is squeezed as it passes through the wrist. CTS can cause pain or aching, tingling and numbness in 
the affected hand. It may disturb sleep and affect people’s ability to do day to day activities.  
 
It is not clear how many people in the UK have CTS or consult their GP for this problem. We are also 
unsure how patients with CTS are being treated in primary care nor how they respond, for example 
how many are given injections by their GP, how many need surgery and how they respond to these 
treatments in the long term.  
 
This study will aim to: 
•  show how many people are getting carpal tunnel syndrome, describe how they are being 
treated and how this has been changing over a period of 24 years 
•  show what usually happens to people’s symptoms and predict which patients will have more 
severe disease and need an operation 
 
The CPRD (a large database of healthcare information from general practice) will be used to estimate 
how many people each year develop CTS and to describe how they are treated. We will then examine 
these patient’s records, in the database, to see if there are features that suggest which patients are 




Carpal tunnel syndrome (CTS) is a symptomatic compression neuropathy of the median nerve at the 
level of the wrist 203. CTS is characterised by numbness, tingling, hand and arm pain and muscle 
dysfunction and is a recognised work-related musculoskeletal disorder (WMSD) caused by strain and 
repeated movements (biomechanical overload) and is hence more common in manual workers 11. CTS 
can be associated with pregnancy and a number of co-morbidities such as diabetes and 
hypothyroidism. Work absence due to CTS appears to cause a significant socio-economic burden 66, 
although we are not aware of UK based data. 
 
A study from the UK General Practice Research Database in 2000, calculated the incidence in men to 
be 8.8 per 10,000 person-years and in women to be 19.3 per 10,000 person-years, with new 
presentations being most frequent at ages 45-54 in women and 75-84 in men 19. Evidence from the 
US based Rochester Epidemiology Project suggested the annual adjusted incidence rates of medically 
diagnosed CTS was higher than in the UK and increased significantly from 25.9 per 10,000 person-
years in 1981-1985 to 42.4 in 2000-2005 96. Although there was a report of referrals for elective 
carpal tunnel surgery to one major UK hand centre rising by 88% between 1989-1990 and 2000 (5.97 
to 11.2 per 10,000 person-years) 104, there is no more recent data regarding the UK incidence of CTS 
or how this, alongside management, may have changed over time.  
 
To further explore the current evidence base of the likely outcome (prognosis) of patients presenting 
with CTS, a structured literature search was carried out. The course of untreated CTS was studied by 
Padua et al (2001) in a relatively short follow-up study over a 10 to 15 month period. The authors 
found clinical and neurophysiological measures improved in patients with more severe initial 
impairment compared with milder initial impairment and the main positive prognostic factors were 
short symptom duration and younger age. Bilateral symptoms and a positive Phalen’s test predicted 
poor prognosis 69. Predictors of post-surgical outcome have been investigated extensively; however 
there has been little discussion in the literature regarding the value of clinical indicators at diagnosis to 
predict the outcome of conservatively managed CTS or to predict the need for surgical intervention. 
None of the papers found were set in the consulting primary care population, suggesting that there is 
a significant opportunity to further investigate the course and prognosis of CTS presenting in primary 
care, particularly over the longer term. 
 
With previous evidence of an increasing incidence of CTS in the US over a period of 20 years 96 and 
evidence of an increasing rate of surgical referrals in the UK over a period of 10 years104, the proposed 
studies will therefore provide the new and updated epidemiological data required to describe the 
current prevalence, incidence and management of carpal tunnel syndrome in the UK. This research 
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will also help to map the likely outcome of patients presenting in primary care with CTS and identify 
factors that may predict the need for surgical intervention. Such evidence will help inform the 
commissioning of appropriate evidence based services in primary care or the primary / secondary care 
interface, where the majority of the management of CTS occurs.  
 
Objective, specific aims and rationale 
 
The proposed research aims to describe the prevalence, incidence and management of CTS over a 
period of 24 years and will provide information currently lacking on the outcomes of patients 
presenting in primary care. Results will inform further research into how treatments may be targeted 
to individual patients.  
 
Our specific objectives are to: 
 
1. Describe the patterns of the age- and sex-standardised annual prevalence of CTS diagnosed 
in primary care between calendar year 1987 and calendar year 2013 
2. Describe the patterns of the age- and sex- standardised incidence of CTS diagnosed in 
primary care between calendar year 1989 and calendar year 2013 
3. Describe the patterns of health care use (corticosteroid injection and  decompression surgery) 
of patients with CTS between calendar year 1987 and 2013  
4. Identify the prognostic value of candidate factors available in primary care consultation data 
to predict the risk of poor outcome in CTS over time, as defined by an episode of carpal 




This will be a descriptive study illustrating epidemiological patterns and a prognostic analysis aiming to 




This study will have two components, which will be described separately:  
 
Part 1. A series of descriptive analyses estimating the annual incidence, prevalence and management 
of patients with CTS 
 
Part 2. A retrospective cohort study for identifying prognostic factors for long-term outcome in CTS. 
This study will be used to observe a cohort of primary care patients with incident carpal tunnel 
syndrome over a maximum period of 24 years (1989 to 2013). We aim to determine the predictors of 
surgical intervention, based on data available from the primary care medical records.  
 
The methods for these analyses have been developed following a pilot study of consultation data from 
11 general practices in North Staffordshire, who contribute to the Consultations in Primary Care 
Archive (CiPCA). CiCPA is a high quality, validated database, containing recorded data from 13 general 
practices in North Staffordshire, UK from 2000 to 2011 (at the time of data collection). 204-206 
 
The primary outcome for the prognostic study will be carpal tunnel release surgery (CTR). National 
recommendations suggest that CTR is reserved for patients who have severe disease or for those who 
have failed conservative treatment. It is therefore of interest to patients, clinicians and commissioners 
to know which patients are likely to require surgery.207 CTR is a procedure that does take place in 
primary care, for example in North Staffordshire, East Kent 208 and Tyne and Wear 209 and as such 
does not necessitate a hospital admission. We therefore aim to use coded entries of CTR recorded in 
general practice data to capture surgical episodes as we believe using HES data to capture CTR is 
likely to underestimate the true frequency.  
 
Using coded entries to record CTR was the approach used by Latinovic in their analysis of GPRD 19 
and has been shown to provide results in agreement with the literature .96 In the CiPCA pilot study, 
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between 2000 and 2010, the percentage of patients with prevalent CTS with a coded episode of CTR 
increased from 10% to 26% (29% - 42% of the incident population of the corresponding calendar 
year). 
 
We aim to include area deprivation in our description of prevalence and incidence of CTS and as one 
of the potential predictors of surgery. So as not to reduce our sample size, the main analysis will be 
run on all CPRD Gold practices (not including deprivation in the analysis), and a subgroup analysis 
based on practices to which linkage is possible, run to analyse the influence of deprivation. Linkage 
will therefore be required to the ITownsend Score (IMD). 
 
 
Part 1: Incidence, prevalence and management of CTS 
 
Sample size/power calculation (Please provide justification of  
sample size in the protocol) 
 
From CiPCA we determined the annual prevalence of CTS in 2000 as 20.0 per 10,000 individuals. 
Given an estimated CPRD annual registered population of 5.5 million, this would suggest we would 
identify around 11,000 patients with a recorded consultation for CTS per year.  
Previous work indicates figures in CPRD may be lower compared to CiPCA, so feasibility work within 
CPRD GOLD has been carried out. This work has shown that between 1987 and 2013 there have been 
203,803 individuals consulting with CTS giving a minimum annual prevalence of 14.25 per 10,000 (it is 
possible individuals presented on multiple occasions over the study period). Using a 95% confidence 
level, the size of population within CPRD allows estimation of annual prevalence with a margin of error 
of less than 1 per 10,000 assuming actual prevalence is around 14 per 10,000.  
 
With regard to the number of patients receiving surgery, 134,761 episodes of carpal tunnel release 
(9.4 per 10,000 individuals per annum) were recorded in general practice records during the same 
period. Using CiPCA data for 2010, 6 per 10,000 individuals per annum were recorded as having a 
CTR. 
 
Conducting the analyses in CiPCA has provided a description of prevalence and practice in a local 
area. However, care pathways for patients with CTS vary significantly between healthcare localities. It 
is possible that incidence will also vary between regions due to factors such as local industry. Analysis 
using CPRD will therefore provide a description of prevalence, incidence and management of CTS 
generalizable to the national population. 
  
Study population  
Inclusion criteria / exclusion criteria 
 
The denominator population for calculation of prevalence and incidence will be the total person-years 
contributed to the database by patients over the age of 18 years with up-to-standard data for each 
annual period between 1 January 1987 and 31 December 2013. 
 
Selection of comparison group(s) or controls 
Not applicable 
 
Exposures, outcomes and covariates 
Not applicable 
 
Data / Statistical Analysis Plan 
Data will be managed and analysed in SPSS version 21 and STATA Intercooled 13.1. For fitting of 
complex models, STATA MP4 is available for use by the study team. 
 
Distinguishing incident from prevalent cases 
The prevalence of individuals consulting with CTS will be calculated per annum. The numerator for 
prevalence will be all individuals aged 18 years and over having a record of a carpal tunnel syndrome 
diagnosis or evidence of a carpal tunnel release or carpal tunnel injection in a given calendar year. 
The Read codes used to identify patients with CTS can be found in appendix 1. 




For determination of the annual incidence of CTS, the numerator will be all patients aged 18 years and 
over having a record of CTS or evidence of carpal tunnel release or carpal tunnel injection, without a 
prior record of these codes during a run-in period of two years. This two year run-in period is based 
on expert consensus in that it was felt unlikely that a patient with ongoing bothersome symptoms 
would not have consulted within this period. CTS can present as a new episode in the contralateral 
wrist sometime after the initial presentation, hence it was not felt possible to use the criteria as ‘no 
previous recorded episode’ to define incidence.  
 
Age and sex specific annual prevalence and incidence will be determined for each year, from 1987 (or 
1989 in the case of incidence) to 2013. For confidence interval calculation and subsequent regression 
modelling, a Poisson or negative binomial distribution will be used as appropriate. Age and sex 
standardised annual figures of CTS prevalence and incidence for each year will also be calculated. 
These figures will be directly standardised to the general age-sex population structure of the UK in 
each calendar year using population estimates provided by the website of the Office of National 
Statistics.  
 
Cases have been described as those with either a specific CTS diagnostic code, or a CTS specific 
treatment code. Using treatment codes as well as diagnostic codes is due to the fact patients may be 
allocated a less specific hand pain code prior to referral or treatment and hence only be identifiable 
after a CTR has been carried out. In part 2, this will not be possible as we need to identify time to 
surgery from diagnosis. This precludes the use of a treatment specific code being used to identify 
cases with CTS. To ensure the use of treatment codes in this manner does not affect the overall 
trend, a sensitivity analysis calculating incidence and prevalence with and without using treatment 
codes, will be performed.  
 
Estimating change in the age-sex standardised annual prevalence and incidence of CTS (objectives 1-
2) 
Emerging patterns will be described and regional variation explored to identify any marked differences. 
We will apply Joinpoint regression to determine average annual percentage change and assess if and 
when there are changes in the underlying trend. This will also be used to explore the potential influence 
of changes in practice, for example the introduction of the 18-week wait target in 2010.  
Describing the patterns of health care use (corticosteroid injection and  decompression surgery) of 
patients with CTS between calendar year 1987 and 2013 (objective 3) 
 
Evidence of the use of management options for CTS will be obtained by using Read coded entries (see 
Appendix 2). Specific interest will be paid to carpal tunnel release surgery and carpal tunnel injection. 
We expect carpal tunnel release to be coded in the patient record. Episodes of carpal tunnel injection 
will also be identified by Read code and by identifying the prescription of an injectable corticosteroid 
(see Appendix 4) within 4 weeks of an index CTS consultation. This time period has been agreed 
through clinical consensus. Feasibility work within CPRD has shown that by using Read coded data 
1,608 patients out of 11,305 with a diagnosis of CTS, received a carpal tunnel injection in primary 
care, in one annual period. 
 
We will also seek evidence of the use of splints by identifying Read coded entries. We are aware 
however of the potential limitation of patients acquiring splints from other sources e.g. ‘over the 
counter’ but hope to capture some detail of their use over time. Evidence of referral to secondary 
care, the utilisation of nerve conduction studies and sickness certification will also be measured 
through Read coded entries (Appendix 5). 
 
We will calculate the use of these interventions per patient with CTS per annum and describe how 
these proportions change over the study period.   
 
Part 2: Identifying predictors of carpal tunnel release 
 
Sample size/power calculation (Please provide justification of  
sample size in the protocol) 
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We aim to describe the prognostic value of 17 previously identified potential predictors of the outcome 
of CTS. From our feasibility work we know CPRD will provide us with a sufficient number of events 
(carpal tunnel release) to develop a prediction model considering these 17 variables (>10 events per 
variable).  
 




The study population will be the incident cases with a diagnostic Read code for CTS as identified in 
part 1, using the same inclusion criteria. Patients with a Read code only for a CTS intervention (carpal 
tunnel release or carpal tunnel injection) will not be included in the cohort as there would be no 
identifiable baseline to measure time to surgery from.  
 
Selection of comparison group(s) or controls 
Not applicable 
 
Exposures, outcomes and covariates 
Exposures (Potential prognostic factors to be tested) 
The following variables will be tested as prognostic factors. They have been defined by a review of the 
literature and clinical consensus and reduced to items that are felt likely to be recorded in CPRD. The 
Read codes to be used are shown in Appendix 3. 
 
Prognostic factor Method of 
measurement 
Time period to be 
applied 
Source of Read 
code list (where 
applicable) 
Age at diagnosis Routinely recorded data At time of index date  
Gender Routinely recorded data At time of index date  
GP Practice Routinely recorded data At time of index date  
Region Routinely recorded data At time of index date  
Deprivation score Routinely recorded data 
for practices which 
provide Index of 
Multiple Deprivation 
scores 
2010 quintile score  
Obesity Read code or from the 
Test table 
The recorded value 
closest to the index 
date 
 
Alcohol status Read code or from the 
Test table 
The recorded value 
closest to the index 
date 
 
Smoking status Read code or from the 
Test table 
The recorded value 
closest to the index 
date 
 
Pregnancy Read code Read code within a 1 
year period prior to 
the index date 
Code list 
developed for 
purpose of this 




Affective disorders Read code Read code within a 2 
year period prior to 
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Hypothyroidism Read code Read code within a 2 
year period prior to 





Diabetes Read code Read code within a 2 
year period prior to 







Read code Read code within a 2 
year period prior to 
the index date 
Code list 
developed for 
purpose of this 
study  
Neck or upper limb 
conditions 
Read code Read code within a 2 
year period prior to 
the index date 
Code list 
developed for use 







Read code Read code within a 2 
year period prior to 
the index date 
Code list 
developed for use 






Read code Read code within a 2 
year period prior to 
the index date 
Code list 
developed for use 





purpose of this 
study  
Previous wrist trauma Read code Read code within a 2 
year period prior to 
the index date 
Code list 
developed for use 










Due to the retrospective design of the study and use of healthcare data, it will not be possible to 
utilise patient reported outcome measures for carpal tunnel syndrome that are commonly used in 
research, such as the Boston Carpal Tunnel Questionnaire (BCTQ)32. Time to carpal tunnel release 
(CTR) surgery will therefore be used as the primary outcome measure and proxy of a poor outcome 
as it suggests that symptoms have either been severe or not responded to conservative management.  
 
 
Data/ Statistical Analysis Plan 
 
1. Estimating the prognostic value of consultation data used to predict long-term outcome in CTS 
Incident CTS cases over each of the annual periods will form a retrospective cohort and be followed 
for at least a one year with a total possible follow up period of 24 years. Only patients with a 
diagnostic Read code for CTS will be included in the cohort. We will exclude cases defined based on a 
condition specific treatment code only to prevent treatment bias and ensure an identifiable baseline. 




Proportional hazard assumption will be tested in Cox models. Cox proportional hazards models will 
then be used to determine the association between potential prognostic factors (listed above) and 
surgical intervention, whereby the first episode of CTR will be used as the endpoint (we are aware 
patients may require further surgery for revision or treatment of the contralateral hand, but for the 
purposes of this study we will focus on the initial surgical episode).  This will be a time to event 
analysis in which patients will be censored at the point they receive CTR or are recorded as deceased, 
leave the practice or the practice no longer contributes to CPRD.  
 
The determination of the prognostic value of a factor will be based on two phases. First the 
correlational structure of the variables will be observed. Provided there is no strong inter-correlation, 
each variable will be added into a multivariable model. A backward selection procedure will then be 
used to determine the prognostic factors in the final multivariable model. Variables eliminated will be 
re-entered in the final multivariable model with adjustment for the remaining significant variables 
(determined prognostic factors) to ensure that no omitted variable significantly reduces the log 
likelihood chi-square of the model. The performance of the multivariable model will be quantified by 
sensitivity/specificity and by concordance statistics (C-statistics), which is analogous to the receiver 
operating characteristics (ROC) curve for binary data. A C-statistic can be interpreted as the 
probability that the model predicts a higher risk of severe outcome for those who actually receive CTR 
compared to those that didn’t receive CTR over the follow-up time. 
 
Limitations of the study design, data sources and analytic methods / missing data / 
confounding 
 
CTS may present bilaterally and the methodology of this study (use of Read codes to identify 
prevalent and incident cases and to describe their prognosis with regard to surgery) does not allow for 
‘wrists’ as opposed to ‘individual patients’ to be described. This is unlikely to be a significant issue 
when describing the prevalence and incidence of the disease or the healthcare use over time. It may 
however impact upon the measurement of time to surgical treatment, where we will be unsure of 
which wrist is being operated on in cases of bilateral CTS. 
 
We are also assuming that surgery is a marker of severe or non-responsive disease. This does not 
allow for the fact that some patients with severe disease or very significant co-morbidities may choose 
not to undertake surgery.   
 
There is potential for the misclassification of cases, in that some individuals may receive a diagnosis of 
CTS when they do not have the condition. It is however more likely that patients with CTS receive a 
less descriptive diagnostic code, such as ‘hand pain.’ We will therefore use condition specific treatment 
codes including ‘carpal tunnel release’ and ‘carpal tunnel injection’ to capture those who may 
previously have been assigned a broader code but go onto to receive condition specific treatment, 
when calculating prevalence and incidence.  
 
We are also aware from our work within CiPCA that splinting and injection interventions are not 
comprehensively coded. We have shown within CPRD however that by identifying prescription codes 
for injectable steroids linked to patients consulting with CTS, we can identify a more likely number of 
patients receiving injections within primary care (of the 11,305 patients consulting with CTS in a 1 
year period, 1,608 were also prescribed an injectable steroid). We will further clarify the criteria for 
assuming a prescription to be for the purpose of treating CTS by ensuring the prescription occurs 
within 4 weeks of a consultation tagged with a diagnostic CTS Read code and that there is an absence 
of any other musculoskeletal code within that same 4 week period.  
 
By using CPRD data to capture surgical intervention, we hope to identify operations occurring in all 
healthcare sectors. It remains possible however that some interventions communicated to primary 
care will not be satisfactorily coded and is hence an important limitation. There are likely to be 
patients with missing information on smoking alcohol and BMI status, especially in the earlier years. 
We will compare the effects on our results of excluding those patients with missing information to an 
analysis including these patients in a missing category. It is also possible that there will be missing 
prognostic factors not coded or recorded in consultation data, such as symptom severity and clinical 
findings (e.g. muscle wasting).  




Plans for disseminating and communicating study results 
Patients and stake-holders will be involved in the interpretation and dissemination of study findings 
through our Research User and Implementation Groups. We aim to publish the findings in 
internationally recognised journals. Our findings will be presented through international 
musculoskeletal and primary care conferences for example, Society of Academic Primary Care. 
 
 
Appendix 1: CTS Read codes 
 
Read Code Term 
F340 Carpal tunnel syndrome                                                                                                                                                                                 
85BE.00 Injection of carpal tunnel 
70560 Carpal tunnel release                                                                                                                                                                                  
70564 Endoscopic carpal tunnel release                                                                                                                                                                       
 
Appendix 2: Treatment codes 
 
Read Code Term 
7056000 Carpal tunnel release 
7056011 Carpal tunnel decompression 
85BE.00 Injection of carpal tunnel 
7L19F Injection of steroid NEC 
7K6ZF  Injection of steroid into wrist joint 
7056200 Re-release of carpal tunnel 
7056400 Endoscopic carpal tunnel release 
705A100 Revision of carpal tunnel release 
 
Appendix 3: Terms for potential prognostic factors 
 
Pregnancy (and associated antenatal terms) 
 
62 Antenatal care                                                                                                                                                                                         
621 Patient currently pregnant                                                                                                                                                                             
6211 Pregnant - urine test confirms                                                                                                                                                                         
6212 Pregnant - blood test confirms                                                                                                                                                                         
6213 Pregnant - V.E. confirms                                                                                                                                                                               
6214 Pregnant - on history                                                                                                                                                                                  
6215 Pregnant - on abdom. palpation                                                                                                                                                                         
6216 Pregnant - planned                                                                                                                                                                                     
6217 Pregnant - unplanned - wanted                                                                                                                                                                          
6218 Pregnant -unplanned-not wanted                                                                                                                                                                         
6219 Patient ? pregnant                                                                                                                                                                                     
621A Pregnancy unplanned ? wanted                                                                                                                                                                           
621B Pregnant - ? planned                                                                                                                                                                                   
621C Unplanned pregnancy                                                                                                                                                                                    
621Z Patient pregnant NOS                                                                                                                                                                                   
622 Antenatal care: gravida No.                                                                                                                                                                            
6221 Antenatal care: primigravida                                                                                                                                                                           
6222 Antenatal care: 2nd pregnancy                                                                                                                                                                          
6223 Antenatal care: 3rd pregnancy                                                                                                                                                                          
6224 Antenatal care: multip                                                                                                                                                                                 
622Z Antenatal care: gravida NOS                                                                                                                                                                            
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623 A/N care: obstetric risk                                                                                                                                                                               
6231 A/N care: uncertain dates                                                                                                                                                                              
6232 A/N care: recurrent aborter                                                                                                                                                                            
6233 A/N care: grand multip                                                                                                                                                                                 
6234 A/N care: H/O stillbirth                                                                                                                                                                               
6235 A/N care: H/O perinatal death                                                                                                                                                                          
6236 A/N care: poor obstetr history                                                                                                                                                                         
6237 A/N care: H/O trophoblast.dis.                                                                                                                                                                         
623Z A/N care: obstetric risk NOS                                                                                                                                                                           
624 A/N care: precious pregnancy                                                                                                                                                                           
6241 A/N care: elderly primip.                                                                                                                                                                              
6242 A/N care: H/O infertility                                                                                                                                                                              
624Z A/N care: precious preg. NOS                                                                                                                                                                           
625 A/N care: social risk                                                                                                                                                                                  
6251 A/N care: poor home conditions                                                                                                                                                                         
6252 A/N care: poor A/N attender                                                                                                                                                                            
6253 A/N care: late booker                                                                                                                                                                                  
6254 A/N care: H/O child abuse                                                                                                                                                                              
625Z A/N care: social risk NOS                                                                                                                                                                              
626 A/N care: medical risk                                                                                                                                                                                 
627 A/N care: gynae. risk                                                                                                                                                                                  
628 A/N care: risk NOS                                                                                                                                                                                     
6281 A/N care: under 5ft tall                                                                                                                                                                               
6282 A/N care:10yrs+since last preg                                                                                                                                                                         
6283 A/N care: primip. < 17 years                                                                                                                                                                           
6284 A/N care: primip. > 30 years                                                                                                                                                                           
6285 A/N care: multip. > 35 years                                                                                                                                                                           
628Z A/N risk NOS                                                                                                                                                                                           
629 No ante-natal care                                                                                                                                                                                     
6291 Ante-natal care: not offered                                                                                                                                                                           
6292 Ante-natal care: not wanted                                                                                                                                                                            
6293 Ante-natal care: not attended                                                                                                                                                                          
6294 No A/N care: not known preg.                                                                                                                                                                           
629Z No ante-natal care NOS                                                                                                                                                                                 
62A A/N care provider                                                                                                                                                                                      
62A1 A/N care from G.P.                                                                                                                                                                                     
62A2 A/N care from consultant                                                                                                                                                                               
62A3 A/N - shared care                                                                                                                                                                                      
62A4 A/N care midwifery led                                                                                                                                                                                 
62AZ A/N care provider NOS                                                                                                                                                                                  
62B Delivery booking place                                                                                                                                                                                 
62B1 Delivery: no place booked                                                                                                                                                                              
62B2 Home delivery booked                                                                                                                                                                                   
62B3 G.P. unit delivery booking                                                                                                                                                                             
62B4 Consultant unit booking                                                                                                                                                                                
62B5 Private home delivery booking                                                                                                                                                                          
62B6 Delivery booking place changed                                                                                                                                                                         
62B7 Domino delivery                                                                                                                                                                                        
62B8 Midwife unit delivery booking                                                                                                                                                                          
62BZ Delivery booking - place NOS                                                                                                                                                                           
62C Deliv.booking - length of stay                                                                                                                                                                         
62C1 Short stay delivery booking                                                                                                                                                                            
62C2 Full stay delivery booking                                                                                                                                                                             
62CZ Delivery booking - stay NOS                                                                                                                                                                            
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62D Parent craft classes                                                                                                                                                                                   
62D1 Parent craft classes offered                                                                                                                                                                           
62D2 Parent craft class not offered                                                                                                                                                                         
62D3 Parent craft not wanted                                                                                                                                                                                
62D4 Parent craft class attended                                                                                                                                                                            
62D5 Parent craft -individual class                                                                                                                                                                         
62D6 Parent craft - group class                                                                                                                                                                             
62DZ Parent craft class NOS                                                                                                                                                                                 
62E Feeding intention                                                                                                                                                                                      
6.20E+02 Feeding intention - not known                                                                                                                                                                          
6.20E+03 Feeding intention - unsure                                                                                                                                                                             
6.20E+04 Feeding intention - breast                                                                                                                                                                             
6.20E+05 Feeding intention - bottle                                                                                                                                                                             
62EZ Feeding intention - NOS                                                                                                                                                                                
62F Antenatal amniocentesis                                                                                                                                                                                
62F1 A/N amniocentesis -not offered                                                                                                                                                                         
62F2 A/N amniocentesis - offered                                                                                                                                                                            
62F3 A/N amniocentesis - not wanted                                                                                                                                                                         
62F4 A/N amniocentesis wanted                                                                                                                                                                               
62F5 A/N amniocentesis - awaited                                                                                                                                                                            
62F6 A/N amniocentesis - normal                                                                                                                                                                             
62F7 A/N amniocentesis - abnormal                                                                                                                                                                           
62F8 A/N amnio. for ? chrom.abnorm.                                                                                                                                                                         
62F9 A/N amnio. for ? neural tube                                                                                                                                                                           
62FZ Antenatal amniocentesis NOS                                                                                                                                                                            
62G Antenatal ultrasound scan                                                                                                                                                                              
62G1 A/N U/S scan not offered                                                                                                                                                                               
62G2 A/N U/S scan offered                                                                                                                                                                                   
62G3 A/N U/S scan not wanted                                                                                                                                                                                
62G4 A/N U/S scan wanted                                                                                                                                                                                    
62G5 A/N U/S scan awaited                                                                                                                                                                                   
62G6 A/N U/S scan normal += dates                                                                                                                                                                           
62G7 A/N U/S scan normal +? dates                                                                                                                                                                           
62G8 A/N U/S scan abnormal                                                                                                                                                                                  
62G9 A/N U/S scan for ? abnormality                                                                                                                                                                         
62GA A/N U/S scan for slow growth                                                                                                                                                                           
62GB Antenatal ultrasounds scan at 4-8 weeks                                                                                                                                                                
62GC Antenatal ultrasound scan at 9-1six weeks                                                                                                                                                                
62GD Antenatal ultrasound scan at 17-22 weeks                                                                                                                                                               
62GE Antenatal ultrasound scan at 22-40 weeks                                                                                                                                                               
62GZ Antenatal ultrasound scan NOS                                                                                                                                                                          
62H A/N Rh antibody screen                                                                                                                                                                                 
62H1 A/N Rh screen not offered                                                                                                                                                                              
62H2 A/N Rh screen offered                                                                                                                                                                                  
62H3 Rh screen - 1st preg. sample                                                                                                                                                                           
62H4 Rh screen - 2nd preg. sample                                                                                                                                                                           
62H5 Rh screen - 3rd preg. sample                                                                                                                                                                           
62H6 Rh screen - cord blood sample                                                                                                                                                                          
62H7 Rh - 6/12 after anti-D sample                                                                                                                                                                          
62H8 Rh - random, non-preg. sample                                                                                                                                                                          
62HZ A/N Rh antibody screen NOS                                                                                                                                                                             
62I Alpha-feto protein blood test                                                                                                                                                                          
62I1 AFP blood test offered                                                                                                                                                                                 
62I2 AFP blood test not offered                                                                                                                                                                             
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62I3 AFP blood test wanted                                                                                                                                                                                  
62I4 AFP blood test not wanted                                                                                                                                                                              
62I5 AFP - blood sent                                                                                                                                                                                       
62IZ AFP blood test NOS                                                                                                                                                                                     
62J Rubella screen                                                                                                                                                                                         
62J1 Rubella screen not offered                                                                                                                                                                             
62J2 Rubella screen offered                                                                                                                                                                                 
62J3 Rubella screen not wanted                                                                                                                                                                              
62J4 Rubella screen wanted                                                                                                                                                                                  
62J5 Rubella screen - blood sent                                                                                                                                                                            
62J6 Rubella status not known                                                                                                                                                                               
62JZ Rubella screen NOS                                                                                                                                                                                     
62K Antenatal syphilis screen                                                                                                                                                                              
62K1 A/N syphilis screen not done                                                                                                                                                                           
62K2 A/N syphilis screen-blood sent                                                                                                                                                                         
62KZ Antenatal syphilis screen NOS                                                                                                                                                                          
62L Antenatal blood group screen                                                                                                                                                                           
62L1 A/N blood gp screen not done                                                                                                                                                                           
62L2 A/N blood group screen done                                                                                                                                                                            
62LZ A/N blood group screen NOS                                                                                                                                                                             
62M Antenatal sickle cell screen                                                                                                                                                                           
62M1 A/N sickle screen not done                                                                                                                                                                             
62M2 A/N sickle cell screen done                                                                                                                                                                            
62MZ A/N sickle cell screen NOS                                                                                                                                                                             
62N Antenatal examinations                                                                                                                                                                                 
62N1 A/N booking examination                                                                                                                                                                                
62N2 A/N 12 weeks examination                                                                                                                                                                               
62N3 A/N 1six week examination                                                                                                                                                                                
62N4 A/N 20 week examination                                                                                                                                                                                
62N5 A/N 24 week examination                                                                                                                                                                                
62N6 A/N 28 week examination                                                                                                                                                                                
62N7 A/N 30 week examination                                                                                                                                                                                
62N8 A/N 32 week examination                                                                                                                                                                                
62N9 A/N 34 week examination                                                                                                                                                                                
62NA A/N 35 week examination                                                                                                                                                                                
62NB A/N 3six week examination                                                                                                                                                                                
62NC A/N 37 week examination                                                                                                                                                                                
62ND A/N 38 week examination                                                                                                                                                                                
62NE A/N 39 week examination                                                                                                                                                                                
62NF A/N 40 week examination                                                                                                                                                                                
62NG A/N 41 week examination                                                                                                                                                                                
62NH A/N 42 week examination                                                                                                                                                                                
62NJ Antenatal 22 week examination                                                                                                                                                                          
62NK Antenatal 25 week examination                                                                                                                                                                          
62NL Antenatal 31 week examination                                                                                                                                                                          
62NZ Antenatal examination NOS                                                                                                                                                                              
62O Misc. antenatal data                                                                                                                                                                                   
62O1 Fetal movements felt                                                                                                                                                                                   
62O2 Fetal movements seen                                                                                                                                                                                   
62O3 Fetal maturity: dates = size                                                                                                                                                                           
62O4 Fetal maturity: dates not=size                                                                                                                                                                         
62O5 Spontaneous membrane rupture                                                                                                                                                                           
62O6 Vaginal show                                                                                                                                                                                           
62O7 Pregnancy prolonged - 41 weeks                                                                                                                                                                         
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62O8 Pregnancy prolonged - 42 weeks                                                                                                                                                                         
62O9 Initial booking of patient                                                                                                                                                                             
62OZ Misc. antenatal data NOS                                                                                                                                                                               
62U Downs screen - blood test                                                                                                                                                                              
62U0 Triple test offered                                                                                                                                                                                    
62U1 Double test offered                                                                                                                                                                                    
62U2 Triple test not offered                                                                                                                                                                                
62U3 Double test not offered                                                                                                                                                                                
62U4 Triple test wanted                                                                                                                                                                                     
62U5 Double test wanted                                                                                                                                                                                     
62U6 Triple test not wanted                                                                                                                                                                                 
62U7 Double test not wanted                                                                                                                                                                                 
62U8 Downs screening - blood sent                                                                                                                                                                           
62U9 Downs screen blood test normal                                                                                                                                                                         
62UA Downs screen blood test abnormal                                                                                                                                                                       
62Uz Downs screening blood test NOS                                                                                                                                                                         
62V Delivery place planned                                                                                                                                                                                 
62V0 Home delivery planned                                                                                                                                                                                  
62W Antenatal blood tests                                                                                                                                                                                  
62X Length of gestation                                                                                                                                                                                    
62X0 Gestation <24 weeks                                                                                                                                                                                    
62X1 Gestation = 24 weeks                                                                                                                                                                                   
62X2 Gestation >24 weeks                                                                                                                                                                                    
62X3 Full term gestation - 40 weeks                                                                                                                                                                         
62X4 Length of gestation at birth                                                                                                                                                                           
62X5 Length of gestation at time of test                                                                                                                                                                    
62Y Routine antenatal care                                                                                                                                                                                 
62Z Maternal care NOS                                                                                                                                                                                      
62c0 Crown rump length                                                                                                                                                                                      
 
Affective disorders 
E200 Anxiety states 
E2000 Anxiety state unspecified 
E2001 Panic disorder 
E2002 Generalised anxiety disorder 
E2003 Anxiety with depression 
E2004 Chronic anxiety 
E2005 Recurrent anxiety 
E200z Anxiety state NOS 
Eu41 [X]Other anxiety disorders 
Eu410 [X]Panic disorder [episodic paroxysmal anxiety] 
Eu411 [X]Generalized anxiety disorder 
Eu412 [X]Mixed anxiety and depressive disorder 
Eu413 [X]Other mixed anxiety disorders 
Eu41y [X]Other specified anxiety disorders 
Eu41z [X]Anxiety disorder, unspecified 
Eu32 [X]Depressive episode 
Eu320 [X]Mild depressive episode 
Eu321 [X]Moderate depressive episode 
Eu322 [X]Severe depressive episode without psychotic symptoms 
Eu323 [X]Severe depressive episode with psychotic symptoms 
Eu324 [X]Mild depression 
Eu32y [X]Other depressive episodes 
Eu32z [X]Depressive episode, unspecified 
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Eu33 [X]Recurrent depressive disorder 
Eu330 [X]Recurrent depressive disorder, current episode mild 
Eu331 [X]Recurrent depressive disorder, current episode moderate 
Eu332 [X]Recurrent depressive disorder, current episode severe without psychotic symptoms 
Eu333 [X]Recurrent depressive disorder, current episode severe with psychotic symptoms 
Eu334 [X]Recurrent depressive disorder, currently in remission 
Eu33y [X]Other recurrent depressive disorders 
Eu33z [X]Recurrent depressive disorder, unspecified 
Eu34 [X]Persistent mood affective disorders 
Eu340 [X]Cyclothymia 
Eu341 [X]Dysthymia 
Eu34y [X]Other persistent mood affective disorders 
Eu34z [X]Persistent mood affective disorder, unspecified 
Eu3y [X]Other mood affective disorders 
Eu3y0 [X]Other single mood affective disorders 
Eu3y1 [X]Other recurrent mood affective disorders 




C04..  Hypothyroidism 
C040.00 Postsurgical hypothyroidism 
C041.00 Other postablative hypothyroidism 
C041000 Irradiation hypothyroidism 
C041z00 Postablative hypothyroidism NOS 
C042.00 Iodine hypothyroidism 
C043.00 Other iatrogenic hypothyroidism 
C043000 Hypothyroidism resulting from para-aminosalicylic acid 
C043100 Hypothyroidism resulting from phenylbutazone 
C043200 Hypothyroidism resulting from resorcinol 
C043z00 Iatrogenic hypothyroidism NOS 
C044.00 Postinfectious hypothyroidism 
C045.00 Acquired atrophy of thyroid 
C046.00 Autoimmune myxoedema 
C047.00 Subclinical hypothyroidism 
C04y.00  Other acquired hypothyroidism 
C04z.00  Hypothyroidism NOS 
C04z000 Premature puberty due to hypothyroidism 
C04z100 Myxoedema coma 
1432.00  H/O: hypothyroidism 
C04..00  Acquired hypothyroidism 
C03y000 Congenital hypothyroidism with diffuse goitre 
C03y100 Congenital hypothyroidism without goitre 
C03z.00  Congenital hypothyroidism NOS 
66BB.00 Hypothyroidism annual review 
9Oj..00  Hypothyroidism monitoring administration 
9Oj0.00  Hypothyroidism monitoring first letter 
9Oj1.00  Hypothyroidism monitoring second letter 
9Oj2.00  Hypothyroidism monitoring third letter 
9Oj3.00  Hypothyroidism monitoring verbal invite 
9Oj4.00  Hypothyroidism monitoring telephone invitation 
C0A5.00 Subclinical iodine-deficiency hypothyroidism 






C10E. Type 1 diabetes mellitus 
C10E0 Type 1 diabetes mellitus with renal complications 
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C10E1 Type 1 diabetes mellitus with ophthalmic complications 
C10E2 Type 1 diabetes mellitus with neurological complications 
C10E3 Type 1 diabetes mellitus with multiple complications 
C10E4 Unstable type 1 diabetes mellitus 
C10E5 Type 1 diabetes mellitus with ulcer 
C10E6 Type 1 diabetes mellitus with gangrene 
C10E7 Type 1 diabetes mellitus with retinopathy 
C10E8 Type 1 diabetes mellitus - poor control 
C10E9 Type 1 diabetes mellitus maturity onset 
C10EA Type 1 diabetes mellitus without complication 
C10EB Type 1 diabetes mellitus with mononeuropathy 
C10EC Type 1 diabetes mellitus with polyneuropathy 
C10ED Type 1 diabetes mellitus with nephropathy 
C10EE Type 1 diabetes mellitus with hypoglycaemic coma 
C10EF Type 1 diabetes mellitus with diabetic cataract 
C10EG Type 1 diabetes mellitus with peripheral angiopathy 
C10EH Type 1 diabetes mellitus with arthropathy 
C10EJ Type 1 diabetes mellitus with neuropathic arthropathy 
C10EK Type 1 diabetes mellitus with persistent proteinuria 
C10EL Type 1 diabetes mellitus with persistent microalbuminuria 
C10EM Type 1 diabetes mellitus with ketoacidosis 
C10EN Type 1 diabetes mellitus with ketoacidotic coma 
C10EP Type 1 diabetes mellitus with exudative maculopathy 
C10EQ Type 1 diabetes mellitus with gastroparesis 
C10ER Latent autoimmune diabetes mellitus in adult 
 
C10F Type 2 diabetes mellitus 
C10F0 Type 2 diabetes mellitus with renal complications 
C10F1 Type 2 diabetes mellitus with ophthalmic complications 
C10F2 Type 2 diabetes mellitus with neurological complications 
C10F3 Type 2 diabetes mellitus with multiple complications 
C10F4 Type 2 diabetes mellitus with ulcer 
C10F5 Type 2 diabetes mellitus with gangrene 
C10F6 Type 2 diabetes mellitus with retinopathy 
C10F| Type 2 diabetes mellitus - poor control 
C10F8 Reaven's syndrome 
C10F9 Type 2 diabetes mellitus without complication 
C10FA Type 2 diabetes mellitus with mononeuropathy 
C10FB Type 2 diabetes mellitus with polyneuropathy 
C10F| Type 2 diabetes mellitus with nephropathy 
C10FD Type 2 diabetes mellitus with hypoglycaemic coma 
C10FE Type 2 diabetes mellitus with diabetic cataract 
C10FF Type 2 diabetes mellitus with peripheral angiopathy 
C10FG Type 2 diabetes mellitus with arthropathy 
C10FH Type 2 diabetes mellitus with neuropathic arthropathy 
C10FJ Insulin treated Type 2 diabetes mellitus 
C10FK Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C10FL Type 2 diabetes mellitus with persistent proteinuria 
C10FM Type 2 diabetes mellitus with persistent microalbuminuria 
C10FN Type 2 diabetes mellitus with ketoacidosis 
C10FP Type 2 diabetes mellitus with ketoacidotic coma 
C10FQ Type 2 diabetes mellitus with exudative maculopathy 
C10FR Type 2 diabetes mellitus with gastroparesis 
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N10 Inflammatory spondylopathies                                                                                                                                                                           
N100 Ankylosing spondylitis                                                                                                                                                                                 
N101 Spinal enthesopathy                                                                                                                                                                                    
N102 Sacroiliitis NEC                                                                                                                                                                                       
N10y Other inflammatory spondylopathies                                                                                                                                                                     
N10y0 Inflammatory spondylopathies in diseases EC                                                                                                                                                            
N10yz Other inflammatory spondylopathies NOS                                                                                                                                                                 
N10z Spondylitis NOS                                                                                                                                                                                        
N04 Inflammatory polyarthropathy                                                                                                                                                                           
N040 Rheumatoid arthritis                                                                                                                                                                                   
N0400 Rheumatoid arthritis of cervical spine                                                                                                                                                                 
N0401 Other rheumatoid arthritis of spine                                                                                                                                                                    
N0402 Rheumatoid arthritis of shoulder                                                                                                                                                                       
N0403 Rheumatoid arthritis of sternoclavicular joint                                                                                                                                                         
N0404 Rheumatoid arthritis of acromioclavicular joint                                                                                                                                                        
N0405 Rheumatoid arthritis of elbow                                                                                                                                                                          
N0406 Rheumatoid arthritis of distal radio-ulnar joint                                                                                                                                                       
N0407 Rheumatoid arthritis of wrist                                                                                                                                                                          
N0408 Rheumatoid arthritis of metacarpophalangeal joint                                                                                                                                                      
N0409 Rheumatoid arthritis of proximal interphalangeal joint of finger                                                                                                                                       
N040A Rheumatoid arthritis of distal interphalangeal joint of finger                                                                                                                                         
N040B Rheumatoid arthritis of hip                                                                                                                                                                            
N040C Rheumatoid arthritis of sacro-iliac joint                                                                                                                                                              
N040D Rheumatoid arthritis of knee                                                                                                                                                                           
N040E Rheumatoid arthritis of tibio-fibular joint                                                                                                                                                            
N040F Rheumatoid arthritis of ankle                                                                                                                                                                          
N040G Rheumatoid arthritis of subtalar joint                                                                                                                                                                 
N040H Rheumatoid arthritis of talonavicular joint                                                                                                                                                            
N040J Rheumatoid arthritis of other tarsal joint                                                                                                                                                             
N040K Rheumatoid arthritis of 1st metatarsophalangeal joint                                                                                                                                                  
N040L Rheumatoid arthritis of lesser metatarsophalangeal joint                                                                                                                                               
N040M Rheumatoid arthritis of interphalangeal joint of toe                                                                                                                                                   
N040N Rheumatoid vasculitis                                                                                                                                                                                  
N040P Seronegative rheumatoid arthritis                                                                                                                                                                      
N040Q Rheumatoid bursitis                                                                                                                                                                                    
N040R Rheumatoid nodule                                                                                                                                                                                      
N040S Rheumatoid arthritis - multiple joint                                                                                                                                                                  
N040T Flare of rheumatoid arthritis                                                                                                                                                                          
N041 Felty's syndrome                                                                                                                                                                                       
N042 Other rheumatoid arthropathy with visceral or systemic involvement                                                                                                                                     
N0420 Rheumatic carditis                                                                                                                                                                                     
N0421 Rheumatoid lung disease                                                                                                                                                                                
N0422 Rheumatoid nodule                                                                                                                                                                                      
N042z Rheumatoid arthropathy with visceral or systemic involvement NOS                                                                                                                                       
N043 Juvenile rheumatoid arthritis - Still's disease                                                                                                                                                        
N0430 Juvenile rheumatoid arthropathy unspecified                                                                                                                                                            
N0431 Acute polyarticular juvenile rheumatoid arthritis                                                                                                                                                      
N0432 Pauciarticular juvenile rheumatoid arthritis                                                                                                                                                           
N0433 Monarticular juvenile rheumatoid arthritis                                                                                                                                                             
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N043z Juvenile rheumatoid arthritis NOS                                                                                                                                                                      
N044 Chronic post-rheumatic arthropathy                                                                                                                                                                     
N045 Other juvenile arthritis                                                                                                                                                                               
N0450 Juvenile ankylosing spondylitis                                                                                                                                                                        
N0451 Juvenile seronegative polyarthritis                                                                                                                                                                    
N0452 Juvenile arthritis in psoriasis                                                                                                                                                                        
N0453 Juvenile arthritis in Crohn's disease                                                                                                                                                                  
N0454 Juvenile arthritis in ulcerative colitis                                                                                                                                                               
N0455 Juvenile rheumatoid arthritis                                                                                                                                                                          
N0456 Pauciarticular onset juvenile chronic arthritis                                                                                                                                                        
N047 Seropositive errosive rheumatoid arthritis                                                                                                                                                             
N04X Seropositive rheumatoid arthritis, unspecified                                                                                                                                                         
N04y Other specified inflammatory polyarthropathy                                                                                                                                                           
N04y0 Rheumatoid lung                                                                                                                                                                                        
N04y1 Sero negative arthritis                                                                                                                                                                                
N04y2 Adult-onset Still's disease                                                                                                                                                                            
N04y3 Remitting seronegative symmetrical synovitis with pitting oedema                                                                                                                                       
N04yz Other specified inflammatory polyarthropathy NOS                                                                                                                                                       
N04z Inflammatory polyarthropathy NOS                                                                                                                                                                       
 
Neck and upper limb conditions 
Read Code Term 
16A Stiff neck symptom 
16A1 No stiff neck 
16A2 Stiff neck 
16A3 Torticollis - symptom 
16A3 Wry neck symptom 
16A3 Wry neck/torticollis 
16AZ Stiff neck symptom NOS 
EGTON309 Sore Neck 
EMISR4QFU
1 
Fusion Of Cervical Spine 
N0400 Rheumatoid arthritis-Cx spine 
N110 Cervical spond.- no myelopathy 
N110 Cervical spond.-no myelopathy 
N110 Cervical spondylosis 
N110 Cervical spondylosis without myelopathy 
N110 Osteoarthritis cervical spine 
N1100 One lev Cx spondyl-no myelop 
N1101 Two lev Cx spondyl-no myelop 
N1102 Mult lev Cx spondyl-no myelop 
N111 Cervical spond.+ myelopathy 
N111 Cervical spond.with myelopathy 
N111 Cervical spondylosis with myelopathy 
N1110 One lev Cx spondyl + myelop 
N1111 Two lev Cx spondyl + myelop 
N1112 Mult lev Cx spondyl + myelop 
N1113 Cervical myelopathy 
N119 Cervical spondylosis with radiculopathy 
N119 Cx spondylosis + radiculopathy 
N1190 One lev Cx spondyl + radiculop 
N1191 Two lev Cx spondyl + radiculop 
N1192 Mult lev Cx spondyl+radiculop 
N11A Cx spondyl + vasc compression 
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N11D0 Osteoarthritis of cervical spine 
N11E Cervical spondylosis 
N120 Cervical disc displ.-no myelop 
N120 Cervical disc displacement 
N120 PID - prol cerv disc,no myelop 
N120 PID - prol cerv discno myelop 
N125 Cervical disc degeneration 
N1291 Cervical disc disord.+myelop. 
N12A1 Cervical postlaminectomy syndr 
N12B0 Cx disc prolapse + myelopathy 
N12C0 Cx disc prolapse+radiculopathy 
N12z1 Other cervical disc disorders 
N12z4 Cervical discitis 
N12z5 Annular tear of cervical disc 
N12z6 Resorption of cervical disc 
N12z7 Calcification of cervical disc 
N12zH Cerv disc disord + radiculopth 
N12zH Cervical disc disorder with radiculopathy 
N13 Cervical disorder NOS 
N13 Other cervical disorders 
N130 Cervical spinal stenosis 
N1300 Idiopathic Cx spinal stenosis 
N1301 Degenerativ Cx spinal stenosis 
N1302 Iatrogenic Cx spinal stenosis 
N1303 Cx spin stenos due to oth dis 
N131 Cervicalgia 
N131 Cervicalgia - pain in neck 
N131 Pain in cervical spine 
N135 Torticollis unspecified 
N1350 Intermittent torticollis 
N1351 Rheumatic torticollis 
N135z Stiff neck NOS 
N135z Torticollis NOS 
N135z Wry neck 
N136 Panniculitis of neck 
N137 Cervical post.long.lig.ossific 
N138 Cervicalgia 
N13y Other cervical syndromes 
N13y0 Cervical syndrome NEC 
N13y1 Klippel's disease 
N13y2 Crick in neck 
N13y3 Cervical root syndrome 
N13yz Other cervical syndromes NOS 
N13z Cervical and neck disorders NOS 
N13z Cervical/neck disorder NOS 
N1480 Atlanto-occipital ankylosis 
N1481 Atlanto-axial ankylosis 
N1482 Cervical spine ankylosis 
N1487 Atlanto-occipital instability 
N1488 Atlanto-axial instability 
N1489 Cervical spine instability 
N1y0 Rec atlantoax subl + myelopath 
N2300 Infective myositis-neck 
N230B Muscle abscess-neck 
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N2405 Fibrositis of neck 
N300A Acute osteomyelitis-cerv spine 
N301A Chronic osteomyelitis-Cx spine 
N301F Brodie's abscess-cervic spine 
N302A Infection of cervical spine 
N303A Periostitis, no osteomye-Cx sp 
N3040 Tuberculosis of cervical spine 
N3080 Subacute osteomyelitis-Cx spin 
N3100 Paget's disease-cervical spine 
N331A Osteopor path # cerv vertebrae 
N331C Pathological # cervical vert 
N331E Collapse of cervical vertebra 
N331H Collap cerv vert due to osteop 
N382 Acquired deformity of neck 
N391 Nonallopathic lesion-cervical 
Nyu57 [X]O recur atlantoaxl subluxtn 
Nyu70 [X]Oth cervicl disc displacmnt 
Nyu71 [X]Oth cervicl disc degeneratn 
Nyu72 [X]Oth cervical disc disorders 
Nyu7B [X]Cervical disc disord, unsp 
OX7131A Osteoarthrosis Cervical Spine /ox 
OX7280AD Pain Neck /ox 
R042 [D]Neck swelling/mass/lump 
S100 Closed # cervical spine 
S100 Closed fracture of cervical spine 
S1000 Clsd # unsp cerv vertebra 
S1001 Closed fracture atlas 
S1002 Closed fracture axis 
S1003 Clsd # third cerv vertebra 
S1004 Clsd # fourth cerv vertebra 
S1005 Clsd # fifth cerv vertebra 
S1006 C6 closed # - no cord lesion 
S1006 Clsd # sixth cerv vertebra 
S1007 C7 closed # - no cord lesion 
S1007 Clsd # seventh cerv vertebra 
S1008 Cls # atlas-isol arch/art prcs 
S1009 Clsd # atlas, comminuted 
S100A Clsd # axis odontoid process 
S100A Clsd # axis, odontoid process 
S100B Clsd # axis, spondylolysis 
S100C Clsd # axis, spinous process 
S100D Clsd # axis, transvrse process 
S100E Clsd # axis, posterior arch 
S100F Clsd # axis, tricolumnar 
S100G Clsd # cerv vert, burst 
S100H Clsd # cerv vert, wedge 
S100J Cls # cerv vert, spondylolysis 
S100K Cls # cerv vert, spinous prcss 
S100L Cls # cerv vert, trnsvrse prcs 
S100M Cls # cerv vert, post arch 
S100N Cls # cerv vert, tricolumnar 
S100x Multiple clsd # cerv vert 
S100z Clsd # cerv spine NOS 
S101 Open fracture cervical spine 
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S1010 Open # unsp cerv vertebra 
S1011 Open fracture atlas 
S1012 Open fracture axis 
S1013 Open # third cerv vertebra 
S1014 Open # fourth cerv vertebra 
S1015 Open # fifth cerv vertebra 
S1016 Open # sixth cerv vertebra 
S1017 Open # seventh cerv vert 
S1018 Opn # atlas-isol arch/art prcs 
S1019 Open # atlas, comminuted 
S101A Open # axis, odontoid prcss 
S101B Open # axis, spondylolysis 
S101C Open # axis, spinous procss 
S101D Opn # axis, trnsvrse process 
S101E Open # axis, posterior arch 
S101F Open # axis, tricolumnar 
S101G Open # cerv vert, burst 
S101H Open # cerv vert, wedge 
S101J Opn # cerv vert, spondylolysis 
S101K Opn # cerv vert, spinous prcs 
S101L Opn # cerv vert, trnsvrse prcs 
S101M Opn # cerv vert, post arch 
S101N Opn # cerv vert, tricolumnar 
S101x Multiple open # cerv vert 
S101z Open # cerv spine NOS 
S10A Fracture of neck 
S10A0 Fracture/1st cervical vertebra 
S10A1 Fracture/2nd cervical vertebra 
S10A2 Multip fracture/cervical spin 
S10A2 Multip fracture/cervical spine 
S110 Closed cervical #+cord lesion 
S1100 Clsd # C1-C4 unspec cord les 
S1101 Clsd # C1-C4 complete cord les 
S1102 Clsd # C1-C4 ant cord lesion 
S1103 Clsd # C1-C4 cent cord lesion 
S1104 Clsd # C1-C4 post cord lesion 
S1105 Clsd # C1-C4 incomp cord les 
S1106 Clsd # C5-C7 unspec cord les 
S1107 Clsd # C5-C7 complete cord les 
S1108 Clsd # C5-C7 ant cord lesion 
S1109 Clsd # C5-C7 cent cord lesion 
S110A Clsd # C5-C7 post cord lesion 
S110B Clsd # C5-C7 incomp cord les 
S110z Closed cervical#+cord lesn.NOS 
S111 Open cervical #+cord lesion 
S1110 Op # C1-C4 unspec cord les 
S1111 Op # C1-4 compl cord lesion 
S1112 Op # C1-4 ant cord lesion 
S1113 Op # C1-4 cent cord lesion 
S1114 Op # C1-4 post cord lesion 
S1115 Op # C1-4 cord les. NOS 
S1116 Op # C5-7 unspec cord lesion 
S1117 Op # C5-7 compl cord lesion 
S1118 Op # C5-7 anterior cord les 
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S1119 Op # C5-7 central cord les 
S111A Op # C5-7 posterior cord lesn 
S111B Op # C5-7 incomp cord les NOS 
S111z Open cervical#+cord lesion NOS 
S1250 Closed fracture larynx 
S1251 Closed #hyoid bone 
S1252 Closed #thyroid cartilage 
S1253 Closed #trachea 
S125z Closed #larynx/trachea NOS 
S126 Open # larynx and trachea 
S1260 Open fracture larynx 
S1261 Open #hyoid bone 
S1262 Open #thyroid cartilage 
S1263 Open #trachea 
S126z Open #larynx/trachea NOS 
S490 Closed dislocation cervical spine 
S490 Cls dslc cervical spine 
S4900 Closed disloc.cerv.spine unsp. 
S4901 Cls dslc atlanto-occipital jnt 
S4902 Cls dslc atlanto-axial joint 
S4903 Closed dislocation C2/C3 
S4904 Closed dislocation C3/C4 
S4905 Closed dislocation C4/C5 
S4906 Closed dislocation C5/C6 
S4907 Closed dislocation C6/C7 
S4908 Closed dislocation C7/T1 
S4909 Cl spnl dslc+cerv crd lsn,unsp 
S490A Cl spnl dslc+comp cerv crd lsn 
S490B Cls spnl dslc+ant cerv crd lsn 
S490C Cl spn dslc+cntrl cerv crd lsn 
S490D Cls spn dslc+post cerv crd lsn 
S490x Closed disloc.mult.cerv.vert. 
S490z Closed disloc.cervic.vert.NOS 
S491 Open dislocation of neck 
S4910 Open disloc.cerv.spine unspec. 
S4911 Open dslc atlanto-occipital jt 
S4912 Open dslc atlanto-axial jt 
S4913 Open dislocation C2/C3 
S4914 Open dislocation C3/C4 
S4915 Open dislocation C4/C5 
S4916 Open dislocation C5/C6 
S4917 Open dislocation C6/C7 
S4918 Open dislocation C7/T1 
S4919 Opn spnl dsl+cerv crd lsn,unsp 
S491A Opn spn dslc+comp cerv crd lsn 
S491B Opn spnl dslc+ant cerv crd lsn 
S491C Opn spn dslc+ctrl cerv crd lsn 
S491D Opn spnl dsl+post cerv crd lsn 
S491x Open disloc.mult.cerv.vertebra 
S491z Open disloc.cervical vert.NOS 
S4965 Cls trm dslc laryngl cartilage 
S4975 Opn dslc laryngl cartilage 
S498 Cls sublux cervical spine 
S4980 Cls sublux cervical spine,unsp 
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S4981 Cls sublux atlanto-occiptl jt 
S4982 Cls sublux atlanto-axial jt 
S4983 Closed subluxation C2/C3 
S4984 Closed subluxation C3/C4 
S4985 Closed subluxation C4/C5 
S4986 Closed subluxation C5/C6 
S4987 Closed subluxation C6/C7 
S4988 Closed subluxation C7/T1 
S4989 Cl spn sublx+cerv crd lsn,unsp 
S498A Cl spn sublx+comp cerv crd lsn 
S498B Cl spn sublux+ant cerv crd lsn 
S498C Cl spn sublx+cntrl crv crd lsn 
S498D Cl spn sublux+post crv crd lsn 
S498x Cls sublux mlti cerv vertebrae 
S498z Cls sublux cerv vertebra NOS 
S499 Open sublux cerv spine 
S4990 Open sublux cerv spine, unsp 
S4991 Opn sublux atlanto-occipitl jt 
S4992 Open sublux atlanto-axial jt 
S4993 Open subluxation C2/C3 
S4994 Open subluxation C3/C4 
S4995 Open subluxation C4/C5 
S4996 Open subluxation C5/C6 
S4997 Open subluxation C6/C7 
S4998 Open subluxation C7/T1 
S4999 Op spn sublx+cerv crd lsn,unsp 
S499A Op spn sublx+comp cerv crd lsn 
S499B Op spn sublux+ant cerv crd lsn 
S499C Op spn sublx+cntrl crv crd lsn 
S499D Op spn sublux+post crv crd lsn 
S499x Opn sublux mlti cerv vertebrae 
S499z Opn sublux cerv vertebra NOS 
S49E5 Cls trm sublux laryngl cart 
S49F5 Opn trm sublux laryngl cartlge 
S570 Neck sprain 
S570 Sprained neck 
S5700 Neck sprain unspecified 
S5700 Torticollis - traumatic 
S5700 Whiplash injury 
S5701 Cervical ant.longit.lig.sprain 
S5702 Atlanto-axial joint sprain 
S5703 Atlanto-occipital joint sprain 
S5704 Whiplash injury 
S570z Neck sprain NOS 
S5E1 Cmplt tr,thyroid region lgmt 
S5N0 Open dvsn, neck ligament 
S5P1 Opn dvsn,thyroid region lgmt 
S5P10 Opn dvsn,cricoarytenoid lgmt 
S5P11 Opn dvsn,cricothyroid ligament 
S5P12 Opn dvsn,thyroid cartilge lgmt 
S5P1z Opn dvsn,thyroid regn lgmt NOS 
S84 Open wound of neck 
SC010 Late effect # cervic vertebra 
SD0 Superficial Injury: Neck 





SF021 Crush injury larynx 
SJ30 Cervical nerve root injury 
SJ30 Cervicalnerverootinjury 
SJ303 Cervical nerve root injury - C4 
SJ304 Cervical nerve root injury - C5 
SJ305 Cervical nerve root injury - C6 
SJ306 Cervical nerve root injury - C7 
SK10y Other neck injuries 
SK10y Otherneckinjuries 
SK10z OtherfaceandneckinjuriesNOS 
Syu1 [X]Injuries to the neck 
Syu12 [X]Superf inj neck part unsp 
Syu15 [X]Fract oth spec cervic vert 
Syu16 [X]Fracture other parts neck 
Syu17 [X]Disloc oth unsp parts neck 
Syu18 [X]Spr/str jt/lg ot/un pt neck 
14G8 H/O: vertebral fracture 
N111 Vertebral artery compr.syndr. 
N148 Ankylosis/instab Cx,Th,Lu spin 
S1 Fracture of neck and trunk 
S1z Fracture of neck and trunk NOS 
N1483 Cervico-thoracic ankylosis 
N148A Cervico-thoracic instability 
N133 Cervicobrachial syndrome 
N132 Cervicocranial syndrome 
R04 [D]Head and neck symptoms 
R042 [D]Swell.masslump head/neck 
R0420 [D]Swelling in head or neck 
R04z [D]Head and neck other sympt. 
R04zz [D]Head and neck symptoms NOS 
S8 Open wound head/neck/trunk 
S8 Open wound of head neck and trunk 
S8z Open wound head/neck/trunk NOS 
SE0z Contusion face scalp+neck NOS 
SK10z Other face and neck injuries NOS 
SK10z Other face/neck injuries NOS 
SR10 Fracture involv head with neck 
SR100 Cls fract invol head with neck 
SR101 Op fract invol head with neck 
SR20 Disloc,sprns+strns inv hd+neck 






1D12 C/O: stiffness 
1DCC Aching muscles 
N04y1 Sero negative arthritis 
N05 Osteoarthritis 
N050 Generalised osteoarthritis - OA 
N0500 Generalised OA-site unspecif. 
N0502 Generalised OA-multiple sites 
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N0504 Primary general osteoarthrosis 
N0505 Secondary multiple arthrosis 
N050z Generalised osteoarthritis NOS 
N05z Joint degeneration 
N05z0 Osteoarthritis NOS-site unspec 
N05z8 Osteoarthritis - other joint 
N05zz Osteoarthritis NOS 
N06 Other/unspecif. arthropathies 
N063 Menopausal arthritis 
N0630 Climacteric arthr.-site unsp. 
N0638 Climacteric arthr.-other spec. 
N0639 Climacteric arthr.-multip.site 
N063z Climacteric arthr.-NOS 
N065 Polyarthropathy NEC 
N0650 Unsp.polyarthr.-site unspecif. 
N0658 Unsp.polyarthr.-other specif. 
N0659 Unsp.polyarthr.-multiple site 
N065A Generalised arthritis 
N065z Polyarthritis 
N2y Nonarticular rheumatism OS 
N2z Nonarticular rheumatism NOS 
N06z Arthritis 
N06z0 Arthropathy NOS-site unspecif. 
N06z8 Arthropathy NOS-other specif. 
N06z9 Arthropathy NOS-multiple sites 
N06zB Chronic arthritis 
N06zz Arthropathy NOS 
N09 Other/unspecif.joint disorders 
N094 Ache in joint 
N0940 Arthralgia - site unspecified 
N0948 Arthralgia - other specified 
N0949 Arthralgia of multiple joints 
N094z Arthralgia NOS 
N095 Joint stiffness NEC 
N0950 Stiff joint NEC-site unspecif. 
N0958 Stiff joint NEC-other specif. 
N0959 Multiple stiff joints 
N095z Joint stiffness NEC NOS 
N096 Musculoskeletal pain - joints 
N0968 Other joint sympt.-other spec. 
N0969 Other joint sympt.-multip.site 
N096z Other joint symptoms NOS 
N09y Other spec. joint disorders 
N09y0 Other joint dis.-site unspec. 
N09y8 Other joint dis.-other specif. 
N09y9 Other joint dis.-multiple site 
N09yz Other joint disorders NOS 
N09z Joint disorders NOS 
N09zz Joint disorders NOS 
N0z Arthropathies NOS 
N2 Rheumatism, excl.the back 
N22yz Other tendon disorder NOS 
N22z Synovium/tendon/bursa dis.NOS 
N23 Muscle/ligament/fascia disord. 
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N233z Other specif.musc.disorder NOS 
N239 Fibromyalgia 
N23y Other muscle/ligament/fascia 
N23yz Other musc./lig./fasc.dis.NOS 
N23z Muscle/ligament/fascia dis.NOS 
N24 Other soft tissue disorders 
N240 Rheumatism/fibrositis unspecif 
N2400 Rheumatism unspecified 
N2401 Fibrositis unspecified 
N2402 Muscular rheumatism 
N2403 Rheumatic pain 
N240z Rheumatism/fibrositis NOS 
N241 Myalgia/myositis unspecified 
N2410 Muscle pain 
N2411 Myositis unspecified 
N2412 Fibromyositis NOS 
N241z Myalgia/myositis NOS 
N247 Other musculoskel.limb sympts. 
N248 Fibromyalgia 
N24z Polyalgia 
N09z0 Joint disord.NOS-site unspecif 
 
Tendonitis / epicondylitis 
Read Code Term 
N21z2 Tendonitis NOS                                                                                                                                                                                         
N2125 Shoulder tendonitis                                                                                                                                                                                    
MHTBAGO1 Golfers Elbow-Epicondylitis 
N2131 Medial epicondylitis of the elbow                                                                                                                                                                      
N2131 Golfer's elbow 
N2131 Medial epicondylitis - elbow 
N2131 Medial epicondylitis of the elbow 
N2132 Lateral epicondylitis of the elbow                                                                                                                                                                     
N2132 Lateral epicondylitis - elbow 
N2132 Lateral epicondylitis of the elbow 
N2132 Tennis elbow 
N2132 Tennis elbow - epicondylitis 
N21z2 Tendonitis adductor                                                                                                                                                                                    
N21z2 Tendonitis bicepital                                                                                                                                                                                   
N2205 Tendonitis of thumb                                                                                                                                                                                    
 
Previous wrist trauma 
Read Code Term 
SK132 Otherwristinjuries 
SK133 Unspecified injury of wrist 
SK133 Unspecifiedinjuryofwrist 
Syu63 [X]Fract other carpal bone(s) 
UNMAPPC4 Wrist injury 
S242 Fracture at wrist and hand level 
S242 Fracture/wrist and hand level 
S52 Sprain of wrist and hand 
S52 Sprain wrist/hand 
S524 Sprain tendon wrist or hand 
S52z Wrist and hand sprain NOS 
S52z Wrist/hand sprain NOS 
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S5A Complete tear, wrist or hand 
S5Az Complete tear wrist/hand NOS 
S5H Open division wrist/hand lgmt 
S5Hz Open dvsn wrist/hand lig NOS 
S5Rz Rupture tendon hand/wrist NOS 
SE32 Bruise - wrist/hand 
SE32 Contusion wrist or hand 
SE32z Contusion wrist and hand NOS 
SF22 Crush injury wrist or hand 
SJ528 Inj/ulnar nerve/wrist+hand lev 
SJ53 Radial nerve injury 
SJ534 Inj/radial nerv/wrist+hand lev 
Syu6 [X]Injuries to the wrist and hand 
Syu65 [X]Frac oth uns part wrist/hnd 
Syu66 [X]Spr/str ot/uns prt wris/hnd 
Syu6C [X]Inj int mus/tn ot finwt/hd 
Syu6M [X]Unsp injury wrist and hand 
Syu6M [X]Unspecified injury of wrist and hand 
 





925 Depo-medrone with lidocaine 40mg/ml+10mg/ml Injection (Pharmacia Ltd) 
1133 Depo-medrone 40mg/ml Injection (Pharmacia Ltd) 
14982 Depo-Medrone 40mg/1ml suspension for injection vials (Pfizer Ltd) 
7405 Depo-Medrone with Lidocaine suspension for injection 1ml vials (Pfizer Ltd) 
16583 Kenalog Intra-articular / Intramuscular 40mg/1ml suspension for injection vials (Bristol-Myers 
Squibb Pharmaceuticals Ltd) 
20157 Depo-Medrone with Lidocaine suspension for injection 2ml vials (Pfizer Ltd) 
1893 Hydrocortistab 25mg/1ml suspension for injection ampoules (Amdipharm Plc) 
768 Kenalog 40mg/ml Injection (E R Squibb and Sons Ltd) 
8864 Adcortyl 10mg/ml Intraarticular / intradermal injection (E R Squibb and Sons Ltd) 
27413 Depo-Medrone 80mg/2ml suspension for injection vials (Pfizer Ltd) 
8108 Hydrocortisone acetate 25mg/1ml suspension for injection ampoules 
9026 Lederspan 20mg/ml Injection (Wyeth Pharmaceuticals) 
14335 Adcortyl Intra-articular / Intradermal 10mg/1ml suspension for injection ampoules (Bristol-Myers 
Squibb Pharmaceuticals Ltd) 
18660 Deltastab 25mg/1ml suspension for injection ampoules (Amdipharm Plc) 
4123 Kenalog 40mg/ml Intraarticular injection (E R Squibb and Sons Ltd) 
3703 Kenalog 80mg/2ml Intramuscular injection (E R Squibb and Sons Ltd) 
33132 Methylprednisolone acetate 40mg/1ml suspension for injection vials 
16582 Triamcinolone acetonide 40mg/ml suspension for injection 
4488 Triamcinolone acetonide 40mg/ml IA/IM 
5493 Methylprednisolone acetate 40mg/ml Injection 
4687 Methylprednisolone acetate with lidocaine 40mg/ml + 10mg/ml Injection 
35156 Methylprednisolone 40mg/1ml / Lidocaine 10mg/1ml (1%) suspension for injection vials 
35040 Depo-Medrone 120mg/3ml suspension for injection vials (Pfizer Ltd) 
14906 Dexamethasone 4mg/1ml solution for injection ampoules 
35349 Methylprednisolone acetate 80mg/2ml suspension for injection vials 
35154 Methylprednisolone 80mg/2ml / Lidocaine 20mg/2ml (1%) suspension for injection vials 
48406 Triamcinolone acetonide 40mg/1ml suspension for injection vials 
14958 Triamcinolone acetonide 10mg/1ml suspension for injection ampoules 
14962 Adcortyl Intra-articular / Intradermal 50mg/5ml suspension for injection vials (Bristol-Myers 
Squibb Pharmaceuticals Ltd) 
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4233 Dexamethasone sodium phosphate 4mg/ml injection 
4125 Triamcinolone acetonide 80mg/2ml intramuscular injection 
11123 Triamcinolone acetonide 10mg/ml IA/ID 
16815 Triamcinolone hexacetonide 20mg/ml Injection 
9368 Triamcinolone acetonide 10mg/ml IA/ID 
7992 Lederspan 5mg/ml Injection (Wyeth Pharmaceuticals) 
8306 Prednisolone 25mg/1ml suspension for injection ampoules 
13981 Adcortyl 10mg/ml Intradermal injection (E R Squibb and Sons Ltd) 
35688 Methylprednisolone acetate 120mg/3ml suspension for injection vials 
13972 Dexamethasone sodium phosphate 5mg/ml injection 
30244 Triamcinolone acetonide 40mg/ml injection 
13952 Decadron 4mg/ml Injection (MSD Thomas Morson Pharmaceuticals) 
14188 Methylprednisolone sodium succinate 500mg powder and solvent for solution for injection vials 
35453 Dexamethasone 3.3mg/1ml solution for injection ampoules 
13397 Methylprednisolone sodium succinate 1g powder and solvent for solution for injection vials 
15717 Betamethasone 4mg/1ml solution for injection ampoules 
37500 Dexamethasone 6.6mg/2ml solution for injection vials 
22577 Betnesol 4mg/1ml solution for injection ampoules (Focus Pharmaceuticals Ltd) 
15016 Triamcinolone hexacetonide 5mg/ml Injection 
18266 Methylprednisolone sodium succinate 125mg powder and solvent for solution for injection vials 
11334 Dexamethasone sodium phosphate iv 4mg/ml injection 
25226 Solu-Medrone 125mg powder and solvent for solution for injection vials (Pfizer Ltd) 
23511 Solu-Medrone 40mg powder and solvent for solution for injection vials (Pfizer Ltd) 
10657 Dexamethasone sodium phosphate 4mg/ml intra-artic injection 
21540 Solu-Medrone 500mg powder and solvent for solution for injection vials (Pfizer Ltd) 
35578 Triamcinolone acetonide 50mg/5ml suspension for injection vials 
18765 Methylprednisolone sodium succinate 40mg powder and solvent for solution for injection vials 
25839 Solu-Medrone 1g powder and solvent for solution for injection vials (Pfizer Ltd) 
34083 Dexamethasone 5mg/ml Injection (Organon Laboratories Ltd) 
48746 Depo-Medrone 40mg/1ml suspension for injection vials (Mawdsley-Brooks & Company Ltd) 
31948 Dexamethasone 4mg/ml Injection (Mayne Pharma Plc 1) 
37737 Kenalog 40mg/ml Injection (E R Squibb and Sons Ltd) 
56940 Dexamethasone 6.6mg/2ml solution for injection ampoules 
48800 Depo-Medrone 40mg/1ml suspension for injection vials (Doncaster Pharmaceuticals Ltd) 
49076 Depo-Medrone with Lidocaine suspension for injection 1ml vials (Lexon (UK) Ltd) 
50253 Depo-Medrone with Lidocaine suspension for injection 1ml vials (Doncaster Pharmaceuticals Ltd) 
24224 Codelsol 16mg/ml Injection (MSD Thomas Morson Pharmaceuticals) 
48748 Depo-Medrone 40mg/1ml suspension for injection vials (Lexon (UK) Ltd) 
50734 Depo-Medrone with Lidocaine suspension for injection 1ml vials (Mawdsley-Brooks & Company 
Ltd) 
12405 Methylprednisolone sodium succinate 2g powder and solvent for solution for injection vials 
26454 Decadron 4mg/ml Injection (MSD Thomas Morson Pharmaceuticals) 
26299 Oradexon-organon 4mg/ml Intraarticular injection (Organon Laboratories Ltd) 
53173 Dexamethasone 4mg/1ml solution for injection ampoules (Merck Sharp & Dohme Ltd) 
 
Appendix 5: Referrals and investigations 
 
8H54 Orthopedic referral 
8H4B Referred to rheumatologist 
8HTd Referral to rheumatology clinic 
8HRE Referral for nerve conduction studies 
70652 Nerve conduction studies 
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1. Linkage to HES data could be considered as an additional means of identifying patients undergoing 
carpal tunnel release surgery in practices eligible for the linkage scheme or for the purposes of a 
sensitivity analysis. Should you decide to link to HES data, submission of an amendment will be required 
(see below). 
2. The study time period is 24 years during which time the management of carpal tunnel syndrome may 
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 Tables associated with figures displayed in chapter 3 
 Prevalence of carpal tunnel syndrome (n/10,000 person years) stratified by age and gender 
Prevalence of carpal tunnel syndrome (n/10,000 person years) stratified by age and gender 
Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Female 18-29 14.66 15.22 16.72 14.60 13.97 13.74 11.98 10.71 9.78 11.87 13.44 13.23 13.28 13.02 13.46 13.49 15.54 14.84 14.30 14.48 13.79 
Female 30-39 42.21 36.87 37.37 36.04 33.57 36.34 34.20 31.94 32.55 36.57 38.21 38.97 39.67 39.34 41.98 42.99 45.15 44.34 41.87 41.24 38.78 
Female 40-49 50.08 53.46 44.75 49.95 46.04 49.25 43.91 43.88 43.57 46.22 47.23 49.51 48.66 47.80 52.37 55.67 54.90 54.84 53.87 56.71 53.94 
Female 50-59 59.46 56.02 57.71 56.78 55.46 56.23 57.87 54.94 58.40 61.41 71.39 78.41 76.71 73.29 70.77 73.87 75.44 73.46 70.48 67.67 70.60 
Female 60-69 31.26 36.03 32.47 32.60 28.06 33.34 31.91 33.92 37.71 40.10 47.64 56.92 52.16 50.23 48.61 56.21 55.19 54.01 50.21 48.92 50.48 
Female 70+ 33.13 31.28 33.53 32.65 32.44 31.40 31.76 34.13 37.52 39.92 44.97 49.08 49.73 53.28 52.85 55.85 61.06 59.96 59.47 58.25 58.05 
Male18-29 5.04 4.00 3.93 4.00 3.55 2.78 2.88 2.42 2.74 2.80 3.22 3.69 3.34 3.31 3.95 3.70 3.41 3.76 4.36 4.21 4.12 
Male 30-39 9.95 11.02 11.36 11.19 11.11 10.60 8.61 10.32 10.78 11.75 12.00 13.06 12.23 11.57 11.30 11.78 12.17 12.94 11.67 12.29 12.55 
Male 40-49 15.85 17.59 17.65 15.30 16.00 16.33 16.73 16.81 17.71 20.15 20.18 22.04 20.02 18.45 21.06 23.14 22.93 24.87 23.06 23.21 22.58 
Male 50-59 18.72 21.66 21.08 20.23 20.36 19.03 19.51 19.64 22.12 24.46 25.71 26.68 26.55 26.62 28.09 29.90 31.06 30.86 31.16 28.64 32.01 
Male 60-69 17.64 19.92 16.22 16.78 15.68 17.62 19.27 19.99 22.91 23.93 24.61 29.08 28.71 28.87 30.73 31.59 34.81 31.41 31.71 34.84 34.75 
Male 70+ 20.95 24.12 22.16 21.69 23.71 23.65 22.11 25.86 27.93 28.43 31.65 34.51 37.91 37.76 39.16 43.19 44.93 45.60 46.33 46.05 49.14 
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Incidence of carpal tunnel syndrome (n/10,000 person years) stratified by age and gender 
Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Female 18-29 12.69 12.69 12.84 12.88 11.45 12.32 11.77 10.14 8.63 10.23 11.54 12.26 10.70 10.48 11.61 9.96 13.90 12.19 11.55 11.89 10.68 
Female 30-39 31.40 28.58 28.00 27.62 28.09 30.09 27.83 25.88 27.18 28.31 30.31 33.31 30.53 30.06 32.17 33.13 34.97 33.96 32.51 31.72 28.69 
Female 40-49 38.43 37.75 33.08 36.31 35.17 37.42 31.74 34.72 34.05 34.94 35.63 37.37 36.27 35.62 40.06 42.51 40.89 40.86 40.05 42.06 39.50 
Female 50-59 39.86 41.02 41.93 40.82 41.44 43.24 44.70 42.33 43.94 46.44 54.52 61.11 54.56 52.25 58.55 54.70 56.14 54.10 51.62 50.07 50.97 
Female 60-69 25.54 29.79 24.64 25.70 25.08 26.41 26.43 26.86 30.23 32.54 39.12 46.20 38.44 36.30 31.00 42.47 42.24 41.87 37.74 35.80 37.32 
Female 70+ 24.45 22.29 24.21 25.28 26.17 25.09 25.25 27.67 29.29 32.87 34.96 39.57 37.78 39.60 39.13 41.89 46.03 44.89 44.46 42.29 43.53 
Male18-29 3.58 3.69 3.09 3.02 2.32 2.29 2.35 1.44 2.24 2.75 2.60 3.14 2.60 2.58 3.33 3.13 2.77 3.00 3.56 3.51 3.35 
Male 30-39 9.09 8.63 8.63 10.67 7.82 8.45 5.92 8.74 8.60 10.01 10.72 11.28 9.76 8.80 9.53 9.16 9.90 10.30 9.19 9.67 9.72 
Male 40-49 14.23 14.35 12.63 11.83 11.86 12.41 13.43 13.26 14.39 16.32 16.08 17.78 14.28 14.25 16.36 18.23 17.76 19.58 17.15 18.13 17.63 
Male 50-59 13.90 17.40 17.11 15.36 16.26 15.17 16.54 15.87 18.00 18.59 19.87 21.36 20.23 20.02 22.30 23.69 23.38 23.91 23.51 24.40 25.45 
Male 60-69 13.62 15.14 11.42 12.22 13.02 13.48 15.58 15.96 18.78 18.49 19.80 23.71 21.12 21.81 23.95 24.79 27.56 23.24 24.59 27.90 26.23 
Male 70+ 14.88 18.38 15.72 16.64 18.34 18.06 17.29 19.27 20.53 21.95 24.71 27.24 27.92 26.94 29.67 31.84 33.81 32.52 33.23 33.78 33.83 
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 Joinpoint analysis plot of the age and gender standardised incidence of carpal tunnel syndrome between 1993 and 2013 
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 Systematic review search terms  
Search Terms for Carpal Tunnel Syndrome 
1 carpal tunnel syndrome .mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, protocol supplementary concept, rare disease supplementary concept, unique identifier] 
2 CTS.mp. 
3 carpal channel mp. 
4 nerve compression*.mp. 
5 entrapment neuropath*.mp. 
6 nerve entrapment*.mp. 
7 hand pain.mp. 
8 wrist pain.mp. 
9 Or/1-8 
Medline Search Filter on OVIDsp for Epidemiology / Prognostic Studies  (from Centre Database) 
10 exp EPIDEMIOLOGY/ 
11 exp PROGNOSIS/  
12 exp DISEASE PROGRESSION/ 
13 predict$.mp. 
14 factor$.mp. 
15 risk$.mp.  
16 model$.mp. 















31 rate$.mp.  
32 occurrence$.mp. 









39 exp EPIDEMIOLOGIC STUDIES/ 
40 cohort$.mp. 
41 follow-up.mp. 
42 ("case control" or "case controlled").mp. 
43 retrospective$.mp. 
44 prospective$.mp. 




49 time series.mp. 
50 OR/39-49 
51 38 and 50 
EMBASE search filter on OVIDsp for Epidemiology / Prognostic Studies  (from Centre Database) 

















69 progress$.mp.  






73 exp COMPARATIVE STUDY/ or exp 
74 CONTROLLED STUDY/ or exp MODEL/ or OBSERVATIONAL STUDY/ or TREND STUDY/  
75 COHORT ANALYSIS/ or CORRELATIONAL STUDY/ or CROSS-SECTIONAL STUDY/ or exp DATA  
COLLECTION METHOD/ or EXPLORATORY RESEARCH/ or MULTIMETHOD STUDY/ or QUANTITATIVE 
STUDY/  
or SECONDARY ANALYSIS/  
76 cohort$.mp. 
77 follow-up.mp.  
78 ("case control" or "case controlled").mp. 
79 retrospective$.mp. 
80 prospective$.mp. 
81 (study or studies).mp. 




86 time series.mp. 
87 outcome$.mp. 
88 Or/73-87 
89 72 and 88 
Search Filter used by SIGN for RCTs for MEDLINE 
90  Randomized Controlled Trials as Topic/ 
91  randomized controlled trial/ 
92  Random Allocation/ 
93  Double Blind Method/ 
94  Single Blind Method/ 
95  clinical trial/ 
96  clinical trial, phase i.pt 
97  clinical trial, phase ii.pt 
98  clinical trial, phase iii.pt 
99  clinical trial, phase iv.pt 
100  controlled clinical trial.pt 
101  randomized controlled trial.pt 
102  multicenter study.pt 
103  clinical trial.pt 
104  exp Clinical Trials as topic/ 
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105  or/90-104 
106  (clinical adj trial$).tw 
107  ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw 
108  PLACEBOS/ 
109  placebo$.tw 
110  randomly allocated.tw 
111  (allocated adj2 random$).tw 
112  or/1106-111 
113  105 or 112 
114  case report.tw 
115  letter/ 
116  historical article/ 
117  or/114-116 
118  113 not 117 
Search Filter used by SIGN for RCTs for EMBASE 
119 Clinical trial/ 
120 Randomized controlled trial/ 
121 Randomization/ 
122 Single blind procedure/ 
123 Double blind procedure/ 
124 Crossover procedure/ 
125 Placebo/ 
126 Randomi?ed controlled trial$.tw. 
127 Rct.tw. 
128 Random allocation.tw. 
129 Randomly allocated.tw. 
130 Allocated randomly.tw. 
131 (allocated adj2 random).tw. 
132 Single blind$.tw. 
133 Double blind$.tw. 
134 ((treble or triple) adj (blind$).tw. 
135 Placebo$.tw. 
136 Prospective study/ 
137 Or/119-136 
138 Case study/ 
140 Case report.tw. 
141 Abstract report/ or letter/ 
142 Or/138-141 
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143 137 not 142 
   
332 
 
 Tables relating to the identification of candidate prognostic factors and predictors of treatment effect used in chapters 4 & 8 
  Table of candidate prognostic factors and predictors of treatment effect identified by GP's in response to a survey 
Suggested candidate prognostic factors of a good outcome from carpal 




Suggested candidate prognostic factors of a poor outcome from carpal 




Short history 15 Thenar muscle weakness or wasting 9 
No thenar muscle weakness or wasting 6 Longer symptom duration 8 
Non severe symptoms 5 Continuous numbness / symptoms 8 
Good work ethic 4 Unemployed / On sickness benefit / Off work because of CTS 7 
Nocturnal or wakening symptoms only 4 Greater symptom severity 5 
Acute onset 4 Underlying osteoarthritis 4 
Symptoms not related to work 3 Co-morbidity 4 
Postural symptoms only 3 Vague description of pain and paraesthesia / Diagnosis unclear 3 
Intermittent symptoms 3 Symptoms related to work 3 
Good function / coping with day to day activities 3 Poor sleep because of CTS 3 
Good patient education 3 Poor patient education/ expectation 3 
No previous anxiety / depression 2 History of anxiety / depression 3 
Symptoms not present at time of examination (may be evident on 
provocation) 
2 Slow insidious worsening 2 
Well defined median nerve distribution 2 Previous surgery on the effected side 2 
Early intervention 2 Previous failed treatment 2 
Good quality sleep 2 Late intervention 2 
Isolated condition with positive diagnostic tests (Phalen’s etc) 2 Mildly abnormal or normal NCS 1 
No co-morbidity 1   
Unilateral 1   
Associated with RA 1   
Previous good outcome with CTS 1   
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Clearly abnormal NCS 1   
Suggested candidate predictors of a good treatment effect from a 
corticosteroid injection 
 Suggested candidate predictors of a poor treatment  effect from a 
corticosteroid injection 
 
Patients willing to try (for 2 weeks) / Good compliance / Motivation 9 Previous failure of splint to other wrist 9 
Previous benefit from splint (to other wrist) 8 Thenar muscle weakness or wasting 6 
Early morning pain and numbness predominate 7 Splinting at night is not acceptable / not willing to try 6 
Pregnant 6 Long history 6 
Nocturnal or wakening symptoms only 5 History of anxiety / depression 4 
Short history 5 Continuous numbness 4 
No thenar muscle weakness or wasting 4 Patients find splints uncomfortable 4 
Good work ethic 3 Daytime symptoms 4 
Postural symptoms only 3 Poor compliance 4 
Patient asks for splint 3 Unemployed / On sickness benefit 3 
Good patient education 3 Poor education 3 
Symptoms not related to work 2 Symptoms related to work 2 
Symptoms not present at time of examination (may be evident on 
provocation) 
2 Previous surgery on the effected side 2 
Unilateral symptoms 2 Poor sleep because of CTS 2 
Intermittent night symptoms 2 Long time interval before commencing treatment 1 
Milder symptoms 2 Patients who normally fail to improve no matter what you offer them 1 
No previous anxiety / depression 1  
Suggested candidate predictors of a good treatment effect from night 
splinting 
 Suggested candidate predictors of a poor treatment effect from night 
splinting 
 
Previous benefit from injection (to other wrist) 11 Previous failure of injection (to other wrist) 15 
Severe / clear symptoms with defined distribution of symptoms 6 Continuous numbness / symtpoms 8 
No thenar muscle weakness or wasting 5 Thenar muscle weakness or wasting 5 
Inflammatory arthritis causing CTS 5 Underlying OA 4 
Nocturnal or wakening symptoms only 4 Diagnostic uncertainty 4 
Short duration of symptoms 4 Previous failure of injection to another joint 3 
Good education 4 Muscle wasting 3 
Previous benefit from injection to another joint 3 Recurrent symptoms 3 
Postural symptoms only 3 Needle phobia 3 
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Accuracy of siting injection 3 Co-existing WRULD or radiculopathy 3 
Intermittent symptoms / mild to moderate symptoms 3 Unemployed / On sickness benefit 2 
Good post injection advice 3 Previous surgery on the effected side 2 
Patient requests 3 Slow progression of symptoms over long period of time 2 
Self-limiting history like pregnancy 3 Severe symptoms  2 
Good work ethic 2 Symptoms related to work 1 
Symptoms not present at time of examination (may be evident on 
provocation) 
2  
Patients flexible to ideas of management 2 
Symptoms not related to work 1 
Positive provocation tests 1 
First attendance 1 
Abnormality in wrist like a previous fracture 1 
Suggested candidate predictors of a good treatment effect from carpal tunnel release 
surgery 
Suggested candidate predictors of a poor treatment effect from carpal tunnel release 
surgery 
Successful surgery on contralateral side 11 Thenar muscle weakness or wasting 10 
Good work ethic 7 Unemployed / On sickness benefit / Poor work ethic 7 
Nocturnal or wakening symptoms only 4 Previous surgery on the effected side 6 
A postive approach to surgery 4 Continuous numbness 4 
Recurrent injections / splints 4 Tethering of the nerve 4 
Short history 4 Those with previous negative response to surgery 4 
Symptoms not related to work 3 Long history 4 
Postural symptoms only 3 Symptoms related to work 3 
Male gender 3 OA wrist 3 
Abnormal NCS 3 Those with a fear of surgery/surgeons 3 
Post op hand therapy 3 Normal or slightly abnormal NCS 3 
No previous anxiety / depression 2 History of anxiety / depression 2 
Symptoms not present at time of examination (may be evident on 
provocation) 
2 Poor post-operative care and poor instruction about the post-operative 
period 
2 
Occupation and activities allowing good post-op care 2 On-going work related upper limb disorder 2 
No wasting 2 Co-morbidity 1 
Severe symptoms 2 Female gender 1 
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No co-morbidity 1 On-going litigation  1 
No thenar muscle weakness or wasting 1  
Correct diagnosis 1 
 Table summarising the candidate predictors of outcome and treatment effect 
Table summarising  
candidate predictors 
of outcome and 





































Hypothyroidism T,L              √√       
Diabetes T,L              √√      √ 
On dialysis L        √ 
Inflammatory 
conditions / 
associated arthritis / 
tendonitis / 
epicondylitis  
T,L,S             √ (1) √√√ (4) √ (ra) (5) √√(oa) (4)    √(oa) (3) 
Double crush 
syndrome  
L        √ 
Thoracic outlet 
syndrome 
L        √ 
Acromegaly L  √       
CTS following trauma T,S  √ √ (1)      
Anxiety and / or 
depression 
T,L,S  √√√ (3)      √√ (2) 
Dyssomnia T,S √ (3) √    √ (2)   
Functional disorders T,L  √√       
Obesity T,L              √√    √   





S √ (1)      √ (1)  
Any comorbidity S  √ (4)       
Absence of anxiety 
and / or depression 
S √ (2)    √ (1)  √ (2)  
Clinical characteristics 
Bilateral symptoms T,L  √√       
Unilateral symptoms S √ (1)    √ (2)    
Affecting dominant 
hand 
L  √       
Well defined 
distribution of 
symptoms / clear 
diagnosis 
S √ (2)  √ (6)    √ (1)  
Vague symptoms / 
diagnostic uncertainty 
T,S  √√ (3)  √ (4)     
Recurrent CTS T,S  √  √ (3)     
Higher symptom 
severity 
T,L,P,S  √√√√ (5) √ √√ (2)   √√ (2)  
Lower symptom 
severity 
L,S √ (5) √ √  √ (2)   √ 
Postural symptoms 
only 




L,S √ (3)  √ (3)  √ (2)  √  
Continuous 
symptoms 
T,S  √√ (8)  √  √ (4)  √ (4) 
Longer symptom 
duration 
P,L,S  √√√ (8)  √  √ (6)  √ (4) 
Shorter symptom 
duration 
L,S √√ (15)  √ (4)  √(5)  √√ (4)  
Acute onset S √ (4)        
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Slow, insidious onset S  √ (2)  √ (2)     
Night / waking 
symptoms 
predominate 
T,S   √ (4)  √√ (7)  √√ (4)  
Daytime symptoms S      √ (4)   
Good quality sleep  S √ (2)        
Multi-site pain P  √       
Lower functional 
severity 
S √ (3)        
Functional severity P  √       
Wasting or weakness 
of the thenar muscles 
T,L,S  √√√ (9)  √√ (5)  √ (6)  √√ (10) 
No wasting or 
weakness of the 
thenar muscles 
S √ (6)  √ (5)  √(4)  √ (2)  
Positive Phalen’s sign L  √ √ (1) √     
No or mild NCS 
changes 
L,S  √√ (1)     √ √ (3) 
Severe / clearly 
abnormal NCS 
changes 
L,S √ (1)   √   √√ (3)  
Less pronounced 
median nerve 
swelling / cross 
sectional area on 
ultrasound 
L   √      
USS evidence of 
tethering of the 
median nerve 
S        √ (4) 
Lower wrist ratio L  √       
Previous CTS surgery T,P,S  √√√ (2)  √ (2)  √ (2)  √ (4) 
Not treated with 
surgery 
L  √       
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Surgical complications L  √       
Previous response to 
surgery on 
contralateral side 
S       √ (11)  
Previous response to 
injection 
L   √ (11)    √  
Previous response to 
injection in another 
joint 
S   √ (3)      
Previous failed 
response to injection 
L,S    √ (15)   √√ (4)  
Previous failed 
response to injection 
in another joint 
S    √ (3)     
Previous benefit from 
splint to the other 
wrist 
S     √ (8)    
Previous failure of 
splint to the other 
wrist 
S      √ (9)   
Previous failure to 
respond to any 
treatment 
S  √ (2)       
Previous good 
outcome with CTS 
S √ (1)        
Patients who 
normally fail to 
improve no matter 
what you offer them 
S      √ (1)   
Splints uncomfortable 
/ not acceptable to 
the patient 
S      √ (4)   
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Injection done at first 
attendance 
S   √ (1)      
Injection accurately 
cited 
S   √ (3)      
Post-operative hand 
therapy 
S       √ (3)  
Poor post-operative 
care and poor 
instruction about the 
post-op period 
S        √ (2) 
Clinical intuition T √  √  √    
Patient choice T √  √  √    
Adherence T     √    
Early treatment 
intervention 
S √ (2)         
Late treatment 
intervention 








S  √ (3)    √ (3)   
Good compliance 
with treatment / 
instructions 
S     √ (9)    
Poor compliance with 
treatment / 
instructions 
S      √ (4)   
Patient request    √ (3)  √ (3)    
Third generation 
COCP 
L  √       
Demographics 
   
340 
 
Female gender T,L,S √ √√ √     √ (1) 
Male gender L,S       √ (3) √ 
Manual / high risk 
occupation 
T,L  √√      √ 
Successful work role 
functioning  
L       √  
Good work ethic S √ (4)  √ (3)  √ (3)  √ (7)  
Supportive employer T,S √      √  
Symptoms not related 
to work 
S √ (3)    √ (2)    
Symptoms related to 
work 
S  √ (3)  √ (1)  √ (2)  √ (3) 
Unemployed / on 
sickness benefit 
S  √ (7)  √ (2)  √ (3)  √ (7) 
Younger age T,L √ √ √      
Middle age L  √       
Older age P,L  √√  √    √ 
Pregnant women L,S √  √ (3)  √ (6)    
Perimenopausal T  √       
Not willing to try 
treatment / phobia of 
needles or surgery 
S    √(3)    √ (3) 
Involved in litigation L,S  √      √√ (1) 
(Realistic) patient 
expectations  
L       √  
Catastrophic thinking L        √ 
Poor perceived health 
scores 
L        √ 
Excess alcohol use L        √ 
Smoking L  √       
Positive approach to 
surgery 
S       √ (4)  
 




COCP = combined oral contraceptive pill CTS = carpal tunnel syndrome  OA = osteoarthritis RA = rheumatoid arthritis   
L = literature  
P = generic prognostic factor (PROG-RES tool)  
S = survey (with sum score)  
T = think-tank 
  
   
342 
 
 Summary of trial characteristics 
Author (Year) 
Country  
Risk of bias 
Cochrane risk of bias  
(low / unclear / high) 
Study population Interventions  Primary outcome 
measure(s) / duration 
follow - up 
Summary of trial findings 
Atroshi et al 2013 
Sweden  
 




CTS diagnosis: Katz 
diagnostic criteria 
Inclusion: primary 
idiopathic CTS, 18-70 
years, classic or probable 
CTS according to the Katz 
diagnostic criteria, 
unsuccessful 2 month 
treatment with wrist 
splinting, symptom 
severity warranting 
referral for consideration 
for surgery, NCS showing 
median nerve neuropathy 
at the wrist 
Exclusion: Previous 
steroid injection, thenar 
muscle atrophy, sensory 












Randomisation was done 
by the research nurse 
who opened the envelope 
containing the group 
assignment 
Blinding: The nurse 
prepared the injection in 
a covered syringe to mask 
the surgeon and patient 
to the substance being 
used. While the needle 
was withdrawn, a 
dressing was pressed over 
Change in CTS symptom 
severity score at 10 weeks 
32 
Rate of surgery at 1 year 
 
Missing data:  
n=1  (Methylprednisolone, 
80mg, 10 wk);  
n=0 at 1 year 
Symptom severity score at 
10 weeks (SD)±: 
Methylprednisolone 80mg 
vs. Placebo -0.64 (-1.06 to 
-0.21) P = 0.003 
Methylprednisolone 40mg 
vs. Placebo -0.88 (-1.30 to  
-0.46) P <0.001 
Methylprednisolone 80mg 
vs. 40mg 0.24 (-0.20 to 
0.69) P = 0.29 
 
Rate of surgery at 1 year, n 
(%) 
Methylprednisolone 80mg 
vs. Placebo 0.24 (0.06 – 
0.95) P = 0.042 





previous CTR, surgery on 
the contralateral side in 
the past 2m, inability to 
respond to 
questionnaires, severe 
illness, drug or alcohol 
abuse 
the puncture site to 
conceal the colour in case 
of leakage. At follow up 
examinations, the nurse 
covered the patient's 
palm with a dressing to 
conceal a possible surgical 
scar. 
Intervention 1: 80mg local 
methylprednisolone (37 
patients) 
Intervention 2: 40mg local 
methylprednisolone (37 
patients) 




vs. Placebo 0.38 (0.09 – 
1.59) P =0.16 
Methylprednisolone 80mg 
vs. 40mg 0.63 (0.21 – 1.89) 
P = 0.41 
 
Celiker et al 2002 
Turkey 
1 / 4 / 2 
 




Inclusion: No previous 
treatment for CTS 




recruited on attending 
clinic for NCS, randomly 
assigned to one of two 
groups using sequentially 
numbered sealed opaque 
envelopes 
Intervention 1: wrist 
splints at night with 
acemetacine 120mg/day 
Visual analogue score 
Symptom severity scale 32  
Motor distal latency (ms) 
Sensory distal latency (ms) 
Follow up: 8 weeks 
Missing data: none 
Pre-treatment and post-
treatment VAS scores not 
different between groups 
(P > 0.05) but decreased 
significantly in both 
groups (P < 0.05) 
Pre-treatment and post-
treatment distal latency 
scores not different 
between groups (P > 0.05) 
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(NSAID) (16 wrists, 11 
patients) 
Intervention 2: 40mg local 
Methylprednisolone (21 
wrists, 12 patients) 
but improved significantly 
in both groups (P < 0.05) 
Difference between 
groups regarding SSS not 
reported 
Gerritsen et al 2002  
The Netherlands 
7 / 0 / 0 
 
Setting: Secondary care 




Inclusion: 18 years and 




treatment with splinting 
or surgery, history of 




clinical signs or symptoms 
or electrophysiological 
findings that could mimic 




blocks of 4 patients were 
formed to ensure near 
equal distribution of 
patients over the 2 
treatment sites. The 
random sequence of the 
permuted blocks was 
generated by using 
random number tables. 
Coded and sealed opaque 
envelopes containing the 
treatment allocation and 
the envelopes used 
sequentially. 
Blinding: Patients were 
requested not to divulge 
treatment to the research 
physiotherapists. Wrists 
were bandaged to 
conceal any wound. 
Intervention 1: night 
splinting for at least six 
weeks (89 patients) 
General improvement 
Number of nights waking 
up due to symptoms 
Severity of symptoms 162  
Follow up: 3, 6, 12 & 18 
months 
Missing data:  
n = 19 (22%) (surgery at 18 
months) 
n = 10 (11%) (splinting at 
18 months) 
Success rate at 18 months 
(Differences surgery 
minus splint in success 
rate and 95% confidence 
interval) 
Surgery vs. splinting 
15 (3  - 27) P = 0.02 
Number of nights waking 
up due to symptoms at 18 
months, mean (SD) 
Surgery vs. splinting 
0.4 (-0.6 - 1.4) P = 0.44 
Severity of main 
complaint at 18 months, 
mean (SD) 
1.2 (0.2  - 2.3) P = 0.02 
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Intervention 2: open 
carpal tunnel release (87 
patients) 
Ly-Pen et al 2004 
Spain 
1 / 3 / 3 
 
Setting: Secondary care 
(designed to represent the 
general population that 
seeks medical attention 
from primary care) 




Inclusion:18 years and 
older,  symptoms for at 
least 3 months, 
unresponsive to at least 2 
weeks of non-steroidal 
anti-inflammatories and 
splinting 
Exclusion: thenar atrophy, 
previous carpal tunnel 









referred by primary care 
physicians. Treatment 
assignments were 
randomly generated by 
computer in blocks of 6 
cases. Sealed envelopes 
containing treatments 
assignments were 
provided by the 
statistician. After 
enrolment, the envelope 
containing the 
assignment for each wrist 
was opened and the 
specific treatment 
assigned 
Blinding: No blinding took 
place 
Intervention 1: local 
steroid injection (83 
wrists) 
Intervention 2: limited 
palmer incision carpal 
tunnel release (80 wrists) 
Percentage of wrists that 
reached ≥ 20% response 
for nocturnal paraesthesia  
Follow up: 3 months 
Missing data:  
n = 13 (16%) (surgery at 3 
months) 
n = 3 (4%) (injection at 3 
months) 
≥ 20% response for 
nocturnal paraesthesia at 
3 months 
Injection vs. surgery 
94.0% vs. 75.0% (P = 
0.001) 
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 Internal data request form 
Arthritis Research UK Primary Care Centre Keele University Internal data request form 
To be completed by the Researcher of proposed study 
Proposed Study Title:  
 
Predicting better response to either corticosteroid injection or night splinting in primary care patients with 
carpal tunnel syndrome 
 
(Sub-study of PhD entitled “The epidemiology, prognosis and management of carpal tunnel syndrome in 
primary care”) 
Researcher: 
Dr Claire Burton 
Supervisor of Researcher (where applicable): 
Dr Linda Chesterton, Dr Ying Chen, Prof Danielle van der Windt 
Co-authors: 
Dr Linda Chesterton, Dr Ying Chen, Prof Danielle van der Windt 
Is the data required for practicing analysis or demonstration/ 
teaching only? 
YES  NO x 
If so, please provide further details 
Research Question / Objective:  
(Not required if data required for practicing analysis or demonstration/teaching only) 
Investigate the predictive value of candidate prognostic factors available from a pragmatic randomised clinical 
trial (INSTinCTS) to predict future change in patient-reported CTS-symptoms following primary care 
management (corticosteroid injection or night splinting)  
Explore if a priori defined prognostic factors (potential treatment moderators) predict a better response to 
either corticosteroid injections or night splinting in primary care patients with CTS 
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Outline design of analysis: 




Study population: the INSTinCTS trial, has recruited around 240 patients (males and females over 18 years of age) 
with mild-to-moderate CTS consulting in primary care or the primary-secondary care interface. Patients 
were randomised on an equal basis to either steroid injection or a night splint. Clinical diagnosis was 
standardized, based on presenting symptoms, routine clinical history and physical tests using criteria 
developed as part of a consensus survey. The eligibility criteria were designed to select a relatively 
homogeneous group of patients with idiopathic CTS, suitable for both splinting and local injection and who 
do not require immediate onward referral for surgery.  
 
Outcome measure: The outcome measure for this analysis will be the absolute score for symptom severity 
and limitations in hand function using the Boston Carpal Tunnel Questionnaire (BCTQ) at six months follow-
up which will be collected as part of the INSTINCTS trial. The BCTQ is a condition-specific patient reported 
outcome measure, which has been shown to be valid, reliable and responsive when used in patients with 
CTS in various settings. The scale includes two subscales: the symptom severity scale (SSS: 11 items) and 
function status scale (FSS: 8 items), both scored on 1-5 scales, with final scores for each dimension 
calculated as a mean score between 1 and 5. Higher scores denote more severe symptoms and greater 
functional impairment. 
 
Candidate predictors: Candidate predictors have been previously identified through my MPhil work and 
have been grouped into different categories (comorbidities, patient or clinical characteristics, patient 
demographics) and are collected as part of the baseline clinical assessment or baseline patient questionnaire 
within the INSTINCTS study, as described below.  
 
Statistical analysis: Descriptive statistics will be used to illustrate the course of symptoms of carpal tunnel 
syndrome in all trial participants, and separately for those in each arm of the study. Next, linear regression 
analysis will be used to determine the association between candidate predictors and symptom severity and 
functional disability (BCTQ) at six months follow-up in all participants, adjusting for baseline score and 
randomly allocated treatment (corticosteroid injection or splint). Multiple linear regression will be used to 
identify the combination of factors is most strongly associated with the future course of symptoms and 
function limitation. Given the sample size of the INSTinCTS trial, not all candidate predictors will be 
introduced in the model at once. A stepwise sequential approach will be used adding blocks of variables to 
investigate the predictive value of adding more complex prognostic information. For each block backwards 
manual selection will be used to identify the most important predictors, which will be carried forward to the 
next step. This approach will ensure that there will be at least 10 subjects per variable introduced into the 




The results of objective 1 will provide a list of prognostic factors that are most strongly associated with 
future changes in symptoms and functional limitations in patients with CTS treated with commonly used 
primary care interventions. For this objective, the extent to which some specific prognostic factors predict a 
differential response to either injection or splints will be explored, as the identification of potential 
treatment moderators could support the design of a decision aid to be tested in future research. The 
INSTinCTS trial is not powered to test treatment moderation (this would require subgroup analysis and 
testing of treatment-moderator interactions) and there are currently no similar trials with which to pool its 
data. This analysis will therefore be an exploratory analysis of a small set of priori defined prognostic factors. 
Study population and outcome measures will be the same as described above. 
 
Candidate treatment moderators: Factors considered to be likely candidates for this analysis will be 
informed by the results of the analysis of objective 1, and by the opinions and expertise from members of 
the Research User Group and a clinical advisory group. No more than 3 or 4 factors will be investigated, for 
which there are plausible reasons that they are associated with a larger improvement of CTS symptoms or 
function following corticosteroid injection versus six weeks of night splints. 
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Statistical analysis: will consist of exploratory subgroup analyses providing estimates of mean change in 
symptom severity and limitation in function for injection versus splints in patient subgroups defined on the 
basis of the prognostic factor. 
 
 
Study (or studies) from which data are requested: 
 
Data will be required from INSTinCTS – Injection versus Splinting in Carpal Tunnel Syndrome 
 
Study population required  
(For quantitative studies please specify if there are specific groups of participants required from the study 
e.g. age range, gender, and for qualitative studies please specify the demographic or sample frame and the 
number of participants you require): 
 
Anonymised data from all randomized participants will be required. 
 
   
349 
 
Precise data required  
(For quantitative data please be specific on survey wave (e.g. baseline data) and list all variables required 
and for qualitative data please detail the type of data required (e.g. interview transcripts, diaries etc): 
 
For all randomised patients I will required the randomization code and the baseline and six month Boston 
Carpal Tunnel Questionnaire sum scores (pre-treatment questionnaire: C9 – 20; six month questionnaire 2-
13). The answer to six month questionnaire F4 (yes / no) will also be required to ascertain whether surgery 
has taken place. If time in my PhD allows, it may at a later date be of interest to obtain the BCTQ score and 
surgical outcome, measured at 12 months. The table below details all variables and their questionnaire 












Gender   Pre-Treatment 
Questionnaire 
A1 
Male / female 
Age   Pre-Treatment 
Questionnaire 
A2 & A3 
Occupation   Pre-Treatment 
Questionnaire 
E 1 (yes / no) 













During the last 
month have 
you often been 
bothered by 









G6: yes / no 
G7: yes / no 
Sleep quality Jenkins 
questions 
Jenkins questions Pre-Treatment 
Questionnaire 
D 1-4 
Not at all / on 
some nights / 
on most nights 
Functional 
disorders 
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else in the last 
month? 
 H4: yes / no 









 Calculated from 







  Pre-Treatment 
Questionnaire 
C 1 





  Pre-Treatment 
Questionnaire 
C2 
Right / left 
Recurrent 
symptoms 
  Pre-Treatment 
Questionnaire 
B1 
Yes / no  
If no, B2 






Levine et al Pre-Treatment 
Questionnaire 









Levine et al Pre-Treatment 
Questionnaire 











Levine et al Pre-Treatment 
Questionnaire 
C 9 – 19 





How long have 







< 3months / 3-
six months / 6 
– 12 months / 
> 12months 










you hold your 
wrist in a 
particular 
position? 
Question created Pre-Treatment 
Questionnaire 
C 5 







Levine et al Pre-Treatment 
Questionnaire 








Levine et al Pre-Treatment 
Questionnaire 
C 12  




































H4 yes / no 
H5  
<3m / 3-6m / 
6-12m / 1-3 
years / >3 
years 
Phalen’s sign Checked at 
eligibility 
screening  

























If B1 = no, 





of great help / 
of some help / 
of little help / 
of no help 
(specific to 




in the past 
detailed in 
Question 4, 
please state for 
each one how 








Answer to B5, 




If B1 = no, 





of great help / 
of some help / 
of little help / 







Have you ever 
had a steroid 
injection into a 
joint other 
than your wrist 
before? 
Yes / no 
 
If yes, How 







If B6 yes, 
answer to B7 
 
ticked options: 
then of great 
help / of some 
help / of little 





…if you were to 


















If you were to 




F2 yes / no 
























 six week 
questionnaire 
G3 




How much do 





















On average to 
what extent 
















If you are not 
doing your 
usual job, is 
this because of 




































There is a lot 
which I can do 
to control my 
symptoms 
 




gets better or 
worse 
 
























control my  
problem   
 






















For splint only,  
…over the past 
six weeks, on 
average, how 
many nights 




 six week 
Questionnaire 
 
If F1 yes, 
answer to F3: 
Every night / 
4-6 nights / 1-



























NORSTOP  Pre-Treatment 
Questionnaire  
H6 
Daily or most 
days / Once or 
twice a week / 
   
355 
 
Once or twice 
a month / 
Once or twice 
a year / Never 















Is new REC approval required?   YES 
 
 NO x 
In order to permit a more complete description of baseline characteristics, additional questions were added 
to the original trial baseline questionnaire. The addition of these questions was approved on 3rd July 2013 
(REC reference 13/NW/0280, amendment 1).  
 
The Patient Information Leaflet includes a paragraph explaining that anonymized data may be used for 
further research. 
 
“The study information collected about you may be shared with other research teams to answer new 
research questions in the future. If this is the case, information will be anonymised. Your full name and 
contact details will not be disclosed.” 
 
Further new REC approval is therefore not required. 
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I confirm that the data specified in this request are required to answer the research 
question. If there are any queries in relation to the data requested I understand that it is 
my responsibility to support the researcher to complete an accurate data request form, 















Date of data release: 
 




NB The data must be stored on your S:drive only in accordance with the Centre’s Procedures for data 
security and management of identifiable and sensitive data relating to research participants and Standard 
Operating Procedures, and the principles and conditions set out in the Data Protection Act 1998, the 
Research Governance Framework, and with proper safeguards to ensure confidentiality. 
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Arthritis Research UK Primary Care Centre 
Keele University 
Internal data request form – Amendment 
To be completed by the Researcher of the study 
Study Title: 
Predicting better response to either corticosteroid 
injection or night splinting in primary care patients 
with carpal tunnel syndrome 
 
(Sub-study of PhD entitled “The epidemiology, 
prognosis and management of carpal tunnel 
syndrome in primary care”) 
 
DCAP number of  
original data request*: n/a – original Internal data request 
form signed 24/2/17 
Researcher: 
Dr Claire Burton 
 
Supervisor of Researcher (where applicable): 
Prof Danielle van der Windt 




Study (or studies) from which data are requested: 
INSTinCTS – The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel 
syndrome (INSTinCTS trial): an open-label, parallel group, randomized controlled trial 
 
Study population required (e.g. age range, gender): 
All participants 
 
Precise data required (please be specific on survey wave (e.g. baseline data) and list all variables required): 
I would like to request the six week outcome data (symptom severity score, function status scale and 
overall BCTQ) for all trial participants, in order to be able to describe more fully the course of symptoms 
of the trial participants as a cohort. This will allow me to more fully discuss the results of the first 
objective of my initial data request (to investigate the predictive value of candidate prognostic factors 
available from a pragmatic randomised clinical trial (INSTinCTS) to predict future change in patient-
reported CTS-symptoms following primary care management (corticosteroid injection or night 
splinting). 
Is the data requested in this amendment to be used to address the stated 
objectives in the original data request form? 
YES x NO  




I confirm that the data variables specified in this request are required to answer the research 
question. If there are any queries in relation to the data requested I understand that it is my 
responsibility to support the researcher to complete an accurate data request form, in line with 




   
358 
 







Date of data release: 
 
Signature of data custodian upon data release: 
NB The data must be stored on your S:drive only, in accordance with the principles and conditions set out in 
the Data Protection Act 1998, the Research Governance Framework, and with proper safeguards to ensure 
confidentiality. 
* - The DCAP number of the original request can be found on the Internal Data Request Repository 
(P:\data request repositories\internal\ Internal Request Register.xls) 
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 Published articles associated with the work presented in this thesis 
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